



(51) International Patent Classification:

C12N 15/74 (2006.01) *A61P 35/00* (2006.01)
A61P 1/04 (2006.01) *A61P 37/06* (2006.01)
A61P 3/04 (2006.01) *C12N 15/70* (2006.01)
A61P 11/06 (2006.01) *C07K 14/24* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/GB2020/051380

(22) International Filing Date:

05 June 2020 (05.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1908155.3 07 June 2019 (07.06.2019) GB

(71) Applicant: **THE UNIVERSITY OF WARWICK** [GB/GB]; University House, Kirby Corner Road, Coventry CV4 8UW (GB).

(72) Inventors: **WATERFIELD, Nicholas R.**; c/o THE UNIVERSITY OF WARWICK, University House, Kirby Corner Road, Coventry CV4 8UW (GB). **HEALEY, Joseph**; c/o THE UNIVERSITY OF WARWICK, University House, Kirby Corner Road, Coventry CV4 8UW (GB). **HAPESHI, Alexia**; c/o THE UNIVERSITY OF WAR-

WICK, University House, Kirby Corner Road, Coventry CV4 8UW (GB).

(74) Agent: **MACLEAN, Martin**; Mathys & Squire LLP, The Shard, 32 London Bridge Street, London, SE1 9SG (GB).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


(54) Title: LEADER SEQUENCE

FIGURE 3

A



B



(57) Abstract: The present invention provides use of a *Photorhabdus Virulence* Cassettes (PVC) effector leader sequence, for packaging a payload into a PVC Needle Complex, and related methods for manufacturing a packaged PVC Needle Complex. The payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof, and the leader sequence and the payload form an effector fusion that is distinct from a wild-type PVC effector protein.



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

Leader Sequence

The present invention relates to a leader sequence, and use of a leader sequence for packaging molecules into protein complexes.

Biological molecules (e.g. peptides, proteins and nucleic acids) have great potential as broadly applicable therapeutics. Indeed, there has been a trend in recent years for the pharmaceutical industry to move away from 'small molecule' drugs, toward more complex macromolecular therapeutics (aka. "biologics"). Such biologics include protein-based therapeutics (notably antibodies, hormones, growth factors and cytokines) and nucleic acid-based treatments (such as short-interfering RNAs, DNA/RNA vaccines and gene therapies).

While the biologics market has developed significantly in recent years, the low availability of effective delivery systems (and practicable methods for manufacturing such delivery systems) has limited the diversity of molecular targets of such bio-therapeutics, especially when the target is cytosolic. Indeed, the majority of approved peptide therapeutics on the market act by targeting extracellular components, such as membrane receptors or secreted molecules (e.g. present in the interstitial space). For example, humira (the most successful therapeutic monoclonal antibody) targets the extracellularly secreted cytokine TNF α . Insulin acts by binding its cognate receptor present on the cell membrane (the same being true of other hormone peptide therapeutics).

Similar problems exist in the agricultural industry, where protein-based pesticides are typically toxins which must target an extracellular component of a cell of a pest. By way of example, *Bacillus thuringiensis* toxins are commonly used natural pesticides which must bind membrane receptors to exert their toxic effects.

Methods for cytosolic delivery of biological molecules have been developed for laboratory research, which generally involve delivering the molecules within lipid vehicles which fuse with the plasma membrane of a cell, before emptying their payload into the cytosol. However, such methods find limited use in medicine and veterinary, e.g. due to the non-specific nature in which they deliver molecules to cells.

Bacterial secretion systems have been explored as potential delivery systems, given their natural ability to secrete (or more particularly 'inject') molecules into target cells. The most studied of such secretion systems is the Type III secretion system (T3SS), a "protein appendage" found in several Gram-negative bacteria. However, a significant drawback of these systems is that they remain associated with the bacterial membrane at all times, requiring use of actual bacterial cells (comprising the secretion system) as the delivery system. As such, it is difficult to fully control what molecules are transferred from the bacteria to the target cell (even when the biologic of interest is overexpressed), as these secretion systems function by providing a connection (e.g. channel) between the bacteria's cytosol and the target cell's cytosol, through which other components (potentially harmful to the host) may flow.

Therefore, there exists not only a need for improved delivery systems, but also means for producing such systems which find compatibility with molecules (payloads) having a range of sizes and molecular properties.

5 The present invention solves one or more of the above-mentioned problems.

The present invention is predicated on the surprising finding that toxigenic *Phototrhaddus Virulence Cassettes* (PVC) effector proteins of *Phototrhaddus* bacteria comprise a previously unknown "leader sequence" (or "leader peptide"), which functions to package (or "load") PVC
10 effectors into a so called PVC Needle Complex(e.g. "nanosyringe"), which subsequently delivers the PVC effector to a target cell where it exerts its toxigenic effect(s) (the PVC effectors representing a payload of such nanosyringes). Moreover, the inventors have found that such leader sequences can be practically utilized to direct a payload linked thereto to be packaged into a PVC Needle Complex (and related/ homologous complexes), a well
15 characterized molecular delivery system of *Phototrhaddus*. Thus, the newly discovered leader sequence surprisingly functions to load the PVC Needle Complex with a molecular payload (or "warhead").

Further to this finding, the inventors have developed an advantageous, practical utility for
20 such leader sequence for packaging/ loading 'heterologous' payloads (including non-*Phototrhaddus* molecules) into PVC Needle Complexes, independent of the size, molecular properties or provenance of the heterologous payload.

In a first aspect the invention provides use of a *Phototrhaddus Virulence Cassettes* (PVC)
25 effector leader sequence, for packaging a payload into a PVC Needle Complex;
wherein the payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof (preferably a polypeptide); and
wherein the leader sequence and the payload form an effector fusion that is distinct from a wild-type PVC effector protein.

30 In one aspect, an aspect of the invention provides use of a PVC effector leader sequence, for packaging a payload into a PVC Needle Complex;
wherein the payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof (preferably a polypeptide); and
35 wherein the leader sequence and the payload form a fusion that is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

In other words, the invention provides in one aspect a method for packaging a payload into a PVC Needle Complex with a PVC effector leader sequence, comprising contacting an
40 (effector) fusion with a PVC Needle Complex, wherein the payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof (preferably a polypeptide); and wherein the leader sequence and the payload form the (effector) fusion, that is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

45 The terms "fusion" and "effector fusion", in the context of a (effector) fusion formed by the leader sequence and the payload (and that is distinct from a wild-type PVC effector protein) are used interchangeably herein.

This use (of the leader sequence) was demonstrated, as outlined in the examples, by expressing an effector fusion (tagged with a detection label) and a PVC Needle Complex in a cell (e.g. host bacterial cell) wherein the effector fusion is packaged into the PVC Needle Complex (via the leader sequence), isolating the PVC Needle Complex, then detecting the presence or absence of the payload within the PVC Needle Complex (e.g. a disrupted version thereof) via Western blot detection of the detection label. The presence of the payload is detected when fused to a leader sequence only, but not when the payload lacks a leader sequence.

The term “PVC effector leader sequence” means the leader region (polypeptide region) from a PVC effector polypeptide which is capable of packaging a payload (e.g. effector) into a PVC Needle Complex, and is preferably amino acids 1-50 of a PVC effector, or amino acids 2-50 when omitting the initial methionine. The inventors have demonstrated that the leader sequence is encompassed within (or may consist essentially of) amino acids 1-50 of a multitude of identified PVC effector polypeptide sequences. However, leader sequences having alternative lengths and positioning within a PVC effector are intended to be encompassed (e.g. with the proviso that said leader sequence is capable of packaging a payload into a PVC Needle Complex).

The remaining (non-leader sequence) portion of a PVC effector is referred to an “effector portion” (e.g. payload) herein. The effector portion preferably comprises or consists essentially of amino acids 51-C terminus of a PVC effector protein.

Thus, in one embodiment, a PVC effector leader sequence is encompassed within amino acids 1-50 or 2-50 (preferably 1-50) of a PVC effector polypeptide.

In embodiment, a PVC effector leader sequence comprises (or consists essentially of) amino acids 1-50 or 2-50 (preferably 1-50) of a PVC effector polypeptide.

The term “wild-type PVC effector protein” is used synonymously with the term “endogenous PVC effector protein”, or simply “PVC effector protein”, and refers to an (e.g. intact) PVC effector sequence having an endogenous leader sequence (i.e. endogenous to the given PVC effector, preferably amino acids 1-50 of the PVC effector) associated with the effector portion (e.g. the payload, preferably amino acids 51-C terminus of a PVC effector protein).

Examples of wild-type PVC effectors may comprise (or consist essentially of) an amino acid sequence of one or more sequence selected from SEQ ID NO.: 1 – SEQ ID NO.: 46. The fusion/ effector fusion of the invention described herein is thus distinct from a PVC effector protein (e.g. wild-type PVC effector protein), as the leader sequence is not fused to an effector portion with which it may be fused in the case of a wild-type PVC effector protein. By way of example, the fusion/ effector fusion may comprise the leader sequence of the “Pnf” PVC effector protein (e.g. the leader of SEQ ID NO.: 78) fused to the effector portion of the *hvnA* (gene *Plu1649*) PVC effector protein (e.g. amino acids 51-295 of SEQ ID NO.: 46), but is not intended to refer to the leader sequence of the “Pnf” PVC effector protein (e.g. the leader of SEQ ID NO.: 78) fused to the effector portion of the Pnf PVC effector protein (e.g. amino acids 51-340 of SEQ ID NO.: 32).

On the other hand, the fusion/ effector fusion may comprise the leader sequence of, e.g., the “Pnf” PVC effector protein (e.g. the leader of SEQ ID NO.: 78) fused to a non-effector portion, for example a non-*Photothabdus* protein such as Cre recombinase. Thus, the leader sequence finds utility in packaging a range of e.g. heterologous (non-wild-type) agents into a PVC Needle Complex, opening the possibility to use the PVC Needle Complex as a modular, diverse delivery system for delivering not only natural effectors, but also ‘unnatural’ payloads to a cell for the first time. As such, it is possible to manufacture a PVC Needle Complex having a payload of choice.

Another aspect of the invention provides a method for manufacturing a PVC Needle Complex comprising a payload (e.g. in other words, a method for manufacturing a packaged PVC Needle Complex), the method comprising:

- a. contacting (e.g. within a host cell) a PVC Needle Complex with an effector fusion comprising a PVC effector leader sequence fused to a payload;
- b. wherein the payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- c. wherein the effector fusion is distinct from a wild-type PVC effector protein.

An aspect of the invention provides a method for manufacturing a PVC Needle Complex comprising a payload (e.g. in other words, a method for manufacturing a packaged PVC Needle Complex), the method comprising:

- a. contacting (e.g. within a host cell) a PVC Needle Complex with a fusion, the fusion comprising a PVC effector leader sequence fused to a payload, wherein the leader sequence and the payload form a fusion that is distinct from a PVC effector protein (e.g. wild-type PVC effector protein); and
- b. wherein the payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide).

In one embodiment, said contacting may occur within a cell (e.g. bacterial host cell), in a cell lysate, or in a purified cell lysate (preferably within a cell). In one embodiment, said contacting may occur within a cell free expression system. Similar, a use described herein may comprise a contacting step (between the fusion/ effector fusion and PVC Needle Complex) occurring within a cell (e.g. bacterial host cell), in a cell lysate, cell free expression system, or in a purified cell lysate (preferably within a cell, more preferably a bacterial host cell).

A cassette (operon) encoding the PVC Needle Complex may be operably linked to a first promoter, and a gene encoding the fusion/ effector fusion (payload) may be operably linked to a second (preferably different) promoter. In one embodiment, said first and/or second promoter is an inducible promoter (e.g. an arabinose inducible promoter such as pBAD, and/or an IPTG inducible promoter). Thus, the invention embraces an expression system wherein an operon encoding the PVC is present within a first vector/ plasmid (optionally operably linked to a first promoter), and the sequence encoding the effector fusion (leader sequence fused to payload) is present within a second (preferably different) plasmid (optionally linked to a second promoter).

In one embodiment, the PVC Needle Complex and/or (preferably and) effector fusion may be expressed in one or more host selected from a bacterial cell, a yeast cell, an insect cell and/or a mammalian cell. In a preferable embodiment, the PVC Needle Complex and effector fusion may be expressed together in a host cell selected from a bacterial cell, a yeast cell, an insect cell and a mammalian cell (preferably a bacterial cell). Suitable mammalian cells include a HEK293 cell and/or a CHO cell.

The PVC Needle Complex and/or (preferably and) the effector fusion (payload) may be expressed in a heterologous bacterial expression system (preferably *E. coli*). In one embodiment, the PVC Needle Complex and/or (preferably and) the PVC effector may be expressed in a *Phototribdus* cell, optionally wherein the PVC operon of the *Phototribdus* cell is endogenous to the cell (and optionally wherein the PVC operon is operably linked to an inducible promoter which may be incorporated into the genome to be operably linked to the PVC operon via genetic engineering). For example, an inducible promoter may be introduced into the genome of a *Phototribdus* cell 5' to a PVC (operon), preferably by recombineering as described in the examples (e.g. Example 3).

The payload may be, for example, a therapeutic payload, such that a PVC Needle Complex finds utility in medical treatment.

In a further aspect, the invention provides a (packaged) PVC Needle Complex, for use in a method of treatment;

- a. wherein the PVC Needle Complex comprises (e.g. is packaged with) an effector fusion which comprises (or consists essentially of) a PVC effector leader sequence fused to a payload;
- b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- c. wherein the effector fusion is distinct from a wild-type PVC effector protein.

A further aspect of the invention provides a (packaged) PVC Needle Complex, for use in a method of treatment;

- a. wherein the PVC Needle Complex holds (e.g. is packaged with) a fusion which comprises (or consists essentially of) a PVC effector leader sequence fused to a payload;
- b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- c. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

In one aspect, the invention provides a method of treating a subject, the method comprising administering a (packaged) PVC Needle Complex to a subject (e.g. a patient);

- a. wherein the PVC Needle Complex comprises (e.g. is packaged with) an effector fusion which comprises (or consists essentially of) a PVC effector leader sequence fused to a payload;
- b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- c. wherein the effector fusion is distinct from a wild-type PVC effector protein.

In other words, an aspect of the invention provides a method of treating a subject, the method comprising administering a (packaged) PVC Needle Complex to a subject (e.g. a patient);

- 5 a. wherein the PVC Needle Complex holds (e.g. is packaged with) a fusion which comprises (or consists essentially of) a PVC effector leader sequence fused to a payload;
- b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- 10 c. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

In a preferable embodiment, the payload is a polypeptide.

The subject may be a mammalian subject, preferably a human subject.

The terms "PVC Needle Complex holds an effector fusion" and "PVC Needle Complex comprising an effector fusion" means a PVC Needle Complex having a packaged effector fusion, or in other words, a PVC Needle Complex that is packaged with an effector fusion.

The term "packaged effector fusion", "fusion" and "effector fusion" (e.g. wherein the fusion/effector fusion is distinct from a wild-type PVC effector protein) embraces a combination of a PVC effector leader sequence and a payload which remains in contact (e.g. fused) subsequent to packaging into PVC Needle Complex (e.g. the leader sequence has not been cleaved off the payload), as well as combination of a PVC effector leader sequence and a payload which are no longer in direct contact (e.g. no longer fused, such as following cleavage of the leader sequence from the payload).

The term "treat" or "treating" as used herein encompasses prophylactic treatment (e.g. to prevent onset of a disease) as well as corrective treatment (treatment of a subject already suffering from a disease). Preferably "treat" or "treating" as used herein means corrective treatment. The term "treat" or "treating" encompasses treating both the disease and a symptom thereof. In some embodiments "treat" or "treating" refers to a symptom of a disease.

Therefore, a PVC Needle Complex may be administered to a subject in a therapeutically effective amount or a prophylactically effective amount.

A "therapeutically effective amount" is any amount of the (packaged/ laden) PVC Needle Complex, which when administered alone or in combination (e.g. with another therapeutic, administered parallel or in series and acting additively or synergistically) to a subject for treating a disease (or a symptom thereof) is sufficient to effect such treatment of the disease, or symptom thereof.

A "prophylactically effective amount" is any amount of the (packaged/ laden) PVC Needle Complex that, when administered alone or in combination (e.g. with another therapeutic, administered parallel or in series and acting additively or synergistically) to a subject inhibits or delays the onset or reoccurrence of a disease (or a symptom thereof). In some

embodiments, the prophylactically effective amount prevents the onset or reoccurrence of a disease entirely. "Inhibiting" the onset means either lessening the likelihood of disease onset (or symptom thereof), or preventing the onset entirely.

- 5 In a related aspect, there is provided a (packaged) PVC Needle Complex comprising (e.g. that holds/ that is packaged with) an effector fusion;
- a. wherein said effector fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said effector fusion is formed by a PVC effector leader sequence and a payload);
 - 10 b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
 - c. wherein the effector fusion is distinct from a wild-type PVC effector protein.

- 15 In other words, one aspect of the invention provides a (packaged) PVC Needle Complex that holds (e.g. is packaged with) a fusion;
- a. wherein said fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said fusion is formed by a PVC effector leader sequence and a payload);
 - b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
 - 20 c. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

- 25 In a preferable embodiment, the (packaged) PVC Needle Complex is an isolated (e.g. non-natural) PVC Needle Complex.

- 30 As explained below, the PVC Needle Complex typically functions in nature to deliver toxigenic PVC effectors to insect targets. By expanding greatly the number and variety of payloads which may be packaged into a PVC Needle Complex, the invention concomitantly expands the number and variety of invertebrates (e.g. pests), such as amoeba, nematodes, helminths and insects, which may be targeted and killed.

- In a further aspect of the invention, there is provided a method for suppressing a pest, the method comprising:
- 35 a. contacting a pest, or a target area comprising a pest, with a (packaged) PVC Needle Complex comprising (e.g. holding/ packaged with) an effector fusion;
 - b. wherein the effector fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said effector fusion is formed by a PVC effector leader sequence and a payload);
 - 40 c. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
 - d. wherein the effector fusion is distinct from a wild-type PVC effector protein.

- An aspect of the invention provides a method for suppressing a pest, the method comprising:
- 45 a. contacting a pest, or a target area comprising a pest, with a (packaged) PVC Needle Complex holding (e.g. packaged with) a fusion;

- b. wherein the fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said fusion is formed by a PVC effector leader sequence and a payload);
- c. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- d. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

The terms "PVC Needle Complex holds an effector fusion" and "PVC Needle Complex comprising an effector fusion" means a PVC Needle Complex having a packaged effector fusion.

The term "target area" refers to an area where a pest is present and/or where a pest may be (e.g. is expected to be, or suspected of being) present.

Thus, in one embodiment, a target area may be contacted before, and/or when a pest is present. The target area may be in the vicinity of (e.g. close proximity to) a pest. Alternatively, the target area may be an area that a user wishes to protect from a pest. For example, a target area may comprise a plant and/or plant product.

The term "suppressing a pest" embraces "pest control", "inhibiting the growth of a pest", "inhibiting the proliferation of pest", and/or "mortality of a pest".

Examples of such pest include one or more insect(s), mite(s), sowbug(s), pillbug(s), centipede(s), mollusk(s), millipede(s), protist(s), fungus (fungi), helminth(s) and/or bloodborne parasite(s). The pest may be at any stage of development e.g. may be a larvae and/or adult pest (e.g. imago).

The invention may be used to target a variety of agricultural, commercial, home and garden pests.

In one embodiment the pest is an insect, a mite, a sowbug, a pillbug, a centipede, a mollusk and/or a millipede. Suitably the pest may be an insect and/or a mite (preferably insect).

Examples of suitable insects include, an insect of the order Lepidoptera, Coleoptera, Diptera, Blattodea, Hymenoptera, Isoptera, Orthoptera, Thysanura, and/or Dermaptera. In one embodiment an insect of the order Lepidoptera may be one or more of a moth and/or a butterfly. Suitable moths include *Manduca Sexta* and/or *Galleria mellonella*.

In one embodiment an insect of the order Coleoptera may be one or more of a European chafer grub, a northern masked chafer grub, a southern masked chafer grub, a Japanese beetle grub, a June beetle grub, a black vine weevil, a strawberry root weevil, a clay-colored weevil, a Colorado potato beetle, and/or a wireworm. In another embodiment an insect of the order Diptera may be one or more of a leatherjacket (e.g. larvae of a crane fly), an onion maggot, a cabbage maggot, a carrot rust fly maggot, a fungus gnat, and/or a mosquito. In another embodiment an insect of the order Blattodea may be a cockroach, suitably one or more cockroach selected from an American cockroach, and/or a German cockroach.

In one embodiment an insect of the order Hymenoptera may be an ant. Suitably, the ant may be one or more of a carpenter ant, an odorous house ant, a pavement ant, an Argentine ant, a Pharaoh ant, a tawny crazy ant, a harvester ant, a red imported fire ant, a Southern fire ant, a European fire ant, and/or a little fire ant. In another embodiment an insect of the order Hymenoptera may be a yellowjacket.

In one embodiment an insect of the order Isoptera may be a termite. Suitably the termite may be one or more of a damp wood termite, a dry wood termite, and/or a subterranean termite. In another embodiment an insect of the order Orthoptera may be one or more of a cricket, a grasshopper, and/or a locust. In one embodiment an insect of the order Thysanura may be a silverfish. In another embodiment an insect of the order Dermaptera may be an earwig.

Examples of suitable molluscs include a slug and/or a snail.

In one embodiment, the pest is a protist. In one embodiment, said protist is one or more selected from *Chaos carolinense*, *Amoeba proteus*, *Naegleria fowleri*, *Dictyostelium discoideum*, *Entamoeba histolytica*, *Trichomonas vaginalis*, *Blastocystis hominis*, *Leishmania Spp.*, and *Giardia lamblia*. In one embodiment, said protist is one or more selected from *Fonticula alba*, *Dictyostelium discoideum*, *Chlamydomonas reinhardtii*, *Cryptomonas paramecium*, *Paulinella chromatophora*, *Nannochloropsis gaditana*, and/or *Tetrahymena Spp.*

In one embodiment, the pest is a fungus. In one embodiment, said fungus is one or more fungus selected from *Encephalitozoon cuniculi*, *Nasema apis*, *Nemema ceranae*, *Vittafoma carneae*, *Enterocytozoan bieneusi*, *Spraguea lophii*, *Vavra culiculis*, *Edhazardia aedes*, *Nematocida parisii*, *Razella Spp.*, *Parasitella parasitica*, *Lichteimia ramose*, *Sporisorium scitamineum*, *Trametes versicolor*, and/or *Punctularia strigosozonata*.

In one embodiment, said fungus is a *Candida* spp. Said *Candida* spp. may be one or more selected from *C. albicans*, *C. ascalaphidarum*, *C. amphixiae*, *C. Antarctica*, *C. argentea*, *C. atlantica*, *C. atmosphaerica*, *C. auris*, *C. blattae*, *C. bromeliacearum*, *C. carpophila*, *C. carvajalis*, *C. cerambycidarum*, *C. chauliodes*, *C. corydalis*, *C. dosseyi*, *C. dubliniensis*, *C. ergatensis*, *C. fructus*, *C. glabrata*, *C. fermentati*, *C. guilliermondii*, *C. haemulonii*, *C. humilis*, *C. insectamens*, *C. insectorum*, *C. intermedia*, *C. jeffresii*, *C. kefir*, *C. keroseneae*, *C. krusei*, *C. lusitaniae*, *C. lyxosophila*, *C. maltose*, *C. marina*, *C. membranifaciens*, *C. mogii*, *C. oleophila*, *C. oregonensis*, *C. parapsilosis*, *C. quercitrusa*, *C. rugose*, *C. sake*, *C. shehatea*, *C. temnochilae*, *C. tenuis*, *C. theae*, *C. tolerans*, *C. tropicalis*, *C. tsuchiyae*, *C. sinolaborantium*, *C. sojae*, *C. subhashii*, *C. viswanathii*, *C. utilis*, *C. ubatubensis*, and/or *C. zemplinina*. Suitably, said *Candida* spp. may be *C. albicans*.

In another embodiment, the pest is a helminth. Said helminth may be one or more selected from the phyla *Annelida*, *Platyhelminthes*, *Nematoda* and/or *Acanthocephala*. In one embodiment, said helminth is a parasitic flatworm. Said parasitic flatworm may be one or more selected from a *Cestoda*, a *Trematoda* and/or a *Monogenea*. In one embodiment, said helminth is a parasitic nematode. Said parasitic nematode may be one or more selected an

ascarid (*Ascaris*), a filaria, a hookworm, a pinworm (*Enterobius*), and/or a whipworm (*Trichuris trichiura*).

In one embodiment, the pest is a bloodborne parasite. Said bloodborne parasite may be one or more selected from *Trypanosoma* Spp (e.g. *Trypanosoma brucei* and/or *T. cruzi*), *Babesia* Spp (e.g. *Babesia microti*), *Leishmania* Spp, *Plasmodium* Spp (e.g. *P. falciparum*), and/or *Toxoplasma* Spp. (e.g. *Toxoplasma gondii*).

The PVC Needle Complex for pest control is suitably environmentally safe (e.g. an environmentally safe pesticidal composition).

Other advantageous utilities include delivering a payload to a cell, for example, during laboratory research. Such cell may be part of an *in vitro* cell line, or may be a cell of an animal (e.g. a research animal model). Additionally or alternatively, the cell may be comprised within an *ex vivo* system, such as an organoid.

Another aspect of the invention provides an *in vitro* (and/or *ex vivo*) method for delivering a payload into a cell, the method comprising:

- a. contacting a cell with a (packaged) PVC Needle Complex comprising (e.g. holding/ packaged with) an effector fusion;
- b. wherein the effector fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said effector fusion is formed by a PVC effector leader sequence and a payload);
- c. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- d. wherein the effector fusion is distinct from a wild-type PVC effector protein.

An aspect of the invention provides an *in vitro* (and/or *ex vivo*) method for delivering a payload into a cell, the method comprising:

- a. contacting a cell with a (packaged) PVC Needle Complex holding (e.g. packaged with) a fusion;
- b. wherein the fusion comprises (or consists essentially of) a PVC effector leader sequence fused to a payload (or in other words, wherein said fusion is formed by a PVC effector leader sequence and a payload);
- c. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- d. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

In one aspect, the invention provides an effector fusion comprising (or consisting essentially of) a PVC effector leader sequence fused to a payload (or in other words, an effector fusion formed by a PVC effector leader sequence and a payload);

- a. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
- b. wherein the effector fusion is distinct from a wild-type PVC effector protein.

An aspect of the invention provides a fusion comprising (or consisting essentially of) a PVC effector leader sequence fused to a payload (or in other words, a fusion formed by a PVC effector leader sequence and a payload);

- a. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof (preferably a polypeptide); and
- b. wherein the fusion is distinct from a PVC effector protein (e.g. wild-type PVC effector protein).

In one embodiment, the fusion/ effector fusion is an isolated fusion/ effector fusion (e.g. an isolated, non-naturally occurring fusion/ effector fusion).

The present invention embraces a nucleic acid comprising a nucleotide sequence which encodes the fusion/ effector fusion, and/or an expression vector comprising said nucleic acid. Also embraced is a host cell comprising said nucleic acid and/or expression vector.

As discussed above, the present inventors have discovered and practically utilised the leader sequence(s) described herein for the first time.

Thus, another aspect of the invention provides an isolated PVC effector leader sequence (e.g. wherein the isolated PVC effector leader sequence is capable of packaging a payload into a PVC Needle Complex).

In a related aspect there is provided an isolated nucleic acid comprising a nucleotide sequence which encodes a PVC effector leader sequence.

The isolated PVC effector leader sequence may be recombinant, synthetic, and/or purified. The isolated nucleic encoding a PVC effector leader sequence may be recombinant, synthetic, and/or purified.

Further details on the background of the invention, and terminology used herein, is provided below.

Photorhabdus is a bacterium of the genus Enterobacteriaceae, represented by three formally recognized (to date) species – namely *P. luminescens*, *P. asymbiotica*, and *P. temperata*. Important strains include *P. asymbiotica* subsp. *australis*, and *P. luminescens* subsp. *laumondii*. Currently available genome sequences are available on GenBank (*Photorhabdus asymbiotica* ATCC43949 complete genome – GenBank Accession Number: FM162591.1; *Photorhabdus laumondii* subsp. *laumondii* strain TT01 chromosome, complete genome – GenBank Accession number: CP024901.1).

Reference to “*Photorhabdus luminescens* subsp. *laumondii*” may be used interchangeably with “*Photorhabdus luminescens* subsp. *laumondii* TT01”, “*Photorhabdus laumondii* subsp. *laumondii* strain TT01” and “*P. luminescens* TT01” herein.

The genome sequence for a further strain of *P. asymbiotica*, namely *P. asymbiotica* Kingscliff, is described in Wilkinson *et. al.* (FEMS Microbiology Letters, Volume 309, Issue 2, August 2010, Pages 136–143), incorporated herein by reference. Further genome

sequences are described in Thanwisai *et. al.* (PLoS ONE 7(9): e43835), incorporated herein by reference.

Each of these species comprise at least one operon known as a *Photorhabdus* Virulence Cassette (PVC) operon, encoding a PVC Needle Complex, which may be referred to as a “nanosyringe” herein. Given that *Photorhabdus* is typically found in nature as an insecticidal bacterium following regurgitation from a (symbiont) entomopathogenic *Heterorhabditis* sp. nematode (e.g. in order to avoid competition for food and resources from insects), it is understood that the PVC Needle Complex functions in nature to suppress insects. Indeed, it has been shown that an isolated PVC Needle Complex (holding/ packaged with a natural effector toxin, such as Pnf) can be used to kill insect larvae – see Example 2. The *Photorhabdus* Virulence Cassettes represent one of at least four well-characterised toxin delivery systems of *Photorhabdus*. Other major classes of *Photorhabdus* protein insecticidal toxins include the “Toxin Complexes” (Tcs), the “binary PirAB toxins”, and the “makes caterpillars floppy” (Mcf) toxins.

The term “*Photorhabdus* Virulence Cassette” (PVC) (used synonymously with the term “PVC operon” herein) means a discrete operon of a *Photorhabdus* genome comprising genes encoding for polypeptide subunits which, when expressed, assemble to provide the macromolecular PVC Needle Complex. The molecular architecture of these cassettes have been well characterized and described, for example in The Molecular Biology of *Photorhabdus* Bacteria (Springer International Publishing AG 2017, ISBN: 978-3-319-52714-7, Chapter 10, pages 159-177), incorporated herein by reference. A PVC (operon) typically comprises around sixteen genes (*pvc1-pvc16*) encoding structural proteins which assemble to provide a “PVC Needle Complex”, which are typically followed by one or more genes at the 3’ end which encode PVC effector genes, having toxic activity (and typically being homologues of typical T3SS-like effectors). A *Photorhabdus* genome typically comprises a plurality of such cassettes (e.g. at least four), which are often associated with different effector payloads, or even a plurality of effector payloads.

Three classes of PVC structural operons (Classes I, II and III) have been observed in the genomes of *Photorhabdus*, and members of other genera. PVCs within each class are similar in terms of the number and type of genes encoding structural proteins they contain (see Figure 1(B)). In more detail, Class I PVCs (which may be referred to as a “prototypical PVC” herein) comprise 16 conserved genes (*pvc1-16*). Class II lack *pvc13* host cell binding fibres and *pvc3*, which (without wishing to be bound by theory) the inventors believe may be a minor specialised sheath subunit that attaches *pvc13* fibre proteins onto the PVC Needle Complex (nanosyringe). As such, it is believed this class may be “non-specific”, injecting payloads into multiple (potential any) cell types. Class III is similar to Class I, but has an additional *Pvc0* gene at the start of the operon (of unknown function) and two additional genes encoded between *pvc13* and *pvc14* that resemble “invasion” type protein genes. This class is typically seen in the human clinical isolate strains of *Photorhabdus* – the inventors have shown that optimal transcription of PVC Class III may occur when the strain (harboring the PVC operon encoding a PVC Class III operon) is grown at 37°C and exposed to human serum, suggesting this class may be a mammalian adapted version of a PVC Needle Complex.

An example cassette (PVC) is shown in Figure 1(D), which shows a map of the model “Class I” PVC operon of *Photorhabdus asymbiotica* ATCC43949 (obtainable from the ATCC, accession number: ATCC 43949), said operon being associated with the downstream effector gene “PAU_03332” (encoding a Pnf protein effector, e.g. SEQ ID NO.: 32). This model operon is referred to as *Pa*^{ATCC43949} PVC_{pnf}. This operon comprises sixteen structural genes (*pvc1-16*), and two genes (3' end) encoding effectors (in this case the *pvc17* / Rhs-like, encoding an Rhs-like effector, and *pvc21*, encoding a Pnf effector). Said genes *pvc1-16* correspond to genes PAU_03353 to PAU_03338 of the sequence of GenBank accession no. FM162591.1, and are represented by the sequence of SEQ ID NO.: 93.

An example PVC operon (e.g. encoding the structural genes, but not a/the PVC effector) is provided in SEQ ID NO: 93 (which encodes the operon shown schematically in Figure 1(D)), with other examples being SEQ ID NO: 94 and in SEQ ID NO: 95. These sequences begin at the ATG start codon of the first structural gene (*pvc1*) of the PVC cassette / operon, and end at the TAA stop codon of the final structural gene (*pvc16*).

A PVC Needle Complex from any one of Classes I-III may be used for a variety of applications. However, PVC Needle Complexes of a certain class may be particularly suitable for delivery to a defined cell type. For example, a PVC Needle Complex for delivery of a payload to a mammalian cell may suitably be a member of Class III. A PVC Needle Complex for delivery of a payload to an insect cell (e.g. to an insect) may suitably be a member of Class I (such as *P. asymbiotica* PVC_{pnf}, encoded by SEQ ID NO.: 93, e.g. as expressed in *E. coli* from a cosmid clone).

Thus, as will be understood by the skilled person, the term “PVC Needle Complex” (used synonymously with the terms “PVC Needle Complex delivery system” and “nanosyringe” herein) means a macromolecular protein complex comprising polypeptide subunits encoded by a PVC (operon) of a *Photorhabdus* bacterium. A PVC Needle Complex is assembled in a nanosyringe structure, having a physical structure (superficially) similar to the antibacterial R-type pyocins (see Figure 3). Functional and molecular studies have shown that a PVC Needle Complex becomes packaged (loaded) with a PVC effector protein(s) (i.e. the PVC effector proteins are packaged therein, or thereon), the packaged PVC Needle Complex is released from the bacterium, and then injects the PVC effector into a target cell such that the PVC effector protein may exert toxicity.

The term “PVC Needle Complex” preferably encompasses PVC Needle Complex-like structures/complexes, encoded by operon(s) comprising genes which are homologous to genes of a *Photorhabdus* PVC operon. PVC-like elements are not restricted to *Photorhabdus*, and a well characterized homologous operon (to a PVC operon) is present on the pADAP plasmid of the insect pathogenic bacteria *Serratia entomophila*. Furthermore, an analogous, and (at least partially) homologous, PVC-like ‘injectosome’ Needle Complex system is employed by the bacterium *Pseudoalteromonas luteoviolacea* (e.g. used to control the metamorphosis of the marine worm *Hydroides elegans*). Structures exist in other Enterobacteriaceae (such as *Yersinia* Spp.) which are encoded by operons having homology to a PVC operon, and may be used with a leader sequence described herein. Each of these (PVC-like) structures are embraced by the term “PVC Needle Complex” as used herein.

Thus, a PVC Needle Complex is a “nanosyringe” complex, with the polypeptide encoded by the effector gene being packaged (loaded) within, or at the end (tip) of, the PVC Needle Complex, thus representing a “payload” or “warhead” of the PVC Needle Complex. The present inventors have demonstrated that the PVC Needle Complex itself (with the payload still loaded) is freely released (e.g. secreted) from *Photorhabdus* cells, before interacting with the membrane of a target cell and injecting the payload into the cell’s cytosol. Indeed, the inventors have successfully expressed and loaded PVC Needle Complexes in heterologous expression systems, before isolating/ purifying the PVC Needle Complexes and using them to suppress (e.g. kill) insect larvae (see Example 2). Thus, the PVC Needle Complexes act as long-range protein delivery systems.

In one embodiment, the PVC Needle Complex is encoded by a sequence having at least 75% sequence identity (preferably at least 85% sequence identity; more preferably at least 95% sequence identity) to a sequence selected from SEQ ID NO.: 93, SEQ ID NO.: 94, and SEQ ID NO.: 95 (for example, SEQ ID NO.: 93).

In one embodiment, the PVC Needle Complex is encoded by a sequence selected from SEQ ID NO.: 93, SEQ ID NO.: 94, and SEQ ID NO.: 95 (for example, SEQ ID NO.: 93).

Leader/ signal sequences are typically peptides, often of 10-30 amino acids long present at the N-terminus of the majority of (newly) expressed proteins that are destined towards the secretory pathway (e.g. for directing said proteins to a protein-conducting channel on the cell membrane). Many proteins require a signal sequence for Golgi or endoplasmic reticulum entry.

The term “leader sequence” (used interchangeably with the terms “leader peptide”, “signal sequence”, “targeting signal”, “localization signal”, “localization sequence”, and “transit peptide” herein), used in the context of a “PVC effector leader sequence” herein, means a polypeptide sequence which functions to direct the PVC effector into the interior, or the end (tip), of a PVC Needle Complex – as such, the leader sequence functions to package a PVC effector into a PVC Needle Complex. The PVC Needle Complex can subsequently deliver (e.g. inject) the PVC effector into a target cell. The PVC Needle Complex may be an assembled PVC Needle Complex. The term “PVC Needle Complex” may refer to a fragment of a PVC Needle Complex (e.g. wherein the leader sequence contacts said fragment, and optionally the PVC Needle Complex assembles around the leader sequence-payload ‘effector fusion’).

A PVC leader sequence is typically present in the N-terminus (characterized by or encompassed within the first 50 amino acids) of a PVC effector or homologue thereof. However, the invention embraces leader sequences of PVC effectors and PVC effector homologues, which may be found in regions other than the N-terminal region of such PVC effectors/ homologues (e.g. in the C-terminal region).

In one embodiment, the leader sequence comprises (or consists essentially of) amino acid residues 1-50 of a PVC effector (e.g. PVC effector protein). Reference to “amino acid residues 1-50” embraces “amino acid residues 2-50”, wherein the N-terminal methionine is omitted e.g. has been cleaved. The leader sequence may be a fragment of the N-terminal

50 amino acids of a PVC effector (e.g. a fragment comprising or consisting essentially of ≤ 45 , ≤ 35 , ≤ 25 , or ≤ 15 amino acids), with the proviso that the fragment is capable of packaging a payload into a PVC Needle Complex.

- 5 In one embodiment, a leader sequence (e.g. isolated leader sequence) of the invention comprises (or consists essentially of) an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% sequence identity to one or more sequence selected from SEQ ID NO.: 47 - SEQ ID NO.: 92 (preferably SEQ ID NO.: 50, SEQ ID NO.: 68, SEQ ID NO.: 71, SEQ ID NO.: 76, SEQ ID NO.: 78, or SEQ ID NO.: 92) – e.g.
- 10 with the proviso that the leader sequence is capable of packaging a payload into a PVC Needle Complex. In a preferable embodiment, a leader sequence comprises (or consists essentially of) an amino acid sequence having at least 60% sequence identity to one or more sequence selected from SEQ ID NO.: 47 - SEQ ID NO.: 92 (preferably SEQ ID NO.: 50, SEQ ID NO.: 68, SEQ ID NO.: 71, SEQ ID NO.: 76, SEQ ID NO.: 78, or SEQ ID NO.: 92) – e.g.
- 15 with the proviso that the leader sequence is capable of packaging a payload into a PVC Needle Complex. In a more preferable embodiment, a leader sequence comprises (or consists essentially of) an amino acid sequence of one or more selected from SEQ ID NO.: 47 - SEQ ID NO.: 92 (preferably SEQ ID NO.: 50, SEQ ID NO.: 68, SEQ ID NO.: 71, SEQ ID NO.: 76, SEQ ID NO.: 78, or SEQ ID NO.: 92). In one embodiment, a leader sequence
- 20 comprises (or consists essentially of) an amino acid sequence selected from SEQ ID NO.: 47 - SEQ ID NO.: 92 (preferably SEQ ID NO.: 50, SEQ ID NO.: 68, SEQ ID NO.: 71, SEQ ID NO.: 76, SEQ ID NO.: 78, or SEQ ID NO.: 92).

In one embodiment, a leader sequence comprises (or consists essentially of) an amino acid sequence selected from SEQ ID NO.: 50, SEQ ID NO.: 68, SEQ ID NO.: 71, SEQ ID NO.: 76, SEQ ID NO.: 78, and SEQ ID NO.: 92.

In one embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 50. In one embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 68. In one embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 71. In one embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 76. In one embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 78. In one

30

35 embodiment, the leader sequence comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 92.

Without wishing to be bound by theory, it is believed that the leader sequences share a “chemical composition consensus”, based on amino acid properties. More particularly, the leader sequences comprise similar charge patterns, the pattern comprising 2x negatively charged regions, each followed by a positively charged region (e.g. [-ve] [+ve] [-ve] [+ve]) – see Figure 9. This is consistent with leader sequences of toxins of the type 2 secretion system, which comprise a charge / property pattern of [+ve] [Hydrophobic] [+ve] [C]. A further theory posits that the leader sequences share a typical “helix-turn-helix” structure.

40

45 Another theory is that the leader sequences form a structure recognised by an ATPase enzyme (e.g. encoded by the gene PAU_03339 (*pvc15*) in the model operon of Figure 1(D)) present in the interior, or at the end (e.g. tip), of a PVC Needle Complex.

The term “PVC effector” (used synonymously with the term “PVC operon-encoded effector”, and “PVC effector protein”) means an effector polypeptide encoded by a *Photorhabdus* PVC operon, more particularly (and typically) found shortly downstream (3') of the structural genes of said operon (preferably shortly or immediately downstream of *pvc16*, and typically within 5kb). The term “PVC effector” preferably embraces homologues thereof. Thus, the leader sequence may also be from a polypeptide encoded by a gene which is a homologue of gene encoding a PVC effector – see Table 1 for examples of such homologues. Indeed, identification of PVC effectors is aided by detecting homology of a gene downstream of *pvc16* with a known toxin polypeptide (e.g. a gene which encodes said toxin polypeptide). As will be understood by the skilled person, the term “homologue” preferably means a gene that descended from the same ancestral gene, and shares similar function – such gene (or polypeptide encoded thereby) is homologous to a gene encoding the PVC effector. A homologue may be from the genome of a *Photorhabdus* species or from a species other than a *Photorhabdus* species. Examples of suitable homologues are outlined in Table 1.

The present inventors have elucidated and characterised, in detail, genes that encode PVC effectors of these PVC Needle Complexes in the three most common (best characterised) strains of *Photorhabdus*, as well as the *P. asymbiotica* Thai strain PB68.1. This was conducted based on analysing proximity of genetic linkage to the 3' end of the PVC structural genes of the operons, and predicted function of the protein sequence of the effector (e.g. a homologue of a known effector/ toxin protein). In more detail, the PVC effectors (e.g. genes encoding the PVC effectors) were typically identified as open reading frames (ORF) having homology to genes encoding known toxin polypeptides (e.g. homologues as outlined in Table 1), and being typically present within a distance of 1 kilobase to 5 kilobase (kb) (e.g. within 1 kb) downstream of the final structural gene of a PVC operon (e.g. *pvc16*) (typically with few or no intervening genes). Typically, there are no “non-toxin-like” ORFs between the end of the operon (encoding the PVC Needle Complex) and the PVC effector gene(s). Although there may be (e.g. one, or two) other small predicted genes present in these regions, these other genes are not assigned as PVC effectors (due to lack of homology to a known effector/ toxin gene, as described above).

In order to assign a putative PVC effector gene (e.g. ORF within a distance of 5kb, for example within 1kb downstream of the final structural gene of a PVC operon) as a PVC effector gene, the inventors used a combination of BlastP and HHPRED (<https://toolkit.tuebingen.mpg.de/#/tools/hhpred>). Putative PVC effector genes were assigned as PVC effector genes based on direct homology to known toxin encoding genes, similarity to a toxin protein family, proximity to the PVC operon (e.g. within 1-5kb downstream of the final structural gene of a PVC operon, *pvc16*) and/or based on domain similarities of predicted secondary structures to that of known toxins.

Thus, a PVC effector (gene) may be identified (within a *Photorhabdus* genome) by (i) identifying *pvc16* (e.g. via sequence homology to a known *pvc16*), (ii) identifying an ORF 3' to *pvc16*, preferably ≤5kb downstream of *pvc16*, and (iii) confirming said ORF encodes a PVC effector through identification of sequence homology to a known gene encoding a toxin polypeptide (for example, a toxin protein described in the column of Table 1 labelled “Homologue(s)”).

By way of example, the PVC effector gene PAU_03337 (referred to herein as “*sepC*” due to homology to virulent *sep* genes) is positioned 325 base pairs (bp) downstream of *pvc16* (PAU_03338) of the PVC operon referred to herein as *PVCpnf* (e.g. of SEQ ID NO. 93), which is found in *P. asymbiotica* ATCC43949. That is, the start codon of PAU_03337 begins 325 bp downstream of the end of the stop codon of PAU_03338.

This can be illustrated by reference to the *P. asymbiotica* ATCC43949 complete genome, accessible via GenBank accession no. FM162591.1 (see also e.g. Wilkinson *et al*, BMC Genomics volume 10, article number: 302 (2009), incorporated herein by reference), in which effector gene PAU_03337 is annotated as being positioned in the genome as follows: complement (3913237..3914247) – that is, at nucleotide positions 3913237..3914247; and PAU_03338 is annotated as being positioned in the genome as follows: complement (3914573..3915454). No other ORF (encoding an effector or otherwise) is found between these two genes.

A further PVC effector gene associated with the PVC operon referred to herein as *PVCpnf* (e.g. of SEQ ID NO. 93), namely PAU_03332 (referred to herein as “*pnf*”), is positioned 3535bp downstream of *pvc16* (PAU_03338).

The PVC effector gene PAU_02095 (referred to herein as “*Rhs-like toxin effector*” due to homology to virulent *Rhs* toxin genes) is positioned 3961bp downstream of *pvc16* (PAU_02099) of a PVC operon referred to herein as *PVClopT* (e.g. of SEQ ID NO. 94), which is found in *P. asymbiotica* ATCC43949. That is, the start codon of PAU_02095 begins 3961bp downstream of the end of the stop codon of PAU_02099.

In a further example, the PVC effector of gene PAU_02009 (referred to as “*cif*” herein due to predicted function as a cell cycle inhibiting factor/ ATP/GTP binding protein) is positioned 157bp downstream of *pvc16* (PAU_02008) of the associated PVC operon, referred to herein as *PVCcif*, found in *P. asymbiotica* ATCC43949.

In yet further examples: with regard to a PVC operon of *P. luminescens* TT01 referred to as a *PVCunit4* operon herein, PVC effector gene “*pvc17*” (e.g. “*plu1651*”) is positioned 104bp downstream of *pvc16* (gene “*plu1655*”); and with regard to a PVC operon of *Photorhabdus temperata* subsp. *temperata* Meg1 referred to as a *PVCcif* operon herein, PVC effector gene “CIF toxin effector” (e.g. MEG1DRAFT_03529) is positioned 4216bp downstream of the relevant *pvc16* gene.

These examples, illustrate that a gene encoding a PVC effector is typically positioned within a distance of ≤ 5 kb downstream of the final gene of a PVC operon (e.g. of *pvc16*), more typically within a distance of ≤ 1 kb downstream of the final gene of a PVC operon.

In summary, there exists 46 PVC effectors that have been identified in these four strains (based on currently available sequence data) (see Table 1). The first 50 amino acids of each of these PVC effectors represent (or encompass) their endogenous leader sequence, and the inventors have demonstrated the leader sequences may be cloned and fused to a variety of payloads to be packaged into a PVC Needle Complex – see Examples 3 and 4. Thus, a PVC effector (as translated) comprises at least two principle domains: the leader sequence

(amino acids 1 to 50) and the actual effector polypeptide (amino acids 51 to C-terminal amino acid) - the latter of which may be referred to as the “effector” (e.g. “effector portion”) or “payload” herein.

- 5 Although the *Photorhabdus* genome sequence(s) continues to be revised, this consolidated list of PVC effector genes represents a comprehensive description of such effectors, and is based on currently available sequence data of the most common (best characterised) *Photorhabdus* strains, and provides the skilled person with an understanding of the term “PVC effector” as well as the sequences of these PVC effectors (as well as how to
- 10 search/mine for further PVC effectors, e.g. in alternative (genome) sequences). As described above, the inventors have found that the PVC effector proteins comprise a leader sequence which is necessary (and sufficient) for directing the PVC effector protein (e.g. payload) to be packaged/ loaded into a PVC Needle Complex.

15 Table 1

Gene (Locus Tag)	Predicted Function	Accession No. (polypeptide sequence)	Homologue(s)	SEQ ID NO.:
PAK_1985	Cell cycle inhibiting factor / ATP/GTP binding protein.	WP_036768136	Cif type III effector	1
PAK_1987	Cytidine deaminase toxin-like.	WP_036768135	YwqJ family	2
PAK_1988	RHS repeat toxin like / Cholera enterotoxin (A chain) ADP Ribosyltransferase like	WP_036768134	RHS repeat-protein	3
PAK_2075	CNF; cytotoxic necrotizing factor (zinc metallo-peptidase) / Neurotoxin A; botulinum	WP_036768069 (exemplary, not 100% identical)	CNF1 family	4
PAK_2077	LopT cysteine proteinase (peptidase C58 family).	WP_036768068	YopT type III effector from <i>Yersinia</i> .	5
PAK_2892	Pvc17; putative nematode symbiosis protein	WP_065822933 (exemplary, not 100% identical)	n/a	6
PAK_2893	Similar to Type III secretion protein GogB	WP_065822917 (exemplary, not 100% identical)	GogB type III effector from <i>Salmonella</i> .	7
PAK_2894	RHS-repeat protein. Function unknown.	WP_036774164	RHS-repeat protein.	8
PAK_3525	CNF/PaTox domain like tyrosine glycosylase UDP-GlcNAc	WP_036768627.1 (exemplary, not 100% identical)	PaTox from <i>Photorhabdus asymbiotica</i> ATCC43949	9
PAT_00148	Cif-like; Cell cycle inhibiting factor / ATP/GTP binding protein.	WP_065823029	Cif type III effector	10
PAT_00149	YwqJ -Cytidine deaminase toxin-like.	WP_065823017.1	YwqJ family	11
PAT_00150	RHS repeat toxin like / Cholera enterotoxin (A chain) ADP	WP_065823018.1	RHS repeat protein	12

	Ribosyltransferase like			
PAT_00152	Domain similar to Colicin A and Glucosyl Transferase	WP_065823019	n/a	13
PAT_02308	Pvc17; putative nematode symbiosis protein	WP_065822933	n/a	14
PAT_02309	Similar to Type III secretion protein GogB	WP_065822917	GogB type III effector from Salmonella.	15
PAT_02310	RHS-repeat protein. Function unknown.	WP_065822916	RHS repeat protein	16
PAT_02956	cytotoxic necrotizing factor (zinc metalloproteinase) / Neurotoxin A; botulinum	WP_065822174	CNF1 family	17
PAT_02957	LopT cysteine proteinase (peptidase C58 family). Similar to YopT type III toxin of Yersinia.	WP_065822175	YopT type III effector from Yersinia.	18
PAT_03171	YwqJ-Cytidine deaminase toxin-like.	WP_065823264	YwqJ family	19
PAT_03172	Cytotoxic necrotizing factor 1, Rho deamidase	WP_065823265	CNF1 family	20
PAT_03177	Calmodulin-sensitive adenylate cyclase	WP_065823268	CyaA family	21
PAU_02009	Cif-like; Cell cycle inhibiting factor / ATP/GTP binding protein.	CAQ84101	Cif type III effector	22
PAU_02010	TccC3 / RHS repeat toxin like.	CAQ84102	RHS repeat protein	23
PAU_02095	TccC2 / RHS repeat toxin like. Neutral metalloproteinase II.	CAQ84187	RHS repeat protein	24
PAU_02096	LopT cysteine proteinase (peptidase C58 family). Similar to YopT type III toxin of Yersinia.	CAQ84188	YopT type III effector from Yersinia.	25
PAU_02097	RHS-repeat protein. Function unknown.	CAQ84189	RHS repeat protein	26
PAU_02098	Dermonecrotic toxin; Pasteurella multocida toxin-like / RtxA-like (Glucosyltransferase)	CAQ84190	RtxA family from Vibrio	27
PAU_2230	PaTox; tyrosine glycosylase and cysteine protease domains.	CAQ84322	Type III effector SseI from Salmonella	28
PAU_02805	Pvc17; putative nematode symbiosis protein	CAQ84177	n/a	29
PAU_02806	Similar to Type III secretion protein GogB	CAQ84895	GogB type III effector from Salmonella.	30
PAU_02807	Similar to Type III secretion protein GogB	CAQ84179	GogB type III effector from Salmonella.	31
PAU_03332	Pnf; Rho GTPase deaminidase and transglutination.	CAQ85420	CNF1 family from <i>E. coli</i>	32

PAU_03337	CyaA-like; Adenylylcyclase toxin (anthrax EF-like).	CAQ85425	Anthrax Edema Factor, <i>Pseudomonas</i> ExoY toxin	33
Plu1651	Pvc17. Putative nematode symbiosis protein. Induces endotokia matricida in <i>C. elegans</i> (experimental)	WP_011145938	n/a	34
Plu1671	RHS repeat toxin like. ADP-ribosyltransferase	WP_011145957	RHS repeat protein	35
Plu1672	RHS repeat toxin like. ADP-ribosyltransferase	WP_011145958	RHS repeat protein	36
Plu1690 / PLU_RS08490	RHS repeat toxin like. Rho deamidase	WP_011145974	RHS repeat protein	37
Plu1691	RHS repeat toxin like. ADP-ribosyltransferase	WP_011145975	RHS repeat protein	38
Plu1712	CyaA calmodulin-sensitive adenylate cyclase like.	WP_011145994	CyaA family	39
Plu1713	Weak similarity to Diphtheria toxin catalytic domain.	WP_011145995	n/a	40
Plu1714	RHS repeat toxin like. Neutral metallo-proteinase II.	WP_041380028	RHS repeat protein	41
Plu2400	Dermonecrotic toxin-like; Pasteurella multocida toxin-like / RtxA-like Glucosyltransferase.	WP_011146635	RtxA family from Vibrio	42
Plu2401	LopT cysteine proteinase (peptidase C58 family). Similar to YopT type III toxin of Yersinia.	WP_011146636	YopT type III effector from Yersinia.	43
Plu2514	Similar to <i>Xenorhabdus</i> Mcf-domain / weak acid phosphatase.	WP_011146737	n/a	44
Plu2515	Cif-like; Cell cycle inhibiting factor / ATP/GTP binding protein.	WP_011146738	Cif type III effector	45
Plu1649	N-acyl homoserine lactonase like	WP_133148775	Weak similarity to HvnA of Vibrio	46

The accession numbers provided in Table 1 are provided for exemplary purposes, providing example amino acid sequences of (or having high similarity to) PVC effectors described herein. The sequences of said accession numbers may be accessed through GenBank

5

The locus tag (beginning with “PAU” or “Plu”) corresponds to the locus tag assigned to the effector in genome sequences available through GenBank above. Locus tags beginning with “PAT” (referring to strain *P. asymbiotica* Thai strain PB68.1) and “PAK” (referring to strain *P. asymbiotica* Kingscliff) have been assigned by the present inventors upon identification of the PVC effector genes within the genomes of said strains (in a consistent manner with the locus tags of publicly available sequences).

10

This locus tags may be used herein to refer to the corresponding PVC effector polypeptide.

In one embodiment, the PVC effector is encoded by one or more gene (with the SEQ ID NO. of the encoded PVC effector protein in parentheses) selected from PAK_1985 (SEQ ID NO: 1), PAK_1987 (SEQ ID NO: 2), PAK_1988 (SEQ ID NO: 3), PAK_2075 (SEQ ID NO: 4), PAK_2077 (SEQ ID NO: 5), PAK_2892 (SEQ ID NO: 6), PAK_2893 (SEQ ID NO: 7), PAK_2894 (SEQ ID NO: 8), PAK_3525 (SEQ ID NO: 9), PAT_00148 (SEQ ID NO: 10), PAT_00149 (SEQ ID NO: 11), PAT_00150 (SEQ ID NO: 12), PAT_00152 (SEQ ID NO: 13), PAT_02308 (SEQ ID NO: 14), PAT_02309 (SEQ ID NO: 15), PAT_02310 (SEQ ID NO: 16), PAT_02956 (SEQ ID NO: 17), PAT_02957 (SEQ ID NO: 18), PAT_03171 (SEQ ID NO: 19), PAT_03172 (SEQ ID NO: 20), PAT_03177 (SEQ ID NO: 21), PAU_02009 (SEQ ID NO: 22), PAU_02010 (SEQ ID NO: 23), PAU_02095 (SEQ ID NO: 24), PAU_02096 (SEQ ID NO: 25), PAU_02097 (SEQ ID NO: 26), PAU_02098 (SEQ ID NO: 27), PAU_02230 (SEQ ID NO: 28), PAU_02805 (SEQ ID NO: 29), PAU_02806 (SEQ ID NO: 30), PAU_02807 (SEQ ID NO: 31), PAU_03332 (SEQ ID NO: 32), PAU_03337 (SEQ ID NO: 33), Plu1651 (SEQ ID NO: 34), Plu1671 (SEQ ID NO: 35), Plu1672 (SEQ ID NO: 36), Plu1690 (SEQ ID NO: 37), Plu1691 (SEQ ID NO: 38), Plu1712 (SEQ ID NO: 39), Plu1713 (SEQ ID NO: 40), Plu1714 (SEQ ID NO: 41), Plu2400 (SEQ ID NO: 42), Plu2401 (SEQ ID NO: 43), Plu2514 (SEQ ID NO: 44), Plu2515 (SEQ ID NO: 45), Plu1649 (SEQ ID NO: 46), or a combination thereof.

In one embodiment, the PVC effector is encoded by one or more gene (with the SEQ ID NO. of the encoded PVC effector protein in parentheses) selected from PAU_02009 (SEQ ID NO: 22), PAU_02010 (SEQ ID NO: 23), PAU_02095 (SEQ ID NO: 24), PAU_02096 (SEQ ID NO: 25), PAU_02097 (SEQ ID NO: 26), PAU_02098 (SEQ ID NO: 27), PAU_02230 (SEQ ID NO: 28), PAU_02805 (SEQ ID NO: 29), PAU_02806 (SEQ ID NO: 30), PAU_02807 (SEQ ID NO: 31), PAU_03332 (SEQ ID NO: 32), PAU_03337 (SEQ ID NO: 33), Plu1651 (SEQ ID NO: 34), Plu1671 (SEQ ID NO: 35), Plu1672 (SEQ ID NO: 36), Plu1690 (SEQ ID NO: 37), Plu1691 (SEQ ID NO: 38), Plu1712 (SEQ ID NO: 39), Plu1713 (SEQ ID NO: 40), Plu1714 (SEQ ID NO: 41), Plu2400 (SEQ ID NO: 42), Plu2401 (SEQ ID NO: 43), Plu2514 (SEQ ID NO: 44), Plu2515 (SEQ ID NO: 45), Plu1649 (SEQ ID NO: 46), or a combination thereof. These gene names correspond to the 'locus tags' of PVC effector genes in the *Photorhabdus* genome sequences accessible via GenBank, as described above. The PAT and PAK locus tags were generated by the present inventors, such that terminology is consistent with the PAU and Plu locus tags of publicly available genome sequences.

Thus, the PVC effector may be encoded by one or more gene listed above.

In one embodiment, the PVC effector is encoded by one or more gene (with the SEQ ID NO. of the encoded PVC effector in parentheses) selected from PAK_02075 (SEQ ID NO: 4), PAU_02009 (SEQ ID NO: 22), PAU_02096 (SEQ ID NO: 25), PAU_02806 (SEQ ID NO: 30), PAU_03332 (SEQ ID NO: 32), Plu1651 (SEQ ID NO: 34), Plu1649 (SEQ ID NO: 46), or a combination thereof.

In a preferable embodiment, the PVC effector is encoded by one or more gene (with the SEQ ID NO. of the encoded PVC effector in parentheses) selected from PAU_02806 (SEQ ID NO: 30), PAU_03332 (SEQ ID NO: 32), Plu1651 (SEQ ID NO: 34), Plu1649 (SEQ ID NO: 46), or a combination thereof.

The PVC effector may have a sequence having at least 80% sequence identity (preferably at least 90% sequence identity; more preferably 100% sequence identity) to an amino acid sequence selected from SEQ ID NO: 1 - SEQ ID NO: 46. For example, the PVC effector may have a sequence having at least 80% sequence identity (preferably at least 90% sequence identity; more preferably 100% sequence identity) to an amino acid sequence selected from SEQ ID NO: 22 - SEQ ID NO: 46.

The present inventors have identified the leader sequences of the *gogB1* (PAU_02806) and *Pnf* (PAU_03332) PVC effectors as being particularly efficient at packaging a (fused) payload into a PVC Needle Complex. In one embodiment, the PVC effector is encoded by PAU_02806 (e.g. has an amino acid sequence of SEQ ID NO: 30). In one embodiment, the PVC effector is encoded by PAU_03332 (e.g. has an amino acid sequence of SEQ ID NO: 32).

In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of one or more selected from SEQ ID NO: 1 - SEQ ID NO: 46 (for example SEQ ID NO: 22 - SEQ ID NO: 46), or a combination thereof. For example, the PVC effector may comprise (or consist essentially of) a sequence selected from SEQ ID NO: 4, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 46.

In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO.: 4. In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO. 22. In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO. 25. In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO: 30. In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO: 32. In one embodiment, the PVC effector comprises (or consists essentially of) an amino acid sequence of SEQ ID NO. 46.

The term “packaging” (used synonymously with the terms “trans-packaging” and “loading”) means the directing of a payload, by a leader sequence of the invention (to which the payload is linked/ fused), into the interior, or end (tip), of an assembled PVC Needle Complex, such that the PVC Needle Complex is subsequently configured for delivering (e.g. injecting) the payload into a target cell. Thus, the payload may be packaged within a PVC Needle Complex, or may be packaged at the end (or tip) of the PVC Needle Complex (e.g. at least a portion of the payload may be external to the PVC Needle Complex).

The term “payload” (used synonymously with the term “warhead” herein) means a molecule which is packaged into the interior, or end (tip), of an assembled PVC Needle Complex, and subsequently delivered (e.g. injected) into a (target) cell. In wild-type *Phototrhhabdus*, the payload is a PVC effector (more particularly, the effector portion of said PVC effector), encoded (as described above) by a gene that is downstream to (3' to) the structural genes of a PVC operon. For example, see model PVC operon of Figure 1(D), having effector genes PAU_03337 (listed as PVCpnf 17), encoding an adenylate cyclase effector (e.g. SEQ ID NO.: 33); and PAU_03332 (listed as PVCpnf 21), encoding a *Pnf* effector (e.g. SEQ ID NO.: 32).

A leader sequence and a payload of the present invention form an “effector fusion” (or simply “fusion”) that is “distinct from a (e.g. wild-type) PVC effector” (e.g. a polypeptide encoded by one of the genes outlined in Table 1). For example, the effector fusion may be a chimaera, formed of a leader sequence from a first PVC effector fused to (an/the effector portion of) a second (different) PVC effector (preferably amino acids 51 to the C-terminal amino acid of said second PVC effector), wherein said first PVC effector and said second PVC effector are different. The effector fusion may be a chimaera, comprising (or consisting essentially of) a leader sequence described herein fused to a non-PVC effector polypeptide. The effector fusion may be a chimaera, comprising (or consisting essentially of) a leader sequence described herein fused to a non-*Photorhabdus* polypeptide. The effector fusion may be a leader sequence-nucleic acid fusion (preferably conjugate), comprising a leader sequence described herein fused to a nucleic acid.

An effector fusion is not limited to a fusion complex comprising a leader sequence fused to a toxic payload (e.g. the leader could be fused to a therapeutic payload). Thus, the term “effector” as used in the context of “effector fusion” means the payload which is packaged into the PVC Needle Complex (which could provide a variety of effects, including toxigenic and/or therapeutic effects). Thus, the term “effector fusion” may be used interchangeably with the term “fusion” herein.

The term “effector fusion” may be used synonymously with the term “leader sequence-payload fusion”, and/or “leader sequence-payload complex”.

Alternatively or additionally, the payload may be distinct from a PVC effector protein (e.g. distinct from amino acids 51 to the C-terminal amino acid of a PVC effector). For example, the payload may be a polypeptide or nucleic acid that is not found in a wild-type *Photorhabdus* bacterium.

Analysis of the size (e.g. polypeptide length) and structure of the various natural PVC effector payloads encoded by *Photorhabdus*, shows that there exists a wide variety of different PVC effector lengths and structures, demonstrating that the applicability of the PVC Needle Complex delivery system of the present invention is not limited by the size or properties of the payload of interest. To summarise, there is no requirement for particular secondary structure, biophysical property, or length of cargoes, confirming that that the PVC Needle Complex can be utilised as a versatile multifunctional delivery vehicle.

The payload may be one or more selected from a polypeptide (e.g. a polypeptide payload), a nucleic acid (e.g. a nucleic acid payload), or a combination thereof. In a preferable embodiment, the payload is a polypeptide.

Examples of polypeptide payloads include an antibody (e.g. an anti-MDM antibody), a nanobody, a peptide vaccine (e.g. a tyrosinase-related protein 2 (TRP2) peptide vaccine), a nuclear factor- κ B inhibitor, a T3SS payload (e.g. a T3SS payload which inhibits the NF- κ B and/or MAPK pathways), an anti-apoptotic peptide (e.g. BH4), nicotinamide adenine dinucleotide quinone internal oxidoreductase (Ndi1), a PHOX complex subunit, a myotubularin, a nucleic acid (preferably DNA)-modifying enzyme, or a combination thereof. Examples of suitable nucleic acid-modifying enzymes include a recombinase (e.g. Cre

recombinase), a transposase, a Cas enzyme (e.g. Cas9), and/or a Mad7 (preferably Mad7, more preferably Cre recombinase). The payload may be, for example, tBid (SEQ ID NO.: 109) and/or BaxBH3 peptide (aa59–73) (SEQ ID NO.: 111).

- 5 Any polypeptide having enzymatic activity may be a payload.

A nucleic acid payload may be conjugated/ crosslinked to a leader sequence of the invention. For example, copper-free click chemistry (e.g. strain-promoted alkyne azide cycloaddition (SPAAC)) may be used to crosslink a nucleic acid to a leader sequence. Examples of
10 nucleic acid payloads include a primer, an mRNA, a nucleic acid analogue, an aptamer, a small interfering RNA (siRNA), a microRNA therapeutic inhibitor (antimiR), a microRNA therapeutic mimic (promiR), a long non-coding RNA modulator, a single guide RNA (sgRNA), or a combination thereof.

- 15 The leader sequence may be fused directly or indirectly (e.g. by means of a spacer) to the payload. The leader sequence may be fused covalently or non-covalently to the payload. In a preferable embodiment, the leader sequence is covalently fused to the payload. For example, the fusion/ effector fusion may be a (recombinant) fusion protein comprising (or
20 consisting essentially of) a PVC effector leader sequence fused to a (polypeptide) payload.

- 25 Another aspect of the invention provides an isolated nucleic acid comprising a nucleotide sequence which encodes a PVC effector leader sequence of the invention. Another aspect of the invention provides an isolated nucleic acid comprising a nucleotide sequence which encodes an effector fusion (e.g. fusion) of the invention, and optionally a nucleotide sequence which encodes a PVC Needle Complex.

- 30 Another aspect of the invention provides an expression vector comprising: a nucleic acid (preferably an isolated nucleic acid) comprising a nucleotide sequence which encodes a PVC effector leader sequence of the invention. Another aspect of the invention provides an expression vector comprising: a nucleic acid (preferably an isolated nucleic acid) comprising a nucleotide sequence which encodes an effector fusion (e.g. fusion) of the invention, and optionally a nucleotide sequence which encodes a PVC Needle Complex.

- 35 Another aspect of the invention provides a host cell comprising an isolated nucleic acid, the isolated nucleic acid comprising a nucleotide sequence which encodes a PVC effector leader sequence of the invention. Another aspect of the invention provides a host cell comprising an isolated nucleic acid, the isolated nucleic acid comprising a nucleotide sequence which encodes an effector fusion (e.g. fusion) of the invention, and optionally a nucleotide sequence which encodes a PVC Needle Complex.

- 40 The term “nucleic acid” may be used synonymously with the term “polynucleotide”.

- 45 Another aspect of the invention provides a host cell comprising an expression vector, the expression vector comprising a nucleotide sequence which encodes a PVC effector leader sequence of the invention. Another aspect of the invention provides a host cell comprising an expression vector, the expression vector comprising a nucleotide sequence which encodes

an effector fusion (e.g. fusion) of the invention, and optionally a nucleotide sequence which encodes a PVC Needle Complex.

5 Said host cell may be a mammalian cell, an insect cell, a yeast cell, a bacterial cell (e.g. *E. coli*), or a plant cell. In a preferable embodiment, the host cell is a bacterial cell (preferably *E. coli*).

10 In one embodiment, the host cell is a *Photorhabdus* cell, optionally wherein the *Photorhabdus* cell comprises a PVC operon operably linked to an inducible promoter (e.g. see Example 3). The PVC operon may be endogenous to the *Photorhabdus* cell (e.g. the PVC operon may be PVCu4). Suitably, the *Photorhabdus* cell may be obtainable from the ATCC under accession no. ATCC 29999.

15 The sequences (e.g. leader sequence and/or nucleic acid sequence) of the present invention include sequences that have been removed from their naturally occurring environment, recombinant or cloned (e.g. DNA) isolates, and chemically synthesized analogues or analogues biologically synthesized by heterologous systems.

20 The leader sequence(s) and/or polynucleotide(s) of the present invention may be prepared by any means known in the art. For example, large amounts of the leader sequence(s) and/or polynucleotide(s) may be produced by replication and/or expression in a suitable host cell. The natural or synthetic DNA fragments coding for a desired fragment will typically be incorporated into recombinant nucleic acid constructs, typically DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the DNA
25 constructs will be suitable for autonomous replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to and integration within the genome of a cultured bacterial, insect, mammalian, plant or other eukaryotic cell lines.

30 The leader sequence(s) and/or polynucleotide(s) of the present invention may also be produced by chemical synthesis, e.g. a polynucleotide by the phosphoramidite method or the tri-ester method, and may be performed on commercial automated oligonucleotide synthesizers. A double-stranded (e.g. DNA) fragment may be obtained from the single stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary
35 strand using DNA polymerase with an appropriate primer sequence.

40 When applied to a leader sequence or nucleic acid sequence, the term "isolated" in the context of the present invention denotes that the leader sequence and/or polynucleotide sequence has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences (but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators), and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment.

SEQUENCE HOMOLOGY

Any of a variety of sequence alignment methods can be used to determine percent identity, including, without limitation, global methods, local methods and hybrid methods, such as, e.g., segment approach methods. Protocols to determine percent identity are routine procedures within the scope of one skilled in the art. Global methods align sequences from the beginning to the end of the molecule and determine the best alignment by adding up scores of individual residue pairs and by imposing gap penalties. Non-limiting methods include, e.g., CLUSTAL W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement, see, e.g., Osamu Gotoh, Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. Mol. Biol. 823-838 (1996). Local methods align sequences by identifying one or more conserved motifs shared by all of the input sequences. Non-limiting methods include, e.g., Match-box, see, e.g., Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501 -509 (1992); Gibbs sampling, see, e.g., C. E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262(5131) Science 208-214 (1993); Align-M, see, e.g., Ivo Van Walle et al., Align-M - A New Algorithm for Multiple Alignment of Highly Divergent Sequences, 20(9) Bioinformatics:1428-1435 (2004).

Thus, percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-16, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-19, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown below (amino acids are indicated by the standard one-letter codes).

The "percent sequence identity" between two or more nucleic acid or amino acid sequences is a function of the number of identical positions shared by the sequences. Thus, % identity may be calculated as the number of identical nucleotides / amino acids divided by the total number of nucleotides / amino acids, multiplied by 100. Calculations of % sequence identity may also take into account the number of gaps, and the length of each gap that needs to be introduced to optimize alignment of two or more sequences. Sequence comparisons and the determination of percent identity between two or more sequences can be carried out using specific mathematical algorithms, such as BLAST, which will be familiar to a skilled person.

ALIGNMENT SCORES FOR DETERMINING SEQUENCE IDENTITY

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
5 N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
10 G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
15 M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5			
20 W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

The percent identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100$$

Substantially homologous polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see below) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag.

40 CONSERVATIVE AMINO ACID SUBSTITUTIONS

Basic: arginine, lysine, histidine

Acidic: glutamic acid, aspartic acid

Polar: glutamine, asparagine

Hydrophobic: leucine, isoleucine, valine

45 Aromatic: phenylalanine, tryptophan, tyrosine

Small: glycine, alanine, serine, threonine, methionine

In addition to the 20 standard amino acids, non-standard amino acids (such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline and α -methyl serine) may be substituted for amino acid residues of the polypeptides of the present invention. A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, and unnatural amino acids may be substituted for polypeptide amino acid residues. The polypeptides of the present invention can also comprise non-naturally occurring amino acid residues.

Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2,4-methano-proline, cis-4-hydroxyproline, trans-4-hydroxy-proline, N-methylglycine, allo-threonine, methyl-threonine, hydroxy-ethylcysteine, hydroxyethylhomo-cysteine, nitro-glutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenyl-alanine, 4-azaphenyl-alanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an in vitro system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell free system comprising an E. coli S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-9, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-9, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. Chem. 271:19991-8, 1996). Within a third method, E. coli cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the polypeptide in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-6, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).

A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for amino acid residues of polypeptides of the present invention.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989). Sites of biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., Science 255:306-12, 1992; Smith et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992. The identities of essential amino acids

can also be inferred from analysis of homologies with related components (e.g. the translocation or protease components) of the polypeptides of the present invention.

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30:10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988).

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30:10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988).

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide the skilled person with a general dictionary of many of the terms used in this disclosure.

This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

The headings provided herein are not limitations of the various aspects or embodiments of this disclosure.

Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation. The term "protein", as used herein, includes proteins, polypeptides, and peptides. As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". In some instances, the

term "amino acid sequence" is synonymous with the term "enzyme". The terms "protein" and "polypeptide" are used interchangeably herein. In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be defined only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an effector" includes a plurality of such effectors and reference to "the effector" includes reference to one or more effectors and equivalents thereof known to those skilled in the art, and so forth.

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention will now be described, by way of example only, with reference to the following Figures and Examples.

Figure 1 shows (A) a schematic representation of one PVC operon layout (gene clusters present in varying regions of the originating genome) encoding a PVC Needle Complex. (B) A schematic representation of Class I, II and III PVC operon layouts. Homologous subunit types amongst the classes are shown as having similar shading (in grey scale). (C) An illustration of an assembled PVC Needle Complex. The numbering shown is used to correlate a gene cluster in (A) with the position of the encoded proteins in the structure in (C) (e.g. the cap '16' cluster in A is shown as '16' in the left-most cap region of (B)). (D) A map of

the model Class I *Pa*ATCC⁴³⁹⁴⁹*PVCpnf* operon (e.g. encoded by SEQ ID NO.: 93), showing two effector genes in the payload region (Rhs-like adenylate cyclase, and PAU_03332).

Figure 2 shows an overview of a cloning procedure for preparation of PVC Needle Complex-expressing plasmids, based on overlapping PCR. PCR fragments (having overlapping regions) are provided from template gDNA of *P. asymbiotica*^{ATCC43949} (available from the ATCC under accession no. ATCC 43949) with relevant primers targeting the PVC operon.

Figure 3 shows a transmission electron micrograph of an (*in vitro*) sample of PVC Needle Complexes (e.g. prepared from cells having the expression vector described above). The PVC Needle Complexes assemble in a distinct 'nanosyringe' structure, consistent with its role as a contractile structure. A 3D rendered model of a PVC Needle Complex as derived from high resolution single particle cryo-EM tomography structure is shown in (B).

Figure 4 shows (A) a transmission electron micrograph of a PVC Needle Complex comprising a Pnf payload following immuno-gold staining with an anti-Pnf (immunogold) antibody, confirming the Pnf-payload toxin is associated with the PVC Needle Complex (referred to as *PVCpnf*). *PVCpnf* Needle Complexes were prepared from supernatants of an *E. coli* cosmid clone, which encodes the *PVCpnf* operon. Anti-peptide antibodies against the Pnf (TGQKPGNNEWKTGR, SEQ ID NO: 96) epitope were used to localise the payload toxin protein. The Pnf toxin could only be detected at the ends of broken or contracted needle complex, providing evidence that the toxins are contained within the complex (arrows). (B) Western blot analysis confirms that the Pnf protein (toxin) can only be detected using the anti-peptide antibody if the PVC Needle Complex is either chemically or physically disrupted. These preparations were taken from *Pa*^{ATCC43949} supernatants. The inability to detect Pnf in clarified supernatants confirms all the protein is associated with the PVC Needle Complex enrichment preparations. Lanes 1+5; sonicated samples, 2+6; 1M NaCl treatments, 3+7; 1% SDS treatments 4+8; 1M Urea treatments. Note the PVC Needle Complex appears stable in 1M NaCl.

Figure 5 shows cryo-SEM image of *ex vivo* hemocytes (insect macrophage/neutrophil equivalents) from 5th instar *Manduca sexta* that had been injected with a native (A) or heat inactivated (B) enriched preparation of *Pa*^{ATCC43949} *PVCpnf* Needle Complexes (nanosyringes) heterologously produced by an *E. coli* cosmid clone. Note the abundant linear structures corresponding to PVC Needle Complexes (nanosyringe) (small arrows) and membrane ruffling effect (large arrows), consistent with the mode of action of the Pnf payload toxin, which are absent from the control treatment. Scale bar = 50µm. 25kV; magnification 40K (A) and 50K (B).

Figure 6 shows experimental results demonstrating the (toxic) cellular phenotype following contact with a PVC Needle Complex is due to intracellular toxin delivery. (A) A Pnf loaded PVC Needle Complex was injected into insects (*Galleria mellonella* insect larvae), showing potent activity within 15 minutes for the given dose (explained in the examples) - note mortality/morbidity is typically associated with the "melanisation" immune response in these dead/dying insects. (B) A control, denatured (via boiling) Pnf loaded PVC Needle Complex injected into animals showed no activity. (C) Purified Pnf (payload), absent the PVC Needle Complex (i.e. Pnf not packaged into the complex), showed no activity against either animals (left) or a HeLa cell line (right). (D) Pnf (payload) delivered into the cytosol of HeLa cells - via 'BioPorter' liposomal preparations containing the protein, or by intracellular expression following transfection with an appropriate plasmid (E) - showed potent activity/toxicity, as evidenced by multi-nucleation in the cells. (F) - The effect of *PVCpnf*+Pnf on the respiration rate of THP1 derived human macrophages as measured by Resazurin plate reader assay.

Note the heat denatured and empty PVC pnf nanosyringes showed no strong adverse effect. These same samples were tested by injection into *Galleria* larvae. The PVC pnf +Pnf samples showed over around 50% mortality within minutes (darkened larvae in the bottom two panels) while the heat denatured and empty PVC pnf injected insects all remained healthy (no darkened larvae in the top two panels).

Figure 7 shows (*in silico*) predicted secondary structures of a range of the endogenous payload (toxin) associated with various PVC operons, demonstrating the large variety of structure types. (B) The amino acid length of various payloads (toxins) plotted against predicted isoelectric point.

Figure 8 shows confirmation that leader sequences (e.g. having 50 amino acids) of the invention are necessary and sufficient for (trans-)packaging payload proteins/peptides into PVC Needle Complexes (nanosyringes) expressed in *Phototrhaddus*. (A) 1-6: Schematic maps of chimeric effector protein expression constructs (trans-expressed in the arabinose-inducible pBAD30 vector), including those expressing Pnf and non-native cre-recombinase and Myc-tags. C-terminal Myc-tag epitopes are shown as black arrows. (B) Western blots using anti-Myc mouse antibody. Samples are from purified PVC(u4) Needle Complexes (nanosyringes) overexpressed from chromosomally engineered *P. luminescens* TT01 which harbour the trans-packaging expression constructs 1-6 shown in (A). A blank pBAD30 plasmid was used as a negative control and showed no signal. Arrows show correct band sizes for expected products.

Figure 9 shows an alignment of the leader sequences, demonstrating the presence of a chemical composition consensus amongst the leader sequences, based on amino acid properties. More particularly, the leader sequences comprise similar charge patterns, of 2x negatively charged regions, each followed by a positively charged region [-ve] [+ve] [-ve] [+ve].

Figure 10 shows (A) western blot analysis of PVC Needle Complexes and payloads from particulate preparations (Cesium Chloride gradient and Monolith FPLC preparations, as described in Materials and Methods). In [1] (pBADPVC pnf , in which PVC16 of the nanosyringe is FLAG-tagged providing PVC16::FLAG detectable with AntiFLAG Ab), a signal from the tagged cap protein of "PVC Pnf" (PVC Needle Complex with a Pnf payload) can be seen, confirming the presence of PVC Needle Complexes in the purified fraction. In [2] (pBADPVC pnf + Cre::Myc, detectable with AntiMyc Ab, the Cre having an N-term fusion of the Pnf leader e.g. SEQ ID NO.: 78), a signal from the Myc-tagged payload protein packaged in abundance, in the same sample as (1), confirming presence of Cre payload in purified PVC Needle Complexes (nanosyringes). In [3] (PVCU4 + Cre::Myc, detectable with AntiMyc Ab, the Cre having an N-term fusion of the Pnf leader e.g. SEQ ID NO.: 78), a different PVC Needle Complex chassis ("PVCU4") purification is probed for Myc-tagged Cre revealing a packaged (packaged Myc-tagged Cre) corresponding band. This is highlighted in the blot for clarity. (B) Transmission electron micrograph of a PVC Needle Complex, shows both wild-type (having a Pnf payload) PVC Needle Complexes and PVC Needle Complexes having an atypical (non-native) recombinase (Cre) payload, in any chassis tested, does not affect morphology of the PVC Needle Complexes, ensuring they are not assembled aberrantly. Figure 10 (C) provides additional/ complementary data to that of (A). In more detail, (C) provides further proof via Western blot analysis of (trans-)packaging of the Cre recombinase into purified PVC pnf expressed in *E. coli*. The Western blot demonstrates that for a given amount of Anti-FLAG antibody Western signal (a specific probe for the nanosyringe due the incorporation of PVC16::FLAG), a much higher amount of the Cre payload is detected (using

the Anti-Myc tag antibody). The numbers denote 2-fold dilutions. Note, upon dilution, the anti-FLAG signal from the nanosyringe is lost, while the payload remains intense in most lanes. CsCl denotes purification by Caesium Chloride density gradient centrifugation. "Mon" denotes the samples were additionally anion exchanged via "Monolithic" columns. "Post-Elution", "Interphase", "Sub-Interph.", denote the liquid fractions where the signal is detected from the purification process. D - Western blot analysis of Cre trans-packaged into PVC_{pnf} in *E. coli*. Payloads are probed for their incorporated 'Myc' tags (C-terminal fusions) after purification of the nanosyringe-payload complex. Western blot analysis of particle preps confirms that all four leaders could efficiently trans-package the exogenous Cre enzyme. E - A phylogenetic tree, demonstrating the exemplified leader sequences are well distributed throughout and are therefore at or close to maximally sequentially diverse (see Example 4.2). **Figure 11** shows western blot analysis of PVC Needle Complexes expressed without (1) and with (2) concomitant expression of (Myc-tagged) Pnf from a separate plasmid, probed simultaneously with an anti-FLAG and anti-Myc antibody. In the lanes marked 1, the PVC Needle Complex (nanosyringe) was expressed and purified without the presence of a 'payload plasmid' (an expression plasmid encoding a payload protein linked to a leader sequence) within *E. coli*. This leads to a band corresponding only to the FLAG tag present on the syringe (PVC Needle Complex) itself. For lanes 2, the same approach was undertaken, but using cultures which also included a (separate) plasmid bearing a tagged payload (Myc-Pnf). Bands can be seen which correspond to the FLAG and Myc tags, confirming presence of the Pnf payload (the four lanes within 1 and 2 are simply different purification fractions from Caesium Chloride gradients).

Figure 12 shows western blot analysis of trans-packing experiments in *P. luminescens* TT01 PVCu4 over-expression strain. Results demonstrate the trans-packaging of a myc-tagged Pvc17 (Plu1651whole::Myc).

Figure 13 shows further western blot analysis of trans-packaging experiments in *P. luminescens* TT01 PVCunit4 over-expression strain (as explained in the Examples). Results demonstrate trans-packing of Myc-tagged Pvc17 (Plu1651::Myc) and a Myc tag alone using the leader of Pnf (PAU_03332 leader), and that the leader is necessary. (A) Lane 1 shows packaging of the leader of fused to a Myc-tag (PAU_03332::Myc); Lane 3 shows a lack of packaging when the leader sequence is absent (Myc only is not packaged); lane 4 shows lack of packaging of HvnA (a natural effector) when the leader sequence is absent; lane 6 shows packaging of Myc-tagged PAU_03332::Plu1649, i.e. a chimera of the leader from PAU_03332 (i.e. amino acids 1-50 of PAU_03332) and the effector (i.e. amino acids 51-C-terminus) from Plu1649. The high intensity of bands in lanes 1 and 6 demonstrate that the Pnf (PAU_03332) leader is particularly effective at packaging a payload). (B) Lane 1 shows packaging of Plu1651 with a C-terminal Myc tag using an anti-Myc antibody Western blot.

Figure 14 shows further Western blot analysis demonstrating the very high level of trans-packaging of Myc-tagged Pnf (PAU_03332::Myc) using the PAU_02806 (GogB) leader (second lane, not including the ladder lane). The first lane demonstrates use of the Plu1649 leader for packaging the PAU_03332 effector (Myc-tagged Plu1649::PAU_03332). The band appears weak due to the relative intensity of the band in the second lane. The experiment involved filter sterilisation of 50 mL culture, 8 M final concentration of urea added to break down PVCs. Samples collected from 10 mL supernatant.

Figure 15 shows further western blot analysis demonstrating trans-packaging of Plu1651 (pvc17) with a C-terminal Myc tag as described in Figure 13 into PVCunit4 expressed from

Photorhabdus. Raw represents particulate preps from supernatants, Be, Be2 and IP represent different “cuts” from a Caesium chloride gradient purification.

Figure 16 (A) provides a diagrammatic explanation of the mechanism of action of Cre in the mouse organoid experiment (of Example 6), and how the positive control (TAM) facilitates Cre activation. White arrows show the location of cells expressing the tdTom fluorescent reporter gene. B - Demonstration of delivery of active trans-packaged Cre-recombinase into murine bile duct organoids by PVC*Cpnf* expressed and purified from *E. coli*. White circles show the location of groups of cells expressing the fluorescent reporter gene. The upper images show a direct grey scale conversion of an images obtained via light microscopy. The lower image shows a corresponding image with false-colour enhancement of positive cells, which is provided simply to aid identification of the difference between effected cells and surrounding unaffected ones within the former grey scale conversion.

Figure 17 shows a dot-blot analysis of nanosyringe expression both with a payload (the Cas9-like protein MAD7) and without. Some leaky expression of the IPTG inducible MAD7 is seen before induction (T1) as is common with this expression system. There is no Myc signal from the PVC only sample at any time point as expected, and the MAD7 signal grows throughout the expression over a ~24 hour period. Strong Myc signal is maintained post purification via ultracentrifugation as described elsewhere, indicating that the protein is incorporated into the nanosyringe chassis system. FLAG signal is robust in the MAD7 sample, and occurs as expected post-induction and persists post-purification, as this promoter system has reduced leaky expression. It is concluded that the nanosyringes and MAD7 are compatible with one another in terms of expression, and that MAD7, the largest protein tested to date, can be packaged in to the nanosyringe system.

Figure 18 shows western dot-blot analysis confirming trans-packaging of the pro-apoptotic tBid protein domain and BaxBH3 (both having the leader sequence of SEQ ID NO.: 78 fused to the N-term) peptide into purified PVC*Cpnf* expressed from *E. coli* (7 & 8). The nanosyringe with its cognate toxin “Pnf” is shown, as purified by 2 different methods (5 & 6) as a positive control. The blots at the bottom of the panel represent the same examples as in 7 & 8 in the panels above. These blots were made from another purification of the same constructs, demonstrating reproducibility of purification. This experiment demonstrated that “tBid protein domain and BaxBH3 peptide” packed samples (nanosyringes) can be successfully prepared, e.g. for used in the apoptosis delivery assays in Example 9.

Figure 19 (A) shows TUNEL-stain microscopic analysis from cells exposed to the packaged nanosyringes for 20 minutes only. First (left) bar = DNase I treated cells (+ control); Second bar = no DNase I or nanosyringe treatment (- control); Third bar = cells were exposed to nanosyringes packaged with tBid (via leader sequence of SEQ ID NO.: 78 fused to the N-term); fourth (right) bar = cells were exposed to nanosyringes packaged with Bax_BH3 domain (via leader sequence of SEQ ID NO.: 78 fused to the N-term). B - Representative micrographs as described in Example 9, showing TUNEL staining of PBMC's, following treatment with nanosyringes and controls. PBMCs were treated with tBID, Bax loaded nanosyringes, and the positive (DNase I treated cells) and negative (no DNase I treatment) controls for 20 minutes at room temperature before performing TUNEL staining to determine an apoptotic response. In the original (non-grayscale) micrographs: Cells negative for apoptotic response show blue or light brown staining. Blue staining (Methyl green) or light brown staining indicates healthy cells with absence of apoptotic signal. Dark brown staining indicates cells undergoing apoptosis.

EXAMPLES

Materials and Methods

Cloning

Plasmids encoding PVC Needle Complexes were prepared using standard molecular techniques known in the art. Briefly, genomic DNA from *P. asymbiotica*^{ATCC43949} (obtainable from the ATCC under accession no. ATCC 43949) was used in PCR (with appropriate primers) to amplify multiple (e.g. four) overlapping regions of the PVC operon. Overlap/extension PCR was employed to prepare a whole operon, and fused (again using overlapping PCR) into an appropriate expression vector as detailed in Figure 1 (using the primers of SEQ ID NO: 101 – SEQ ID NO: 106).

Briefly: four overlapping PVC fragments (generated with primers of SEQ ID NO: 101 (F1) and SEQ ID NO: 105 (R1); SEQ ID NO: 102 (F2) and SEQ ID NO: 106 (R2); SEQ ID NO: 103 (F3) and SEQ ID NO: 107 (R3); and SEQ ID NO: 104 (F4) and SEQ ID NO: 108 (R4), respectively) were made covering the PVC operon (e.g. of SEQ ID NO: 93). The target cloning vector was cut at the required insertion site. These 5 DNA fragments were then assembled by overlapping PCR (using primers of SEQ ID NO: 101 and of SEQ ID NO: 108), and the resulting fragment was ligated into the cloning vector. Products were transformed into laboratory *E. coli* and recovered with vector marker selection (e.g. due to ampicillin resistance).

The operons are typically operably linked to an inducible promoter (e.g. arabinose inducible, and/or IPTG inducible) as is known in the art. This is generally achieved by cloning into pBAD family plasmids (inducible via arabinose) (Invitrogen, catalog number: V43001) and pVTRa (inducible via IPTG) (Biomedal, S.L.) vectors (although any combination of compatible expression vector systems should suffice).

A PVC Needle Complex can be expressed independently of the payload (toxin), and vice versa. Separate expression vectors (e.g. having differing inducible promoters) may harbour the PVC Needle Complex and the payload, respectively.

Expression (e.g. laboratory scale expression) / Purification of PVC Needle Complexes in *E. coli*

A typical process to purify a PVC Needle Complex from a 1L culture of an *E. coli* expression strain (transformed with an appropriate expression vector/ cosmid) is as follows:

1- An overnight culture of the bacteria (transformed with PVC Needle Complex expression vector) is prepared by picking a colony from a plate and inoculating 100 mL of LB media. The culture is grown at 37°C with shaking.

a. Typically, the media may be routinely supplemented with 0.2% d-Glucose to aid repression of the genetic constructs for optimal cell health.

b. The media is also supplemented with the relevant antibiotics for maintenance of the expression (PVC Needle Complex) vector. If a payload vector is also being used, the relevant antibiotic for that vector is also supplied.

2- The next day, a 1L flask is inoculated via dilution in a 1:100 ratio from the overnight culture. The media for the 1L flask is identical to the overnight media but typically does not contain glucose.

- 3- Cultures are grown to approximately mid-to-late exponential (an OD_{600nm} of ~0.8) at which point the plasmids are induced.
 - a. For the PVC Needle Complex (nanosyringe) plasmid, typically 0.2% arabinose is added to induce expression. For the payload plasmid (plasmid encoding for the payload, such as Pnf), IPTG concentrations may typically be optimised on a per-protein basis, and a typical starting figure of 0.1 mM is preferable.
- 4- The cultures are returned to the incubator post-induction and cultured at 18°C until the following day.
- 5- Cultures are harvested by centrifugation in appropriate centrifuges/bottles/rotors at 5000xg for 30 mins.
- 6- Cell pellets are then lysed to release PVC Needle Complexes (nanosyringes).
 - a. The following lysis methods may be used:
 - (i) Lysozyme incubation overnight.
 - (ii) Sonication with a needle sonicator (with or without first treating with lysozyme.
 - (iii) Cell disruptor/homogenisers.
- 7- Optionally, DNase, and protease inhibitors can be added to the lysate.
- 8- Cell debris is removed by centrifugation at 50,000xg, 4°C, for 20 minutes in a high speed centrifuge.
- 9- Concentrate the lysate through a 100,000 kDa MWCO centrifugation column to reduce volumes and remove small proteins. Once the volume is down to a manageable volume, centrifuge several times replacing the retentate solution with an appropriate sample buffer such as TM (20 mM Tris-HCl, 8 mM MgCl₂, pH 7.4) to dialyse.

A subsequent process for purification via Caesium Chloride density gradient is as follows:

1. Prepare CsCl density solutions as follows:
 - (a) 1.7 g/mL CsCl in H₂O; (B) 1.5 g/mL CsCl in H₂O; (C) 1.45 g/mL CsCl in H₂O
2. Gradients (from bottom-to-top of the tube) are then set up in ultracentrifuge tubes like so:
 - (1) (bottom of tube) – 2mL density, 1.7 CsCl; (2) – 3ml density, 1.5 CsCl; (3) – 3mL density, 1.45 CsCl; (4) (top of tube) – sample in TM buffer. Suitably, apply each density carefully to side of tube so as not to blend the boundary with the previous density layer.
3. Balanced tubes are then subjected to ultracentrifugation at 35,000 RPM in an SW40Ti swinging bucket rotor, equivalent to 155,000 xg, for 2 hours, 4°C.
4. The correct gradient fraction will be the region just above a 'blue-ish-white' halo that appears. Fractions are extracted via puncturing the tube with a syringe and needle.
5. PVC Needle Complexes of good purity can be obtained in this manner, and stored in buffer at 4°C. Suitably, dialyse back in to TM buffer to remove the CsCl.

Following, or in place of CsCl gradient purification, PVCs can be extracted via Monolith anion exchange chromatography, as follows (note all steps can be performed manually with a peristaltic pump or syringe apparatus, or via F/HPLC):

1. Unless already done, dialyse the sample extract into the binding mobile phase (typically TM buffer) with a low concentration of salt (20 mM NaCl).
2. Equilibrate the column according to the manufacturer's guidelines, briefly:
 - a. At least 5 Column Volumes (CV) of dH₂O;
 - b. At least 5 CV of binding buffer (TM, with low salt);
 - c. At least 5 CV of elution buffer (TM with high salt, >= 1M NaCl);
 - d. At least 10 CV of binding buffer once more.

3. Apply the sample to the column at a low flow rate (1-2mL/min)
4. Wash the column with up to 200 mM NaCl-containing TM buffer.
5. Elute with 1M NaCl-containing TM buffer (alternatively, use a gradient elution if using an FPLC machine).
- 5 6. PVC Needle Complexes are present in the elution fractions. If a fraction collector is used, subsequent SDS-PAGE or similar may be needed to identify the correct fraction.

The column (of e.g. step 2) was of the CIMmultus™ Quaternary Amine anion exchange columns (BIA Separations d.o.o.). For example, the CIMmultus™ QA-1, which is a
 10 monolithic column with 1.3 µm channel size and a column volume of 1 mL.

Alternatively, a DEAE (a weak anion exchanger) column may be used.

Alternatively, for use with a *Photorhabdus* expression system, PVC Needle Complexes can
 15 be purified from supernatants as well as/instead of cell pellets, with the following additions/modifications:

1. Following cell harvest from the standard protocol above, supernatants are transferred to a pyrex bottle, and can optionally be concentrated via 100,000 MWCO columns if necessary.
- 20 a. DNase (0.25U/mL) and protease inhibitors can optionally be added.
2. NaCl is added to a final concentration of 0.5M, and 80 g/L of PEG6000 is also added. The solution is mixed at 4°C overnight.
3. The solution is centrifuged to pellet the PEG6000 at 8000xg, 4°C for 30 mins.
4. The pellet is resuspended in a small volume (~5 mL) of TM buffer (or similar) and
 25 incubated for 2 hours at room temperature, shaking.
5. Pellet by centrifugation at 13,000 xg for 10 mins, and collect the supernatant to a new tube. Proceed with purification method of choice.

Other methods for purifying PVC Needle Complexes have been described elsewhere, for
 30 example in Yang et al (J Bacteriol. 2006 Mar; 188(6): 2254–2261), incorporated herein by reference.

Construction of an arabinose inducible over-expression strains for *P. luminescens* TT01 PVCunit4 (chassis encoded by genes plu1667 – plu1652)

35 *Photorhabdus* strains overexpressing a PVC Needle Complex were prepared using chromosomal recombineering to place a PVC (operon) of choice (operon encoding PVCunit4 Needle Complex was used here, as an example) under the control of an arabinose inducible transcription promoter. The recombineered strains are then genetically transformed with effector expression plasmids (e.g. based on the arabinose inducible expression vector
 40 pBAD30) to facilitate PVC Needle Complex over-expression, PVC effector expression, PVC effector trans-packaging, and secretion of the whole complex simply through the addition of the arabinose sugar.

Recombinant *Photorhabdus* PVC over-expression strain construction

45 The promoter region of PVCunit4 was amplified using primers PVCpromF (5'-TATCATATGTCTACAACCTCCAGAACAAATTGCTG-3', SEQ ID NO: 97) and PVCpromR (5'-ATCTCTAGAACAGATATTCCAGCCAGC-3', SEQ ID NO: 98) using genomic DNA from *P.*

luminescens strain DJC (aka strain TT01) as a template. A suitable *P. luminescens* strain is obtainable from the ATCC under accession no. ATCC 29999. The PCR product was digested with NdeI and XbaI and introduced by ligation into the suicide vector pCEP (ThermoFisher, catalog number: V04450), using *E. coli* DH5 α λ -pir (Biomedal S.L.) as the carrier strain. The resulting plasmid was transferred to the *E. coli* donor strain S17.1 λ -pir (Biomedal S.L.) for conjugation into *Photorhabdus*. Briefly, overnight cultures of the donor strain and a rifampicin resistant (Rif^R) isolate of *P. luminescens* DJC were diluted in LB supplemented with 10 mM MgSO₄ and grown to mid-exponential (OD₆₀₀ ~0.5). Then, 3 ml of each culture were harvested, washed twice and re-suspended in 100 μ l of LB supplemented with 10 mM MgSO₄. 80 μ l of *P. luminescens* DJC Rif^R were mixed with 20 μ l of the donor bacteria (resulting in a recipient to donor ratio of 4:1) and placed in the centre of an LB agar plate supplemented with 0.1 % pyruvate and 10 mM MgSO₄. The plate was incubated overnight at 30°C and the resulting growth was harvested in 1.5 ml LB. Aliquots were plated on plates containing rifampicin (50 μ g/ml) and chloramphenicol (25 μ g/ml) to select for trans-conjugants and the plates were incubated at 30°C for 3 days. Possible transconjugants were re-streaked and confirmed by PCR using primers ParalNF (5'-GGCGTCACACTTTGCTATG-3', SEQ ID NO: 99) and tPVCpR (5'-TCGGTGGCAGTAAATTGTCC-3', SEQ ID NO: 100).

PVC Needle Complex over-expression and purification from *Photorhabdus*

Overnight cultures of *P. luminescens* DJC PVCunit4::pCEP were diluted in 2x 250 ml LB supplemented with chloramphenicol (25 μ g/ml) and incubated at 28 °C, 180 rpm. After 2-3 h, arabinose (0.2 %) was added and the cultures were returned to the incubator for another 26 h. The cells were pelleted by centrifugation (7000 g for 30 min) and the supernatant was collected. DNase I was added to the supernatant at a concentration of 0.25 U/ml to degrade any extracellular DNA. Following an incubation of 30 min at room temperature, polyethylene glycol 8000 (8 %) and NaCl (0.5 M) were added to precipitate the proteins. The supernatants were incubated overnight at 4°C, stirring. The precipitated proteins were then collected by centrifugation at 8000 g for 30 min at 4°C. The pellets were re-suspended in 8 ml TM buffer (20 mM TrisHCl, 20 mM MgCl₂, pH7.4) and incubated at room temperature for 2h with gentle shaking. Any remaining debris was removed by centrifugation at 13000g for 10 min and the supernatant containing PVC Needle Complexes was applied to a CsCl density gradient and centrifuged at 35000 rpm for 2h in a Beckman coulter Optima L-90K or XPN-80K ultracentrifuge. The CsCl density gradient was made by layering TM buffer containing CsCl at ρ = 1.7 (2 ml), 1.5 (3 ml), and 1.45 (3 ml) from the bottom of the tube, respectively. The fraction containing PVC Needle Complexes was collected and Ultracel-100K devices (Amicon) were used to remove the CsCl and exchange the buffer for TMS (20 mM TrisHCl, 8 mM MgSO₄, pH7.4). The PVC Needle Complexes were further purified using a CIMmultus™ quarternary amine 2 μ m pore anion exchange column (BIAseparations). The column was washed with TMS buffer containing 200 mM NaCl and the PVC Needle Complexes were eluted in TMS containing 1 M NaCl. The NaCl was removed by buffer exchange using an Ultracel-100K device and the sample was applied to a CIMmultus™ DEAE 2 μ m pore column (BIA separations) for a final purification. The column was washed in TMS containing 200 mM NaCl and the sample was eluted in TMS containing 500 mM NaCl.

It is possible to perform this with and without lysis (e.g. because the PVC Needle Complexes appear to be secreted from live cell, and can be collected in supernatant) of the cells (to release the PVC Needle Complexes).

5 Transmission electron microscopy

For transmission electron microscopy (TEM) pioloform-covered 300-mesh copper grids that were coated with a fine layer of carbon were used as substrates for the protein fractions. A preferred aqueous negative stain is 3% methylamine tungstate. The coated grids were exposed to UV light for 16 h immediately prior to use to ensure adequate wetting of the substrate. A 10 µl drop was applied to the TEM grid, and the protein was allowed to settle for 5 min. Liquid was absorbed with filter paper from the edge of the grid and replaced immediately with 10 µl of filtered negative stain. The drop was partially removed with filter paper, and the grids were allowed to air dry thoroughly before they were viewed with a JEOL 1200EX transmission electron microscope (JEOL, Tokyo, Japan) operating at 80 kV.

15 BioPORTER assay and actin stress fibre analysis.

For BioPORTER assays (Genlantis), 80 µl of purified wild-type and mutant Pnf proteins (500 µg ml⁻¹), or PBS as a negative control, were added to one BioPORTER tube (Genlantis) and re-suspended in 920 µl of DMEM. The samples were added to HeLa cells grown in 6-well plates and incubated for 4h. BioPORTER/protein or PBS mixes were replaced by fresh complete medium and the cells were incubated for 20–48 h. To visualize cell morphology and actin cytoskeleton, cells were fixed for 15 min in 4% PBS-formaldehyde, permeabilized with 0.1% Triton X-100 and stained with Tetramethylrhodamine B isothiocyanate (TRITC)-phalloidin (Sigma) and DAPI dihydrochloride (Sigma). Images were acquired with a LSM510 confocal microscope (Leica).

EXAMPLE 1

Cloning and expression of PVC Needle Complexes

The inventors have successfully excised (cloned) the required expression genes from the host bacterium, *Photothabdus* (e.g. which are comprised within SEQ ID NO: 93, SEQ ID NO:94 and/or SEQ ID NO:95), and have devised a reliable, scalable expression system in laboratory *E. coli* as explained above. It has been demonstrated that trans-expression on separate plasmids enables incorporation of payloads (e.g. Pnf) into the syringes, creating a multi-plasmid (modular) platform.

Following purification from *E. coli*, electron microscopy analysis demonstrated that the purified PVC Needle Complexes retained the correct 'nanosyringe' structure (see Figure 3). Furthermore, PVC Needle Complexes remained correctly associated with the payload (e.g. Pnf) following purification (see Figure 4), demonstrating that the inventors have successfully prepared the PVC Needle Complexes (nanosyringes) having the correct structure for payload delivery to cells.

Furthermore, electron microscopy analysis demonstrated that the purified complexes appropriately localise to the cell surface of cells, and PVC Needle Complexes with a Pnf payload (PVC_{Pnf}) induces a phenotype (ruffling) consistent with the postulated mechanism of the effector (PVC) – see Figure 5.

EXAMPLE 2**2.1 Demonstrating PVC Needle Complexes exert effect via intracellular delivery of effector**

The polypeptide Pnf was identified as a PVC effector as follows. This was identified within the *Photothabdus asymbiotica* ATCC43949 complete genome – GenBank Accession Number: FM162591.1.

The final gene of the PVC operon (*P. asymbiotica* ATCC43949 PVC*pnf* operon, which has a sequence of SEQ ID NO: 93) was identified, namely *pvc16* (e.g. PAU_03338). The position of the *pvc16* genes of a PVC locus is illustrated in Figures 1(A), (B) and (D). ORFs shortly 3' of *pvc16* (e.g. within about 5kb downstream of *pvc16*) were identified – one such ORF (PAU_03332) being 3535bp downstream of *pvc16*. The predicted function of the polypeptide (having a sequence of SEQ ID NO.: 32) encoded by this putative effector ORF was obtained by a combination of BlastP and HHPRED (<https://toolkit.tuebingen.mpg.de/#/tools/hhpred>). This ORF could then be assigned as a PVC effector based on direct homology to a known bacterial toxin (e.g. of the CNF1 family from *E. coli*).

A Pnf loaded PVC Needle Complex was then prepared according to Example 1.

The inventors have demonstrated that these packaged (e.g. laden) PVC Needle Complexes exert cellular effects consistent with the provenance of the cargoes they carry. By way of example, cells and whole insect animals exposed to PVC Needle Complexes loaded with the cytoskeleton toxin Pnf undergo cell death in a manner consistent with cytoskeleton toxicity.

Injection experiments (injection into the insect larvae) were performed by injection of 10µl of supernatant, provided following centrifugation (pelleting) of an overnight culture (typically 1L) of a culture of *E. coli* harbouring a cosmid clone encoding the PVC Needle Complex with Pnf (PVC*Pnf*) – e.g. a PVC encoded by SEQ ID NO.: 93, packaged with a PVC effector of SEQ ID NO.: 32.

Demonstrating that the PVC Needle Complexes are responsible for the phenotype due to intracellular delivery (e.g. injection) of the Pnf payload, the toxic effect could only be reconstituted when the same protein (Pnf) is provided with another route to access the cell cytosol (transfection and expression of an expression plasmid, or conductance via liposomal preparations containing the protein) – see Figure 6. Conversely, denatured (via boiling) PVC Needle Complex preparations, toxin proteins overlaid on tissue culture cells or toxin proteins injected into whole animals showed no activity.

2.2. Evidence of delivery of the toxic effector enzyme Pnf into cultured human macrophages

To complement the data outlined above, the inventors conducted additional experimentation providing further evidence of delivery of the toxic effector enzyme *Pnf* into cultured human macrophages.

Concept: The inventors tested PVC*pnf* expressed and purified from *E. coli*, (trans-)packaged with the native Pnf toxin on cultured human THP1 derived macrophages. Unlike the lethal effect of the Pnf toxin in insect models, previous liposome mediated Pnf protein transfection

experiments indicated a subtler phenotype in human Hela cells. In those experiments the cells showed actin stress fibre formation at 24h and multinucleation at 48 h. The inventors therefore tested the effect of the purified PVC_{pnf} (the nanosyringe) holding/ packaged with the Pnf PVC effector on macrophage respiration rate using a Resazurin colourimetric assay.

Methods:

Background behind Resazurin assays. The blue compound resazurin was explored for use in assays to determine the activity of PVCs on macrophages (M0). Resazurin is metabolically reduced in cell mitochondria, producing a pink and highly fluorescent compound, resorufin. The effect of PVCs on macrophage metabolism can be determined by introducing resazurin into the culture media. The number of macrophages affected by PVCs can be inferred by comparing the fluorescence measured to that of the cell density optimisation curve (see Czekanska, *Methods in Molecular Biology*, 2011, 740, 27-32, incorporated herein by reference).

Optimisation of use of Resazurin for THP1 derived macrophages. The metabolism of macrophages over 18 h was assessed at different seed densities to determine the optimum cell density for use of this assay with PVCs. A 30 mL culture of THP-1 cells was pelleted at 1000 rpm for 4 min, before resuspension in 2 mL of RPMI media (also containing 10 % FBS (v/v) and 2 mM L-glutamine). Cells were counted using a cell haemocytometer, then diluted in media to a density of 2×10^6 cells mL⁻¹. THP-1 cells were then activated with phorbol 12-myristate-13-acetate (PMA) immediately before plating. 200 µL of the cells were plated in quadruplicate in a 96-well plate, and a 2-fold serial dilution was performed until reaching a final cell density of 1.5625×10^3 cell mL⁻¹. 125 µL of the starting cell dilution was also plated in quadruplicate on the same plate, for a 5-fold serial dilution, until reaching a cell density of 0.32×10^3 cells mL⁻¹. Four blank wells were also prepared, containing RPMI and PMA. The plate was incubated at 37 °C with 5 % CO₂ for 48 h. Media was aspirated from the wells and replaced with fresh RPMI, and the macrophages were incubated for a further 24 h. A resazurin tablet (VWR) was dissolved in RPMI (12.5 mg/mL), and 10 µL added to each well in quick succession (well concentration of 1.25 mg/mL). The fluorescence produced was measured on a plate reader every 30 min for 18 h (excitation: 530-570 nm, emission: 580-620 nm, maintained at 37 °C and 5 % CO₂). The optimum cell density over time was then determined for use with PVCs.

Use of assay for PVC testing. THP-1 cells, diluted to 1.25×10^5 mL⁻¹, were activated and seeded in a 96-well plate, where wells contained 100 µL of cells at a final well density of 1.25×10^4 cells mL⁻¹. Blank wells were also prepared in quadruplicate, containing cells without PVC samples, as well as wells containing media and PMA only. The plate was incubated for 48 h at 37 °C with 5 % CO₂. The media was then replaced with fresh RPMI, before addition of 10 µL of each PVC sample. The plate was incubated for a further 24 h, before the addition of 10 µL resazurin (12.5 mg/mL) to each well, and the fluorescence was measured every 30 min for 18 h (excitation: 530-570 nm, emission: 580-620 nm, maintained at 37 °C and 5 % CO₂).

Results: Figure 6F shows that challenge with PVC_{pnf}+Pnf did indeed lower the respiration rate of the macrophage, while heat denatured or empty PVC_{pnf} nanosyringes had no strong adverse effect. Nevertheless, control cells with no sample addition still showed the best

respiration rates. The effects on macrophage were correlated with insect injection toxicity assays. In this case the two PVC $_{pnf}$ +Pnf preparations showed lethality to over half the insect cohort, while the heat denatured and empty PVC $_{pnf}$ injected insects all remained healthy.

5 **EXAMPLE 3**

Demonstrating that a leader sequence is responsible for payload packaging into PVC Needle Complexes

Surprisingly, the inventors have found that the provision of a 'leader' peptide sequence, preferably on the N-terminus of a payload (toxin) protein, can direct the payload to the PVC complex and allow for (e.g. trigger) the packaging of the payload into the PVC Needle Complex. The inventors have demonstrated that amino acid residues 1-50 of a PVC effector protein is/ comprises a leader sequence.

To demonstrate this, an expression construct (overexpression in chromosomally engineered *P. luminescens* TT01) was prepared, in which the leader sequence (the N-terminal amino acid residues 1-50) was ablated such that the payload expressed by Plu1649 (referred to as "hvnA" in the figure, and having a sequence of SEQ ID NO.: 46) (Myc-tagged for detection purposes) was absent a leader sequence (see Figure 8A – construct 1). Following expression (of both the payload and PVC Needle Complex) and isolation of the PVC Needle Complex (and running the components thereof, which includes any packaged payload, on a gel), no (Myc-tagged) Plu1649 ("hvnA") was detectable within the PVC Needle Complex via western blot analysis, demonstrating that the payload (absent the leader sequence) was not packaged into the complex (see Figure 8B, lane 1), and thus not associated with the isolated complex. Successful packaging was seen, however, for hvnA which did retain the leader sequence, see lane 2 (note that the band appears weak, due to the relative intensity of the band of lane 3).

Surprisingly, hvnA having a leader sequence from a different (non-hvnA) PVC effector (i.e. corresponding to the N-terminal amino acid residues 1-50 from the PAU_03332 effector) (see Figure 8A, construct 3) was correctly packaged into the complex and remained associated with the PVC Needle Complex upon isolation/ purification, as demonstrated by Western blot detection of the Myc-tagged hvnA (see Figure 8B, lane 3). Thus, the inventors have demonstrated the surprising ability of the 'PAU_03332' leader sequence (which is associated with a different payload, Pnf) for packaging of a hvnA payload (i.e. a different payload to that of PAU_03332). This demonstrates the ability to swap the leader sequences of the PVC effector, allowing use of an optimal leader sequence (having optimal packaging activity) for packaging.

EXAMPLE 4

4.1 Demonstrating that a leader sequence directs packaging (into PVC Needle Complexes) of atypical/ exogenous payloads

In an unexpected technical effect of the invention, the inventors have found that fusing a leader sequence described herein to exogenous (non-*Photobacterium*) polypeptides (preferably at the N-terminus) allows for packaging of said exogenous polypeptides into a PVC Needle Complex, with the exogenous polypeptides remaining associated with the PVC Needle Complex upon isolation/ purification. By way of example, see Figure 8B (lane 4) demonstrating that a non-*Photobacterium* 'Myc' polypeptide (<10kDa) is packaged into the

PVC Needle Complex when fused to a leader sequence, and lane 6, demonstrating a much larger non-*Photorhabdus* 'Cre-recombinase' polypeptide (>32kDa) can likewise be appropriately packaged into PVC Needle Complex when fused to a leader polypeptide of the invention.

5

The inventors performed in-depth analysis of the size (e.g. polypeptide length) and structure of the various natural PVC effector payloads encoded by *Photorhabdus* (see Figure 7), which show a wide variety of different lengths and structure, demonstrating that the applicability of the PVC Needle Complex (nanosyringe) delivery system of the present invention is not limited by the size or properties of the payload protein of interest. To summarise, there is no requirement for particular secondary structure, biophysical property, or length of cargoes, confirming that the PVC Needle Complex (nanosyringe) chassis can be utilised as a versatile multifunctional delivery vehicle.

10

15

Furthermore, this packaging of exogenous polypeptides is independent of the chosen PVC Needle Complex chassis e.g. has been accomplished using both a "PVCpnf" chassis (SEQ ID NO.: 93) and a "PVCU4" (e.g. *PVCunit4*) chassis (endogenous to the *Photorhabdus* overexpression strain) (see Figure 10A). Importantly, the inventors have demonstrated that packaging exogenous payloads in either chassis does not affect morphology of the PVC Needle Complexes, ensuring they are not assembled aberrantly (see Figure 10B).

20

In data shown herein, payload proteins are supplied in 'trans' on separate genetic constructs. The leader sequences are surprisingly sufficient to target these separately synthesised proteins for packaging into the PVC Needle Complex vehicle (see Figure 11). This applies in *E. coli* when the chassis (PVC) genes themselves are also present on a plasmid, as well as with chassis genes being integrated into the chromosome, as is the case in *Photorhabdus*, the host organism.

25

Further exemplification of trans-packaging of high levels of the Cre site specific recombinase into the PVCpnf nanosyringe expressed in *E. coli* is provided in Figure 10(C). In more detail, the inventors constructed a laboratory *E. coli* expression strain harbouring (i) the arabinose inducible expression plasmid for the *P. asymbiotica* ATCC43949 PVCpnf operon e.g. of SEQ ID NO.: 93 (with a C-terminal FLAG tag on Pvc16, e.g. immediately 3' to SEQ ID NO.: 93) and (ii) a second IPTG inducible expression plasmid containing the Cre recombinase with a N-terminal fusion of the natural Pnf effector 50 amino acid leader sequence (e.g. leader of SEQ ID NO.: 78) and a C-terminal Myc-TAG epitope. The PVC operon and effector (Cre + leader sequence) were co-induced for 24 hours and the chimeric nanosyringes purified. Western blot analysis was used to confirm the presence of the FLAG-tagged Pvc16 cap protein (and therefore the nanosyringe chassis) and the trans-packaged Myc-tagged Cre recombinase post purification.

30

35

40

4.2 Trans-packaging using additional leaders demonstrating functionality of a larger, diverse sequence space

Complementing the data outlined in Example 3, Figure 10D demonstrates (trans-) packaging of Cre into PVCpnf (in *E. coli*) using the following four additional leader sequences (thus demonstrating the functionality of a larger sequence space):

45

- Lane 1: the leader of PAU_02096 (leader sequence = SEQ ID NO.: 71), experiment referred to as "NanoSyringe + *lopt50::cre::Myc* in Figure 10D;
- Lane 2: the leader of PAK_02075 (leader sequence = SEQ ID NO.: 50), experiment referred to as "NanoSyringe + *cnf50::cre::Myc* in Figure 10D;
- Lane 3: the leader of PAU_02009 (leader sequence = SEQ ID NO.: 68), experiment referred to as "NanoSyringe + *cif50::cre::Myc* in Figure 10D; and
- Lane 4: the leader of PAU_02806 (leader sequence = SEQ ID NO.: 76), experiment referred to as "NanoSyringe + *gog50::cre::Myc* in Figure 10D.

These results also demonstrate the utility of leader sequences showing greater sequence diversity for (trans-)packaging a payload. Indeed, to provide further validation, the inventors performed a CLUSTALW sequence comparison of a panel of leader sequences to determine diversity. PVC effectors are identified as proteins encoding recognisable toxin-like domains that are encoded immediately downstream of the *pvc16* structural gene. Each PVC operon can encode just a single effector, or several different effector genes in tandem array. A phylogenetic tree is shown in Figure 10E, with the identities of leader sequences exemplified herein for packaging payload proteins into the nanosyringe complexes being elaborated by either the *P. asymbiotica* ATCC43949 PVC*pnf* operon (solid arrows) or the *P. luminescens* TT01 PVC*unit4* operons (dashed arrows) or both.

As can be seen from the tree of Figure 10E, the exemplified leader sequences are well distributed throughout and are therefore at or close to maximally sequentially diverse.

EXAMPLE 5

Tail Fibre / binding domain modification

PVC Needle Complexes are known to comprise tail fibres (see the 3D rendered PVC structure, left most asterix of the rightmost image) which are believed to allow for cell-type specific targeting of the PVC complexes. The inventors have successfully demonstrated that modification of a tail fibre region to incorporate non-natural amino acids (e.g. a substitution of an amino acid in the wild-type sequence for an alternative amino acid of the 20 standard amino acids) does not affect expression of tail fibres.

EXAMPLE 6

Demonstrating delivery of an active (exogenous) enzyme/ payload into ex vivo murine organoids with a leader sequence-packaged PVC Needle Complex

Concept: Obtaining data for the delivery of an exogenous functional enzyme to a mammalian tissue. The inventors have demonstrated the delivery of a trans-packaged bacteriophage derived recombinase protein known as "Cre" into *ex vivo* mouse bile duct organoids. The organoids are derived from a mouse line in which the expression of a chromosomally encoded red fluorescent protein (RFP) reporter is normally prevented by a stop signal flanked by *loxP* recognition sites for the Cre-recombinase. If the recombinase is present, the stop signal is recombined out and the cells then go on to express the reporter protein. The general principle behind this experimental demonstration is summarised in Figure 16A.

Method: The Bile Duct organoid preparation: murine primary bile ducts were isolated and expanded as organoids in matrigel using “BD expansion media” for 12 passages following Huch et al (Regen Med. 2013 Jul;8(4):385-7. PMID: 23826690; DOI:10.2217/rme.13.39) protocol. Cells were then plated in 2D and cultured in BD expansion media. Mouse Genotype: LSL-Tom reporter in Rosa26 locus + Axin2CreRT (inducible upon 4OHT treatment). Cells were cultured in uncoated polystyrene plates at a seeding density: of 10,000 cells/well. Nanosyringes were prepared as 30% volume syringe preparation in PBS + 70% culture media. Total volume of 100 µl per well. The positive control represented 500nM 4OHT (in ethanol) at 1:1000 (v/v) as positive control for the recombination. The negative control represents 1:1000 (v/v) ethanol dilution only. Cells were seeded and grown for 48h, nanosyringes added and then cultured for another 24h before fixing (4% PFA fixation 15min RT) and staining for microscopic examination. Staining: Primary antibody Anti-RFP (1:1000) from Rockland. Secondary Anti-Rabbit 568 (used at 1:500 v/v). Samples were visualized on a laser-confocal microscope.

Result: Figure 16B includes representative micrographs from these experiments demonstrating signal for the RFP protein could be detected in a number of cells when treated with the Cre loaded PVC*pnf* nanosyringe. As these are *ex vivo* organoids, rather than simple cell monolayers, some stochasticity in the number of cells that are dosed is expected, and this is even observed in the positive control, which is a small molecule inducer (rather than a large protein complex). It is anticipated that, as these are organoids, there will be some level of cellular differentiation present which may alter the binding characteristics of the nanosyringes. A further interesting observation from this preliminary run, is that while information on total amounts of nanosyringes applied to the system is not yet available, the inventors demonstrate that the TAM small molecule inducer does not appear to have appreciably greater tissue penetration than the nanosyringes, suggesting their ability to distribute is not majorly hampered by their size.

Additional interpretation: To summarise, the inventors have demonstrated the ability to deliver (e.g. dose) exogenous enzymes to a cellular target. Moreover, this “nanosyringe + Cre” experiment is a promising proof of concept for a biotechnology tool/aide, by demonstrating the ability to provide a DNA change leading to a transformed cell. This experiment therefore demonstrates the use of exogenous payloads (a protein of viruses rather than bacteria), and nucleic acid modifying enzymes in particular. It is evident that the Cre enzyme is delivered in a functional manner and is capable of traversing the cellular interior to the nucleus to affect its DNA modifying changes.

EXAMPLE 7

Trans-packaging of MAD7 site specific recombinase (exogenous payload) into the PVC*pnf* nanosyringe expressed in *E. coli*

Concept: As with the Cre data (of Example 6), and other examples of packaged payloads provided herein, the inventors have demonstrated packaging of the Cas-like enzyme MAD7 into a nanosyringe via a leader sequence. This is the largest exogenous example (MAD7 = 147.9 kDa) of a payload described herein.

Methods: Briefly, the chassis genes and the MAD7 gene (the latter being tagged with a C-terminal Myc tag for detection, and a leader sequence for nanosyringe incorporation described herein), were expressed (upon induction) simultaneously in *E. coli*. Upon harvesting and purification of the nanosyringe complex, payload packaging was probed via dot blot analysis (e.g. for detection of the Myc tag). The purification method described herein (using ultracentrifugation) can be employed to select for (e.g. exceedingly) high molecular weight protein complexes/ biological matter, enabling recovery of the nanosyringes and any cargo (payload) they carry. 'Loose'/ unpackaged payload remains in solution and is not subject to sufficient centrifugal force and as such is lost during purification, unless contained within the much larger nanosyringe 'shell' (that is, when successfully packaged). Successful packaging of MAD7 is demonstrated by Figure 17.

EXAMPLE 8

Trans-packaging of apoptosis inducing payloads into PVC_{pnf}, expressed in *E. coli*

Using the *E. coli* PVC_{pnf} leader::payload::Myc trans-packaging system described in Figure 10C (PVC_{pnf} leader = SEQ ID NO.: 78), the inventors demonstrated the ability to trans-package at least two pro-apoptotic human derived protein sequences or peptides (e.g. the sequences of SEQ ID NO.: 109 and SEQ ID NO.: 111). The Pnf effector protein leader sequence (e.g. SEQ ID NO.: 78) was fused to the N-terminus, and a Myc epitope tag was fused to the C-terminus. Western dot blot analysis (similar to that of Example 7) confirmed the presence of these human derived proteins in purified nanosyringes (Figure 18).

EXAMPLE 9

Demonstration of the induction of apoptosis in cultured *ex vivo* human cells by nanosyringe delivery of (trans-)packaged pro-apoptotic human polypeptides

A preliminary test has confirmed the ability to use the PVC_{pnf} nanosyringe, produced in *E. coli*, to deliver trans-packaged human protein sequences (e.g. packaged according to Example 8) and induce apoptosis in *ex vivo* circulating PBMC cells from human donors. The assay is a TUNEL-stain microscopic analysis from cells exposed to the packaged nanosyringes for 20 minutes only. Results are shown in Figure 19A, demonstrating (via successful induction of apoptosis) delivery of tBid p15 fragment and BaxBH3 domain.

- tBid p15 fragment (SEQ ID NO: 109) is part of the normal human apoptosis regulation pathway. Cellular effects: a pro-apoptotic member of the Bcl-2 family. The C-terminal part of Bid (tBid) translocates to the mitochondria, where it induces the release of cytochrome c. Bid is normally cleaved by caspase 8 from its latent cytosolic full-length pro-Bid form.
- BaxBH3 (aa59–73) (SEQ ID NO: 111) is a minimal BH3 domain synthetic peptide, comprising critical 15 residues of the defined Bax BH3 domain. Cellular effects: these 15 residues contain sufficient information to bind to, and functionally antagonize, Bcl-xL and to induce specifically Bax/Bak. Appears to abrogate Bak/Bcl-2 interactions – freeing up pro-apoptosis factors.

A more detailed test of the delivery of pro-apoptotic human peptides into *ex vivo* Peripheral Blood Mononuclear Cells (PBMCs) is now described. The aim of this study was to investigate whether the pro-apoptotic peptide loaded PVC nanosyringes could induce

apoptosis in *ex vivo* human Peripheral Blood Mononuclear Cells. The nanosyringes were first assessed for any immediate cell toxicity using Trypan blue dye exclusion assays and then for apoptosis response by using the TUNEL assay.

- 5 **Trypan Blue Exclusion Test for cell viability:** Trypan blue is a Diazo dye commonly used to selectively colour dead tissue or cells, hence, dead cells are shown as a distinctive blue colour under a microscope while live cells or tissues with intact cell membranes remain uncoloured. Since live cells are excluded from staining, this staining method is also described as a Dye Exclusion Method. Trypan blue is commonly used for assessment of
- 10 tissue or cell viability. A suitable number of cells (2×10^5) were exposed to the nanosyringes and empty nanosyringe for 20 minutes. A suitable volume of cells (30 μ L) were added to an equal volume of 0.4% Trypan blue and the number of viable (unstained) and dead (stained) cells counted using a hemocytometer. Each compound was tested at 3 concentrations. Blood cells from two independent human donors was tested for each compound at each
- 15 concentration and each sample was tested in duplicate.

Treatment and preparation of cells for microscopy: The viability of Peripheral Blood Mononuclear Cells (PBMCs) from two independent healthy human donors was determined after 20-minute treatment with the two chimeric nanosyringes (e.g. loaded with the

20 exogenous pro-apoptotic peptides) at 3 test concentrations in 2 independent tests. PBMCs were harvested by centrifugation and resuspended in media at 1×10^6 cells/ml. Cells were fixed in 2.5% formalin and incubated for 20 mins at room temperature. Poly-L-lysine coated slides were prepared by spraying with 70% ethanol and leaving to air dry. Cells were centrifuged for 30 seconds. Supernatant was removed and cells were resuspended in 200 μ l

25 dH₂O. 5 μ l of cell suspension was added to each slide/fixation. Two fixations were performed per slide to allow staining to be performed in duplicate. Cell suspension was left to air dry.

Results of PBMC cell viability assay: The Trypan blue viability assays confirmed that the PVC preparations were not immediately toxic in themselves to PBMCs taken from healthy

30 human donors (Table 2). Nanosyringe treatment showed > 60% viability indicating low toxicity at maximum dose concentration (Table 2). The inventors then moved on to test the ability of the chimeric nanosyringes to induce apoptosis.

Blood donor sample 1	Neat		1/10		1/100	
	Well 1	Well 2	Well 1	Well 2	Well 1	Well 2
Compounds						
TBID	60	70	75	75	80	80
Bax	78	82	80	80	83	87
PBMC Controls	93	97				
Blood donor sample 2	Neat		1/10		1/100	
	Well 1	Well 2	Well 1	Well 2	Well 1	Well 2
Compounds						
TBID	70	72	81	81	84	84
Bax	80	80	84	88	87	87
PBMC Controls	95	95				

Table 2. Viability of Peripheral Blood Mononuclear Cells (PBMCs) from two independent human blood donors after exposure to each compound for 20 minutes at 3 test concentrations (v/v dilutions). PBMC controls are untreated.

- 5 **Testing for chimeric nanosyringe induced apoptosis using the TUNEL assay:** The TUNEL assay was then used to identify apoptotic nuclei in single cell suspensions fixed on slides. In the assay Terminal deoxynucleotidyl Transferase (TdT) binds to the exposed 3'-OH ends of DNA fragments which are generated in response to apoptotic signal factors. This in turn catalyses the addition of biotin-labelled deoxynucleotides which can be detected using a
- 10 streptavidin-horseradish peroxidase (HRP) conjugate. Diamineobenzidine (DAB) reacts with the HRP-labelled sample to generate an insoluble brown substrate at the site of DNA fragmentation. Methyl green counterstaining enables the visualisation of normal and apoptotic cells.
- 15 The induction of apoptosis following exposure of human PMBCs to the nanosyringes was determined. A TUNEL assay kit (Abcam) was used for detection of apoptotic cells. The assay was performed following the manufacturer's instructions. Briefly, slides were covered with 100µL proteinase K solution or 5 minutes, slides were rinsed with 1x TRIS buffer saline (TBS). The treatment of nanosyringes or the DNase I positive kit control was performed for
- 20 20 minutes at room temperature. Slides were rinsed with TBS. Slides were then incubated with TdT equilibrium buffer for 30 minutes before the addition of TdT labelling reaction mix. Slides were incubated at 37° for 19 minutes. Slides were then washed with TBS before application of the stop buffer and incubation at room temperature for 5 minutes. Slides were washed again with TBS before addition of the blocking buffer for 10 minutes at room
- 25 temperature. Detection was performed by application of the conjugate to the samples for 30 minutes. Slides were rinsed with TBS before application of the DAB solution for 15 minutes. Slides were rinsed with dH₂O followed by counterstaining with methyl green. Slides were dehydrated in 100% ethanol followed by xylene and mounted with a glass cover slip. All staining was performed in duplicate. An apoptosis endpoint, indicative of positive staining in the apoptosis detection assay is represented by dark brown (DAB) signal. Lighter shades of brown and/or shades of blue/green to green/brown indicate a non-reactive negative cell for apoptosis.
- 30

- Analysis was performed by selecting 5 random sections of cells on the slide, positive stained cells (dark brown) and negative stain cells (blue or light brown) were counted and the percentage of cells showing apoptotic bodies was determined.
- 35

- To generate a positive control, slides were treated with 1µg/µl DNase I (the kit positive control) for 20 minutes at room temperature following the proteinase K treatment step detailed below. The DNase I treatment fragments DNA in normal cells to generate free 3'-OH groups identical to those generated during apoptosis. A negative control was generated by substituting DNase I with dH₂O in the reaction mix during the treatment stage.
- 40

- Results of PMBC apoptosis assays:** TUNEL staining using PBMCs was performed following treatment with the intact tBID and Bax loaded nanosyringes, with appropriate positive and negative kit controls. Treatment was performed for 20 mins to determine if the nanosyringes elicited an apoptotic signal. A positive control (DNase I treatment) and negative
- 45

control (no DNase I treatment) was included. Results showed both nanosyringes, containing either tBID or Bax, showed strong apoptotic signals (**89%** and **78%** positive, respectively) on the PBMCs. The positive control showed a strong apoptotic signal (**79%**), whereas the negative control showed no apoptotic signal (**100%** negative). Also observed was a significant loss of the numbers of attached cells in the nanosyringe treated samples, presumably indicative of a rapid and comprehensive apoptosis response, and a failure to be retained after washing. Note this effect is even more pronounced than the kit positive control suggesting a more rapid response. Representative micrographs are shown in Figure 19B.

Conclusion: It is concluded that the tBID and Bax loaded nanosyringes are able to rapidly induce extensive apoptosis in human Peripheral Blood Mononuclear Cells. Furthermore, Trypan Blue dye exclusion assays have confirmed that these chimeric nanosyringes do not cause rapid lethal lysis or extensive membrane damage to the cells.

EXAMPLE 10

Exemplification of practical utility of leader sequences and PVC Needle Complexes - Intracellular delivery of atypical (non-*Photorhabdus*) payload

(1) An anti-MDM (p53 inhibitor) antibody is linked to a leader sequence described herein, and expressed together with a PVC Needle Complex for packaging therein. Isolated PVC Needle Complex (comprising the antibody payload) is contacted with a tumour for intracellular delivery of the antibody (said tumour cells being characterised by having high MDM-suppression of p53 activity for MDM inhibition). The tumour is suppressed by the activity of the anti-MDM antibody.

(2) A PVC Needle Complex is used to (intracellularly) deliver anti-tumour peptide vaccine to activate the MHC-I dependent cytotoxic T-cell lymphocyte (CTL) response. A tyrosinase-related protein 2 (TRP2) peptide vaccine is delivered for enhancing cross-presentation to CTLs occurs and antitumor effects against TRP2-expressing tumours. The tumour is suppressed by the activity of the peptide vaccine.

(3) A PVC Needle Complex is used to (intracellularly) deliver a nuclear factor- κ B inhibitors (which are used for the control of inflammatory disorders, such as rheumatoid arthritis) to a cell. The cell subsequently demonstrates a reduced expression of pro-inflammatory cytokines.

(4) A PVC Needle Complex is used to (intracellularly) deliver a T3SS payload (which inhibits NF- κ B and MAPK pathways). This is completed with an isolated (purified) PVC Needle Complex, without any need for the PVC Needle Complex to remain associated with the bacterial cell from which it derives.

(5) A PVC Needle Complex is used to (intracellularly) deliver, to a cell, anti-apoptotic peptides including BH4, the Bcl-xL-protein, and/or a peptide inhibitor of c-Jun N-terminal kinase (which can protect the heart and brain against ischemic injuries (a restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism)). For example, Jun-kinase inhibition via a 20 amino-acid binding motif of the JUN kinase is sufficient. A release of e.g. cytochrome c in the cell is inhibited.

(6) A PVC Needle Complex is used to (intracellularly) deliver nicotinamide adenine dinucleotide quinone internal oxidoreductase (Ndi1), the single-subunit yeast analog of complex I (which provides significant cardioprotective effects) to complex I-deficient mutant cells. The Ndi1 protein is correctly targeted to the matrix side of the inner mitochondrial membranes, and restores the NADH oxidase activity to the complex I-deficient cells.

(7) A PVC Needle Complex is used to deliver one of two of the essential subunits of the PHOX complex (which are used in enzyme replacement therapy to restore production of ROS in chronic granulomatous disease) to a chronic granulomatous disease cell. A restoration in production of ROS is observed.

(8) A PVC Needle Complex is used to (intracellularly) deliver (e.g. intramuscularly) a myotubularin (which is used for improving local and distant muscle performance in X-linked myotubular myopathy patients). Myotubularin- dephosphorylation of phosphatidylinositol 3-phosphate and phosphatidylinositol (3,5)-bi-phosphate is observed.

(9) A PVC Needle Complex is used to (intracellularly) deliver a recombinase "Cre" (which is capable of excising defined genetic cassettes) into a mouse cell line, in which the genome has loxP recombination sites flanking a stop signal upstream of an mCherry gene. The Cre payload excises the recombination sites, and removes the stop signal, allowing for expression of the mCherry gene in the cell.

(10) A PVC Needle Complex is used to (intracellularly) deliver a ~15kDa nanobody (antibody fragment) with affinity for an intracellular component. A nanobody-intracellular complex is detected.

(11) A PVC Needle Complex is used to intracellularly deliver (e.g. into insect cells) an atypical (non-*Photorhabdus*) polypeptide toxin for insect crop pests and animal parasites. Suppression of the pests is observed.

(12) A PVC Needle Complex is used to (intracellularly) deliver a nuclease (e.g. Cas9 and/or Mad7) into a target cell comprising a guide RNA. The nuclease performs site-directed gene inactivation

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

SEQUENCES

Where an initial Met amino acid residue or a corresponding initial codon is indicated in any of the following SEQ ID NOs, said residue/codon may be optional.

5 SEQ ID NO: 1 (PAK 1985)

MMREYSNEDDFIKEKTNLVKSENVEADNYLETEYLTYLAKLIGMTERENHHLNSIKLIDDIELHNDRKGNKLL
WNDNWQDKIIDRLQSIFFKIDEMVSEFGGLEAYKDIVGENPYDPTPEVCGYSAQNIFKLMTEGEYAVDPVK
MAKTGKINGNQFAEKLHLNSSNNYVALINDHRLGHMFLVDIPSTNRERVGYIYQSDLGDGALPALKIADWL
KSRGKESINVNKLKKFLNDEFTMLPDNEQKGLIAEFDLNKDIDSVKSGKIKKDKAVDIYLYREYDINDFISNIEKL
10 KTKLA

10 SEQ ID NO: 2 (PAK 1987)

MFQNRIRNEKTTQSGKGKTLDRMTDSLYLEIPNVEAVTLAYQKLTSKYRKFDNKTCLLDSSDEFSQLKSEK
QRKGFSKSGLKNNGVSDRKFIYTKNALKNFAAHAGYEHNGHYEDEFVNFKDNNKNLAKGKLFPGISLIERR
KLSIVKNKEGKWEHKETDEAEAYKVTIDIEKFISGVSRMYLQGNTFLHAKTEALIRKHIANNENILPTMAGIAGL
15 HAEVQALNNLFISGDGKTKKREKWKYIRNMLESSIFTQRLTTGQAGKDFAAACHNCSGILSSPVNVITGKVES
AGDNFLSTLSRYKTSQESPI

20 SEQ ID NO: 3 (PAK 1988)

MEREYSEKQKNPSKLSRKTAISERIAALERSGLSNSNQPVQFARPYTSNRPVVNINPGRSSIAVATANSTS
PVNIPTPAPASPKLLPSTSCDTTSSILIVGKYNLELTSQGKIVVFRGDNRTPEQIVAAGGFYPWSKQDVGKI
20 KKLIDEFIEIGPSAHMMGHVRSNPNYVSTGMNMDSGGFGEQSNLYKMEIPGLKPQDMNERTLGEKIRQ
DKRGINYPHFLMSHLTAESEFVAMIPARSEELTFITPIPLSYITSYRKRGNTWLPMLPKK

25 SEQ ID NO: 4 (PAK 2075)

MSNYEYDIVTQHDYQIKDNEYTVVNGKYWQYEQEGNKNNNKVSISLMKENQNDPVWITSDIKEISLYIENL
FSYHKFSAELQHTLKNVAVFNEYSEIKYSELLHNINIFNLFFIKIYNTSDIDTAINILTAKIEYDKLEKINQDK
25 TDSNNTNVDIWEELGINAEPELLKIYRQAFSTGDDIDDEVYSDALLTFMSDGNLELGDKEKSDYNQRIKDKTDL
FESYKKGIEKVASLITNNINPGIPITYPETEKSINIGDLLLLAQLAKEEIALKKQNRTEYSQQDIFELQTLQAAK
YHLLILSSLGALLYQIAPNVEKMTKGHG DYRDIIFSQEQAESLFKKHNIQYDTNHVLSQESKHIEMEGCIILTAA
IYRMRKENATVEQALNYSTLETIKLFENDKKKLNPFNTNNVKPAGYFSFIDFKKRDKFDSDQYNFNEQFNVYK
NKYSHYESISFSKLILSSPAAQLTAEIIVNPPEEAFLYSVEQGMGNVAMIKMYQGNWL VISTIQQGVKAKKYS
30 RQQVDSNPTLRAMSKPNALFLIERKMETGMGILMPNMMVNTGKRLFPTGYERAKTLSGFAETSRYSKNSYN
AFWNDYYGITSGMNVGISFTGSPKFNFYKEENLLSVTATIIQQGLNDIAIKSKQALDITSGWHIAATILIPFYNI
YKSTTDSEYELTGEDIGSIVFDANVLLVATLGMSLTESMAAKVTQTTLRLRQAGLTGRALITAVVRTLPEH
GIITLRQSSGILGLDLIEPLPIRSTLTLYRGVINAVGAMRNSIKLEKSFADIFGKSTRGLGKLNKNEWKVSNL
PLEEIVPHSNGGEIYKGIYSIRPTNPETAVKQNFYIKEAGANYQVKWDDANHTWRVWNPTYPEQFSYWPVAV
35 KLDKNHGWTHADVSNKFLILEQSKRIDQELAAHSNNNDNILDAFIHINTAFKDCERYDIDKLSIDITDLTHF
FEKSLKPGDKKAIFSTEIMSIQQA WIREVILPLQNNSSISIEKINAIKTEL PYLLRKTFPIESQLPNQLVANKIALAI
EEIPNTRIPKYTSGNISKTVQYTSLENNHVDIPPVGITITGNDTFINQVTRVLSEIDEIPSGNIVIQELEKQGLNI
QPPTMNDIVREKNGQFYANNSAGSHIAFDPENHLIGTEEKLIDEPWRTREPAIALYHEMLHIYNNRYPTWFT
SIDNKVIDQKVSGGFSLLEESRIVGTYKYVNDKNTLDFDNDSDYLLENNSALLTENRFRAEYAFKKNKSEYVIR
40 PYSGKGDSQIPLTKTKININESHRNVMGVGSGKPEKMPNESATDYRNRVREWRKANKQPEADIGTGDMRK
TKAEARVKLLKENYPQFEPQKIELGGAFLWTPNEPANLMLSSHGYFFSDSAATQVPAGKTIQFLGPHG
KTLLEAPENPLYSPFDVTLGNSGFTVQPYATIESGNKAGLGSVKIGDKTFTVNDIQNIATDDVENYLLATGVE
ANASNHGKVRNYGIKYYEKMPDEEVKAAIWKNRADETSTHKYDALLVSPEAGNRKKLSDFALMKTDERMS
KYDEITFVACREELNRINMKSIHDTGLGGGYEPKLEPTVILSRRRREATFTADGAIYSIIAVNLHNNFITEEIVG
45 IAPFLFINN

50 SEQ ID NO: 5 (PAK 2077)

MEHEYNEKEKQRNSAIKLNDAIRNNEENMDMTSPLELNFQNTNRKSRGLRERFSATLQRNLPGHSM LDRE
LTTDGQKNQESRFSPPGMIMDRLMHFGVVRTRLGKVRNSASKYGGQVTFKFAQTGKTFDQIMKHKDTSGGV
CESISAHWISAHAKGDSIFNQLYVGGKKGKFHIDTLFSIKQLQMDGYLDDEQSTMT EYWLGTQGMQPNIQR
50 NDDTDEHSSKVVGGETGNRGTKDLLHAILDTGDKGSGYKKISFLGKMAGHTVAAYVDDQKGVTFDFPNFGE
FSFPDKTSFSHWFTDDFWPKSWYSLEIGLGQEFVFNYAPEAP

55 SEQ ID NO: 6 (PAK 2892)

MPNKKYSENTHQGGKPLMKSEANNEHDIQNSSLGIGLDLNSMMGNSSTSLSHIQDYSEFWKENISEYYKWM
VVVKAHLKQLDWTLKSMDSPESAGTNIAKNTGTALQTLNTGGSIAGAAIGGAIGSAIAPGVGTIAGMGIGA
LAGTGLNYLNDTVIEKLNKLEIAYPYPKTRNMIFDINNYDKNPIIAIKKKTNDNLKVTAGSSLSQLVGKVT
SPIKFPAYKLADLAIALAGLSSDKARHILDFTDSIREVLNESHSDAVAFMRKNYGDNAMGLAGLSSRIK
60

SEQ ID NO: 7 (PAK 2893)

MEREYSEKEKHKRPIQLRNSIEQHEEETANNSLGLGLDLNQATNPPKVPKDNYN EENGDLFYGLANQRG
RYIKSVNPNFDPDKINSSPMIIDVYNNNVSNITLKNYPLDKLVKLSGNPQKYANNIKVENSLQQDVASSKRGW
YPLWNDYFKTGNNKKFNIADYKETRNNQYGSDDYYHTWHTPTGAAPKLLWKRGSKLGIEMAASNEKTKIHF

VLDGLNIQEVVNKQKGSTPLEQGRGESITASELRYAYRNRERLAGKIHFYENDQETVAPWEKSPELWQNYI
PKNKNQNESSTPQRNNGTLYRLGGPFRKLRASLRKRS

SEQ ID NO: 8 (PAK 2894)

MMEHEYSKEEEKKRQQSKPNNATHDESNLPLELEKHFNARTPATASHKWFTYENDTEVELTTERIKEIFSN
KQPKIIAGDGHNKPPFQYAKNIPDVNSSFDAGTLQLYIEATDEQINENNPEYIPKEFMAKPGLFTNKNRRAEI
VGWEDSELSNAMKEMFELSDKSTREKLTPETSSFYKLHETAIRHFFRPEFNQLRDEFFEILAKAGSNRELD
KIALEMIGFTSGTWRDEYINPTLAEKIAKHAAEKENHTFVVSIGDAHLSNPMQEYLNKRRNGGEFKHQIIFT
RDKRPILPDNMKTGNKNS

SEQ ID NO: 9 (PAK 3525)

MLKYANPQAVPTQRTKNTAKKPSSSSSFDGQLELSNGEWSKHSEMGLKRGGGLINSIRRIARNGNIGRFNE
LIDSEAKKWPEPVDKNIHMIWIGTRNISEKNIKLSIDTAKKNPDYNTSIIYDSGISGHEGARNFMLEKFEGSN
VNXSLAFPKGIGVMREYAPEAGKATAFPNTPIAVTKNNPIINKTLDLAVGNYQRGEKNVLKLAGPDVFTQALY
QEIPGLNSKVLNAQLDQFELAKRQALGLPLEKPKSFADEKLTSVEKEKINRPYQSMRGLSGHVMNGADHS
WAVDTEVLGH

SEQ ID NO: 10 (PAT 00148)

MMREYSNEDDCTKEKTNLVKSENVEADNYLEMEHLTYLAKLISMTERENHHLNSIKLIDDIELHNDRKGNKL
LWNDNWQDKIIDRLQSIFKKIDEMVSEFGGLEAYKDIVGESPYDPTPEVCGYSAQNIFKLMTEGEYAVDPV
KMAKTGKINGNQFAEKLEHLNSSNNYVALINDHRLGHMFLVDIPSTNRERVGYIYQSDLGDGALPALKIADW
LKSRGKESINVNKLKFLNDEFTMLPENEQKGLIAEIFDLNKDIDSVKSGKIKKDKAVDIYFREYDINDFISNVE
KLKTKLA

SEQ ID NO: 11 (PAT 00149)

MIFKMLNLAVFYLLGNIFHYLICQKFICYFCSVLKSVTMFLTQVAVQIALYLNILPTMAGIAGLHAEVQALNNLFI
SGDRGTEKRENWKYIRNMLESTIFTQRLTAGQAGKDFAAACHNCSGILSSPVNVITGKVESAGGNFFINIISI

SEQ ID NO: 12 (PAT 00150)

MEREYSEKPKNLSQLSRKTAISERRAMFERNASSNNEQVPVPQFARSYTSNRSVVNINPGRSSIAVVTANST
SPVNISTPAAASPDKLLPSTSCDTTSSTLTVGKYKLELTSQGKVVVFRGDNRTPEQIVAAGGFGEQSNYLYK
MEIPGLKPQDMNERTLGEKIRQDSRGN

SEQ ID NO: 13 (PAT 00152)

MKYDPRRLRTWVEDDFDYKFNFKQTDYINYKDLEKQLKENVDYIYALLDENEAIIFLKELGCDIKSFLNDTAFP
VTDVLSNFAGNIKDALGVFKVAKNFKPINIGIFTYIINELKGKGIKAEYLGKNGERYIKLTDRPGIRKYLNATRY
LINNKKIMEVGIGSVAMEGSIVKGARFGVIYSAAYRSVELMFKSEYDLTNFFVNLSDMAKIIVATIIAKSTVAA
ATSFVVTAALSTTAIAIGVFIIGALVWGLMWLDDEFKISETIIRRLKEHKVKTPISTYHSDQIFNAWGRYYRG

SEQ ID NO: 14 (PAT 02308)

MPNKKHSENTHQGRKPLIKSEANNEHDIENSSLGIGLDLNSTIGNNSASLSQIQDYFSFWKENISEYYKWMVV
VKAHLKQLDWTLSMDSSSAGTNIKNIGTTALQTLLNTGGSAGGAIGSAIAPGVGTIAGMGIGALA
GTGLNYLNDTVIEKLEKLEIAYPYPKTRNMIFDINNYDKNPIIAIKKKTNDNLKVTAGSSLTSQLVGKVTSP
IKFPAYKLSDLAISHNRLAGLSSDKARHILDFTDSIREVLNESHSDAVAFMRKNYGDNAMGLSGLSSRIKGE
KLTLATLARTRNKIENRINSINKQTLKLSSKNSNE

SEQ ID NO: 15 (PAT 02309)

MEREYSEKEKHKKRPIQLRNSIEQHEEETANNSLGLGLDLNQATNPPKVPKDNYEENGDLFYGLATQRGR
YIKSVNPNFDPDKINSSPMIIDVYNNNNVSNITLKNYPLDKLVKLSGNPQKYANNIKVENNLQQDVASSKRGWY
PLWNDYFKIGNENKKFNIADYKETRNQYGSDDYHTWHTPTGAAPKLLWKRGSKLGIEMAASNEKTKIHVFL
DGLNIQEVVNKQKGSTPLEQGRGESITASELRYAYRNRERLAGKIHFYENDQETVAPWEKSPELWQNYIPK
NKNQNESSTPQRNNGALYRLGGPFRKLRASLRKRS

SEQ ID NO: 16 (PAT 02310)

MMEHEYSKEEEKKRQQSKPNNATHDESNLPLELEKHSNARTSATAYSKWFTYENDMEVELTTERVREIFS
NKQPKIIAGDGHNKPPFQYTKNIPDVNSSFDAGTLQLYIEATDEQINENNPEYIPKEFMAKPGLFTNKNRRA
EIVGWEDSELSNAMKEMFELSDKSTREKLTPETSSFYKLHETAIRHFFRPEFNQLRDEFFEILAKAGSNRE
LDKIALEMIGFTSGTWRDEYINPTLAEKIAKHAAEKENHTFVVSIGDAHLSNPMQEYLNKRRNGGEFKHQII
FTRDKRPILPDNMKTGKKN

SEQ ID NO: 17 (PAT 02956)

MSNYEYDIVTQHDYTIQKDNEYTVVNGKYWQYEQEGNKNNNKISISLMKDNQNDPVWITSIDIKEISLYIENL
FSYHKFSAELQHTLKNVAVFNEYSEIKYSELLHNINNIFNLFFIKTYNTSDINTAINILTAKIEIYDKLEKINQD
KTDLNNTKVDIWEELGINAEELLKIYRQAFSTGDIDDEVYSDALLTFMSDGNLKLGDKEKSDYNQRIKDKTD
LFESYKKGIEKVASLITNNINPGIPITYPETEKSINIGDLLLLAQLAKEEIALKKQNRTEYSQQDIFELQTLQAA
KYHLLILSSLGALLYQIAPNVEKMTKGHGDIYRDIIFSQEQAESLFKKHNIQYDTNHVLSQESKHIEMEGCIILTA
AIYRMRKENATVEQALNYSTLETIKLFENDKKLNPFNTNNVKPAGYFSFIDFKRKDFDSQYNFNEQFNVI
KNKYSHYESISFSKLILSSPAAQLTAEIIVNPPEETFLYVSVEQGMGNVAMIKMYQGNWLTVSTIQQGVKARK
YSQQQVDSQPTLRAMSRPNALFLIERKIMIGIGIFMENQIVNTGKRLFPTGYERAKTLSGFAETSRYKNSYNA
FWNDYYGITSGMNVGISFTGSPKFNFYKEENLLSVTATIIQQGLNDIAIKSKQALDITSGWHIAATILIPFYNVII
KSTTDSEYELTGEDIGSIVFDTANVLLVATLGMSLTESMAAKVTQTTLRLRQAGLTGRALITAVVRTLPEHGI
ITLRQSSGILGLIDLIEPLPIRSTLTLYRGVISAVGAMRNSIKLEKSFADIFGKSTRGLGKLKHEWKVSNLPL

EEIVPHSNGGEIYKGIYSIRHTNPETAVKQNFYIKEAGANYQVKWDDANHTWRVVNPTYPEQFSYWPAVKL
 DKNHGWVTHADISNKFLEKSKRIDQELEAAHSNINNDNILDAFIHINTAFKDCERYDIDKLSDITDTLTHFFE
 KSLKPGDKKAIFSTEIMSIQQAWAREVILPLQNNSSISIEKINAIKTELPYLLRKTFFIESQLPNQLVANKIALAIEE
 IPNTRIPKYTSGNISKTVQYTSLENNHVDIPPVGITITGNDTFINQVTRVLSEIDEIPSGNIVIQELEKQGLNIQ
 5 PTMNDIVREKNGQFYANNSAGSHIAFDPENHLIGTEEKLIDEPWRTREPAIALYHEMLHIYYNRYPTWFTSID
 NKVIDQKVSQGGFSLLEESRIVGTYKYVNDKDTLDFDNDSDYLLENNALLTENRFRAEYAFKKNKSEYVIRPY
 SGKGDSSIPLTKTKININESHRNVMGVGSGKPEKMPNESATDYRNRVREWRKANKQPEADIGTGDMRKT
 AEARVLLKENYPQFEPQKIELGGAFQLWTVPNEPANKLMLSSHGYFFSDSAATQVPAGKTIQFLGPHGKT
 LLEAPENPLNSPFDVTLGNSGFTVQPYATIESGNKAGLGSVKIGDKTFTVNDIQNIATDDVENYLLATGVEAN
 10 ASNHGKVRNYGIKYYEKMPDEEVKAAIWKNRADETSTHKYDALLVSPEAGNRKKLSDFALMKTDERMSKY
 DEITFVACREELNRINMKSIHDTGLGGGYEPKLEPTVILSRRRREATFTADGAIYSIIAVNLHNNFITEEIVGIA
 PFLFIDN

SEQ ID NO: 18 (PAT 02957)

MEHEYNEKEKQRNSAIKLNDAIRNNEENMDMTSPLELNSQNTNRKSRGLRERFSATLQRNLPGHSMLDRE
 15 LTTDGQKNQESRFSFGMIMDRMHFGVRTRLGKVRNSASKYGGQVTFKFAQTKGTFLDQIMKHKDTSGGV
 CESISAHWISAHAKGDSIFNQLYVGGQKGFHIDTLFSIKQLQMDGYLDDEQSTMTYWLGTQGMQPNQR
 NDDTDEHSSKVVGEGTKGTDLLHAILDTGDKSGYKISFLGKMAGHTVAAYVDDQKGVTFDFPNFGEF
 SFPDKTSFSHWFTDDFWPKSWYSLEIGLGQEFVFNYPKEP

SEQ ID NO: 19 (PAT 03171)

MFKYDTSEKMAKFGKGTSDGMMLDTLYLEIPDEKAVMSAYKSQLDELRFSEKTHSFFSGKKPLYSKKYL
 20 ANLAAHAGYVHVTDYNSIGNYKDGFFVNFKDNSRNLAEGKLFPGIRLIKRPKLSIVRDKETERWKKQESDEAD
 AYEITDIESFISGVRDMYSRANVDLHPVIESLIRNHIVNNDHVLPTMAGIAGLHAEVQALNNLLILADGRAGKIV
 GGRKIEEYMQDMLKSFIQTQLTTKQAGNDFAACHNCSGILSVPANVITGKVASAGSNFSLILSRYSKNSQES
 PI

SEQ ID NO: 20 (PAT 03172)

MLKHANPQTVSTQRTKSTAKKPSSSSSFDRQFELSSENQPGEGNKDWTIKGWRQRFADRSLNKGHISPL
 25 MNKGLLVGSEEALINVPVVAHRYDSSHQLTDAGPLKADSHSNLDPFYGVVTGFRGDQVTSSESQSGSIG
 GHWGKNTLDSNITGINVNGASGTVGIRIALKDIQHGAIVVTSALSGCTMVYAVKNGYFFAYHTGQKPGD
 KEWKTGRQGVVATYRSHQALSPDEPMAGVGEQNNDLVNIFASYDQGIITYMGKPGVIIDNTAENVGVFNID
 30 EVKLEKPDIRAGYSYALLAKDDKGKVNKVLSEDVIVPLGNKGKTIKAINSLKKRLL

SEQ ID NO: 21 (PAT 03177)

MPRYANYQINPKQNTKNSHGKSSSSNFSSGYFSSSNLDDSLIRQQVKREFIWEGHMKEIEEASRLGNFA
 VSFRAAGGPTLRALGKGAAGKHDILEKTIKPGSINKAYPKDEASNVIKKVQEAGIEGYVGHWDKKTGRLLGI
 35 YMSSGHGLSDEQVNGKIPIIDLNNLEASLSALKTKENWAALPFTGDYDMHDMISFTGQPHSVPSNSSEERK
 IIDRINRLVARSDPNRPFQDIEHNVRHGAQVSYPAFAMDKEEIEKKHGGIVKAVAEPGEFPVAIVSKGKWTI
 ANNIDELNQFYNSIGAKMKVSWKPGAENPGFVSNPQRPGRMARFSRKR

SEQ ID NO: 22 (PAU 02009)

MMREYSKEDDCVKEKTNLAESSENVEADNYLEMDCLNYLAKLNGMPERKDHSLNSTKLIDDIKLHNDRKGN
 40 KLLWNDNWQDKIIDRDLESIFKKIDEMVSEFGGIEIYKDIVGENPYDPTPEVCGYSAQNIFKLMTEGEHAVDP
 VKMAQTGKINGNEFAEKLEQLNSSNNYVALINDHRLGHMFLVDIPSTNREKVGYYQSDLGDGALPALKIAD
 WLKSRGKESINVNKLKFLSNEFTMLSESEQELIAEFDINKDIANVKLGKIKKDKAVDVYLYREYDLNDFISNI
 EKLKTKLV

SEQ ID NO: 23 (PAU 02010)

MPIIGHKEDLIRTERSSVDLTRSSNNRQTDNLELNIPQHNRDNKDIEHAVIYGFSGHRGPEMQKAFADNKNP
 45 VTIDEYNAGLGIMGELSLSDYFRISQDLKENRLELNEKNIQNHSLKYFDAMGVNMKSADPNVKEEAKQQ
 RAYTRSWGFYMMENKEKLDIQSKINNLIPKKSFFSKSPGEDEYKKLDEFILKNSNGSNLTIPKQRKILMKFA
 SAKNAVDVTKNLSGEEQWTKDIIATAFFRQTSKLGMSWFIEQLASPDFFRVIVGFNGEELTTDQIRSNKPW
 KHGNRRKEGASEYAEPITFSEIRHAHRKGYDSKINFIKK

SEQ ID NO: 24 (PAU 02095)

MISTFDPAICAGTPTVTVDNRNLTREIVFHRAKAGGDTDTLITRHQYDLRGNLTQSLDPRLYDLMQKDNT
 50 VQPNFYWQHDLLGRVLHTVSDAGGTVTLSDIEDRPALNVNAMGVVKTWQYEANSLPGRLLSVSEQSANE
 AVPRVIEHFIWAGNSQAEKDLNLAGQYMRHYDTAGLDQLNSLSLTGAHLSQSLQLLKDDQMPDWAGDNES
 VWQNKLKNEVHTTQSTTDTAGAPLTQTDAKENMQRLAYNVTGQLKSSWLTNGQLEQIIVKSLAYSESGQK
 IREEHNGNVVTKYSYEPDTQRLINITTQRSGHVFSEKLLQDLLYEYDPVGNIVSILNRAEATHFWRNQKVSP
 55 RNTYTYDSLYQLIQSTGREMADIGQQNNKMPTPLVPLSSDDKVYTTYTRTYSYDRGNLTKIHRAPASHNI
 YTTEITVSNRSNRAVLSHNGLTPREVDAQFDASGHQISLPTGQNLWNQRGELQQATTINRDNSATDREW
 YRYNAGSARILKVSEQQTGNSTQQQVTYLPGLELRTTKSGTNTTEDLQVITMVETERTQVRILHWSAGKP
 NDIANNQVRYSDNLIESNVMELDTKGKISQEEYYPYGGTAIWARNQIEASYKTVRYSGKERDKTGLYYY
 RHRYYPWLGRWLSADPAGTVGDLNLYRMVKNPIRYQDESGTNANDKAQAIFKEGKKIAINQLKIASNFL
 60 KDSKNSENALEIYRIFFGGHQDIEQLPQWKKRIDSVIYGLDKLTKKHVHYQQDKSGSSSTVADLNVDEYKK
 WSEGNKSIYVNVYADALKRVYEDPLLGREHVAHIAIHELHSHGLVLTQDHKYIGVLSSPGSHDLTDLLSILMPP
 ANEQDRTEKQRRATGARKALENADSFTLSARYLYYTAQDPNPLSSLRKAHRDFNNKKTDRLIIRPPERR

SEQ ID NO: 25 (PAU 02096)

MEREYNKKEKQKKSAILDDAVGNNEENMDMTSPLELNSQYTNRKRPLRERFSATLQRNLPGHSMLDRE
LTTDGQKNQESRFSFGMIMDRIMHLGVTRLGKVRNSASKYGGQVTFKFAQTKGTFLDQIMKHKDTSGGV
CESISAHWISAHAKGESIFDQLYVGGQKGFHIDTLFSIKQLQMDGYLDDEQSTMTHEYWLGTQGIQPNRQK
NDNMNEHSSKIVGETGTRGTDLLRAILDGDKSGYKISFLGKMAGHTVAAYVDDQKGVTFDPNFGEF
NFPDKVSFSHWFTDDFWPKSWYSLEIGLQGEFEVFNYPEKEP

SEQ ID NO: 26 (PAU 02097)

MVVEYAKTNDKRKLSTQSDNYEEKSFSPVLDLSRNNQNTPNMEDEYETPQNFINRTGREKLFRAIRMVAS
NKRDPITKDQVSVPPDGNLFTLKDHLDRAAEYKKLKTWPTHASIIATSPSANTPIAQHVSGDDALSPYIST
GDKPGAVQNTVRNWNIGIPASERRLRPEKTWSPIIEIDVNKLPTTTKIFDLNKPNTFFSTTNSDIAQNAFAD
KEVLISPEIPGLAITRVINDPEEIKQIANLNPSSQLIEKKNTIPEEKIIFEEKKSVPIHDSADIPSSSFVFPKRKKP
RNIRSRTDS

SEQ ID NO: 27 (PAU 02098)

MVFEHDKTVERKRKPSIQLGNDKEKSSEQALELPQSKQNNPLLDLITSNNLRKEAAVFAKQIGPSYQGILD
GLEHLHNLSGNEQLTAGFELHRRITRYLEEHPDSKRNAALRRRTQTQLGDLMTGTGLQEVHRPLLEMAETRP
AMASQIYQIARDEAKGNTPLGTLDMVRWVKEDPYLAAKSGYQKIPNDLPFEPKFHVELGDQFGEFKTWLD
TAQNQGLLTHTRLDEQNKQVHLGYSYNELDMTGGSVSKMAVYFLKEAAKQAEPGSAKSQEAILLNRFA
NPAYLTQLEQGRLAQMEAIYHSSHNTDVAAWDQQFSPDALTFQNHQLDNSVDLNSQLSFLKDRQGLLIGE
SHGSDNLNGLRFVEEQMDALKAHGVTVIGLEHLRSDLAQPLIDKFLTSENEPMPAELAAMLKTKHLSVNLFEQ
ARSKQMIIALDNNSTTRPAEGEHSMLYRAGAANNVAVERLQQLPAEEKFVAIYGNAHLQSHEGIDHFLPGI
THRLGLPALKVDENNRFTAQADNINQRKCYDDVVEVSRIQLTS

SEQ ID NO: 28 (PAU 02230)

MKGIEGVIMLSHDILPEKLLVSEKKHENVGSYFSDDIGEQSEQTEVSHFNLSLDDAFDIYADISIENQQELKNK
DNNTNIWSSLGRGDDHNLKKIINDAFKEKLPQLMEYRRKGYNVIGLDKEGIKKLEGMLKAVPPEIQQPTMK
NLYSAAQELLNTLKQHPLPENQDMIQQSNLVIRNLSDALEAINAVSKVNQVEWWEEVHKTNKAQSDRLIAA
TLEELFFKVKDKRLPGSNDYCYQEREETERKIKDLLLYDGYQLTAEHFKFGRRLKSLAESRVTRLKLAEY
LEKKSVMGILTAARDAKMYAMKILLAQTRNNGFNKADLINAGQVNDRLLSFQQYARHIRAVDGEIDGILSNPLV
VACIKETNDEPAHIKARAILPVSEELGTVSKVLRETKEKVQPSKPKEELNHPHQDWWNRGDELWKYIKKTS
WNIKETSVMHTQVMGYEASKTASRAKHKLKESYSEINGAVKGTALLLLDEIQQAENRIRQIPQFAWDVQE
AVEQHSSVIQRTAYPDELPELSELLNEQLKHEEARWQAVKKQSRDKLQELIAPITRLAQEKWAQDLYFQLG
EELRKERQDRWKDIQQFDEIMAEAVGQFAEMARELDSEAVRLAEHGHSGGKELQEKVAKWLRDLSKLKGG
VKAGVAKITGTSLDNFSRSGMLARGMSEWAEDLKQSYLQETLQEGSAVAELFERTLMEVVEENRTHFAK
ESDPEAERFLKRLALALKHAAENTTVYPPPTPEELAGSRSLPEDIRHWAEEKVVSAGISAAFRGGFKLVTGTF
SLPVRVIRGAKTGGTLRGVRRAINRSVRLGQGPATQVKSFINQELSKTAFRLTSLSPVLAWGMAASITA
GRLYNEKDYPEKIIKNIVIDLPEELLWIGGYAGINAAIRAHAEKAIQQAQIHALDEQADKLALRINKEIAGKSADV
NVEIIPQETSVPASAEATQSTPEPLSDFASTSQTLMPELIDIQDNNNSAQQPKVRRKRDVSVSEISIDNLNIINA
NTRREDKVNSEIKSELKRFENDANSMPDVERAIFIDFLYKNKYEVSESQDYKNTWLKFRRELESQ
ENKEIKEYLRFRSIIIEAYEYIDKKRLDDDTIPEAGTIIKEVIDFFQKLKENPITFMKLAEMVKFQYEEEDEN
EDRYFKMAEIIYFLNKTENEKSKTFHLDIIDKYPNENNRLDDEFFLNKNNNNPDLEIYKLQSMQEKYRES
YEMLSKVENIHQVLSDDSKNEENIFLDNRIIAAQVFDGSINISLQDKKKWLNRYDQIRNEEGSDGWKLMHIES
ILINLRRINTAINLTAMKSESALLIDKLLNFQKKARENILHISETPHEDFTSYSQFKTRKELGNDSSKYAQQFD
NYKDNHDAEKEAKEILSQVVARASLSFSELDKVESIKLFSFVYKNRDGGAPLAAPGRTTVIKFPGKDTGGL
VISNLFRLNHVKRISTKEMEDLKPLTEGMYTRATQHRSLSGYYHIGSQSEHTNALEILSGMNKEELKTHLKK
QGIWFGEPALFSNEYPKQENTGHLENTTLKNAIGVSTIQNNAAANYLRSTMYESTGWEKLGDRFIPFYEIGR
RKHYDREYEINSEQLTLDIITSIAIYPAARGIVATIRSSAIPSLKSGLRGSALFKSLSELGKMGFNASKVFGG
AVYELIEPYPINSHLNRHNVFNKVKDTAWEFHTDVGLKGGGLKDFIDRFTKEPKEITISGYKFKRIKYNQENF
DTMQRMALDYAYNPDSKGKIAQAQQAYKTGKEDYNAPQYDNFNGLSLDKKIERYISPDTDATTKGVLAKG
MNESIKDINAFQTAQDAQSWKKSANKANKVVLTPQNLYLKGGKPSCELPESVLMGWALQSSQDAKLSKMLM
GIYSSNDITSNPLYKSLKELHANGNASKFNASATISININVSNLATSETKLFPTISSVRVDAPKHTMLISKIKN
RENKIKYVFYDPNYGMAYFDKHSDMAAFFQKKMQQYDFPDSSVSFHPDYSNVSDIKISGRNLNEIIDGEIP
LLYKQEGVQLEGITPRDGIYRVPPKNTLGVQETKHYYIIVNNDIYQVEWDQTNNTWRVFDPSNTNRSRPTVPV
KQDTNGEWFKHSETGLKGGGPIDDIRKYIARSAIKIFNQSINYSATKWPEPIDKNIHMIWIGTKNISEKNIKL
SIDTAKKNPDYNTSIIYDSGISGHEGAKKFMLEKFQDSNVNIIDFRKKSYSFSQLKQEPSFAYYEQVIAENKYAQ
ASDILRLLVLKYEGGIYKDIDDQVKGFGSLTFPKGIGVMREYAPEAGKATAFPNTPIAVTKNNPIINKTLDLAV
SNYQRGEKNVLKLAGPDVFTQALYQEIPGLDSKVLNAQLYQLELAKRQALGVPLEKPKNFADEQLTSAEKE
KINRPYQSIRGLSGYVENGADHSWAVDTNIPSTSTQTSTIVTPLAPKTEMLPPVPSSSTKSSTSAVLQEKIS
YNLATDIDATDYLNLQKQKTNNINKISSPAGQCESLMKPVSDFMRENGFTDIRYRGMFIWNNATEQIPMNHF
VVVGKKGKDYVFDVSAHQFENKGMPLDNLGPLILAAEDWAKKYRGATTRKLIYSDFKNASTATNTYNALP
RELVLKESMEGKTFITSPNWWYQTFKRTHNIHPEVTVDSPATFSLNYSVNPTAENLSPPPPPPIPSHGQVPKTV
TPPPPPMRSPLSKPLERLPANKTKPIGNFNGENKASFSKLEAGKHYYKDDKSRQAAPVNTMSDFDNRY
LSHTTEAPAPSNVAHLAPGNIYNTKVTAKGAEKPAYDIYISKDGESLITSSSYKVDDITDTSKFGKPLPYSEIM

FNSLKKSGVDPKNLKRSVQASIENKVTQDVISAIGTRIQRGQVIRVSPTENPDAFYTLTGTDNCKATLHMLNQ
HAEFGHKVVTSTIEFKGTGYLMNIGTSTQTSTIVTPPPMPGTSQLVQ

SEQ ID NO: 29 (PAU 02805)

MPNKKYSENTHQGGKPLIKSEANNEHAIDNSPLGIGLDLNSILGNNSASLSQIHDYSFWKENISEYYKWMV
5 VKAHLKQLDWTLSMDSPESAGANIAKNIGTTTTLTLLNTGSSIAGGAIGGAIGSAIAPGVGTIAGMGIGALA
GTGLNYLNDTAIEKLENEKLEIAYPYPKTRNMIFDINNYDKNPLIKAIKKKTKKDNLKV MAGSSLTSQLGRITPI
KIPAYKLADLAVSHHRALAGLSSDKARHILDFTNSIREVLNESHSDAVAFMRKNYGDAMGLSGLSSKIKGD
KLTLDTLARTRNKIENRINSINKQTLKLSSKNSNE

SEQ ID NO: 30 (PAU 02806)

MEREYSEKEKHKHPIQLRDAIEQHAEETANNSLGLGLDLHQAINTPKVPKDNYNEENGDLFYGLAAQRGR
10 YIKSVNPNFDPDKTNSSPMVIDVYNNHVSNTILNKYPLDKLGKLYGNPQKYAKDIKVTNSLQQDVAASKRGW
YPLWNDYFKAGNENKKFNIADYKETRNYGSDYYHTWHEPTGAAPKLLWKRGSKLGIAMAASNEKTKIH
VLDGLNIQEVVVKQKSTPLEQGRGESITASELRYAYRNRERLAGKIHFYENDQETIAPWEKSPELWQNYIP
KNKSQNESSTPQRNNGALYRLGGPFRKLRLASLRKS

SEQ ID NO: 31 (PAU 02807)

MVHEYSINDRQKRHSFSSANPIDPEVTNRENSRHRFPKDNYNKGHGDLFYGLAPERGKYIKEANPKFDPNN
15 PENAAMIIDVYNDEISRVLNNNANKISTNRLLNFIYFRKNRLENLMKNPEKYAKDIKVDNLRENISPKKIEK
YPLWNDYFEAGIRNKKFNIAEIFKETASQYNSDYHAWHIGGNSAPRLLWKRGSKLGIASQRTKIHFIL
DGLKIEDVVNKTGPAPLKAGPGESITASELRYAYRNRARLAGRIHFYENGKETIAPWDKPELWQKYTPKN
20 RSGMEL

SEQ ID NO: 32 (PAU 03332)

MLKYANPQTVATQRTKNTAKKPPSSSTSFSGHLELSNGENQPYEGHKIRKIKGLRQHLADRSLNKGHISPLM
NKGLLVGSKDVSIDIPVIAHRYDSSHQLTDAEPLKADSHSNHLDPFYGVIAFGFRGDQVTSSESGSGSIGVHW
25 GKNTLDSNIMGVNVVNGASGTVGIRIALKDIQHGSPVIVTSGALSGCTMVYSVKNGYFFAYHTGQKPGNNE
WKTGRQGVVATYLSHQALSPDSEPMTVGEQNNDLVNIFANYDQSVITYMGKPGVLIDKMAENVGVFNYDEI
KPEKPAIRAGYSYALLAKDDKGKVNKVLSEDVIVSSGKQGNTVKAINSLKKRLL

SEQ ID NO: 33 (PAU 03337)

MPRYANYQINPKQNIKNSHGKSSSSDFSSGYLSFSNNSLDDPFIRQQVKREFIWEGHMKEIEEASRLGNFA
30 VSFRAAGGPTLRALGKGAAAKGHDILEKTIKPGSINKAYPKDEASDVIKKVQEAGIEGYVGHWDKKTGRLLGI
YMSSGHGLSDEQVNGKIYPIDLNNLEASLSALKAKENWAALPFTGDYDMHDMISFTGQPHSVPSNSSEERK
IIDRINRLVARSDSNRPFQDIEHNVIRHGAQVSYPAFAMDKEKEEIKKHGGIVKAVAEPGEFPVAIVSKGKWTI
ANNIDELNQFYNSIGAKMKVSWKPGAENPGFVSNPQRPGRMARFSRKR

SEQ ID NO: 34 (Plu1651)

MPNKKYSENTHQGKNPLMKSGANNEHDLQDSPLGIGLDLNSMLVNSSTLSLQIQDYFWKENISEYYKWM
35 VVESHKQLDWTLSMDSPESAGTNVAKNMGVTALQSLNTGSSIAGGAIGGAIGSAIAPGVGTIAGAGIG
ALAGTGLNYLNDTAMSKLSKKLEIAHPYPKTRNMILDINNYDKNPIIKAIKKNVKDNLKV TAGSSLTSLKLVGT
VTSPKFPAYKFAELAVSHHRALEGLSDDKARHILDFTNSIREVLKESHSDAVAFMRKNYGDAMGLSGFSS
KIKREKLTNTLAKTKNEIENRINSINKQTLKVSSRSRNE

SEQ ID NO: 35 (Plu1671)

MLSTEKHNKDTKHPRNREKKFSIQPENSTQDDEDIKNNSLGVGLDLQDMIRNTSSTLTNAPQKPEDGYYYHI
40 SRGNNLQSFLQNGFKPQGGSPGPTLSEEDFSRRKIGIILYIIATTINKNRKAKKISKDNFLMPQEFWHEFKN
FYQNIPTQTNIDDQLLKKSTESIDKLDQNKFMKHSRDKQTIINNERAILQQDERINEIISRRAKMIQQREAE
NTEGYIYLAPHKNTLLEYMKHLQEEKNLFLILAVKEDIFTEKLEQDPQEPHGAVRYK GALSTEELNFVNQE
GQICAI PASIGEMDYGDFILNQQQVIDFCK

SEQ ID NO: 36 (Plu1672)

MPINDLKKKFEISPQAAQAIGAPARSNSSKQAEHQTEHLELDTSKNRRDRKDLNAQATPNQQHTKKLETEV
35 NNGGNKSQAQAHPTDLMVKKESSVTPNTRKSPNEKIKAEIDIFHRYKDRFSPSDRELPEIMNEITNNGIAFS
SEKAPESHLDKVKDKKFTLRHYTSGNGQEKPTEFNEIGSNFNLVNEGILTKRTQGSNTNEDDWNRLGNTAF
TFFLLAIDGEVSDRKFLSNTTHFAEIDIENPAELKELGLDETEFFASPDLLHEKNLSQAPAVKGKLSDLKSLLL
50 KQSGIKPVQLQSLGAKGILERIDSKFNGSLEIKIPGNVKVKEWKVEK

SEQ ID NO: 37 (Plu1690)

MPNSKYSEKVNHSANGAEKCSIHSNQYNNINCTLGLGLDLNKKLRTGNERNIEGAQPFIPFSPKQKQYSTSP
45 IAMADILNESALTSQPIITDLINPQKIKMSDGVKNILNNKEGGDLVFKALQIKPSDETLPFNALKIVDTYQEEM
PNKDMISISAYWAPQGGYVDIPAQPDISRHPQYVFTPNFSGCSFVVDKMNEDTLRVRHVQGGQEDVEYNN
55 QNIDHGMGMITAMEFRDYGHEADDKVIENTYGF AFLKFNQEKQWQLHYQKIAAAPNIINIKTKSSWLPFS
KPSIEADTFTFKNMKVPGYSRKNINNN

SEQ ID NO: 38 (Plu1691)

MPKLTLLSRFENPIQNQPNHISKKNPISNSKVLNNSEEKTAPLELKHDDSKIKSQVSIPNLVKKNEKPAASNT
60 PNNSHEKVKAEDIFNRFSKFDPYDRELPDFDIMNKITNNEIKFSSEKSKDDYLAKVKDKKFTLRHYTAGTGQE
KPTFDEISSNFNLVNGIKTLNRTQGSNTNEDDWNRLGNTAFTFYLLAIDGEVSNRKFLSNTTHFAEINIEDS
EELKELGLDQAEFFASPDLLHEKNLSQAPAVKGKLSDLKSLLLKRSGLSSVQLGRDLAKAILKSIDNEFGNSL
EIKIPGNVKVNKWNKI

SEQ ID NO: 39 (Plu1712)

MPRYSNSQRTPTQSTKNTRRTSPSSNSSTEHLSSLNAPTNDSSVRQEVKEKFIWEGHWEGHMEAEIKASIL
GNFAVSFRAAGKPTLEALGKGAAAGHDIKTIKPGSIEKAYPENEASDVIKKVVREAGIEGYVGHWNKETG
RLEGIYMSSGHGLPNGQVNGKIYPIDLNLEASLAPLKEKKNWAALPFTGDYDMHDMISFTTQPHSVPSNS
5 SEEKKIIDRINEYIAKSDSNRPFEDIEHNVRHGPQVSYPAFAMDKEKKEIKERGGIVKAVAEPGEFPVAIVSK
GKWTIANNINELEQFYNSIGAKMKASWKPGAGNPGFVSNPQKPGMARFSRKK

SEQ ID NO: 40 (Plu1713)

MFSTYSSKNDNQNTINKINTEEKHENTETDNHLEINLEHTGKSKPDIEPKDVTTGTINAGTLLYKTTAIPFELDN
AKSLGLAEYEKRHKDIQDYLNLGKAEDAELKKNKSQWAGQYFALEKSYDEYANEAPDSYNNLLKNAGKDLL
10 ENTTEEKVFVLYTFKVTDKIVLKPNNNSNSYYVGDTEGWKEAKEIMNDVQSQSEKNDNPFPELKNLEDKNF
LLEELGEKGYAWMGPLHAKEGAEGKTEFSYELAISPNNLRQHLTLESEELLGTYKNRYGYWDKK

SEQ ID NO: 41 (Plu1714)

MKKTDEKYQQYEQDEEDITSYPIAWTNPDPNGKIYIGINSPEYSHLNNKGESELNLAIIISTIIHESLHASSHQH
KGLQSQDTGADNLNYDEYVTDYFAREVYKQILPKDYVANCFTKGLGGENKIWGGNIVEFMIQ

SEQ ID NO: 42 (Plu2400)

MVYEYDKTIERRRNPISQLNNEKSSEQAELSQQNNPLLHDLITSNNLRKEAAVFAKRIGPSYQEILDELEHL
HHLSGNEQLAAGFELHRRITHYLEEHPDSKRNTALRRQTQFGDLMFTGTQLKIRHSLEMAETREPMASHI
YQIAREEVKGNTPGLTDLNVRWVKEDPYLAAKTGYQGKIPNDLPFEPKFHVELGAQFDDFKKWLDTAQSK
ELLTHTRLDEQNKQVHLGYSYNELDMTGVESVQMAVYFLKEAAKQAEPGSTKSQEDILLHRFANPTYLAQ
20 LEHSRLAQIEAIYHSSHDTDVTAWDQQFASDALTFQNHQLNNTVDLNSQLSLLLKDRQGLLIGESHGSDNLG
LRFVEEQMEVLKAHGVTVIGLEHLRSDLAQPLIDKFLASGNEMPAPLAALLKTKHLSANLFEQARSKQMKII
ALDNNSTTRPTVEGTQHGLMYRAGAANNVAVERLRQLPAGEKFVAIYGNAHLQSHGIDHFLPGITHRLGL
PALKVDENNRFTAQVDNINQRKRYDDVVELPRIQLTS

SEQ ID NO: 43 (Plu2401)

MEHEYSEKEKPQKCPQLRDSIEHDKEDINTTTPLELNSQYTNRKRAGLRERFSTTLQRNLPGHSMMLDRELT
TDGMKNQESRFSAMIMDRMMHFGVTRRLGKVRNSASKHGGQVTFKFAQTGTFDQIMKHKDTSGGVC
ESISAHWISAHAKGESIFDQLYVGGQKGFHIDSLVSIKQLQMDSYLDDEQSTMTYEWLGTQGIQIPIMQKN
VDEHSSKVVGQTGNKGTDLRLAILDTGDKGSGYKKISFLGKMAGHTVAAVYDDQKGVIFFDPNFGEFSFP
SITSFSRWFTDDFWPKSWYNLEIGLQQQFEVFNELKKS

SEQ ID NO: 44 (Plu2514)

MYDSKKKNSEPTTKKKFERSNYSQWDDSIHYEDMNRARIKNRNDILTTVDYFGEKKKTMTHTFEYQSDIKH
DTNFNNKNKSLFESFAASFVLQNPSSFSGVIDKLSKKLFNIIISKIDERNNFQKKLYDFIEKDTSPGQFGRFTL
GKNEILNLVQVKSPTPQLFVKKMLLIKSLGAFIIFSSKDIGNYDFIDGKGREVNIIIEKNRPTNLFKVRGRTN
35 IKSSQHRSDIGILDTPTFDSLTEEQKSFLTPELTKRRLFRFTTHELDAEDKRVVESVFNRTFDCDSPLIGS
VSGSTSCVLVAADILFPDMTMVERKKLAITFAFLVGGGYHSATEVFDVAYPGLDLNKEIEELIENNPQENA
GVATLRQLIGNSGF

SEQ ID NO: 45 (Plu2515)

MPISNLAKESEVRVAVKDIPCKNIETDNHLEIGLSSGLSRSKDTSKFKKNSINTIKLIDDIILHNDPKGNKLLWN
DNWQDKIINRDLANIFEKIDESVSELGGLEMYQEMGVNPDPTPEVCGLSAQNIFKLMTEGEHAVDPVEM
AQTGKIDGNEFAESVDQLSSAKNYVALVNDRLGHMFLIDIPSNDQETVGYIYQSDLGQGalPPLKIADWLN
SRGKDAVSLNKLKLLSREFNLLSDDEKRALISETLDIHKDVSNVELDRIKRDGRVDIYLYTEYDVNNFYENIET
LKSCLSNDYDKLSKPK

SEQ ID NO: 46 (Plu1649)

MLANVLPNLASFLKYKETPLFFIEDGFNFQNLNPGRVPLIKTPEQRKAGDTQSPAFLCSGVILRGTHSNDY
KFWQSPSSIKSGGVFSYLRKDAKFKRLAYGYKNGFIIFPEHIAPEDRVDFSVLCAFPIDGYTNERANQGC
GENITKAKDKGKSCQEQNVTNSDDWIKNYRKVNSQDFFQCGFNVTKDVNNPAIAFYQMLESIKKLPRTPNT
PPKQNEIRISTWEESDPNKLPIEALFYSENSGLADAQKDQRDYKNATGKFLPIVKMLLPRTLNEALFKFNIK
DQVINP

**Leader Sequences (e.g. with SEQ ID NO: 47 – 92 corresponding to amino acids 1-50 of
SEQ ID NO: 1 – SEQ ID NO: 46, respectively)**

Sequen ce ID	Amino acid sequence	Sequence ID	Amino acid sequence
SEQ ID NO: 47	MMREYSNEDDFIKEKTNLVKSENVE ADNYLETEYLTYLAKLIGMTERENH	SEQ ID NO: 70	MISTFDPAICAGTPTVTVDNLRNLTVREIVF HRAKAGGDTDTLITRHQYD
SEQ ID NO: 48	MFQNRIRNEKTTQSGKGKTLDRMTD SLYLEIPNVEAVTLAYQKLSKYRK	SEQ ID NO: 71	MEREYNKKEKQKKSAILDDAVGNNEEN MDMTSPLELNSQYTNRKRPGLR
SEQ ID NO: 49	MEREYSEKQKNPSKLSRKTAISERIA ALERSGLSNSNQPVQFARPYTSN	SEQ ID NO: 72	MVYEYAKTNDKRKRLSTQSDNYEEKSFS PVLDSLRRNNQNTNPNMEDEYETP

SEQ ID NO: 50	MSNYEYDIVTQHDTYQIKDNEYTVVN GKYWQYEQEGNKNNKVSISLMKE	SEQ ID NO: 73	MVFEHDKTVERKRKPSIQLGNDKESSQ ALELPQSKQNNPLLHDLITSN
SEQ ID NO: 51	MEHEYNEKEKQRNSAIKLNDIAIRNNE ENMDMTSPLELNFQNTNRKSRGLR	SEQ ID NO: 74	MKGIEGVIMLSHDILPEKLLVSEKKHENVG SYFSDDIGEQQSEQTEVSHFN
SEQ ID NO: 52	MPNKKYSENTHQGGKPLMKSEANN EHDIQNSSLGIGLDLNSMMGNSSTSL	SEQ ID NO: 75	MPNKKYSENTHQGGKPLIKSEANNEHAID NSPLGIGLDLNSILGNNSASL
SEQ ID NO: 53	MEREYSEKEKHKRPIQLRNSIEQHE EETANNSLGLGLDLNQATNPPKVP	SEQ ID NO: 76	MEREYSEKEKHKHPIQLRDAIEQHAET ANNSLGLGLDLHQAINTPKVP
SEQ ID NO: 54	MMEHEYSKEEEKKRQQSKPNNATH DESNLPLELEKHFNARTPATASKW F	SEQ ID NO: 77	MVHEYSINDRQKRHSFSSANPIDPEVTNR ENSRHRFPKDNYNKGHGDLFY
SEQ ID NO: 55	MLKYANPQAVPTQRTKNTAKKPSSS SSFDGQLELSNGEWSKHSEMGLKR G	SEQ ID NO: 78	MLKYANPQTVATQRTKNTAKKPPSSSTFD GHLELSNGENQPYEGHKIRKI
SEQ ID NO: 56	MMREYSNEDDCTKEKTNLVKSENVE ADNYLEMEHLTYLAKLISMTERENH	SEQ ID NO: 79	MPRYANYQINPKQNIKNSHGKSSSSDFSS GYLSFSNNSLDDPFIRQQVKR
SEQ ID NO: 57	MIFKMLNLAVFYLLGNIFHYLICQKFC YFCSVLKSVTMFLTKVAVQIAL	SEQ ID NO: 80	MPNKKYSENTHQGKNPLMKSGANNEHDL QDSPLGIGLDLNSMLVNSSTSL
SEQ ID NO: 58	MEREYSEKPKNLSQLSRKTAISERRA MFERNASSNNEQVPVPQFARSYTSN	SEQ ID NO: 81	MLSTEKHNKDTKHPRNREKKFSIQPENST QDDEDIKNNSLVGLDLDDQMI
SEQ ID NO: 59	MKYDPRLRTWEDDFDYKFNFKKQ TDYINYKDLEKQLKENVDYYALLDEN	SEQ ID NO: 82	MPINDLKKKFEISPQAAQAIGAPARSNSSK QAEHQTEHLELDTSKNRRDR
SEQ ID NO: 60	MPNKKHSENTHQGRKPLIKSEANNE HDIENSSLGIGLDLNSTIGNNSASL	SEQ ID NO: 83	MPNSKYSEKVNHSANGAEKCSIHSNQYNI NNCTLGLGLDLNKKLRTGNER
SEQ ID NO: 61	MEREYSEKEKHKRPIQLRNSIEQHE EETANNSLGLGLDLNQATNPPKVP	SEQ ID NO: 84	MPKLELLSRFENPIQNQPNHISKKNPISN SKVLNNSEEKTAPLELKHDD
SEQ ID NO: 62	MMEHEYSKEEEKKRQQSKPNNATH DESNLPLELEKHSNARTSATAYSKW F	SEQ ID NO: 85	MPRYSNSQRTPTQSTKNTRRTSPSSNSS TEHLSLSNAPTNDSSVRQEVKE
SEQ ID NO: 63	MSNYEYDIVTQHDTYQIKDNEYTVVN GKYWQYEQEGNKNNKISISLMKD	SEQ ID NO: 86	MFSTYSSKNDNQNTINKINTEEKHENTETD NHLEINLEHTGKSKPDIEPKD
SEQ ID NO: 64	MEHEYNEKEKQRNSAIKLNDIAIRNNE ENMDMTSPLELNSQNTNRKSRGLR	SEQ ID NO: 87	MKKTDEKYGQYQYKDEEDITSYPIAWTNPD NGKIYIGINSPEYSHLNNKGE
SEQ ID NO: 65	MFKYDTSEKMAKFGKGTSDGMILLD TLYLEIPDEKAVMSAYKSQILDEL	SEQ ID NO: 88	MVYDYDKTIERRRNPSIQLNNNEKSSEQA LELSQNNPLLHDLITSNNLRK
SEQ ID NO: 66	MLKHANPQTVSTQRTKSTAKKPSSS SSFDRQFELSSENQPGEGNKDWTI	SEQ ID NO: 89	MEHEYSEKEKPKQCPQLRDSIEHDKEDIN TTTPELNSQYTNKRAGLR
SEQ ID NO: 67	MPRYANYQINPKQNTKNSHGKSSSS NFSSGYFSSSNNSLDDSLIRQQVKR	SEQ ID NO: 90	MYDSKKKNSEPTTKKKFERSNYSQWDDS INHEDMNRARIKRNNDILTTV
SEQ ID NO: 68	MREYSKEDDCVKEKTNLAESENVEA DNYLEMDCLNYLAKLNGMPERKDHS	SEQ ID NO: 91	MPISNLAKESEVRAVKDIPCKNIETDNHLEI GLSSGLSRKDTSKFKKNS
SEQ ID NO: 69	MPIIGHKEDLIRTERSSVDLTRSSNN RQTDNLELNIPQHKRDNDKIEHAV	SEQ ID NO: 92	MLANVLPNLASFLKYKETPLFFIEDGFNF QNLNPGRVPLIKTPEQRKAG

SEQ ID NO: 93 (*Photorhabdus asymbiotica* strain ATCC43949 PVCPnf operon, *pvc1* – *pvc16*; e.g. corresponding to genes PAU 03353 to PAU 03338 of the sequence of GenBank accession no. FM162591.1)

5

10

15

ATGTCTACAAGTACATCTCAAATTGCGGTTGAATATCCTATTCTGTCTATCGCTTTATTGTTTCTGTGCGGAGA
TGAGAAAATTCCATTTAATAGTGTTTCAGGATTAGATATTAGTTATGACACCATTTGAATACCGAGATGGTGTTG
GTAATTGGTTCAAAATGCCGGGTCAGAGTCAGAGCACTAATATCACCTTGCCTAAAGGCGTTTTCCCGGGGA
AAACAGAAGTGTGTTGATTGGATTAACTCTATTACGCTTAATCAGGTAGAGAAAAAGGATATTACCATCAGTTTA
ACTAATGATGCAGGTACCGAATTATTAATGACCTGGAATGTTCTAATGCTTTTCCCACCTTATTGACTTCACC
TTCAATTTGATGCCACCAGTAATGATATTGCAGTACAGGAAATTACGCTGATGGCAGATCGGGTGATTATGCAG
GCTGTTTGAAGCATTGATATTTAATCATCTCATATAAGGGAACCTTTATGACAACCGTTACCAGTTATCCTGGC
GTTTATATTGAAGAAATTAATAGCCTGGCCTTGTCTAGTTTCAAATAGCGCCACAGCGTTTCTGTTTTTCTGTG
GGACGAACAAAACCAATATATTAGTGAAGATAATGCAATCCGTATTAATTCGTGGATGGATTATCTTAATCTGA
TTGGCAATTTTAATAATGAAGACAAATTAGATGTTTCTGTGCGTGCTTATTTTGCCAATGGAGGTGGATATTGT
TATCTCGTCAAAACAACGAGTTTAGAAAAAATTATCCAACCTTGGATGATGTAACCTTATTGGTTGCTGCGG

GCGAAGATATTAACGACAGTAGATGTTTTATGTCAGCCAGGAAAAGGGTTATTGCGAGTCTTTGATGGCCC
TGAAACAGAGTTGACTATCAACGGTGCGGAAGAGGCCAAAACAAGCCTATACCGCCACACCATTGCTGCGGT
TTATTATCCTTGTTGAAAGCGGATTGGGCTAACATAGATATTCCACCCAGTGCAGTGATGGCGGGAGTTTAT
GCATCGGTGGATTTATCCCGTGGTGTATGGAAAGCGCCTGCCAATGTTGCGTTGAAAGGGGGCCTGGAACC
5 TAAATTTTTAGTCACGGATGAATTGCAGGGTGAATATAACACTGGCCGCGCTATCAATATGATTGCTAATTTCA
GTAACACAGGTACTACGGTTTGGGGTGCAAGAACCCTGGAAGATAAAGACAATTGGCGTTATGTTCCAGTGC
GACGCTTGTTAATTCTGTGGAGCGGGATATCAAGCGTGCCATGAGCTTTGCTATGTTGAGCCTAATAATCA
GCCTACTTGGGAGCGGGTACGGGCGGCGATTAGCAACTACCTTTATAGCCTGTGGCAACAGGGGGGATTAG
CTGGCAGCAAAGAAGACGCTTATTTGTGCAAAATTGGTAAAGGTATAACGATGACACAGGAGCAGATTG
10 ATGCAGGGCAAATGATTGTTAAAGTCGGTTTGGCTGCTGTACGGCCTGCGGAATTTATCATTCTCCAGTTTAC
GCAAGATGTAGAACAGCGTTAATCATATGATTATGAGGAGTTATCATGTCTGCTATTCTGAAAGCGCCTGGCG
TTTATATTGAAGAAGACGCTTCCCTAGCGTTGTCTGTACGTAACAGCGCGACTGCCGTGCCTGTTTTATCGG
AAAATTTACTCCGACAGTGGTTGATTCAATCCAAGTCTGTACCCGTATCAGCAACTGGCTTGAAATTCACCTCC
TCTTTTCCCTAGCTCCAACAGTTGAGATTGTTGTCCAATCTAACACTGAATCTGAATCTGAACTTA
15 CCACTATATTGAGACAATCAATTTATCTCCAGCTGTGGAAGCATTTGCGACTCTATTTTCAAATGGCGGAGGA
GCTTGCTATATCTACCCATTAAATGATGCTAGAGATGATTGTTGTTTCTGGCGGCCATACGAGGAGGA
AGAAAGGTGATATTACTCTGTTGGTTTGGCCGGAACCTCGATCTGGATTACAAAATAAGATCTATGGCGCAGT
GAGCTCACTGTTGAATGATAACAAAGTGGGCTATTTCTGATTGCGGATAGCAATGATGGAGAATCTGTGTCA
GGAGTATGGAATAGTGCTAAGGCCGCGCCTATTATCCCCAGTTGGAAGTAACCTAAAATTTTCCACGTTGC
20 CTGGGGATAAGGACATTGCTATCAGCGGTTATCAGGATGATGATGAAACACATAAACCGAAAACTTGGATG
AGCTCAGGACAATCAACGAGGCGTTGGCACAGGATATTGATGCAAGATTGCTCGAGGAGAAACAACGTGCT
GTCATCATTCGCCAAGTGTGCCATTGCGGGCATTATTTGCCAAACGGATAATCGTCGCGGTGTTTGAAA
GCGCCAGCCAACGTTGCGCTCACAGGGATCGGGAGTTTGTGATAAGGTAGACGATGAACGGCAGGGAGA
GATGAATGACAAGGGAATCAATGTCATCCGTTTACGACCGTGGTTTTATGGTCTGGGGAGCCCGTAC
25 TTGTGTGGACGCTGCCAACATCAGCTGGCGTTATATTCCTGTTGCTGCGCTGTTCAATTCGTTGAACGAGAT
ATCCGCCAGGCGCTGCGCGCTGTGTTGTTGAACTAATAGTCAGCCTACCTGGGTACGTGCTAAGGCTGC
CGTTGATCAATATCTTTATACCCCTTTGGCAGAAAAATGCATTGATGGGTGCTCGCCCGGAAGAAGCTTATTT
GTGCAAAATTGGTCAGGATATCACCATGTCCGAGGCTGATATTAACAGGGTAAGATGATCATGACTGTTGGTT
TGGCAGCAGTGCGGCCAGCTGAGTTCATCATTCTGCAATTTACGCAGGATGTTGTTGAGTAATCTCCATGACT
30 AAACGCCAGGCACTGATTGACAGTGCCTACTCTAACCATCTTGGAGGAGGTGATGATGATGAGAGACTCC
AACC GGATGTGACTTTAACAGAAAGTATAATCAGATGCGGTCAATGCAAGGATACCCAGTGTGCTGCGCGTGT
TTATTGGTTACACCGTTGTTATCCGGAACAATCGGAAGCATCAGTCCGTATCGACAGTTTGGCCGAGTATAC
CAGCCTGTTTGGTGACGACCATGTGATGATGTTTGTGTCAGGCACTATTTTGATAATGGCGGGCAACAGGC
ATTTGTTTTACCCCTGAAGGACAATATGCCATCAGTGGAGATGACCACAGCTGAAGCGGAAAATCTGATAGC
35 CGCATTGCGCTCTGCTACGGTTAGCGAAGCCATTGGTGGGCATAGTCAGATTACACTGATTTTGGTACCGGA
TATGGCTCGGCTTAATGACAGTGATATTGATGACTCCTCAACCCAGGTAAGCCTGTGGTCCCAAGGCTGGGA
GGCGTGCTGCAATTGAGTCAGTTAGGCCCAACCTCTTTGTGCTGTTAGATGCGCCGGATAATGTTGAACA
GGCGCAGAGTGATTTAACAGAAAGTATCCTGATGCTGCAATGGGGGACAGTATGCGCTGCTGCTGCTG
AACTACCTATCAGAAAGAAATATCTGGCAAGGACAATGAATCTCAGGGAATTTTCCAGGGGACTGTTCTGTC
40 ACCCACAGCCGCGGTGCGCAGCGGTAATTCAACGCACGGATAACGACGCGGGTGTGTTGAAAAGCACCGGCC
AATATTGCCATTATCCAGGTTATTCGACCTGTTAATCTTATCTTCAGGGAAGTGTACTGTTTAACAGCAGCG
GCACTTCGCTCAATGTGATCCGCACTTTCCAGGTAAGGGCATACGGGTATGGGGATGCCGCACTCTGGAA
AACACGGATAATACGCAGTGGCGCTATCTGCAACACGCTCGGCTGGTTTCTATGTAACAGCGCAATTTGACC
CAATTGGCTCGCATGTATGCTTTGAGCCAAATGAATTAACCTGGATGAAGTTAAAAGGACAAAGTTTACA
45 CATTGGTTACGGCAATTATGTTGAGGCTGGCTGTGATGTTGTTGACAGGAGGATGAGCAATTAACATTCTGT
TAGGCGTAAACGAGACGATGACTGAGGATGATGTTGCTGCAGGAAAAATGATCATGAAAGTTGAGTTGGCTG
TGTTGTTTCTGCGCAATTTATTGAGATCAGTTTGGTGTGTTAATACCCAAACAGAGGCGCTGTCTTAAGAAGG
AAAAAGTACGATGAACGATTATTACACACCCGTGGTATCCCATCGTTTTATGGCGAGTTTTATTTTAAACCGCA
TTCCCGATCCGCTGGATATTCGTTTTAGCGTATCTCTGGCCTTAGTCGGGAACCTACAGGTGACTCAGTACA
50 GTGAGGGAGGAGAAAAATGCCCGTAATAACTATTTAGCTGAGAAAAATCCAACACGGTACGTTGACTTTGGAAC
GGGCGTGATGACAGTCTCGCCATTGACCTGGATGTTTATCGGGTATTGAGTGGTGAATAATCGCTTATG
CCGATGTGGTGGTATGCTACTGAATGAAAATCACTGCCATTGTCCAGTTGACGTTGAGCAATGCGCTGC
CGGTACGCTGGCAAAACAGCGACTTTGACGCTAACAGCAATGCCATATTGGTGAATACCCCTGAATTGCGTT
ACCAGGATATGCGCTGGCTTGGAGTCAAAATATGACAGTAGAAATCAGAGAGTTACTTATCCAGGCAAAAGGT
55 AGTGCCATCAACACGACCGACTGAATCAGAACGGCAAAACCATTCTTTGATACAGGAAAGTCTGGATGAGGC
GACTTGGGTGGAACGATAAAACGCGAAGTGTGGCCGCAATTACGCGATGAGGAAGGGTGGCGTCCATGAG
TCTGATTGAACGTGGTTTAGCTAAGCTGACAATTAATGCTTATAAGGATAGGGAAGGGGAAGATACGGGCAGG
AACGTTGACAGGCCATGTATAACCCCTGACTCCTTGCAACTGGATTACCAAACGGATTATCAGCAATCCCAAGC
GATTAATAGCGAAAAAGTACGATTTATGACAGGCCAAGCCCGCAGGGTTACTTTGAATTAATTTTT
60 GATGCCACGATGCCGGGTAAACAAACCCCATTTGAAGAGCAGCTCATGCAGCTCAAGCAACTGTGCAGTGT
GGATGCAACCAGTAACGAGACGCGATTCTGCAAGTTAAATGGGGCAAAATGCGTTGGGAAAGTCGGGGTT
ACTTTGCTGGCAGGGCCAAGAGTTTGTCTGTGAATTACACTTTGTTTGTGCTGATGCGACTCCCTTGAGGGT
ACGGGTAATATTGGCATTAGTGGCTGATGAAAGTCTGGTGTTCAGGAGACTGAACAAAATCTGCAATCTCC
GGCAAAAATCGCATTACGCATACAGGATGGGGTATCTCTGGCTCTGATGGCAGCCAGTACGGCATCAACATT
65 GTCAGGCGGTGTGGATTATCTGACGCTGGCCTGGCAAAACGGTCTGGATAATCTCAATGGGTTGTTCCGG
GTGAAATATTGCAGGCCACCAGGGGAGACGAATCATGAGCCACCAACTGAAAATATTGCAGATGGTAAGGC

ACTGTCACTTTTGGCCGCGGTAGATGTGGACACCTGTTATCGGGTTAACAGTATACCTTCTGCGACATTGAAA
CTGAGCGTACCGGATAGGCCACTCTCTTTTCAGTCAGACGGATGTTCAAGACAGAACTGGCCCACTGTCAG
GTAGGGAAAACCCCTGCGTCTGGAATTGATTGATGGTAGCAAAAAATGGGTGCTGTTAATGGTCTTATTACCC
GTAAGGCTCTGAGAATTAAGAATAAGCAATTATTGCTCACTCTGGTTGTCAAGCATCGGTTGCAACTGATGGT
5 GGATACCCAGCATTACAGCTGTTTAAAGACAAAAGCGAAAAAGCGATCTTAAGCACGCTATTGAATCAGACC
GGAATCAATGCTCGCTTCGGAAGATAGCGGCGTTAGATCAAAAGCATGAACAGATGGTGCAATTTCTGTTGT
TCAGACTGGCATTCTGTTGTGCCGACTGTCGGCAACCGGTGCATGGTTGTACCTGCCATAGAAGACGTT
CAGTTTGTTCACCTGATGCTCTGAAATCAAACCTCAGCCTATACCTTGAAGAGCAGGGGGGATGAGAACAAA
GACATCGTTGTCAAGGATGCTTACTGGCAGTTTGACAATCAAATCAACCCCGCTTTGCTGGAAGTCAGTGCG
10 TGGGATATCAGTAAGCAGCAGGTACAATCAGGCGGTGCTACGGA AAAAATCGCGTTGGGTAAGGCGGCACT
CTCTCCTGATGGATTGGCATCCCTTAATAAAACGGGTGGGACATTTGTTATAGCAGTCCGTTAACAACCCAG
GAAAGCGGTTATCTGGCACAGGGATTATTGCTTAACCAGCGCATTTCTGGGGTGACAGGAGAATTTTTGCTC
AAAGGAGATGGGCGTTACCAGTTGGGAGACAACATTTCAGCTGACTGGATTTGGTTACAGTTAGATGGTACG
GCAAGCATTACTGAGGTTGCCACCGTCTTAATCGGCGAATTGATTGGGAAACCACGGTGAGCATTGGTTTA
15 CAACATGAATATTTGCCGATATTACCTGATGCTCCGGAACATACATTGCGACAGTAGCGAAATATCAGCAGG
ACATCGGTTGTTAAACCGTATCCCCATTATTCTCGCGGTATGAATCGTCCCAATGCTTTTGTGGGCCAG
ATTGGGGAACCTTATGCTAGCCATGAAAGCGGTTTCTGTTTTTACCCAGAGCCAGGTGACGAAGTTATTATT
GGTTTTTTTGA AAATGATCCGCGTTATCCAGTTATTTTAGGTGCTATGCATAATCCGAAAAATAAGGCCCTTT
TGAACCAACCAAGATAATAGGGAAAAAGTATTGATCGTTAAAAAAGGTGAAGCGCAACAACATTAGTCATT
20 GATGGCAAAGAGAAAATGATCCGAATTAATGCGGGTGAAAATCAAATAATGCTTCAGCAAGATAAAGACATTT
CTCTGTCAACGAAAAAAGAATTAACACTGAAAGCGCAGACAATGAATGCCACGATGGATAAATCATTGGCAAT
GTCCGGGAAAAACAGTGTTGAAATCAAAGGCGCAAAAATTAATCTTACCCAATGAAAGGTGACGATGAATGG
AAAATCAAATACTGACACAACCTCTATGGTCGTGGTTGGGCTTTTCTCCGGTCTTTCCCTTGAAAAGGGGGT
AGAGATGGCTGAAGGGGCGGAAGATGTGAGACAAAGTTTGAGATTCTGTTTAGTACTGAGCCGGGGGAAC
25 GTCTTATGCGTGAAAATTATGGCTGCGGATTAAATGATTTTATGTTTGA AAATATCCGCAATGAACCTATTGCT
GAAATTGAATCCCATATCCATGACAACGTATTACGATATGAACCCCGGGCTGATATGACTGATATTCAGGTTT
GTCAATCCCCTGGCATGGGGAATACTTTGCAAGTGCAAGTCAATGATCGCCTGAGAGGGAGTGATATCAATC
AACAAATCCAGGGAGTACTTGCACTGAGTGAAGGCCGGGTGACGGAGGTAGTATGAGTGAAGCGATTGTGG
TGGATGGTGACGTGTTACAGTTTGATCCCACTTTGGCAATCGGCAGGTGACGGTTCCAGCCCAGGAAAAA
30 TTAGCGGCACAGGACATGCGCAGGTAAAGTGAAAAAAGGTGTATTCTGGGGATGAGAAACAGGTGACG
GTTTCTGCAAGCATATATTACAACAACACTTACGCCCTGGAAGCAGGAACCACTATCATGCTGCTGGATG
CTGGCCAGCAGGCCCTTCAGTGTACCAGTGGGGCGGCTTTAATTATCAAGGGGCAGCAATTTACGGCGATG
TTTACGCCTGAATTGCCAGCCATGAATAATACAGTGACTCCGCCACAACCGGATGTTACGACACCTTCATCAG
GAAAAGGACGTTTTATCACTCAACAAAATTTTGTACCGTAAATTAGAGTATTGACTGAATTAATAGAATTAA
35 CGAAGGTGTAAATAATTATTTATTTGCTGACGAATCGCTGTGACAAATAAACACAGGTGATGTTATGGAATTAA
ATGAGTTAACTAACAAATTTGTCAAATTTGGTGCCAATGACCGATTTTAAATTAGATAATCGAGCCAGTTTGCAA
TTGCTTAAATATATTGAAGCGTATACGAAGATAATACCTTTAATTCTGGCGATAAATATTGGAATGACTTTTTT
TTTATGTCAGGAATATACGCCAGAGAACTTGCACGCTTATATCAGAAAGAAATAGAACCCAATGGGAGGAT
TACCTCAGCAGGCTTTTTTGTGGCGGTTTTGCGTTTATTGGAACACCAATATCCTTATTAATGTATTACCT
40 GCTGCTCATCGTGAGCTCTATTATCGGGAGCTTTTAGGCTTGTCTTCCCATGCGGCACAGCCTGATCAGTT
GCTTTATCTATGGAACCTGAATTCGACAGTGATGGAACAGCTGCTCCCTGAAGGAACCTGTTTGAGGCTGGT
CAGGATGAACAAGGCAATGCATTGCAATATGCCCTGGATGCCAGTTTGCTGGCTAATCGTGATATATCAGT
GACTTGCGCTGGTTACGGAATGACGGGGAAAAGCAATGGGTTACTTCTGCTCCATGGGATTTACAGGCACAG
GTGCTACTGCCGTCTGATGGGATACGATTATTTGGTAAGACAAATAGTGATCAGCAGGTATTTGGTGGGGT
45 TTGATAACGTGACTCTTCTGGCGATGTAAGCGGGGATAAGGAAGATCATTGTTTGGACAGGAGATG
AACACCCAAGAACTGGTGGCACAGGTGAGCAGTGGAATCAATGGCTAACATTGACGCTGAGGTAAATAAG
AAAGAGGTCACACTGACACTGTCAGACAAAGAACCGGCAATCAGTGCGCCAGAGGATCTGGATAATCTCTTT
TTCACGCAACCGGTACTCAGGCTACAGGGAAGGATAGTCAGGCACTGCCGGAGGTGACGGGTATCAGCGT
TTCGGAAGGATGATACTAAGGATACCTCTTTTGAGATGTATCACTTAACACCATTTGGTTATAGCAGTGATA
50 TAGAGCCATTGGAGGAAAATCCAGCGTTATATTTAGGCTTTACTGATGTAAAGCCAGGGCAAACTGGCGC
TGTATTGGAAATTA AAATCCCCGCAGCAACCAACCGTTTCTGGTATTACCTGGATCAACATAATCAATGGGC
TGAATTGGATTTCATGGGTCAGTGATGGAACCCAGAATCTGTATCAGGATGGTACTTGGCACGTTGAGTTGCC
TGTGGATGCATCCAATCAGGCAGAGCAGATGCCAGTTGGACGCTATTGGTTGCGGGCAGTGGTGGAGGTAC
CCGCTCATGAGGGGGCGTTGGGGAAGGCTCCTTGGCTATATGGTCTAATCTATAACGCCATGACGGCAACC
55 TTGGTTAATGTAGATAGCATCAGTGACAGCCATTTCTTAACCCCTTTGCCTGCCAGCAGCATAACAGCGCCC
GTTGAACCCATCATTGTGTTGGCATCGGTCAACCAGCCTTGGGCATCATGGGGTGGACGTATACCTGAATCC
TACAGTGCCTTTTTTGAACGGATAGCTCAAAACCTGTCTCATCGAAACCGGTCTTAACCTGGGGAAATATGG
TGACATTACTCAAAGAGCGTTATGTCAGCATCTTTGATGTTAAGTATCCAGGTAATGATGAACCTCACCAGAGT
GCCAGACTTTGGAGCAGCAACTAACAGTGATTCAGCAACCGGTACAACGATAGCGATGATTCTCTGCG
60 TCCGGTACTGAATCCTGCTGCTGCTGCAAGAGATGGCTGATTGGTTGCAGCAGAAAGACTCTCCCTGGGCCTC
TATTGAGGTCAGGAATCCAGAATACTTGGATGTGAAAATCCATTACGAGGTGATTTTTAAACCTGATGTGAAC
GAAGATTTTGGCTATCGCCAGCTACAGCAGCAACTGTGTGAGGTGTATATGCCTTGGAGCATAGATGAGCAG
CGGCCCGTTGATTGAATAACAGCATTAAATTTTCCAGTTGTTAGCCACTATTCAACAGCAACCGCTGGTTG
AGCGAGTCACTCGTCTGACACTACATCGGGCTGATTCTTCTGATGAGAGTGATGGTACAGCATCTGTGGAAG
65 CCAAAGATAATGAAGTGCTTATTTTAGTCTGGGAAGAGGACGATAATCTGCAATACCGAGGAAATGACTATGA
GTAATCAGGATGCACTGTTTCATAGCGTTAAAGACGATATTCACTTTGATACCTTGTGGAACAAGCTCATCA

GGTGATTGAAAAACAGGCTGAAAAACTGTGGAGTGATACGGCAGAGCATGATCCGGGTATCACATTTTTGCA
GGGAATCAGTTACGGTGTGTCAAGATTTGGCTTACCGACATACATTACCCCTGAAAAGATTTACTGACTCCGGC
GCCGGATGAGCAGCAGCAAGAGGGAATTTTTCTGCCGAATTTGGCCCGCATAATACACTGACTTGTGGGC
CGGTGACAGCGGATGATTATCGCAAGGCATTGTTAGATCTACACAGCAGCGACAGCCTGGATGGTACTCAG
5 CAGGATGAGGGGGATTTCTGTTCCGGAGTGTGCAACTGGTGCCTGAACCGGAAAAACAGCGTTATACCTAT
TGGTATGATGCAACCAAGAGGGAATATAGCTTTGTCAACAGTGAAGGGGGCTAAAGAGTTTACCTTGCGGGGG
AATTACTGGTTGTATCTGGAACCAACCCGTTGGACTCAGGGTAATATTGCCGCTGCTACCAGACAACCTGACA
GAATTTTTGACTAAAAATCGCAATATTGGTGAATCTGTCAGCAACATTATCTGGCTACAACCGGTTGATCTGC
CACTGTTGCTGGATGTTGAACTGGATGATGATGAGGTGCACAGGATGTCCCGGATTTTTTGGCGCGGTGT
10 ATAGCACCGCAGAGCAGTATCTGATGCCTGGAGCACAGCGTTACCGTACGGAAGTACTGCAAAATGCTGGG
ATGAGCAATGATCAAATCTTCGAAGGTCCATTATTGGAACATGGCTGGATACCAGAGCTGCCGGCAGCCCGT
GATTATACTCAAAGGCTCACTCTCAATCTTAGCCGGTTGGTAAATAGTCTGCTTGAGATTGAGGGCATTAAAC
ATGTGAATCGTCTTCGTCTGGATGATAGCTTCGATAAAACGCTATTGAACCCGTTAAGGGGGATACCTGGTC
GTGGTCGATCAAAGAGGGCTATTATCCACGTCTTTGGGGAGAAGACCCACTTAACCAATTGGCGCAACAAAA
15 TGGCCCGCTTAGGGTGATGCCAAAGGAGGGATTAGCTCAGTGTGAGTAAAGAGCAAATCCAGGCCAGTT
TACCTGTTGCTGGATGATTCAAAATGAGCGGTAATTTGGCTTACGGCCAGCAGCATGCTGAGCGCT
ATTATCCCGTCAGTGATACTTTGCCGCTTGCTATGGACTACAACATTCTTTGTCTGAAAGTGAACACTTATTG
CCACTTCATCAATTTATGTTGCCATTTGAACAATTATTGGCCTGTGGTTGTCAACAGATAGCCATGCTCCCGC
GGTACTGGCTTTTCAGCGCGAAGGTTATGAGGTTTGGGGTGATCAGTGGCCCTTTAAGTCAGGCTCAGTGA
20 ATGATGACGCCCATCAAGATTATGCCCTGCATTAAAGGATTTGTTAGGACAGATTGCGCTGGATAGTGATCA
TGAATTGGATATTATTAATTACTTGTGGTTACTTTGGCACACAGCGGGCACC CGGTACCTTTACGACACAA
CTCGATGATTTTCGTGCGGTCCAACAGGGTTATCTGGCCAGCAACCGACATTGACTTACCACCGCTCCAAT
ATTCGTATCGATCAGGTATCGTCGCTACAAAAACGTAATTGCTGCTCGCATGGGGCTGGGCGGTGAGTTGTTT
AAACCTCAACCGGATCTGAGCCAACCTGCCTTTTATTGATTGAACATCGAGCGTTGCTGCCAGTCAAACCCA
25 ATAGTCAGTTTGATAAGGAACAGAAACCAGCCTCGGTGACAGAGGAGGGGGGCAGCCAAACAGGTCAACAT
TATGTGGTCATTGAACAGAAGGGCATTGATGGCAAGCTGACACAGGGGCAAGTGATCAATTTAATTCTGTAT
GAAGGAGAGCAGGGAGAAACCCAATTTACGATACGCGGTGATGATTCAAAACCGAGGGGGATAAGTT
TTGGTTGGATGTGAATAATAGTGCGCAACTGGAATATAATCTGGCGCGGGTAATGACAGCAGCCAAGGCGAG
TAAACTCTTTTGGCAAAACAGCCCGGTATGGATGGAGGATATGGGCTATCGTCTGGCCTATGCTAGTGACCA
30 ATCCTCATTGCCTGTGAATCAACGGCGCTTGACCCGCACAGTGCAAACTCCATTCCCGCCGATGGTTGTTGT
AGGTAGCGAAATCACCTGTTAAAGCAGGTGGGGATAGTCAATTTAAAAAAGCGGAGTCAAGAAAACTTTAT
GCAAAAGTTGTTAGCTTTGATCGCATTGAAGGGACCTTGATTATTGAGCGTTTGGGTAATTCACCTCTGGCTT
TTCTACCTCGGAAGAGGCGTGGCGGTATAGTTGGTATTTTTCGGGGAGAAATATGAAAGGACTGACCGCT
TTTCATTTGTGATTAGCGTAGTAGTGAACAGTGACTTAATTAATTGCCCGGTGTTGATCCCTATAAATTGGAA
35 GAATGGGTGAAAGAAACGATTCTTACCGAATTTCCAGCTCATATTTCTATGATTATCCATTGGATGGATCGGG
AAGCCTTTTTAAATTTGCGCAATACCTATCAGCGTTGGCAAAATAATGGTACGCCACTGGGGGATGCGGCTTA
TTCCATTCTAGAAAGTTTGACACTTGGTAAATTGCCATCTGCCTTAAAGGTGTTGGCACAATGCGTATTGCC
ACATCTAGTCAAAAGAGAAGTGGTGGGTGAGTGGTGAATGATGATCAATGGAATACAGTAACCCAGAAAT
GAATTATTCTATGTTCTAAAGAGAGCTAGGAAAAATAAATATCTGCCACTAATGATGTTGAATTAATATGTTT
40 TCTGGAGTTAATCATGAACGAACTCGTTATAATGCAACTGTACAAGAACAACAACATTATCTAATCCAAAAG
CTGTTGGACCTGACATCGATAAATTAAGGATAAATTTAAAGAGGGCAGTATTCCTCGCAACCGATTTCAA
TGAGTTAATTGATATTGCCGATATTGGACGTAAAGCCTGTGGTCAAGCGCCACAACAAAATGGCCAGGAGA
AGGATTGAAATTGGCTGATGACGGTACGCTTAATTTAAAAATAGGCACTTTTTCCAATAAAGACTTTTCTCCAT
TAATATTAAGAGATGATGTTTTATCTGTAGATCTTGGTAGTGGTCTGACTAATGAAACCAATGGAATCTGTGC
45 GGTACGGGCGATGATTACAGTTAACTAGCTAATGATAGCTGTAAGTAAAGTAAAGCTAATGCGGAATTAAGCTACTA
GTAGTGGTGGTGTGGCGTTAAAGTTAGTGCTAATAAGGGACTTAGCGTTGATAGTAGTGGTGTTCAGTTAA
AGTTAATACTGATAAGGGAATTAGCGTTGATGGTAATGGTGTTCAGTTAAAGTTAATACTAGTAAAGGAATTA
GCGTTGATAATACAGGTGTTGCAGTTATAGCTAATGCTAGTAAGGGAATTAGCGTTGATGGTAGTGGTGTTC
AGTTATAGCTAATACTAGTAAAGGAATTAGCGTTGATGGTAGTGGTGTTCAGTTATAGCTAATACTAGTAAA
50 GGAATTAGCGTTGATAATACAGGTGTTGCAGTTATAGCTAATGCTAGTAAGGGAATTAGCGTTGATGGTAGTG
GTGTTGCAGTTATAGCTAATACTAGTAAAGGAATTAGCGTTGATGGTAGTGGTGTTCAGTTATAGCTAATAC
TAGTAAAGGAATTAGCGTTGATAGTAGTGGTGTTCAGTTAAAGTAAAGCTAATGGCGGAATTAAGTAGAT
GCTAATGGTGTTCGAATTGATCCTAATAATGTACTCCCCAAGGGAGTGATTGTAATGTTCTCTGGCAGTACTG
CACCAACTGGTTGGGCGTTATGTGATGGCAATAATGGTACACCAAAATTTAATCGATCGATTTATTTTAGGTGG
55 GAAAGGGACTGATATTAATGGAGTGAGTACTAATACAGCTTCAGGTACTAAAAATAGTAAGTTATTGATTTCA
GTTCTGATGAAGCTACATTAATCTGATGGTAAACACTGGGGAGAGCATTATCGTTACAGCAAATACCTAA
TCATGCACACTTTAGTGGAATAATTATGGATACAGAGAAAGTTAATTATTATGGAAGTAAAAAATCACAAACAA
ATGTGTGGGGTGTAAACAACAGGAGATAATACTCAGTACGATATTTTATAAGTCATCAGGTGTACTTGACTC
TAACAATAATGTCTCCAACAGTACCTTAGCGGGAACAGTCTGCAGACGCACGATGATGATTAAGATAACG
60 GGCACAGGAAACATCTCACAAAAACAGTAACAGTCCCTTATTATATTCTGGCTTATCATATAAAGCTTTA
ATATATATGAAAAATTGAAATATAAATTATCCATTAATAATAAAGAGGATATTAGCATGACTTCGGAGCCAAAT
CTGTTAAACCGGATTACAATTACTATTGAAGCTAATAATCAACAAGTAGCTAGAAAAAGTATTGCATGGCTCCTT
GCTTAATCAAGCTAATATAAATAAATTATTTAATTCATCTTTAATGAATATGAAATTAATAGGGGTGTTTATTTA
GAAACATTAATCCTGAATCTTGGTACGATAAATTTCCATGATTTTAATTCATTGTTTCTACTCTCCTAAAAGCT
65 GCATTGAATAAAGAAATTCAGTCAATATCAGATAAACAACCATAGGGAAGAAATGCTATTTAATGAGACAATATC
AAATCAAGCTACTGATAAGTCTTACATATTTGGCGATAACAAATTAATTGATGCAGAGAATTTCACTCACTTTT

ATATCAAAAGCATTCCACATTAAATCTAGTAGAAGCAATGGGAAATAATGGTATTGAAAAATTAACAAATCAGT
TAACACAAATAGAAAAATAAATTTGCGTTATTATTGGCAAAAAGTTGTTTGTCTGAGGAAGGCTTAAACGACTC
TTGGCTATCAAAACAACCCGATTTATTAATCGCTATCAATCGCAGATTATCTGAAAGAATAAATAGACCACAATA
TCAGGAGAAGCTTGTTCCTGCGGACAACCTGATATTTAGTGCTCTGGGATATATACAACAGTACAATATACAG
5 GAAATTCCTAAACCGGATGAAAAAGTTATTGCACGCATAACAACCTGAACCTTAATAATAATGGTTTGCTTAATAC
AATACCTATTATTACACTATTTTCGTGAGAGTGGGATTAACGATTCATCACTAAATGATTGGCTAAAGAAAAATCT
GGCAGGTGAGATCAATTTACAGTTATGCAGAAAAGTATCTTTCTGCTAAGGAATACCAATATCTGTCAGAACAA
TTTTGTTTCAAAGAGCGTCGATAAAAAATAGATATGATGAAGAGCCCCGTAAATCAGAGCATATTATCAAGGTTG
AATAATAATTCATTAAAGAAGGAAATAATCACAGTCAACTCTGTACTCTCAGTAGACTATATTCTGAACCCGT
10 TGTATTACCTGAACAAACCATTTCTACGTCAGGTTAGTAATACAGTAGATCAGAGCATATTATCAAGGTTGAATA
ATGCCTCCATTAAAGAAGGAAATAACCAAAGTCAACTTCGCACTCTCAGTAGACTATATTCTGAGCCCGTTGC
ATTACCTGAACAAACCATTTCCACGTCAGGTTAGTAATACAGGTATATTAATTCTATGGCCAATGCTACCTACAC
TATTTAACAGCTTGGTCTACTTGAGAAAAAGAAATTTATCCATCGTCAGGCCAGTTTAAATGCCGTTGATTTT
CTTGATTACCTGATTTGGGGAACCGAAGATGTGAAAGTGAACGAAAGGTTTTGAATAATGTTCTATGTGGGT
15 TAATGGCTGATGAAATTAAGTGAACCAATGCCTATTGAACAGAAAAACAATGGATAATAATTCAATGGCTGGA
CGCTATTATCTCCCAACTTTCTGGCTGGAAAAAGTTAAGTCGTAATGACGTCCGTCAATTATTTCTACAACGAC
CAGGAGAATTACTGATCAATGAACAGGAAATTAATAATCACAATACAGCAACAACCATTTGATGCTCTGTAACT
GATTGGCCGTGGCCAATGAATATGGCTTGTGTTTAGCTGGTTGAGTCAACCATTAAACCATACGTGGTTATAAC
CATTGACCACAATGACTTAGTCTGAGTAAAAAATATGAATATATCGCCTGTTTTTTATGATTCATTGAATCAGG
20 ATAACGACCGTGATCTATCGTTTTTATTTAGCGAACTGGAACGAATAGATCTCGCTCTTCAACACCATTTTTAT
TGTGTAGAAAGTCAGCGAAGTGAGCTCCTGGATGAGTTTTCTGCTCACTGAGGCGGAAGTGGTGACCAGGCT
GGATAAGCCACTTTGGTAAACCTCATTGGATAAATGATGATTATCTGGCGATATCGCAAAAGGGCAATGTAAGC
CTAATGGCAGCGTCCAGATTAATGGATCTGATCGAACGCTTTGAACCTGACTGATTTTTGAGCGCATGTTTTAC
TATTAGGCTTATTGCCCCATTTTGATAGCCGCTATTATCGACTGTTTTCGCTGATTTCAAGGGGGACAACAGGG
25 TCGATTACCTTCTTTGCGCTGGCATTGGAAGTGTGTTGCGCACTCGGCGCTGGAGAAACAGGTACAGCAAGC
GAGTTTTCTGCACCGGGCACCTTTGATGGGTTGCCAGCTATTATCCATCGATACTAGTCAAAAAACGCTGGC
CTGGCTCCAGACTCCCTTTATTACTGACAGCGGGGTATATCACTTTTTACTGGGGCATCACTACATTATGCCG
GCTTTAGAACATTGTGCTGAGTGGTTAACACCGACAGGGATTGGCTGTTATCCTGAAGGATTAACAACAAGTAC
TGGGTAACGTATTGTTATCTGACAACGATAATATTAGACCGATTGTCTTATTACGGGGAATGGCCGGCAGTGC
30 CAGAGCTTATACCATTACTAATATGATGGCTTCCAGAAAGGGAAGCAAAACACTGCTGCTAGATATATCCAACT
GCTGATGCGATCGAAGGAAACATTATTTCTCAGAGTAAAGCAATATTTTGCGGAAACCCGCATCGGTAACAGCAT
GTTTATTATTACGGAATTTTTGCTTGTTAGTGGAACAGAATAACAACCTATTGGACTCCCTGTCAGAGTTATTG
AATCAACCTGAATTAAGAATTGTTTGCCTGATTGAGCCTTATTTCCCATTTGGTATGGCTGAAAAAGATACCGG
TATTACTGATTGAGATGCCACTTTTAACGCCTGCGGAAAAAGCCAGATTGTTAATTGCCAGCTTACCGGATAA
35 TTGTTCCGAGGATATTGATACGATAACTTTAAGCCAGCGTTACACTTTTAACCCAGAAACCCCTGCCATTGATTT
TGCAAGAGGCCCAGCTTTATCAACAGCAGCGAGATCCGCTGGATATCTTGCAAGCAATGCGATATACGCCAGG
CATTAAATTTGCGTGCTCAACAAAATTTCCGTCATTGGCACAGCGGATTATTCCTAAGCGCTCATTAAAGGA
TTTATTGGTATCGATGAGATTGCTCAGCAGTACGGGAATATCTATAGCAATTAAGCAATTAAGCAATTAAGCA
CTGGCGGGAGGGTTTAAAGATAAAATTTGCCTATGGCACTGGTATCAGCGCCCTGTTTTATGGTGATTACAGGC
40 ACTGGAACCAACATGGCAGCAGAAGTGATTGCTGACCACATTGGCGTTGACTTAATAAAAGTGGATTTATCTA
CAGTAGTGAATAAATACATCGGTGAAACAGAAAAAACTTATCCCGTATTTTCGATTTGGCGGAACAGGATGC
AGGGGTATTATTCTTTGATGAAGCTGACGCACTGTTTGGTAAACGCAGTGAAACTAAAGATTCCCAGGACAGA
CATGCCAATATTGAAGTTTCTTACTTATTACAGCGCCTGGAGAATTACCCGGGTCTGGTCATTTTATCCACCA
ATAATCGTGGTCATTTAGACAGTGCTTTTAAATCGTCGTTTTACTTTTATTACCCGTTTTACTTACCCGGATGAA
45 AAAATCCGTAAAAAAATGTGGCAGGAAATTTGGCCTAGAAATATAAAAAATATCGGAAGATATCGATTTTAACGA
ATTAGCTCAACGAACAAGCGTGACTGGCGCAATATCCGCAATATTGCTTTATTGTCTTCATTCTTTGCTTCA
GAGCAGGGGAATGATGAAGTCAGTAATGAAAATATTGAAATTGCATTGAAGCGTGAATTAGCTAAAGTCGGA
CGATTAACATTTTAAAGTTATCACAATGAAAGTATTGAAATATTAATAAATTTATTACCAAAAAAGTTATCACG
ATATAATTTAAGAGAGGTTTTTTATGTTAAACACGCAAACTATTATTGATGTCAATAAGGCAATGGATGCCATG
50 CTGCGCGCATATCTGAATCAAGATATTGCCATTGTTTTGATCTACCTGAATTGGATACTATGCAATCTGATGC
GATGGTAAGTATCTTTCTTTATGACATTCATGAAGATTTACAGCTTCGCTCGGCAGAAATCAAGAGGGTTTGAT
GTTTATGCCGGGAGGTTATTGCCTGGTTGGGTAATATTAATGTAACCTATCTGATTACCTATTGGGAAGCTT
CTAAGCCAGCGACTGATGCCAGCAGTCCGGATAGCCAACCTGATAACCAGGCAATACAAGTGATGTCACAAG
TATTAATGCCTTGATTAATAATCGTCAATTGGCAGGTATTCCTGGTGCTTATACTCAGGTTGTACCGCCTAAA
55 GAGAGTTTAAATAGCCTGGGGAATTTCTGGCAATCACTGGGTAATCGCCACGGCTTTCTCTCAATTATTCAG
TGACAGTACCTGTTAGCCTAAACGATGGTCAGGATAGCGGACTCCGGTTACCGCGGTTTCTTCTACAGTGG
AACAAACGGCATCGCTCAGTCAAGAAGTGGTTAGTCATGCTTTACGCGAATTACTCATTACGGAATTAGGAG
GAGGAGAGGATAACCGGTTGGTACTGAGTAAAGTTGAATTATCCGCACTGAAAGAGACGATGACTCAAGACA
GTCCGGCTCAGATGATTATATTGTTGCTGTTTCAGGCATTACACGACAGGAATATTTGAAGGAAATTGATAAT
60 ATCTTTGATCGTTGGGTAATAATGCTGAAGTTATTACCACTATTGATGATTGTGGGATTAGAATTGAAAGTAT
AACGAAAGATAATCTTGTAGGAATTTAA

SEQ ID NO: 94 (*Photorhabdus asymbiotica* strain ATCC43949 PVClopT operon, *pvc1* – *pvc16*; e.g. corresponding to genes PAU 02112 to PAU 02099 of the sequence of GenBank accession no. FM162591.1)

5 ATGGCCACAACCACAGTTGACTATCCAATACCGGCTTATCGATTTGTTGTCTCCGTTGGTGATGAACAAATCC
CTTTTAAACAGCGTTTCGGGGCTGGATATTACTTATGATGTCATCGAGTATAAAGATGGCACC GGTAATTATTAT
AAAATGCCGGGTCAACGTCAGTTAATCAATATTACACTGCGTAAAGGGGTATTCCCTGGCGACACTAAACTTT
TTGATTGGCTTAATTCATTACAGCTTAATCAGGTTGAGAAAAAGATGTTTCAATTAGCTTGACCAACGAAGTT
10 GGAAGTGAATTTTAATGACCTGGAGCGTAGCCAATGCATTCCCAACCTCATTAAACATCTCCTTCTTTTGATG
CCACCAGCAATGATATCGCTGTTCAAGAAATAAACTGACTGCCGATCGAGTCACTATTACAGGCAGCTTAAAG
CATCACGATGATTGATATCAGACGGGACAAAATGATCCTCAAAATTTGGCACAACGGCTACCCGTTCCAAC
AAATTTACCTCTTACAGTTACGCAAAAATATCGCACAATAAATTGGAGGCAATATGCCAACAACAACCTTATC
CCGGCGTTTATATTGAAGAAGACGCCCTACTGTCACTTTCCGTTCCGCTCAAGTGCAACGGCGGTGCCCGTTT
TTACCGTTGAAGTGAACGTCAGTCAACTTCATACTCTCAACACAGGTAAATAGTTGGTTAGAATATCTGACAAAAA
15 GCAGATAAAAAATTCATTCTACCGACAACTTGATATCGCATTGCGCGCTTATTTTATTAACGGCGGCGGAT
ATGGTTATCTCGTCAAAGCGGGTGAATTAACAAATCAAATTCAAAACCTAACGATGTCACATTACTGGTCGC
GGCTGGAGAAAATATCAAAGATGCTGTGAGTACACTTTGTCAACCGGGCAAAGGCTTATTTGCCATTCTGGAT
GGCCCAACCGAAGAGTTAAAGTCTGATGGCAAATCCAGAGATCCGTATGATCAAAGCCCTTTTGCCGCCGTT
TATTACCCCTGGCTAGTTGCTGATTGGGCAGACAATATCCGCCAAGCGCGGCCATTGCCGGTATCTATTGT
20 TCAGTTGACCGTACCCGCGGTGTCTGGAAGCCCCAGCAAATGTCATATTACAAGCGGGGTGAACCGGAA
GTTTAAAGTCAACGATGACTTACAAGGTATTTACAACACAGGTAAAGCCATCAATATGATCCGTGAATTTCCG
AATACCGGTGTCACCATCTGGGGCGCCCGCACACTTAAGGACGAAGATAACTGGCGTTACATCCAGTTCCG
CCGCCTGTTTAAACAGTGCAGAGCGAGACATTAATAATGCCATGAGTTTCCGCGTCTTTGAACCTAACAGCCA
ACCCACCTGGAAAGCTGTACACCGAGCTATTGATAATTATCTCTATGCCCTTTGGCAACAAGGAGGGCTAGC
25 AGGAAACAAAGCTGAACAAGCTTACTTTGTCAAATTTGGTAAAGGGGATAACCATGACCGATGATGATATCAAG
CAAGGGAAAATGATTGTTAAAGTGGGTATGGCCGCAGTGCGCCCGGCTGAATTTATCATCCTTCAATTTTAC
AAAATGTAGCACAGTAACCGTACTGAGGCGCGGTTTAAACACCGCGTCCATTAGTCTATTGAATGGAGGAGA
CAATAATGATAACCGAGATAAAAACAGCCGGGCGTCAACATCACGGAAAATTCGATATCCCCGAAATCAGATA
ATGAATTTATCGGCGTCCCCGTTTTTATTGGCCATACCGAAAAAATTCAGCCATAAAACGGCTGTTAAACTA
30 AATAGCCTGATGGACTTTACCCAAGCTTTCCGTGCATCAGGATTAACCTATTATTAGTACGCCACTTTTTTGA
AAATGGTGGACAGCAAGCTTATATCTTGTCACTGGGGATTAATCAACAGCTAAAAGATTTTCAATCATTGATTA
CCGCCCTGCAATGGAAGTGGGTAAAACAAGCCATTGCCGCAGAAAACGAAATCACATTGATTGTTGTGCCTG
ATATTACCCGTTTTAATGATCTCAGCGCTCAAAAAAGCCTTTGGCTACAACCTCTGGCAATCAATACTTGAAGT
TGTAAGTTCGCGCTGGCATCATGGGATTACTGGACGCGCTGATGATCCAACATTAGCAACTGAGTGTTTA
35 AAACAATTCTCTTCCATGATCGCCAATGGGCGCGGTATATGCGCAAGGCTAAAAGTACCTACCAAGAA
AACCGTTACATACATTGTACTTTACCTACTGCTGCGGTGCGCGCTTATGCAACGCAATGACAGTCAGAAA
GGCATATGGACTGCTCCCGCCAATGTGGCTTTAGCCAACGTCATCGGTCCGGTACGTTCTTACATTGAAGCT
GGAACCTTGCTGAATCAAGAAGGCACTTCGTTGAATCTGGTGCCTAGCTTCCCCGGCAAAGGCATTAAATC
TGGGGCTGCCGCACTCTGGATAACATACCTCATTCTCCCTGGCGTTATATCCAAATTCGCCGTTTGGTTTCCT
40 ATATCGAAGCTCATATAACCCAACCTTGCCGCGCCTTTGTCTTTGAACCCAACAACGCCATCACCTGGATGAA
ATTTAAAGGTCAGGCCCACAACCTGGCTACGTCAATTATGGCTAAAAGGTGGATTACGGGGGCATCAGGAAGA
TCAAGCATTTGAGGTGTTACTGGGTGTTAATGAATCCATGAGTGAAACGGATATCTTGGCCGAAAAATGATC
ATGAAAATCAGGCTGGCGCTGTTAATTCGGCAGAAATTTAGAGCTGAGTCTGAGCTTTGATATCCGTAACA
ATACCGTACCTAGCTAATCTAAACAGGGGAAAAACATGTACAACCTTATACACCCCGCTCAGTATCTCACCGTTT
45 TATCGCCAGTTTTCTGTTTAAACAACATTCCCAGCCCACTTGATATCGCCTTTACGCGTATATCTGGCCTGAGC
CGAGAAGTCAAACACCCAACATAGCCAAGGTGGAGAAAACGCCAGAAACGCTCTGGTTATCCGAGAAGAT
CCAACATGGCAGCCTGGTGCTGGAGCGCGGTGTTATGACCATCACTCCCCCACCTTGGTTTTTGATCGCGT
GCTGCGCGGTGAAAAAGCCGTGTATGCCGATGTTGTCATCATGCTACTGAATGAAAATGCGTTACCCGTGGC
GAGCTGGACAGTCAGTAACGCGCTACCGGTTGTTGGTCCACCAGCGACTTTGATGCTAATAGCAACACCGT
50 ACTGGTGAGTTCTCTGGAATTACGTTATCAGGATATGCGCTGGTTAGGAGTAAAAGCATGACGGTGAAGAAATTA
AAGAACTGATTATTCAGGCTAAAGTCACCGATTCTACGAGTGATCAACTCGCCCCAAGAACATTAGCCCAAGA
AAAGCTGGATAACGCCCCGTTTGATTGACATAGTGAACGGGAAGTGTAGAGGCATTACGTGAAGGAGGCCA
TCATGAGTTTAAATTGAACGTGGTTTATCCAGACTCACCTAACCGCTTTTAAAGACCGAGAAGGTAAAGTTTC
CGTGGGTGCTTACAAGCCATGTATAACCCCGATACGATCCAGCTTGACTACCAACCCCGCTACCAACAGGA
55 TGAAAGTGTTAATCGTGCCAGCCAAAGCAGCCGTTATGTATTATCCCAACCCCGCCGATTATCCTTAGTTCTG
CTGTTTGATGCCCTGATGCCCGATAATAACATGCCGATAGAAACCCAGCTTGCGACCTGAAATCCCTGTGT
GCGATTGATGCCAGCACCAAGTACCCCACTTCTTAAATCAAATGGGGCAAAATGCGCTGGGGAACAAA
GGTTATTTTGCCTGCCGAGCCAGTAGCCTGGCCGTCAACTATACCCTGTTTGACCGGGATGCCACACCATTG
CGGGCCAGCGCCACTCTATCTCTGGTAGCGGACGAAAGCTTTATTATTCAAGCTACCGAACGGCAGTTAAAA
60 TCACCGCCGGCCACTGCGGTTAGCGTAAGTATGCTCTCCCTGCCTTTGATTGCTTTAGATGCTGGAGCG
TCTCTGGCTGGTGGCATTGATTATCTCTCGCTGGCCTGGCAAAACGGTCTGGATAATCTTGATGACTTTACCC
CCGGACAAACACTGCAAGCGCGGGGGGATGCATGAAGATACCCATGATAACCCCTCAAAATAGGTGGCAAAA
CGTCAATCAATTGACTGTATCAGTCTGACAATAAACCATCAAATCAATGGCATTCCCTCGACCAACATCAC
CTTGGGATCGCTGGCAGCCATATTTTCGACACCAAGCCCAAGCTGAAGTGGCAAGTTGTCCGC
65 CCAATAATGAACTCACCTACAGATCCAAAAAACCGTGGTGTAAAGGGAGCATCTCGACAAGCACTTGA

ACTGAAAGGTCAAGACAGCATCATTACCCTGACAGCAAAACATCCACTACAAAAGTTAACTCATAGCCTCCAT
TCACAATTATTCAGTCAACAGAGTGATGAAGCGATTATCAGGAAATTTCAATCAGGCGGGTATCCAAACAA
CGATAAAGCAGGCTCCTCAACTTAAAACCGTTCATGAACAAATGGTGCAATTTGTTGCAATGACTGGGCATT
CCTAAAAAGCCGATTGATTGCCACTAATACCTGGCTGTTGCCCGGCAATGAATCGGTTACTTTGATAACACCT
5 AAGGCCCTGAATCAATCGACAGTGCATACTCTTCATCGACAGGCCAGTGCTGAAGATATTGTGTTATTTGCAG
CGGATCTCCAATGGAATAACCAATATAGCCCTAAAACGGTGAGTGACGTGCCTGGGATATTGCTCAACAAA
AGCTTTCCCCAGCAATTAATACCCAAAACAGTCAGCTTGGCAGTCATAAATTGGCCGTGGACAGTATCGCCG
CACTGGCTGATAAAGAGTGGCAATGGGCTTACAGCTATCCATTAGATAATGAACAAGCCAAACACCTTGCTCA
AGGCATTATGAATAACCTGCGAAGCCATAATATATCTGGCAGTTTTGAAATCGAAGGTAATACCGTTATCAA
10 CCGGGGGATGTCTTGGCGTTAAATGGTTTTGGTCAGGGGATGGACGGTCAAGGGATTATCACCGGAGTCAG
TCAGATAATTAATCAGCGGCAAGGCTGGCACACCCTATTAACCTTAGGCATGTTACCCGATGTAGAACCGCC
GGTGCCTCAGGTGAAAGAGTTGCATATCGGTATCGTGAAAAAATACCAGCAAGACCGCCAATCACTAAGCCG
TATCCAGTCAGAATACCCGCATTAACTTGACCAAAGGTGTCTTTTTGCCCGGCTAGGTAAACCTTATGCC
AGTCATGAAAGCGGATTTTGCTTTTATCCCGAACCGGGAGATGAAGTGATTATCGGATTCTTTGAATGTGATC
15 CTCGTTTTCCAGTGATATTAGGTTCCATGCATAATCCGAAAAATAAACCACCGTTAGAACCCAGTGAAAAAAT
CCGGTAAAAACTTTGATTATCAAGCAAGGGGATAAACAAGCATTAAATTCGATAATCAAGCAAGCAAGCG
TGGCACTTAATAGCGGCGAAAAATAAAGTCTCTCTGCAACAGGATAAAAAACATTACGCTCAATTCAACTAAAA
TCTCATCACTCAGGCCCAAGAAATTAATATACAAGCGGAAAAATCTCTGTCAGCCACAGGAAAAATCTGGCGTC
GATATTAAGGGCGCGAAAAATTAACCTTAACCCAGTAATGAGGTATTGAAATGACAAGCCAAATATTAGCCAATA
20 TTTACGGTTGCGGCTGGAAATTTCCGCCACAGTTTTCTATTGAAACTGGCGTAGAAATGGCCGAAGGTGCCG
AAAACGTTCCGCCAAAGTATGAAATCCTTTTTTAACTGAACCCGGTGAACGAATTATGCGTGAAGATTATGG
TTGTGGTCTGAATGATTACATGTTTAAAAATATCAGTGATGAATTATTATCGGAGATTCAAACCCGCATTGAAG
AACGAGTATTGCGCTATGAACCCCGTGCTGAAATCACAGATATCCAAGTAACCTCAGAAAACAGACTCACCGA
ATACTTTACATATTCAAGTGACCTATGCCCTGAGAGGCAGCCAAATCAGTCAACAGCTTGAAAGGGGTTCTTGA
25 GATCAACGAAGGTCAGGCAAAGGTGAGTCTATGAGCAAACAACCTCATTATTGATGGCGACAGCCTGCTATTC
GAGCCATTATTCGGCAACCGGCAGGTCACTATTTTGATGCCAGCGACCATCAGAGGCAGCGGACACGCGCA
AATCCAAGGCAGAAAGATAGCGATTGTGCGGCATGAAAAAAGGTACAACCTCAAGCGCAATACATTACCCC
AAGCCACCCGGTACCTGGCATAGGCACAGTTACCATTGCTCAATTAGATACCAGCCAGCAAGTCAACTTTTG
CCACAGCCCTGCCACAGTGATAGTTGTGCGGCGCAATTTACCGCTCGATTTACCCCATCACAGCCGGCAAT
30 TAATCCGTCAACCGGCCAGATGTCACAACACCCAGTATGGGCAAGGCCGTTTTATTGCCAGTCAACATAC
TATCAACGCGCGGATAAATACTCTGCAAAATCATTATTAATCAAGCTTCCTATTCTGCAATGCTATCAGCAAT
ATATTCAAATAACAGGTGGTATAATATGGGACTCACCGAATTAAAAAATAAACTCTCTGCTATCGTACTCGATA
CGGATTTTAACTTGATGAAAGAAGTACACTGGATATTTTAACTGGCTACAAGAATATGCTAAAAAATCCCT
TTCAATCAAGAGAAAAAACAGTTCTGGGATAGTTTCTATTTTATTCAGGAAAAATAGTCTGAGAAATTAGCCGA
35 TCTTTACCAAACGTTAATAAAACGAATGGCCATTTACCGGCCCATCAAGCTTTTGTTTTAGCCTTTTTAAAC
TTTTAGAAACCACCAAAGTATTATTTAATACTTTTCCGGCAGCAGATCGTGATCTTTATTACCGGGAATTATTA
GGTCTAAACCCAGAAATGCCAAGCAGATAGTGTGCTTTAGGCATTACCTTAATACAGATAACACAGAAAC
ATCTTATTCCTAAGAAACCTTGTTCCGATGCGGGCGAGGCGGAAATCCGCTACATAAGCAATCGCATCAA
ATGCAGATTTACTGGCGAATCAAGGAAAAATTGAGCGATCTGCGTTGGTGTGCAAAAGATAATGATAGCTGGC
40 AATCTGCAATACTACTGAACCACTCAGATAATATTGAATTACCTGAAAACAGTATTCGACTTTTTAGTCCAACG
CCGGATGATATTCCTGTTTTATCCGGTTATTTGATACTTCGTCTTTATTTGCTATGCCAACGGGGGAACGCA
GTATTACATTGACTTTAGCAGATAATTGGCATGGTGATATTAAGCACATCACCGCTAAAATCAGTTCGGGAGA
TCACTGGCTTTCACTATCAGTAAAAAAGAACAAGACAATAGTATTCATCTTAACTTTATTTATCAACCAA
TGATGACCCCATCGTCTCTCTGATGCTTTGGATAATATAGCGTTTGATGTACCGGTATTAAGCTGGGCAT
45 GTTCAGGACCTATACTACCAAGATTACGGGTATTGAAATTAGCATTAAACGGCAAGCAATGTACATTATT
CCTCTGATAACGGTATTGAAAAATAGATGCAGCTAGTTTTCCCTTTGGACAATCACCGTCACCAGGTTCCGG
TTTTAATCTGATTGCCCTGAATGGTATGGTACAGAAAGCGCCAAAATTACTCTTACTCCTCAATGGACTGGA
TTACCCAAAGAGGGGTTTTAAGAGTGGTATCAAGGATATAGTTCTACCCCGAAAAATAATGCATTTAAAGTAC
AGGCTTATTTAATCACACCTCAAAAGAGAGAAAAATTTAATGAAGCTCAGTCATTATTTAATGAAAGTAAAGAC
50 AAGAAACCACAAGGAAAAAGCCTAACTTTTACCTTACCTGCAATGGATTATTCCTTTGCAAACAGCCCATCAT
CTAATAACTGGCCCGCATCAATACGCATAGAACTAACCGAACAGGATTTTATGCATGCCCAATATTGGCAAAA
TCCTACGGGTAAAAAACAGCCCTATACCCCAAAATGAACACATTACAAATTCAGTTCAGTGCCAAAGTTAAA
CCCGAACAAATTTCCGTTTATTCTCTCACGCCCTTTTGGTTGGGGAAAAACAGGAGAAAAATAGAATCATTA
CCCATGATACATTCTATTTAGGTTTTACCGATGTATTACCAGGACAACTTTATCCCTGTACTGGCAGTTAGAA
55 GGTATTAAGAGCTCCCTTTATCCTGGTCTTATCTGAATCAAGAAAATACCTGGAGTCCATTGGATAATCAGGT
GCATGACCAAACCCACAACCTATTTGATCGAGGAATCTGGCGTACCTCATTGCCACATGATGCTTCAAACCAA
GCCTCTCAAATGCCAAAAGGACAATATTGGGTGAAGGCACACATTTTACAAACGAATCAAGCAACCCCTGACT
GATCTGTATTGGTATCGAAAAGATAATGATGTCTGGAAATCCGCAACACCTCTTAGCCTTTCAAATAACATGAA
ATTACCGCGCAACCGTATTCAGATTTTTAGCCCAAGATCTCATGATGTTCCAGTTCGATACGGCTACCTAATTA
60 TTTTCTCTTTTATTCTCATTCTCAAGAAAGGACGCAATATCAGATTAATTTTAGCAGGAGATAGCTGGGAGGG
TAATCCTGAAAACATCACCGCTAAAATCAGTTCAGGAAATCACTGGTTAACACTATCCGTCGAATATCTGAGT
AATACTAATAGTCTTAAGTTGCAATTATCAGATAATAATAATGATCCCATCAGCCCCCTAATGCTCTGGATAA
TATGACGTTTGACACGCCATTGTTAAACTAGAAGCCACTCAGGATTTCACTTTGCCCTGGATTTATAAGGTAT
GCGTTAATAGCAACAATATACTCTCTACCTCTGACAGCTCAGATGCAGCGATTACTCGTTTTCCCTTTGGCCA
65 ATCACCATCGTTGGGTTCCAGCTTTAGTCCGAAAAATCGTTTTCCCGGAATGGTTTGAATCTGAATACGCATCA
GACACCACGATCACGATTACCCCTCAATGGGTTAACCTGCCACAGAAAACTTTTCATCGTGGTATGACGGA

TATATTAATAAACCTGCCGATAATAGCGTATTTAAAAATAGAGGGTATTTACTTACTCATTATCAGGGAAAAATC
AAACTCACAGAAGCTGAGACAGGAAGCGAAACCCAAGCATTATTCAATGGAAACAATGCACCACAAGGAAAA
AGCCTGACTTTTCACTTTACCTAATAGGTATAACTTCTATCCGCGCAACCATCAGTCAATGAAGATAGAAATAAA
ACTCGTTAAACAAGACTTTATGCACACTCAACATAAGAGCAATCCCACAGGCAAAAAACCACCCTATACCCCG
5 CAAATCAGTGCCTTACAGGTGGAATTCATGCTACAGCTTTCCATCGAAAATTCTCCGTTTATCCTCTCACGC
CTTTTGGCTGGGGCAAAACAGGAGAAAATAGCACACCATTAATTCATGATACATTTTATTTAGGCTTGACCGA
TATATCACCAGAGCAAACCTTTTTCTCTGTATTGGCAGCTAAAGGGCCTTAAAGAGCTACCTTTGTCTTGTTTT
ATCTAAGTGAAGAAAAATAGCTGGAAATCATTAAATAGATCAACTTACAACCAAAACCACAACCTGTTTGAATCA
GCAGAACAAAGTATCCTATTACCACGGGATGCTTCAAACCAAGCCTCTCAAATGCCATTAGGACGGTATTGG
10 CTGAAAGCACAGATAGAACAGGAGAAAAAACAGATAAAGATAGCGCTTCTGATTATTATCCAAGAATCAGG
GGGCTGTTGTATAACGCTACCATCGCCACTTTAATCAACGCTGAAGCTGTTGAGCAATCTCACCTTATCAACG
GATTGGCTGCTAACAACATTAAACAACCGGTTAACTCATCCGTTGCCATCAACGAAGTTATTCAACCCTGGAC
ATCCTGGAACGGTCGCCCAAAAGAAACCGAGTCAGCATTCTGGCACGAGTTCTGCCCGGCTCTCTCATC
GTAACCGAGTGCTAAGCTGGGGTAACATTGCCACTTTATTAAGAGAATTTTAGTAGCTTATTCGATGTCAA
15 ATACCTTTCTGTCACTGAATTAACCAAAATCCAGCGCCAGAAAAGCGACAATTAACCATCATCCCCGACAAC
CGCTATAAAGATGATTGATTCACTACGCCAGTATTGAACCAAGCCAGACTGACCGAGATGCCGATTGG
TTAGATCGATTAAGTAGCCCTTGGACAACCTATTGAAATTAATAATCCCACATATGTTAACGTTCTGATCCACTA
TGAAGTATATTTACCTCGGATGTTAACCCCGATTATGGCCTCCATCAGCTACAACAAGAACTCAGTCGAAAA
TATATGCCGTGGGGAGAAAATGCAGCTATTGGCGTAACACCCGGTAATCGTATTGACTACTTCCAGTTATTAG
20 CCTCAATTCAACAATCACCGCTGGTTGAACGGGTCACCAACTTAACGTTAAAAAAGGCAGCCAGCCTACCG
TAAGTGAAAGTATAGAAGCCGCCGATGATGAAGTACTGATTTTAGTCTGGTCATAAAAACTTCCCCAACCTAA
GGAATTAACAAATGAATAATCGAGATATGCTATTTCTATCATTAAAGACGATATTACCTTTGATTCTTTATTCG
CCAGGCCAAAAGCCGTTATTGAACAACAATCGGGGCGAGCTCTGGAATAATACAGGTGAAAATGATCCCGGCA
TTACTTTATTAGAAGCCTGTTGTTATGGCGCATCCGATCTGGCCTATCGCCACACATTGCCACTGCGAGATTT
25 GCTTACTCCTCAAGAAAATGAACGAATAGATGATGGCATTTTTCCCAAAGAAATTTGGTCCACAACAAATACTG
ACCTGCGGCCCAATTACCGCGGAAGATTACCGTCGAGCTTTGTTAGATTTGCGTAGTGATAACACCGTTGAA
GGTTATTTTTTCTTTAATGATGCACAGCTCATTCGTGAACCGGAAAATCAACGCTATTCTATTTGGTATAACAA
AGAAAAACGCGAATACAGTTTTACTCAAGACCAATACAGCGAACAATTACAGTTAACACTGAGAGGAACTAT
TGGCTCTATTTACTTCCAGTCGGAAAACCCAGCTCGATAACACCCTGGCTGAAGAAAGACTCAACATTTTTTC
30 TGAAAGATAACCGAACTTAGGAGAATCGTGAGTAAATTTATTTGGCTAGAACCATTAACTGTCTATTGAA
AATTGATTTTCACTTGATGATGACGCCAAGATATTGCTGATATTTTGTAAAGTTTATATGATTCCGAGAAC
AAATGGTGCTTGAAAAACCAATTACGTTATACCACTCAAGCGATGAAAGAAGTGGGTTACAGTCAGGAACAAAT
ATTTGAAGGCCCTTATTTACACCACGGTTGGATACCGAAATTACCTCAAACCAAGATTATACTCACCCTACC
GTATTAATCTCAGTCCTTTAATTAATCAGTTACTGGCTATCAAAGGGGTGAAACATATTACCCAATTTACATT
35 GGATAAGCCTGATAAAAAATTTCTAAGTTACCAATGATAATTGGTCTTGGGAAATCGCTCCGGGATATTAC
CCAAAATATGGGGAGATACTCCATTAGAATTAATTACCTCACCAACAAGCCCACTCACCATCACGGCAAAAG
GGGAATTAATAATGCTATTACTAAACAACAGATAGAAAAAACATAATGACAGAACCATAATTAATACACAG
CGGATGATTTTCACTTGAGTAAACATCGCAAGATCTCTGGATTACTATCCGATAAGGTTATGATTCCGCGCTT
GCTATGGATTACAACTAATACCCAACAACAGCTACAGTTGCATCAATTTATGCTGCCTTTTGAACAAATGCTA
40 GCGAATAACTGCGCTGAACCTTGCTTTATTGCCAAGACTATTAGCTTTTAAACAACGAGGAAATACGGTACATG
GCATTCAATGGCCTTTTAAAGAAAATACGGTTGGTCAACATGTTTCATAAGGACATAGTATCTAATTTAAACAAT
AATGCTACGAAAATCGATAAATGCCGATGACTACGACAAGGAACCTCGTTATTCTAGATTATTTGTTAAGATA
TTTTGGGGCTCAATGTGCAATCCCACGACTATCACGAGCCACCACAATCATCATTAAACAGAACCTCAGACT
45 AAAAAAGATTTTCTATCTACTCAGCGCAATATCTGGCTCAACAGCCAAAACCTGACTTATCAGCGTAAACAAT
TCGGATTGATAAAGTATCAGCACTGCAAAACGTATCTGCTGCCGATTAGGTCTGGGAGGAGAACTTTTCAA
AGCAGAGCCTGACTTAGCTCACCTTCTTTCTACCTCATTGAACATCGTAGGCTCTTACCAGTAAACCTGAT
ATAAAATTCTATATTGAGCAACAACCTAATTCTCTGGAATTGAAAATGATAAATTAATAATCACACAGAAAGAT
TCAGCGGGTTCGGTTACTGCAAGGTCAAGTTATTAACCTGGAATTTCTGAGGGCTATGATGAATTTACATTGC
TAAACTTAATGATAACTGAAGTGACAAGAGATACATTACCATTAGCATTAAATAGCCGTGATCTCAGAGAC
50 AATCTGGACAAAGTGCAACACGCGTTTGAACAAACGAATAATCTGAGCTGGCACAATAGCTTAATATGGATGG
AAGATATGGATTATCAATTGGTTTATGCCAATGGAGAACAACTGGAAAAAGCGGAAAAAGAACGATGGATTAC
CATTAAACAATCAAAGTGCTTTCCCTGCTATGATCGGAGAGAATGATGAAATCACACTAAAAATTCAATCCGATT
ATGAACCTAAAACCAAAGTCGTGCGGCTTGATTATAACAACAAAAAAATTTCTGATTATAAAAGATGCGACATCA
ATAAATAATTTTCCGCCAAAAAGAGAAGCATCATATTATTCTTGCTCTTCTCTAAAAGACAATGGGTACGGATA
55 TTCGGATGAATATAAATATGAACTTACTTATATTGATACAGATTCTACAAAAGAAAATGAGTGCTGGATTACTAT
CAGCGATCCAAATAATTTGTTTTCTCCTGATATCATCGCAGAGAATGACGAAATTATTTGAAAGCTAACCCCTA
ATTATGAGTTTAAACGCGACGTAGTAAAATTTGATCGTATTAATAGACAAATATTACTTAGGAAAAATACAGAC
CTGAAAAATAATTTTCCATCAGAAAAACAACATCGCACTATCGCTGGCATTCTCTGGTGAATAATATGCCC
AACTGACCATTTTCTGTTTGTCTGAGTGAATCGAATTAATTGAGAGGGGACAGATCGATCT
60 CTATAAATTAGAGTCTTGGGTAAAACTGAGATTTTATCTGAATTACCCGCGCATATCTCACTCGTTATTCTATT
GGCTATCATCGGAAGAATTGAAAAATTTGCCAGTACTTATAAAGTTTGGCAAAATAATGGCGCTCCTTTAGG
TGATCACGCATATAAAATTTCTAGAAACATTAACACTTGGGAAAAAACCTTCTACTTCAGCAAGAAGGTCCAGC
AGCTATATAGAAGCACAGTAATAATTCTTACAGAACATTAACCCATATTTATCTTATAATATCAAACATCATAAA
AACAACTTTCAGCTCATTATAATGACATATTTTCACTCAGGTTTCTTCATATCTGTTAATTACAAAGAGAATAT
65 TAATATGATCTCAGCACCAATCTGTAAATCGGATTATCATTACTATTGAAGCGAATAACGCACAGGCAGCTA
AAAAAGTATTGCATGGCTCCCTGCTTAATCAATCCAGTATAAACAACTCTTTGATTCTACTTTAACCAATAT

GTTGTTAATCAGACTATCTACCTGAAGACACTCACCTGAATCTTGGCGAAATACGATTAATAGTTTTAATTC
ACAGTTTTGTTATTCGGCTTAATACTATTCTGAGTCAAGCATTGAGCCAATATCAGGTAAATAATCAAACCTGATA
TTGAGAAATTTATTTATTACTTATATCGAAAAGATTCTATATTAACCCAATAGAGGAAATCAATAATCGTGAAA
TTACTGACATCAATATTAAGCAATTAATTAACCAATTACCCAGATACAAAACAATTGGACACTATTATTGGCA
5 AAAAGCTGTTTATCCACACATAGCCTGAAAAAACTCCTGGCTATCAAAAAACAGCTTTATTAACCGCCATTAA
TCGTAAATTATCTGAAAAGATCAATATATCACCCCTATCAGCAGGAATCGGTTTCCACCTGGCAATTGATACTGA
ATGCGCTGAAATATATACAGCGACATAATACACAGGAAATACCTGAACCCGATGCGAAAGTCATATCACTCAT
TACAACGGAACCTCAATGACAATGCCATTAATACAGCACCAATTATTGCATTATTTGCGCAAGTTATAACCAACC
ATTCCCCACTGAAATAAGTGGCTGGAACCACTGTGGCAAAACAAGCGAATTTACAGTTATGTAAAAAACAGCT
10 GTCAATTGAAGAATACCAACATCTATCGAGCGCTTTATTGCCAAACACGGGAATAAAAAATAAATCTGATAAA
AAATCATCCATGACTTCCGAACCGCTGTTATTACCTGAACACCCTCCACCACGTCAGGTCAATAATGCTGGAA
TATTAGTTCTGTGGCCGATGTTACCTACTCTATTTAACCAATTGGCCCTGTTTGAAAAACAAAAATTTATTCATC
GTCAAGCTCAATTTAGGGCTGTTAATCTACTTGATTATCTCATTTGGGGAAACGAAGAAACACAGACAGAACG
AAAAATATTGAATTGCGTTCTGTGTGGGTAAATTGCCGATGAGGACACGGAATCAATCCCTATTGAGCCAGAA
15 AAACAACAGGTAATAAGACAATGGTTAGATGCAGTTATCAGTCAACTTCCTGCCTGGAAAAAATAAGCCGCA
ATGATAGCCGCAATTGTTTTACAACGCCCGGGGGAATTGCTGACAAATGAGCAGGAAATCAAAATTACGG
TACAACCTCAACCATTTCGATGCACTGTAAATAACTGGCCCTGGCCGTTAAATATCGCCAAACTTCCTGGCT
GGATCGCCCTTTATTAATCAACTGGTAAACATTGACAAGGTTTATATGAAAGAACATCAATATAGAATAGTCG
ATCTACGCTGGATTTATTCCTTTGGAGCGCATCGATCTGCTGTTACAACGTCCTATTACCAAAAAGAGAGA
20 CAAATACGATTCATTGCCAGAAAGTTTTTGTGTAAGAAGATGAATTAGAACAACGCTTAGCAAAACCGTTG
GGTATTCCTCATTGGCTAACAGCAAATACCGGCGCTGGTGATACAGAAACAGAAAATCATTCTGCTTCCGGC
ACATTATCACTGCTAGTCACGCGTTTTAACTCACTGAATTTGAACGTGATGTGTTATTGCTAGGTTTTATTACC
GCATTTTGACAACCGCTATCATGCGTTATTTGCTACTCTGCACGGTAACAGTAAAAAACAGTGCCCGATTTT
GATTTAGCGATTGAATTTATTTAGCCAACATCAAAGTAAGTGGCAATTATTTCAACACCCTTTTTACCGCAAGC
25 TCCATTAATCAATCACCATTTATTACGACTCAATAACCAAGAGGAACCCATTTGGCTACAACTCAATTTTTAA
CTCACAATGCAGTCTGGTCTTTTTATCCGGTCAGCGCGTCATTTTACCTCCCTTAATATCCTGCGCTTACTG
GCATATTCACACCTCACAGACTTGGTATCCACCAATCCTTGGTCATGCATTTGAAAAAATATTGCTGAATGAAA
CGGACGAAATACGCCCGCTGGTGGTTCTTAAAGGAAAAACAGGACAGCGCCAGAGAACTGGCAGTCAGTAAT
ATTATGGGAATTCACGGCATTAACTTTAACGTTTCGATTTATTTACCTGCCAGATGAAGAGTGCACCACT
30 CAATACTCAATCTGCTAATAGATGCAATACGAGAAACCCGGCTACATAATGCCTGTTTATTAATCCGTAACCTT
TCTTTGCTGGCAGAGGAAAAGAGAATATCGCATAGAGAATTATCAGCTCTACTGAATCAACCCAAATTCAGTG
TGGTTTGTCTGGCAGAGTCAGAAGAATCATTAGCATGGGTAAACACCTGCCGATAGTGCAAATTAATATGCC
ACCGGCGACGCTGGCAGATAAAAAACGATGCTGGAAGCCAGTTTGCCAGATAATGTCACTAAAGGAATTA
TATAACTCAATTATGTCAACGTTTTTCATTTACAGCAGAAACATTACCGTTAATTATCAAGGAAGCTCATCAATA
35 CCAAAATCCTCCGACAACCGGAAGATCAATTGAAAGAATCTGATCTACGTAAGGCATTAAATTGCCGCGCCCA
ACAAAATTTCCGGTAAATTAGCCCAGCGTATGACACCAAAACGAAGTTTTAATGATTTGGTTATTTCCGCTGACT
TAACTCAACAGTTGAAAGAAATCATCGCAGCAATTAATACCGTGACCAAATTCGGGCGCAGGTTTTCCGGA
AAAAATCAGTATGCTAGGTTAGCGCCATTTTACGGTGAATCCGGGACGGGAAAACCAATTCGCGC
AGAAGTGATTGCCAGCTATCTTGGTGTGATCTGATTAAGGTAGATCTTTCTACCGTGGTGAATAAATACATC
40 GGTGAAACCGAAAAAATATCTCCCGTATTTTCGATCTGGCCGAAGCGGATTCCGGGGTGCTGTTTTTCGAT
GAAGCCGATGCCTTATTCGGTAAACGCACTGAAACCAAGATGCCAAGATAGACATGCCAATATTGAAGTTT
CTTATTTATTACAGCGACTAGAAAATTATCCGGGATTAGTGATTTTAGCGACTAACCAATCGCAACCATTTGGAT
AGTGCGTTTAATCGCCGCTTTACCTTTATTACCCGCTTTACTTATCCCGATGAAGCATTACGCAAAGCAATGT
GGCAGGCAATTTGGCCTGAACAACTTAAGTTATCAGATCAACTTGATTTTGAGCATTGGCTAAACAGGCCAAA
45 TCTGACCGGTGCTAATATCAGAAAATTGCCTTATTATCATCAATATTAGCTACAGATAAATAAGTGATCAAAAT
TGAAAAATAAACATATAGCGCGAGCATTGATACTTGAATTAATAAAACGGGCCGATTGATTTTTTAATCATTTA
TACCAATAAATTTTCGAGTTGCAGCGCGCGCGGCAAGTGAACGAATCCCCAGGAGCATAGATAACTATGTGAC
TGGGGTGAGTGAAAGCAGCCAACAAGCAGCAACTTGAAGGATGAAGGGTATATAGAATTGGAGTGAATATG
ACAAATATAATTAACCTAATAATGCGATTCTTGAAAGTTAATAACGCATTAAATGATTTTTATCTCAGTATTTA
50 ACTAATATTGATATCCGCTTTGATCTACCAGAAATAAATTCAATCCCATCAACCCCTACAGTGAGTATATTTCTT
TATGATATACATGAAGACCTACAATTACGTTCTGCTGAACCAAGAAGTTATCATCTACCACCAGCTCATTATT
GCCGGGATGGGTAAATATTAATTATAACTATTTAATTACTTACTGGCATTCAAGTAATCCATCAAGCGACAGTT
CTACCCCTGATAGTCAACCCAATAATCAAGCGGCACAAGTCATGACTGCTATTTTAAATGCATTGGTTAACAA
CCGACAATTACCTAAAATTCTGGCGCATATACCAGAGTCATTCCACCTCAAGAAAATCTAAATAGCTTAGGT
55 AACTTTTTGGCAAGCGCTTGGCAATCGCCCTCGCCTTTCTTTATTATATTCAATTACCGCACCGGTAAACTGC
AAAATATTAAGATGTCATAAAGCCCATTAGCCAAATTTCCACTTCTGTGGATCAAAAAATCAAAATCTGGATAAT
TCGCAAAATCAACCAAGCCTTATTTAGCAAAATTGGGTGCCGATTTAGGTGGCACACAAGATGTTCTGCTTGTCTC
TTGCGAAAGTGAATCTGACAACCAACCTGCTAAAGAAAATAATGAAAATCAAAATAATAAAAAATGTAATTATT
GAAGTTTCTGGCATTACCCATTTGGATTATTTACCCAGAATAAAAGGTATTCTTTCAACATGGGTAATAGTCA
60 TAGTGCTGTTGTTAGGATAAATGATATTGGTATTATTGTTTCAGAATATAAATATGATAAATTAACAGGCGTTTA
A

SEQ ID NO: 95 (*Photorhabdus asymbiotica* strain ATCC43949 PVCPaTox operon, *pvc1* – *pvc16*)

ATGAATACAGCTCAAGAAATTATTAACCGTTTATCGGGGAGAGCCGTTACGCTTGTTGGGATGTTGTTATTG
CTTATGACCGAAAAAAATTAACACTCTGTTAGAGCAACAATATGTTGAAAAGGTAAAAACGGGGAGAACTT
5 CCCGCTTATCAACTGGGAGAACAGAGAAAAACACTTCAATTTAAAGATCTTCAATTAGGTGTTCCACTTATTT
CTTTTGAGAATTCAACACTGGAAAATTCAAGGGCGCTTGCCACGATAGAATTTATTTGAGGAGCTATTATTGAA
TTTAGTGACTCCGGGCAAATAATCAACTATAAGAAGATTGAACCTAGTCATGGTTATGGCATGGTGTGCTACTA
TCGATCTCATGGCTGGTACAGGTTCAAGTGAAGAACAAGGTCGGGTGATAATAAATCTTAACGAAGGCGCCA
10 TACTCGATTTGCATGTTATCCAACAACCGCCAGCAGAAGTGGTAGAATTTTTCCGCACTTGGTTGATGGCTAA
TAAAATGACTTATGAATTAGGTAAGCTGGATCTGAGTAGTCAAGCTGGTCTAGTGCCTCGTTCTTTTCGTATTG
GTACTCAGCGGGCGCTGAAAAAATTCGTAAGCGACGAGCGATGAAGGAAATGGCGCTGTTTTGTTGTTTG
TTGCCACTAATACTAACCCCTACAAGTGGAACTTTACCTGCCAAGGATTATCCGTGGCTAATCCCTGAGGA
15 TTCAGGCGCATTGCTTATCGGTAATAAATGCTTATTTAAGACATTCTGAAACCGAATCTGGATCAGTTGTTTG
ATAAAGGGGAATGGACATTAAGTTTCAGCAAACGGATTCTGATCAACTGCTGCATTATCTGGAGGCAAACCTC
TGCATATATAACAGATAAGCCTTATATGGCAGACTTTGAAGGAACTCAGGATGGAGTCTGGACAGGACGTTAT
AAATTTGAGACTGGCCGGGGACATTATGGGGTGTATGAAAATGTACGCTTTCCTATCAATGGAATGTTGATGA
AACCGGCTAAAACCTGGATTACAGTTATCAATAGATTCAACACAAAGCCATCAATTTAATGTTGATTTCCGAATG
AAGTGTTCCATTGTGCTAATAATGTGTGTTATTCCTGGTTAACGAGACTTACCCATTTTATCTTGATGG
20 AAAATCAATTTTATCAAGTTTCATATTGACCTTGATAAAGAGGTGATTTATTTTACTGGGCCAGATGAAGATATTA
ATATTGTAGGAAATTACAGCCCGCCTGCGTGGTGGCAATCTAAATGGCAAAAACATATCAGTGATGATTTTAC
GGATATTTCTCGGAAAAATTTAAGCGACTCAGTCAAATAAAATTGCCAGAAATATGCATGTTTGCCGTGAAC
CATTTATTATTTCTGGTCATAATACTTTGCTGTTGAAAGACGTTTATTTACCGGGTGATATGGTGATTTTCGG
TGATATTAACCCATCACTTACCGCTTTTCGGGTTACGCCATTAAGGCAACAGTGGTGGCAAAGGGAACCCAA
25 CAATTTAAAGCCATAGAAAATAATTGATGATTATACCCTTCATCCTTCAAGTTGCTGCTTTGTTGGCTACGTTT
ACTCACCCAGTCACATAGTTAGCTATGCTCCCGGGGATTGCTCCCTGGCCGTGCGATGCTATGTTGAAAT
CCATAGGGTATATATTTAATTGGATAAGTCTTTTTTATTTTAAACATTATAACCTGATTTCTTTTGGATAAAATTA
AGGATTATTAACATGTCTATTACACAAGAACAATCGCTGCTGAATATCCTATTCTAGTTACCGTTTTATGGT
TTCTATAGGAGATGTGCAAGTCCCTTTTAAAGTGTTCGGGATTAGATAGGAAATATGAGGTTATTGAATATA
30 AAGATGGCATTGGTAATTATTATAAAATGCCAGGACAAATACAGAGGGTTGATATTACACTTCGGAAGGCAT
ATTCTCTGGGAAAAATGATTTATTTAATTGGATTAAATCCATTGAACTCAATCGGGTAGAAAAAAGGATATTA
CAATTAGTTTAACTAATGATACTGGCAGTAAAGTCTTAATGAGTTGGGTTGTTTCGAACGCCTTTCCGAGCTC
ACTGACGGCCCTTCATTGATGCTTCAAGTAATGAAATGTCAGTACAAGAAATTTCTAGTTGCTGATCGG
GTAACAAGTTACAGTTACCTGATACTAAAGCTTTAAGGAAAAATATGTCTGTACAACAACACTTATCCGGAA
35 TTTATATTGAAGAAGATGCATGTTGCTCTATCTATCAATAATAGTCCAACAGCAATCCCTGTTTTTATCGGTA
AATTTTACAACCTGGATGGTTCCTTACCTAAAGTGGGAACATGTTCTAGAATTACCAGTTGGTTAGATTTCACT
AAAAAATTTTCGGTAGCTCCTCCTCAAACCATTTTATTGATCGCGTCGCCAATTGCTGACACACAAGAAAGTG
TACCCAAAGCAGTTCAATATACTTATAAGGCCGAGTTTGAACCTCAGAAAATCTGGCAAATGGTGCCTATGC
GGTACAACATTATTTCCAGAATGGCGGTGGTATTGCTATATCATACCTTTAGTTAGCGTGAAAAAAGAGGAT
GCTGCGATTGAGTTAACAATAATACCTGAATTAATTGAAAGACAACAAGAGATTACGTTAATCGTCTGCCCGG
40 AGGACGATAAGACGCTCACTGTTGATAGCAGTAAAAATCGGATGTTTATAACAGCATCAATACATTATTGAG
TAATAAGGTAGGTTATTTTCTCATTGCAGATTCAGATGATGGCAAAGCAGTTCCGTGATACGTTGCCGGAAAA
ACTGCGGTCTATTATCCTGGTTTACTAATCTTTTACACAACGCTATGCCCGACCTGCCGATTCTGCTATCAA
AGTGACCGGTATTACAAATATATCAACTCTGGCTGATATTACACCAACTTGGCCGATGACTACTCAACAGCA
AGTCAGGTTATTAATGATGTTTTGGAAAAAATAATAAGCTCGCATCGTCTCCCATTTATTTACCTCCAGCGC
45 CGCTGTTGCTGGTGCTTATGCCGCTGTTGATGTGAGTCGTGGTGGTTGGAAAGCACCTGCGAATGTGATGTT
AAGTAATGCCACGCCAATCATTAGTATTTCCGATGCGGAACAAGGTGTGATGAACCCATTAGGTATTAATGCT
ATTCGTAGTTTACTGGTAGAGTACTTTGATTGGGGAGCTGCTACTCTGGATAAAACGGGATACTGGCGCT
ATGTTCTGTACGTGCTTTTATCAATAGCGCAGGAGATTAAGGTTAGCAATGCGTTTTCGATTTTGA
GCCTAACTCCCAACCAATTTGGGAAAAGGTCAAGGCTGCTATCAATAGCTATTTGCAGTCACTTTGGCAGCAA
50 GGTGCACTGCAAGGCAATAAACCCGATGAAGCCTGGTTTGACAAATTGGTAAGGCGTGACCATGACAGAT
GATGATATTAAGAATGGGAGAATGATTATCAAAATCGGCATGGCGGCAGTACGTCCGGCAGAATTCATTATTT
TACAGTTTACGCAGAATATCGCCCAGTAACTTAGGTCTATACCCTATAGATTTCAAGATGCATCGCGGCGGCA
AGGGAGCGAATCCCCGGGAGCATATACCCAATAGATTTCAAGTTGCAGTGCGGCGGCAAGTGAACGCATCC
CCAGGAGCATAGATAACTATGTGACTGGGTAAAGTGAACGACGCAACAAAGCAGCAGTTGAAAGATGAA
55 GGGTATAGATAACGATGTGACCGGGTGAGTGAGTGACGCAACAAGAGGCAACTTGAAAGATAACGGGT
ATATTTAATATGGGCGATTTATTGCCCATTTTTGTGAAAGGAAATGAGTTATGTGCCAACGCTACCCGGTGT
AACGATGACTCAGGCGCAGATAACAGCGTTCCGGTGCAGTACATTAAATATGCCCGTATTCATAGGGTATTGT
ACGAGATTGCCTGCCTTTTTCAGCGCCTGTAAAAGTAAACAGTTTAGCTGAAACAGAACAAATAATAGGGAAAG
AAGGGCGTTTGTATGCTCTATTGCGCCACTTTTTCGATAACGATGGGATACAAGCTTTTTATTCTGTGCTTAGG
60 CGCACCTGCTGGGGAAAAATGCTAATAGTTGGCTTGAGGCATTACAACAGCCCCGATTTGTATGCGGCTGTTGC
AGCAGAGCCGCTAATTACACTTTTAGCCGTCGTTGAGGCAAGTGAACCTGAACCAAAAAGAAGGTAATGAGGC
TGTGGAAGCTTGGCGACAGTACTGGAAAGCAGTATTAGCGTTATGTCAGGCACGCACTGACTGTTTGCCAT
ATTGGAGGCACAGATGATACCGCATTAATCAAGCGTAGTTTGCAGGATTTTTCATCATAAGGCACGTCAGTTT
GGCGCTCTCTACTGGCCAAGGCTAGAAACATCTTATCAATCCTCTCAGTTAAAAATTTTGTCTCTATTGGTG
65 CAGTAGCAGCGGTTATTCAAAGTAATGATGTCCGGCGAGGGGTAGGACATGCACCTGCCAATATAGCGTTAA
AACAGACGATTGCCCGATAAAGTCCCGCCTGGAATTAGAAGAGTTGTATGAAGAATCGGATGGTTCACTGA

ATCTGATTTGTAGTTTTCCAGCTCGTGGTACTCGTATTTGGGGATGTCGTACGTTGGCGGGTATTGATTCACC
TTGGCGTTATATTCAAACCCGATTATTGACTTCACACGTGGAAAGGCAACTCAGCCAGTTAGGGTGCATGTTG
ATGTTTGAACCTAATAACGCAGTCACTTGGATGAAGTTTAAAGGCCATGCTGGGAATCTATTAAGGCAGCTTT
GGTTACAAGGGGTGCTGTATGGGCAGCGTGAAGATGAAGCCTTTTCCGTTGAAATAGATGAAAACGAAACGA
5 TGACTCGCCAGGATATTGATGAAGGCAGAATGATTGCTCGTATTCATTTGGCATTGTTAGCACCGGCAGAGTT
TATCGCTGTGACTTTGAATTTTGATACTCGCTCAGGCATTGCGACGAGTACATAATAAATCGGAATATCTCCAT
GACACTACCAGCAGAGCTTTATACCCAGCGGTTTCACATCGTTTTATTGTTAATTTCTTTTTAAAGGTTTAC
TTCCTTCTCCCGTAGATATTGATTTCAACGTGTTTCTGGTTTAGGGCGTGAGTTACAGGTTGAACAGCGCCA
TCAGGGGGGAGAAAACGCACGGAATCATTGGTTGGCTGAACGTATACAGCATAAATAGCTTGATATTAGAAAAG
10 AGGGGTTATGGTCGTTACCCCTTTAACACTGATGTTTGATCAGGTGATGCGGGGGGAAACTCTCAATTGGGC
AGATGTGGTAATTATTCTTCTCGATCAGGCTCAACGTCCGATAACAAGTTGGACCTTGAGTCATGCGCTACCG
GTTTCGCTGGCAAACAGGAGATTAGATGCCAACAGTAACCAAGTGCTGATTAAACACCTTAGAGCTGCGTTAT
GAAGATATGCGCATTATAGGGGTAAAATTATGACTATCGAAATCCGTGAACCTCATTGTTCAAGCCCGTGTTGT
CGGGACTGATACCAAACAACACGAACCGTTCCTTTATCTATTGTGCAAATGGAAACACTTATAGAACAACGT
15 CTGGTTGAAAAAGTGAAGCGGGAGATATTAGACGTACTCCGGGAAGAACAAGGTGGTGGGTTATGAGCTTG
CTGAGGCTGAGGTCTGGCTAAACTCAGCATTCACGGTTGGAACGAGCGTGAGCGTGAGCGTAACTGTTGAAA
CTAGAAGCAATGTATAACCCGGAACACTTCAACTGGATTATCAAACCTGATTATCTCCCTGATGTTAGCAATAA
TCAGGTAACAGTGAGTAACCGCTACGTTTTGTCAAAGCCCGCAGGGTTAACACTATCCTTGTTATTTGATGCC
AATATGGCTGGTCTTACGACAACCGCTCGAGTCCCAATCACTACCCTCAAATCGCTTTGTTTAGTTAATGCAA
20 GTACTGATGAACCAATTTTTTGGAAATTAATTGGGGGGCAATGCGTTGGGAAAATAAAAAATTATTTGTTGGT
CGGGCTAGTGATTGTCTCTGACTTATTTGCGCTTTGATCGTAACGCAACACCATTGCGTGTGAGTGCGCAG
CTCACATTAGTCGCAGATGAAAGCTTTGTGCTCCAGGATAACCAAGCCAAGTTAGATGCGCCGCCGGTATCA
GTAGTTAATGTCCCGGATCTGACTTCATTACCTGCATCGCGAATATCGCTAGCGTAACCACTATGTTGGGA
GTGGATTATTTAATGTTAGCCCGCACCAATGATATGGATAATTTGGATGATATGCAGCCAGGTCAGACATTGC
25 GAACACCGGAGGCATCATGAGTTTTTTAGATAACAGTAACTTCAAGCCATCAGATATCAAACCTGTTGTTAAC
ATTCAGGGAGTGAGAGAAGGAACCTCAACGAACCTGATAGTAAGCGAATTGAAAATCTCCCGACGTATCAATGCC
ATTCGCGCAGGCAGTTGTAAAGCTAAGAGCGAAAGAGAGTGAAAAGTGGTGTATATCAGTCTGATGTACAGCGG
ATGTTGAAGAGTTGCCGTCCGGGAGTAAAGGCAGAGCTTCGTATTTGAATACCCGGCTATTCAGTGCGCAT
ATTGTGCAGCAAAAAACAGAGTTAGTGTATGCGAAAAACACACTATCAAATTTGGTGCTACGCCATGACTTAC
30 AGCGCATACCCGTAATTTTCTACAGAGTGTGTTGCGAATACCCGTGATCGTAAAGTGATAGCCGATCTATT
GAATACCGCAACATTAAGGCCGCGATTTTCGGGAGACATACATTGGGATATAGATCATGAGCAACTGTTTCA
GTATCGTTGCAGTGATTGGCAATTTTTGTTGCAACGGCTCTATGCTACGAATAGCTGGTTGTTAGCTGAAGAA
GATAAAGATAAACTCAGGGGAAAGTGACCATTATTGCTCCAAATTTTGGCCCTGAATGAGCGTTGGACAC
TGCAACATCAGGCTGATCATCAGGCTATCCGGCTTTACAGCACGGAGCTGATGCTGGATAACCGGTTTGATA
35 CAGCGGAGGCTGTTGTTAGTGCTTGGGATATTGATGATCAGGCATTACTCGTGGCGTGGAAGAAACCCCTTA
GTCAAGTTGGGAAAGATGCGTTAGCGTCAGATAATTTTAGCCAGACAAATAAAGATTGAGTGAACCTGTTATT
AAGTTGTCCGCTCTCTACAAAAGAAGTTCAATTTTTAACCGGTAGCCAATTAGTCATGCGGCGCTTGACGGCC
GTTTCGTGCTCACTGAAGGTTGAAGCGAGTAACTTAAACCGTATGAGGATGAAGTGAAGTGAAGTGAAGTGAAG
40 GGTGAAAATATGGATGGCTCACAATACTGACGGGAGTGGATCATCGAATAACGGCAGAAGAAAGTTGGA
ACAACCTTACATGTGGGATTAGAAGTCCGTTAAAGGCAGAGTATGTCACTCAGGTTAACGGTGTTTCATATCG
GCAAGGTTGCTGATTATCAATCAGATAGCAAAAAATGGGATCGTATTCCTGTTTTGATCCCTGCATTTGGAAC
GAATATTCCTTGTGTTGCCCGATTGGGAAAACCTACGCCAGCCACCAAAGTGGATTTGTTTCTATCCTGAA
ACGGGTGATGAAGTCATTCTCAGTTTTTTGGAAGGGGACCCTCGTTATCCTGTCAATTATTGATTCCCTGCATA
ATCCTAAACAACAGACTCCATTGCAATCAGCAAGAGAATAATCTCAAAATGTTGATGATTAAAGCAGAGCGCA
45 TAAAGATGAGCAACAATTGTTATTGATAGCCAGCAACAACAGTCGCGTTAATCGGTAAAGAAATAATCAG
GTTAAAGGTGAGTATATCAACCTGACTAAATCAAAGGGGACTCGATAATGGCAATACGCTTATTGGCCAGGT
ATATGGTCAAGGATGGGCTTTTCCCATTAATTTATTCCTGATAATAAAGAAACCGCAGATCAAACAGCCGGT
ATTGTTATGGCTCAAGGGATTGAAGATGTCAGTCAATCGCTGGAAATATTATTTCTTACCGAGCCTGGCGAAC
GAATTATGCGTGAAGATTTTGGTTGTGGTTACAAGATTTTGTGTTTGAAGTATAGTGATACGCTAATTTCTG
50 CCATCAAAAAATCGTATTCAGCAAGCAATATTACGTTATGAACCTCGCGCATATTTATTGAACGTTGATATTC
ACCAAAGAAAACCAACCTGGACATCTGCTCATTACAGATTAATTGGAATTACGTGGTAGTGATATATCTCAGC
GTTTAGACGGAGTGCTTAGACTCCATTACAGGTCAAGCATTGGAACCTGTTATGACCAATTATATTATTATCGAC
GGGGATCTCATTCAAATAAATCCCAAATTTGAGGGTGATCGAACTCTTACGATTAATGGTATTCCTAAAATAAG
CGGGAATGGAGATGCGCAAATTGAAGGAAAAAATATTTGTGTGTCAGGTGATCACTTAACGTCTCAATTCCA
55 GCCATTTATATAACCTCCAGACATCCTGTTGCAGGTAGTGGAAGAGTGAAGTAACTTAATCTGACGACC
AACTAGCAGAAATTTGTGTTAGTGGGGATGTTGTGATTATTGAAGGCAGTCAGTTTGAAGCTCAGTTTACACC
GGATAAGCCGGCCACTAATCCAAGTAACCAAGATGCAGATAATCCTGCGCCTTCGAATGGGAGTGGGAGATT
TATACACTCACAGAACTTCGTTAAGGCAGAAAAATAAAAAATTTTGCCGAAGCGGTTAATAAGTATGAATAAG
CGGGGCGGATAAAAAACATGGATCTTGTGTAATTAATAATACGTTGATGAATGACTTACCAACGACCAATTTT
60 AAGTTAGAAAACAAAGGACCCATTAACGCAATTAAGAGTGTTTACAACGTTATACAGAAAATTTCTTTTTATGC
GAATGATGATTATTTCTGGCATCAATTCTGGTTCTTAAAAATCACACACCAGAAGCGCTCTTTGCTCGTTTGC
AAGGTGAAACGTTGGCTGATGGAGAATTGCCTCCTCATCAAGCGCTATTGCTGGCCTTTTTACAACAGCTTAA
GACGCCAGGAATCATGCTTGATACTTTTTAGCCCGTCATCGGCAATTGACTATCAGGAATTGCTAGGGATA
ACGCAGAAAGATGCACAACCTGATCATGTGGCGCTTGGCGTGGTATTAAGTACTGGTATTGCAGAAATTTTAT
65 TACCGACAGGCACATTAGTGGATGGTGGACAAGACAGCAGCGGAAATTCAGTCAATATGCGTTGGATACCG
ATTTATTGGTTAATCCAGGGCAATTAACAGATGTTTCGCTACAGCTATTTGGATCATAAGACCTATAAAATCTTC

ATCTTGCAAGATGATAAAGCGAATATCAGTTGGCCCTCTTCAGGCGCTCGTTTATTTGTAGCACCTGAGGGCA
ACGGACAGGAAAAGGCACCTGAACAAAAGTTGGCACTTTACCTGGGATTTGATGATATACAGCCAGGGCAAA
CTCTTTCTTTATTTTGGCAATTCATTGCATCAACTCCCCTGACATTAATAATGGTTTTATCTGAACGAGATAAATA
ACTGGGTGAAGCTAGATAGTGTGAGAGATAACACGGATGGCTTTTTATCAGTGGATTATGGCAAGCGATATT
5 ACCTGATGATGCGGTGAAAATGTATTTTCCAGAGACAACTTCTGTAAAACGCTACTGGATTAAAGCTGAGGTG
GAATCGCTTACTGAATCTGGCGATTTGTGGCAACCGCTATTAGAAGGCATCTTGTATAACGCTCAAACAGCAA
CGCTGGTTGATGCAGACAACACAGATGAAAAGCACTTTCATGATGGGCTGATGCCTTTAGCGTGCAGCATT
TGGTCAACACCGTTTCAGAGGTAAAAAATTGAGCAGCCCTGGTCTTCTTGGGGGGGAACGCCACAGGAA
GACACTACTGATTTCTCCATCGAGCGGCAACACGCTTTCAGCATCGCCAGCGTGGTTAATTGGGATAAC
10 CAAATTGCCATGTTGAAGGCTGAATTTCCGCGGATTTATGATGTCATCTACCAAATATCACGTGGATGAACC
AACTTCAGACATCAAATACGCAAACGCTGATCGTTATTCCTGATGTGAACACAGCGACAACAAGGATCGCTT
ACGGCCACAATTCAGCCCTGCCAGCTTGCAGCAAATGAGTGACTGGTTACAGATTACACTAGCGCATGGGC
GAATCCACAAGTGGAAAATCCAATTTATATTGATGTCTCTGTGACCTATGAGGTGCAATTTAGTGCGGGTGTG
AATCCTGATTATGCCCTCCGGCAATTACAACAATGGTTGAGTTCATTTATATGCCATGGTATCACGCAGATA
15 AAAAAGGTGTTGCCGCTGGCGATCAAATCGATTTTACCACTGTTTGCAGATATTCAGCGAGTACCTTACGT
GGAGCATGCAAAACATTGACATTGACCACAAAAGCACCTTACCAATGCAATGGCAGTTATTAAGGACACA
GCAAAATGAAGTGCTGGTGGTATGGCAACAAGGAGAACAATTAGGCAGGGAGAATCGAAATGAGGCA
GCATAATGAGTTATTTCTGTAGTAAAAGACGCGATAAGCTTTGAAAACCTGCAAGCTCAGGGTGAGAAGGT
ATTAGTGATCAGTCCGGTAACATATGGAGCGATAAAGATAAACATGATCCTGGTATAACATTACTAGACTCTT
20 AAGTTACGGTGTTCGATTTAGCGTATCGGCACTCATTACCTTTAACCGATTTATTAACCATTTGCTGGAAAAG
ATACGCTTTTTCCAGCCGAATTCGGGCCACAGCAGACGCTAACTTGTGGCCCTATAACACTGGATGATTACC
GGCGTGCGTTACTTGATTTACATGGTAATGATGCATTTAAATATCAGCTAGTGACCCAGAGACTTTTTGTTT
CAGGATATACAGTTAAATTTGTGAGCCAAAAGTAAGCGTTATAAATACTATTTCAATCCCGAAACGCTTGAATA
TACATTACGCCACCTTCAGGGGATAAATTTAAACTTTAACACTACGAGGGAATTTATGGCTTTATTGGATAC
25 CAACCCGTTGGGCAGGTAAATCAGCTAATTTGCCGTTAGTTAAGCGGGTGATGGAAGATTTTCTCCGTGAAA
ATCGAAATTTGGGGGAAAATGTTGTTCAAGTGACACGGGTGATATCAACGCCTATTTATCCTGAGCTGGTCAT
TGAGCTGGCGGATGATATTACAGATGCGGCATCAGTATTAGCATCAATCTATATGCTATTAGAACAGTGGGC
GATGCCGATGCCTGCTCGCTTTACTACCGAAGCATTACAGGCCAAGGGATTAACAAACGAAGAGATCTTTGA
TGGGCCGTGGTTGCGTCATGGTTGGATACCTCAGTTACCGACCTCTCAAACTACCATACAGGCATGGTTCT
30 GAAGATGAATCATCTGATTAACCAATTGCTGGCGTTGAAGGTATAAAGCGCGTAGTTAGCTGACGTTGCC
AGAAACAGAAATTTTGCATCAGATAAAAGATGAAATTTAGCCTGGCAATTAGATTGGTTATTATCCATTAT
TATGGGGAGCTAATCCACTAGAGGTAAATACAGAGAAAAATAACAATTATGTCAAATTGTTGCAAAAAGGTGG
GGTACGATTACAACCTGATCAGAAAAGTGTGAGCGGTTATTATCACAGGAATCACTCATTAAATGCTGCA
TCCACGTTACCGGCTGGTAAGGTGCGTGATCTCAAAGCCTATACACCTATAAGCCGCAGGTTGCCTGCCTGT
35 TATGGTTTGCAGAATACTTTGCAAAAGTTAAACCTGAACAACGACACTTATATCAGTTCCCTATTACCATTGGA
GCAAAATGCTTGCTGATGGATGTGCGCGGCTTGCAATTTTGCACATTTGTTAGCATTTAGGGACCGAAGCGG
AAATATCAGTGATACACTCTGGCCTTTCAAGAATACAGAGGACACAATTGCCAACAGGTTTCATCAGGAATAT
GCCGGTACATTAAGCCTTTCAACAGCAGGAAATTTAGCCTGTTGATGATAAAAATAGACCGCATTCATGGCA
ATATCAATCGGGAATTAGATATTCTTGATTATCTGCTAGGGTATTTTGGTACACAACGTGCAAAGCGTCCATTA
40 ACGCAGGATATTCATGATTTTCTGCAACCCAGCGAGGTTATTTGGCACAGCAGCCGGAGTTGGGTTATCAG
CGTGATAATATCCGATTTGATCGAGTTTTCAGCTTTACAAAACGTATAGCAGCCCGAATTGGGCTAGATGGTA
CTATTTTCAAGAATCGGTTGATTTAAGTAAGTTACCTTTTATTTGATTGAACATCGTCAGCTTTTACCAAATT
TACCCCATCTTGACTTTCAACATGATCAAACCTCCCAATCTTTTGTGATTTCCGACAACATTGTTAAAGTGAAA
CAAGCGGGAATAGCAGATAAAATCGTTCTGGACAGCTTATGATTTTATAGATATTTGAAAGCAAAATTTACCG
45 TTCGTGCCCAAATGATTGTGCTGTAGAGGGAATGAATTTCTCTGGATACAAAATAGATTCACTTGAAGAA
AAGAATCTGCAGTTATTACAATCAGCGTCTGAGAAAAACAATTTACGATGGAGAAATAGCACGGCGTGGTTAG
AGGATATGACGTATCGTATCAATTATACTGACGATCAGGTTATAGACGATAAAACAAAACAATGTCGTTTACAA
AGTAATACTAAATCGCCTTTTCCAGCCTTAATTGCACCAAAAAATAAGATTACGATTATTAAGCAATCTTCTCC
ACTCTCCAGTATTGCTGAATTTACTGATGAACCAGAATTCAAATTAGTTGCAACGGTGACAGAGATTGATCGG
50 ATTGAAGGGATATTGACTATCGAACGGGATGACAACCAACTCCCTTTCCCGACTAAAGAAGAGAGTAATCAAT
ATATATGGTACATATCTGATGAAAATATATTTCAAGTGATCGTTTCTCTTTTGTGGTGAGCGTCTGCTGAAT
CGCGGTTTGGTTGAAAGGGAAGATATTGATCAATATAAGCTAGAGGAATGGATAGAGCGTGAACACTTGCA
GAGTTTCTGCACATATTTCTGTTAATTACTCATTGGCTGGCATCTGAAAATTTTCGATGATTTTGCAGAGACATA
TCAACGTTGGCAAAACAATGGGGCGCAGTTAGGGGATGAATCCTACACCATTTTGGAAAACTGACATTAGG
55 GCATTTACCAACAGGACTTACTGGCATTAGTAATATGTTTATTGCTACAGAAGCTCAGCGTCTAGAAGTTGTT
GGCGAGAGTGGTAATGAGTGGAATACCCAGGCAATTATTAACAACGAACATTCTATGTTCCCTCACAGAATA
GTTAATACCGAGTGTTGTGATCAACTTTTATTATAAGCCGGAGGATAAATGGACAACAAAAATAACAAACCTAC
TGATCAAGAGATTCTAAAAACATCACGGGCTGTCGGAGAAATTCCTTCAGCGGATAATTTAAAAAATCGTTTAA
AAGCTCGTTCCGATTTAGAGACGGATTTTACTAATCTCATTGACCTTGCTGAAGTTGGACGATTGGCTAT
60 CGGCCAGTCACCATCGCAGCAAAGTAAACGCTTGGCACCAGGAATGGAATTAACCTCGGATGGTAAATTACA
AGTCAAGGCTGGGGCAGGTGTTGATATCGATAATAATAATCGTATTACTATTAAGTCTGGTCATGGAATTAAG
GTTGATGGAACGGCATTTCCGTTAAACCAGGTTCCGGTATTAAGGTTGATAGTAATGGTGTAATGTCAATA
TTGATGATTTTTGGGAGGAAATACGCAATAAAATTATGCCTAAAGGAACCATGCTGCCTATTTATGGCACACC
TAACCCCTCTGCGCTGCCAACAGGATGGGAATGGTGTGATGGTAAAGATGGCAGACCTAATTTAAAAAAGG
65 GAAATATAACTTACTATCAGGTGAGTCTTCAGGTACTGATACTTTTTGGGCAGATAATAAGAATGGAGATACA
GAGATCAACGTGTTATTTGTTTACTATATGATTAAGGTTGTGTAATATCTTAAGTAATATGCATTACTCTAAAT

GAATGATTTATATTTAAGTAACATAATAATTAAGTTGTGTTGTAGGGCTGTTTTATGAGAAATATAAAAAACGGA
GGTAATAATTGGCTTCAAAATATCAGTGATGAAATAGAGTTATTTTCGCTTTATAAAAAATTTTGTATTTCTTTT
AATAATTATTTATAGAAGGTAATGATATGTGCACACAAAAAACGTGTTAGATAGACTGAAAGATAGAAATATT
ACATTGGGTTGGGATGTTGTTGTTGCATATAACCAAGAAAAGTGTTAATAAGTTATTGAAGCAACAATATGTTGA
5 AAAAGTTTACTCAAATGAACATTTTGTATTTAAAGATTGGCATGATGATAATAAACGAAATTTATTGAGGGATT
AACAGTAGGCGCTCCACTAGTTTCATTTGAGGAGGCGTCTTTATCCGATGCTAATGTAAAAGTGACACTTAAC
TTTCTTTCTGGTAGATGGAGAGTTATACAAGCAAATACCGGCACACCAATTGAATGGAAAGAAATTTGTTCTTG
GCAGTGGCTATAAAGCAGAATTAGTTGTTCCGCTTAAATCAATAACTGGTAGTGTAAGTAAAAAGATATCATA
10 TTAATAATTCAAAGATGCTGTCGTAAAAAAAATAAATTTATTTGACAAATCAAGAGCCTGATTTTATTAATTATTTT
AAGCAATCGATCAGTGAGGGAAATTATACTTTAGGGCAACTGGTGACAGACAGCACACCGGGATTAATTCCT
GCTGAATTTTCATATTCGTACTCAACCCCATCCAAAAACACGTGAGCGTGGTTCTCAATATGTAGGAAATGGTG
CGGTACTGTTGTTTATTAACACGCAATATGGCGGAAGTGGAACATTGCCTGTAAATGATTTTGATTGGTTAATT
CCTGATGATCATACTAGCGCATTAGTCATTTGAGTAAGACCATGATGGGGCAAATATTGCCAAAACAATACA
15 AAGATAAATTGCCTGGTGATCCTCAGTTTAGCCCAACAAAAAGAGTCAATGATAAACAAGACTCTGCTTATTAT
ATTACGATTACCGATGGTGGATTGATGGTAAGCCCTATAGAGAAGTCATGGTTACGTTCTGATTATAGCA
ATGGGATTTGGACTGGTAACGTGGTAATGCTATTATTGGTGAAAAAGGAAAGCCTGATTTTATTAATTTTCT
CATACCAAAATTTTGTATTAACCTCATGGTGAATCGTTATTTCAAGGATGGGAGAATAAGATAAATTACACT
CAAAAGTGTGCAAGATATTTCCGACATCATAGTAATAGTATAACTTTTGAAGATACTGCATTAATGGATCTCAG
TATTGGTGGACAAGGTAGTATCAATTGCCAGATTGATGGTGAACATTTCTATTTAAATCAGATGATTTTCCC
20 CCAATGTCAGCTATGAACCAACTTCATTCTGGGATAAATTTATCGGTGGGGTGGATGCAAATGTGAAAGATGA
ATTCAGAGATGAATTAGCACAAACAGGCAGAAGCAAAGTTAAACAGGTATTTAATATTGAATTGCCTGAAATC
AGTCTGTTTTCTATTAACATCTGCTCTTTCTGGCATGGATGTTATGCAACTTAAACAGGGTTATTTCCAGG
AGATTTGATTATCTTTGGGATATTTACCTAAATGACCACAATTCAGGTGGCTCCTTTGGAAGCCATGGTT
GCCCTTAAAGAAAAATCAAAAATTCAGTGTCTGACCTGAAAAATAAAATGTTAGTTGGAAGTTGGATCATAAG
25 TGAGGCTATCAATGATCCGGGAAATATTGATGATAAAGGTATTTATACGGCACCGGGCAGAATCAGATCTGG
TTCTGAAGTCATTAAAGTCACTGCAACTGACGGCGATGGAATCAGGCATCGGCGGCGCTGACGTTGGTTCC
TTCTTCTGTTGCATTAACACCTTCTTTTGTCTTTATCTCTGAAGCAGATAAGAAACCTATATTATTATGGCGAA
TGTCCTAGACGGAAAAGCAGTAACATGGAATGTGGAAGCTGTACAGGCAGCCAATGTGGTTCTGTTGATCA
GAATGGGCTTTATACTCCACCAGCAGGGCGTTTTAACGATGGATTTACTTTTGCATCCATCACCGCAACTGCA
30 AAAGATGGTAGTCAAGCAGCAACCATTTATTTGCTAATGGCATCAATGCCAGGACATGTTTTTACAAGGTTG
AACCTAATTTACGTTTGAATGTGAAAGTATGGGGAAGAAATTTATCTTTAAAGCGCAGGCAGATTAATTAATGG
TGATCCTGATACTTGGGAAATTTTCCCTCCTCGCGGAAAATTAAGTGAACCTGAGTTTGAACCAATAATGAT
CCTGAAACTAATGATACAATTTTGGTCAATTATAAGGTGACCTATACCGCGCCGACTAATGTTACCTCACCTG
AATTGCTTGTGTCCATGTATGGGAGAAAAATAGGCATAATGAGAAAAACAAAGGTAAGGCAGGATATGCACT
35 TATTGAAATTATCCCAGATGATAAATAGAAAATTTATTTAAATAAAAAATCACAGCGGGTTTATCTCGCTGTGATT
AAAGTCATCTTTTTTATAGATTGTTTATCTCTAATAAATTTTATTTTATAATATAAAGGAAATTAATGAATA
ATGAATATAAAAAATAACCCGTGAATTGGCGTATTTACCTGATACGGTAGGAAGTATTGATAATAACGGTTTA
TATACAGCACCTAAGTTGGGTAAAGAATATCGGAATTTGTCGAATGGAAGTAAAGGCAAGCAGATTAATTAAT
CTTCTGCGATTATTACTGTTATTTCCCTCTTCTGTTGCGTTAACGCCATCGTTTACTTTTATCTCTGAGGCAAAA
40 AAAACATCAGTCACTTTTAAAGCGACAGAACTTGAAGGGAAGAAAGTGACATGGAGTATAAATAATTATACCA
GTAATCAGTATGTTCCATCGATCAAAATGGTATCTACACACCACCGGAAAGTCGTTTTAACGATGGATATAC
TTTTGTATCTATTACAGCAAAAGCGGAAAATGGCGCTGAAGCGCAAGCGCTTATTTGCTTGATGGCCAAAATT
CCAGGGCATGCCTTTTTTCGATGTTTCAGCCTAATATATGTTAAGTGTGAAGCCTGGAGAAGAAATCATTTTTA
GAGCTAACGCAGATCGTTATAATGGTGATCCTGATCTCGGAAATTTTCCGCTCTCTTGGTAAATTTGGGTGA
45 GCCTGAGTATATAAAAAATAACGATCCAGAAATTCCTATTATGATATTATCAAGTGAATATTGCGCCAA
CCAATATAAATTCTTCCAAATACTCGTTGTGCGTACTTGGGAATATGACAAACATGATGAGCATAATCAAGGT
AAAGCAGGATATGCATTCATTGAAATTGTGCCAGAAAATGAGCTTTAATATATATACCAATAGATTTTCAGGCC
GCAGCGCGGCGGCAAGTGAATGAATCCCAGGAGCATAGATAACGATGTGACTGGGGTGAGTGAACGCAG
CCAACAAAGAGGTAACCTGAAAGATAATGAGTATAAATGACTTTAGTAAGAGAAATTATGGCTTCATTGAGAAC
50 TATTTATTAGAGTAATTAACCTTTATAAAGACATTTAATGGAAAATATAATAGAAAAATTTAATATTAATTGAAG
TCTCATCTGAAATTATTGGAGAGAGTTTATTAACCTCCCTTTATTGATGAGTAGAGAAATCAGCAATCAATTA
TCTGAAATATTATTAGATTATAAAGAATATAATATTGCATTGGATAAGTTAGTGTTAAATATAGGAGAAATACCC
TATGAAATATTTGAACAACAATTCTATGGTCGTTTGGGAAAATTATTAATGAAAAGTTAACAATAATAAAT
GATAAATTATTGGTAAAAAACATATCAACCTCGTTATTTCTGAATGTTTTAGTGAAGAAAGAAACCCATTATTA
55 AATAGAGTCATAAAAAATTTACCTTCTAATTTGGTTTTTGAAGTTCATTCAATGGTAAAAATAGAATCAGTAAAT
AACAAAAAACAAAGCTAATATATTGACATCTTATCTGGCTTATTCTTTTTTAAATAAAGCAAAATTACAACAACAT
TTATTTTCCACTAGTAATAATAAATTAATTGAGAGCTTATACGCCTTTTTCTAACGGATCAGAATCGAATACCT
ACTGCTCATAAAAATAGGAAAAGGTGCACTTATACTATCTGCCCTTATTTGGCTTTATTCTAATTTCCAATGATTAT
CTGCCCCAACCCAGAAAGCACTCTGTTGTTACAAATAGACAGGATATAAACAAGGATATTTGCTTTTAAAGT
60 TGTTAATCACTTTTCTCCAGAACAGATAATGGCGGCGTGTTTTTTGGCATTGGCAGTATCGTTTATGGCAAT
CGATATCATCAAAAATCACTTAGGCATTAATAAACATCGAAAGAACCCCATTTACGGGAGAAAATAATGTTAC
AACCAGTTAATGCTTCTGATCGATCCTCTGTGCTGATATCAGACGAAAAATTGACAATACCGTTAACAATTACA
GGTGCGGGATTAGTGCTTCTCTGGCCACTATTAACCTCACTATTTTCTGCTTTTTGATTTGTTAGATAAGAAAAG
TTTTTCAGACAATTTGGCACAGGAAATAGCATTTAATTTATTGGAATGGTTAGTCTGGGGAGATGAGATGCTG
65 TTACATCAGGAATCATCATTATCTTTATTACTCTGCGGAATAGATCACCAACAATACTGGAGCGCCAGGTTCT
TATTCCTGAGCACAAAGGAAAAATTAATAACTGGTTGCAAGGTATTTGTAACCTTTTCTCTTGGAAAAAGC

TAGGGATCGATGATATGCGCCAACTTTTTTTCGACGCTCAGGCTGCACTTTATTATGAAGATGATGGCCGTTG
GTTATTAACGGTGCAGCGTGAAGCTTATGATGTATTACTGACTCAAATGCCTTGGCCGTGGCCATTGAATATT
GTGACATTACCTTGGCTAGCTGAGCCGATTAGTATCACTTGGGAAGGTATCTCTGAACCAACGGATTTGTCAT
TTTGGTAATCCAATATCTCATTAGGAACTCTATGCATGTACGATTTATCTGATGATCTTGCCAGACAGAATATT
5 TCACCGGAATATGAATTGACGGTTTTGCTGTCTCAGACTGCTATATTGGATAAACGAATTCGTTTACGAATTCA
GGAATTAATGCAACAGCAAACACTATTGGGAGAAAGTGGACAGACGCTTTTTGATGATATTTTCATTTTCATTC
GTTTCGAGTGAACAACAAAAATCATCTTATTTGGTGTCAACCGCATCAAAATTGGACGAAAGAGGATTTTCCTC
CTGAGCCGATCCCATCTCGTAGCCGTCTAGGACAATTAGTTGAACGGTTTGACTTAACTCAATTTGAAATTGA
TTTGATTTTATTGTGCGCTGTTGCCTCATCTTGACAGACGTTATCTAACGTTATTTTCTCTTGTCCGGTAAGTG
10 GAGGTAATAACAGCAAAAAGCAGATGTTAACGTTGGGATTGGCTTTGGAGTTGCTTTGTCCGAGTGTAGTAG
AGCGCAATGCGCAACGTGCCAGTTTATTACCACAGGCACCGCTTTGGGATTATCGTTTATTTTCAGTTGCGCG
GTGATATGTCTGTTTCTACGATGAAATACCGTTAGCAATCGATAATTCTCTTATGCATTGGTTATTGGGGCAT
GATGCTCTCCCGATTTCTCTTCTCTCCCGGGCTCATTGGCTTCTGTTCTGAAGTGCCTGATATTTTGCCTG
ATTTACCAACCAATTGATAGAATCTGCCAAATGGAACAAGAGGGGATGCTGACAATAATCGCCGGCGGAG
15 CCGGAAGTGGCAGCAAAAACAAGTGTTCACGCGCAGCATCACAAGTAGGGCGCTCTGTATTGTTGTTATCGT
TAGCATCAGTGACATGAGTGAACATGAACTATTACACTGATAACACTGGCATTGGAAGCACAATAAG
AAATGCCTGTCTTATGTTTGAAGCTTTGGATGAGTTTGTGAAGCACGCCCGCTTTGCAGCTCTGGCTAGGA
AATCGACTGGCTCGTTGTTTCGATTCCGCTGTTTTGTCAATTACCTAAGCAAGCATCATTATTGCCATTGGATG
CAATTTTACAAGTTGTATTGTCTATGCCAATGCCTTCTTTAATGGTGAAGGCTGCAGCATTAGCTTCAATGATG
20 ACGAATTATTTTCCAGACAATTCATTGGATGTTGAAAGTTTAGTGACATGTTTCCATCCTTCTCCATTGATATTG
AAAAAGGCCCTTAGTGAAGCAGAAATTTATCGCCGACTACGGGGGGAACGGCTAGTTTGAAGATTAGATGAT
GTGCAAAATGTCCTGCGTTTTCGGTTACAGCAGAATTTTGGACGTTTAGCACAGAGAATTACACCACAACGAA
CCTTTGATGATTTGATCATCAGTGAATCTCAACAGCAACAATTACAAGAAATCCTGGCGGCTATTCCGCAACG
AGATAGGATGCTAGAGCAAGGATTTGCTCGTAAAGTGAGCTATGGGACGGGTATCAGCACGCTATTTTTTGG
25 TGAATCTGGCACAGGAAAAACGATGGTAGCAGAAGTGTTAGCTGGTGTGTTTAGGTGTGGATTTGATCAAGGT
AGATTTGTCCACTGTGGTTAACAAATATATTGGTGAAGTGAACCAATCTGGCTCGTGTGTTTGTATTATGCCC
AAGAAGACGCCGGGGTATTGTTCTTTGATGAGGCAGATGCATTGTTTGGCAAACGAAGTGAAGTAAAGATG
CAAAAGATCGTCATGCTAATATTGAAGTTTCTACCTATTGCAACGCCCTTGAAGTTATCCAGGGCTGGTGAT
ATTAGCCACCAATTACCGTAATCATTAGACTCAGCATTAGTCTGCTCGCTGACTTTTTTCGGTACGATTCTCTT
30 TTCCAGATGTTTCTTACGGGAACGGATGTGGCGGATTATCTGGCCATCGGGAATTCAATTAGCCGACGACA
TCCATTTTTTCAGCGTTGGCAAAACGGCTGAATTAACGGGGGCGAATATCCGTAATATTGCGCTACTCGCTA
GTTGGCTGGCAGTAGATGAAGGAAATGAAAAATTACTATGGCTCATATTGAATGCGCATTACGACGTGAAGT
GAGTAAAGTTGGGCGCATTGATTTACCTTAATTTTTCTTTGTAATCGGGAGACAATATGGTTAAAAATATCAA
ATCAGATGAAACCTTACTGATATTAATAGTAAATAGAAGATGCATTAAAGCGTATTTACCGGGCGAAGAT
35 GTCGTTATTCGGTTCGATATGTTTGGTAAAAATGAAATCCAGATTCTCCTACCGTGTGCGTTTTTCTTTATGA
TATTCAGGAAGATCTGCAATTACGCGTGGGAGAAGGGCGGCAATACCTGCCTGCGACAGGAAATTTTGTCCC
GGGATGTGTCAATGTTCTGTTGTAATTATCTTATTTCTACTGGGAGCCGGAACAGAGCGGAGGGCAGGGATC
GCCAATTTTACGCTTGAATAGTCAATCAATGAAGATAATGAAGTGTGATTGAATGCATTAATTAATCATCGTT
CATTTCTGTTTTACCCAGAACTTATACGAGAGTTCTTCTCCTAATGAACAATTAAATAGCTTAGGAACTTT
40 TGGCAATCATTAGATAATAAGCCTCGACTATGTTTAAGTTATATGGTGAATTTCTTATTCAACTTACCCCGCC
GACAGAGAAGGTATCTCCTGTCAATACCTCAAAAACCTGATATTACTCGAAAACCATCGCTTAACCTTTATCTTG
AGGCAGATGAAATTATCCGTCAGGCATTAGTTGATGCCTTAATATCTCAAACAACAGAATCTATGGATACGAT
AACTAGCTGGCTGGCAAAAGTTGTTATTATTTGTGACACCAGAAATAATGAATAAACAATGATTGAACAAA
CTGTGAAATTAATTATTGCTGGAATTACAGAAGAGGGATTAGCTGGAAATATAAAGACAATCACTCAAAAGTG
45 GTTGGAAAGAGAAGCATTATTGGTGAATCGACGATGTTTCTCTAGTTATTTCCCAAGTTGACACGACAGC
GTTGTCTGCTGTAACAATACCGACATCTGTTTAA

SEQ ID NO: 96 (Pnf epitope)

TGQKPGNNEWKTGR

50

SEQ ID NO: 97 (PVCpromF)

TATCATATGTCTACAACCTCCAGAACAAATTGCTG

SEQ ID NO: 98 (PVCpromR)

55 ATCTCTAGAACAGATATTCCAGCCAGC

SEQ ID NO: 99 (ParaINF)

GGCGTCACACTTTGCTATG

SEQ ID NO: 100 (ParaINF)

60 TCGGTGGCAGTAAATTGTCC

SEQ ID NO: 101 (F1 primer)

ATGTCTACAAGTACATCTCAAATTGCG

SEQ ID NO: 102 (F2 primer)

GACTCCCTTGAGGGTACGG

5 **SEQ ID NO: 103 (F3 primer)**

TTCTGATGAGAGTGATGGTAC

10 **SEQ ID NO: 104 (F4 primer)**

TGAATAAAGAATTCAGTCAATATC

SEQ ID NO: 105 (R1 primer)

TAGTGGCTGATGAAAGTCTG

15 **SEQ ID NO: 106 (R2 primer)**

GGAAGCCAAAGATAATGAAGTG

SEQ ID NO: 107 (R3 primer)

CATTCTTCCCTATGGTTG

20 **SEQ ID NO: 108 (R4 primer)**

TTAAATTCCTACAAGATTATCTTT

SEQ ID NO: 109 (tBid amino acid sequence)25 RSSHSRLGRIEADSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLALQLRNTSRSEEDRNRDLATAL
EQLLQAYPRDMEKEKTMVLALLLAKKVASHTPSLLRDVFHTTVNFINQLRITYVRSLARNGMD**SEQ ID NO: 110 (E. coli Sequence Optimised tBid bases)**30 CGGTCAAGTCACTCGCGTCTGGGGAGAATCGAGGCTGATAGTGAGAGCCAAGAGGATATCATAA
GAAACATAGCACGCCATTTGGCACAGGTAGGCGATTCTATGGATCGCTCCATCCCGCCTGGACTT
GTCAATGGTCTTGGCGTTCAACTTCGTAACACTTCCCGGTCCGAGGAAGACAGAAATCGGGACCT
TGCGACTGCTCTGGAACAACTGCTTCAAGCATATCCTCGTGACATGGAGAAAGAAAAGACTATGT
TAGTATTAGCTCTTCTTTTAGCTAAAAAGGTAGCTTCGCACACTCCAAGTTTATTGCGGGACGTTT
TTCACACCACTGTTAATTTTCATCAATCAGAACCTGCGTACTTATGTGAGATCTTTGGCGAGAAATG
GTATGGAT

35

SEQ ID NO: 111 (BaxBH3 peptide (aa59–73))

LSESLKRIGDELDSN

40 **SEQ ID NO: 112 (E. coli Sequence Optimised BaxBH3 bases)**

CTGTCGGAGAGTTTGAAGCGTATAGGTGACGAGCTGGACAGCAAT

CLAIMS

1. Use of a *Photorhabdus* Virulence Cassettes (PVC) effector leader sequence, for packaging a payload into a PVC Needle Complex;
5 wherein the payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof; and
wherein the leader sequence and the payload form an effector fusion that is distinct from a wild-type PVC effector protein.
- 10 2. The use according to claim 1, wherein the leader sequence comprises amino acid residues 1-50 of a PVC effector.
3. The use according to claim 1 or claim 2, wherein the leader sequence comprises an amino acid sequence having at least 60% sequence identity to one or more sequence
15 selected sequence from SEQ ID NO.: 47 - SEQ ID NO.: 92.
4. The use according to any one of the preceding claims, wherein the PVC effector comprises an amino acid sequence of one or more sequence selected from SEQ ID NO.: 1 - SEQ ID NO.: 46.
20
5. The use according to any one of the preceding claims, wherein the PVC effector comprises a sequence selected from SEQ ID NO: 4, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 46.
- 25 6. The use according to any one of the preceding claims, wherein the leader sequence is covalently fused to the payload, preferably at an N-terminus of the payload.
7. A method for manufacturing a PVC Needle Complex comprising a payload, the method comprising:
30 a. contacting a PVC Needle Complex with an effector fusion comprising a PVC effector leader sequence fused to a payload;
b. wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
c. wherein the effector fusion is distinct from a wild-type PVC effector protein.
35
8. The method according to claim 7, wherein said contacting occurs within a cell, in a cell lysate, or in a purified cell lysate.
9. An *in vitro* and/or *ex vivo* method for delivering a payload into a cell, the method comprising:
40 a. contacting a cell with a PVC Needle Complex comprising an effector fusion;
b. wherein the effector fusion comprises a PVC effector leader sequence fused to a payload;
c. wherein said payload is one or more selected from a polypeptide, a nucleic acid
45 or a combination thereof; and
d. wherein the effector fusion is distinct from a wild-type PVC effector protein.

10. A method for suppressing a pest, the method comprising:
- contacting a pest, or a target area comprising a pest, with a PVC Needle Complex comprising an effector fusion;
 - wherein the effector fusion comprises a PVC effector leader sequence fused to a payload;
 - wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
 - wherein the effector fusion is distinct from a wild-type PVC effector protein.
11. A PVC Needle Complex, for use in a method of treatment;
- wherein the PVC Needle Complex comprises an effector fusion which comprises a PVC effector leader sequence fused to a payload;
 - wherein said payload is one or more selected from a polypeptide, a nucleic acid, or a combination thereof; and
 - wherein the effector fusion is distinct from a wild-type PVC effector protein.
12. A PVC Needle Complex comprising an effector fusion;
- wherein said effector fusion comprises a PVC effector leader sequence fused to a payload;
 - wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
 - wherein the effector fusion is distinct from a wild-type PVC effector protein.
13. An effector fusion, comprising a PVC effector leader sequence fused to a payload;
- wherein said payload is one or more selected from a polypeptide, a nucleic acid or a combination thereof; and
 - wherein the effector fusion is distinct from a wild-type PVC effector protein.
14. An isolated PVC effector leader sequence.
15. The method, PVC Needle Complex for use, PVC Needle Complex, effector fusion, or isolated PVC effector leader sequence according to any one of claims 7-14, wherein the leader sequence comprises amino acid residues 1-50 of a PVC effector.
16. The method, PVC Needle Complex for use, PVC Needle Complex, effector fusion or isolated PVC effector leader sequence according to any one of claims 7-15, wherein the leader sequence comprises an amino acid sequence having at least 60% sequence identity to one or more sequence selected from SEQ ID NO.: 47 - SEQ ID NO.: 92.
17. The method, PVC Needle Complex for use, PVC Needle Complex, effector fusion or isolated PVC effector leader sequence according any one of claims 7-16, wherein the PVC effector comprises an amino acid sequence of one or more sequence selected from SEQ ID NO.: 1 - SEQ ID NO.: 46.
18. The method, PVC Needle Complex for use, PVC Needle Complex, effector fusion or isolated PVC effector leader sequence according any one of claims 7-17, wherein the

PVC effector comprises a sequence selected from SEQ ID NO: 4, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 32 and SEQ ID NO: 46.

- 5 19. The method, PVC Needle Complex for use, PVC Needle Complex, effector fusion or isolated PVC effector leader sequence according to any one of claims 7-18, wherein the leader sequence is covalently fused to a payload.
- 10 20. An isolated nucleic acid comprising a nucleotide sequence which encodes the isolated PVC effector leader sequence of any one of claims 14-19.
21. An expression vector comprising an isolated nucleic acid molecule of claim 20.
- 15 22. A host cell comprising an isolated nucleic acid molecule of claim 20, or an expression vector of claim 21.
23. The host cell of claim 22, wherein said host cell is one or more a selected from a mammalian cell, an insect cell, a yeast cell, a bacterial cell, and/or a plant cell; preferably wherein said bacterial cell is an *E. coli* cell.
- 20 24. The host cell of claim 22, wherein said host cell is a *Photorhabdus* cell.
25. The host cell of claim 24, wherein said *Photorhabdus* cell comprises a *Photorhabdus* PVC operon operably linked to an inducible promoter.

FIGURE 1





FIGURE 1 (continued)



Locus	Locus Tag	PDB Hit	I Probab	E-Value	P-Value	Score	Protein Function/Description
PVCpnf_1	PAU_03353	6RAP	99.8	3.70E-24	5.90E-29	147.9	Inner sheath tube protein
PVCpnf_2	PAU_03352	6RAP	100	2.30E-60	3.70E-65	427.9	Major outer sheath protein
PVCpnf_3	PAU_03351	6J0N	100	1.70E-74	2.80E-79	524	Minor outer sheath protein and tail fibre docking region
PVCpnf_4	PAU_03350	6RBN	100	4.80E-52	7.60E-57	380.4	Outer sheath tube initiator complex subunit
PVCpnf_5	PAU_03349	6RAO	99.8	5.30E-23	8.40E-28	141.1	Inner sheath tube initiator complex subunit
PVCpnf_6	PAU_03348	3SLS	75.1	1.60E+00	2.50E-05	26.7	Unknown (NR)
PVCpnf_7	PAU_03347	6J0N	99.9	2.10E-28	3.30E-33	183.8	Outer sheath tube initiator complex subunit
PVCpnf_8	PAU_03346	6J0M	100	4.70E-61	7.50E-66	425.4	vgrG-like major spike protein
PVCpnf_9	PAU_03345	6J0N	99.8	1.10E-25	1.80E-30	151.7	Baseplate/spike hub organizing subunit
PVCpnf_10	PAU_03344	1WEY	71	2.40E+00	3.70E-05	26.9	PAAR-like spike tip protein
PVCpnf_11	PAU_03343	6J0N	100	2.00E-130	3.00E-135	1002.4	Major baseplate complex subunit
PVCpnf_12	PAU_03342	6J0N	100	3.00E-246	5.00E-251	1989.6	Major baseplate complex subunit
PVCpnf_13	PAU_03341	2XGF	90.7	7.90E-02	1.30E-06	48.9	Tail fibre
PVCpnf_14	PAU_03340	3C9P	28.5	3.80E+01	6.10E-04	31.5	Putative tape measure protein (NR)
PVCpnf_15	PAU_03339	6FVV	99.8	2.20E-23	3.50E-28	202.1	Putative payload loading AAA+ ATPase (NR)
PVCpnf_16	PAU_03338	6J0F	100	3.10E-62	4.90E-67	425.3	Tube terminator/cap protein complex subunit
PVCpnf_17	PAU_03337	5XNW	97.3	1.40E-06	2.20E-11	82.4	Adenylate cyclase ExoY virulence effector (<i>P. aeruginosa</i>)
PVCpnf_18	PAU_03336	2I0X	74.2	1.70E+00	2.80E-05	25.3	Unknown function
PVCpnf_19	PAU_03334	3L3U	75.5	1.50E+00	2.40E-05	23.4	Unknown function
PVCpnf_20	PAU_03333	5Z72	99.7	1.40E-20	2.20E-25	117.8	Unknown function (likely LysR type regulator)
PVCpnf_21	PAU_03332	1HQ0	100	2.60E-54	4.10E-59	390.4	>1HQ0_A CYTOTOXIC NECROTIZING FACTOR 1

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 6 (continued)

F



Resazurin assay for respiration in THP1 derived human macrophageEffect on *Galleria*

FIGURE 7

A



B




FIGURE 8





FIGURE 9




FIGURE 10


A



B



C



D




FIGURE 10 (continued)

E




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16

A

Axin2^{CRE} R26-LSL-tdTom organoid model: Preliminary test done on mouse bile duct organoids




FIGURE 16 (continued)

B




FIGURE 17




FIGURE 18






FIGURE 19

A



B



SEQUENCE LISTING

<110> THE UNIVERSITY OF WARWICK

<120> LEADER SEQUENCE

<130> P61200WO

<150> GB1908155.3

<151> 2019-06-07

<160> 112

<170> PatentIn version 3.5

<210> 1

<211> 299

<212> PRT

<213> Photorhabdus

<400> 1

Met	Met	Arg	Glu	Tyr	Ser	Asn	Glu	Asp	Asp	Phe	Ile	Lys	Glu	Lys	Thr
1				5					10					15	

Asn	Leu	Val	Lys	Ser	Glu	Asn	Val	Glu	Ala	Asp	Asn	Tyr	Leu	Glu	Thr
			20					25					30		

Glu	Tyr	Leu	Thr	Tyr	Leu	Ala	Lys	Leu	Ile	Gly	Met	Thr	Glu	Arg	Glu
		35					40					45			

Asn	His	His	Leu	Asn	Ser	Ile	Lys	Leu	Ile	Asp	Asp	Ile	Ile	Glu	Leu
	50					55				60					

His	Asn	Asp	Arg	Lys	Gly	Asn	Lys	Leu	Leu	Trp	Asn	Asp	Asn	Trp	Gln
65					70					75					80

Asp	Lys	Ile	Ile	Asp	Arg	Asp	Leu	Gln	Ser	Ile	Phe	Lys	Lys	Ile	Asp
				85					90					95	

Glu	Met	Val	Ser	Glu	Phe	Gly	Gly	Leu	Glu	Ala	Tyr	Lys	Asp	Ile	Val
			100					105					110		

Gly Glu Asn Pro Tyr Asp Pro Thr Glu Pro Val Cys Gly Tyr Ser Ala
115 120 125

Gln Asn Ile Phe Lys Leu Met Thr Glu Gly Glu Tyr Ala Val Asp Pro
130 135 140

Val Lys Met Ala Lys Thr Gly Lys Ile Asn Gly Asn Gln Phe Ala Glu
145 150 155 160

Lys Leu Glu His Leu Asn Ser Ser Asn Asn Tyr Val Ala Leu Ile Asn
165 170 175

Asp His Arg Leu Gly His Met Phe Leu Val Asp Ile Pro Ser Thr Asn
180 185 190

Arg Glu Arg Val Gly Tyr Ile Tyr Gln Ser Asp Leu Gly Asp Gly Ala
195 200 205

Leu Pro Ala Leu Lys Ile Ala Asp Trp Leu Lys Ser Arg Gly Lys Glu
210 215 220

Ser Ile Asn Val Asn Lys Leu Lys Lys Phe Leu Asn Asp Glu Phe Thr
225 230 235 240

Met Leu Pro Asp Asn Glu Gln Lys Gly Leu Ile Ala Glu Ile Phe Asp
245 250 255

Leu Asn Lys Asp Ile Asp Ser Val Lys Ser Gly Lys Ile Lys Lys Asp
260 265 270

Lys Ala Val Asp Ile Tyr Leu Arg Glu Tyr Asp Ile Asn Asp Phe Ile
275 280 285

Ser Asn Ile Glu Lys Leu Lys Thr Lys Leu Ala
290 295

<210> 2

<211> 309

<212> PRT

<213> Photorhabdus

<400> 2

Met Phe Gln Asn Arg Ile Arg Asn Glu Lys Thr Thr Gln Ser Gly Lys
1 5 10 15

Gly Lys Thr Leu Asp Arg Met Thr Asp Ser Leu Tyr Leu Glu Ile Pro
20 25 30

Asn Val Glu Ala Val Thr Leu Ala Tyr Gln Lys Leu Thr Ser Lys Tyr
35 40 45

Arg Lys Phe Asp Asn Lys Thr Lys Leu Ile Leu Asp Ser Ser Asp Glu
50 55 60

Phe Ser Gln Leu Lys Ser Glu Lys Gln Arg Lys Gly Phe Ser Lys Ser
65 70 75 80

Gly Leu Lys Asn Asn Gly Val Ser Asp Arg Lys Phe Ile Tyr Thr Lys
85 90 95

Asn Ala Leu Lys Asn Phe Ala Ala His Ala Gly Tyr Glu His Asn Gly
100 105 110

His Tyr Glu Asp Glu Phe Val Asn Phe Lys Asp Asn Asn Lys Asn Leu
115 120 125

Ala Lys Gly Lys Leu Phe Pro Gly Ile Ser Leu Ile Glu Arg Arg Lys
130 135 140

Leu Ser Ile Val Lys Asn Lys Glu Gly Lys Trp Glu His Lys Glu Thr
145 150 155 160

Asp Glu Ala Glu Ala Tyr Lys Val Thr Asp Ile Glu Lys Phe Ile Ser
165 170 175

Gly Val Arg Ser Met Tyr Leu Gln Gly Asn Thr Phe Leu His Ala Lys

180

185

190

Thr Glu Ala Leu Ile Arg Lys His Ile Ala Asn Asn Glu Asn Ile Leu
 195 200 205

Pro Thr Met Ala Gly Ile Ala Gly Leu His Ala Glu Val Gln Ala Leu
 210 215 220

Asn Asn Leu Phe Ile Ser Gly Asp Lys Gly Thr Lys Lys Arg Glu Lys
 225 230 235 240

Trp Lys Tyr Ile Arg Asn Met Leu Glu Ser Ser Ile Phe Thr Gln Arg
 245 250 255

Leu Thr Thr Gly Gln Ala Gly Lys Asp Phe Ala Ala Cys His Asn Cys
 260 265 270

Ser Gly Ile Leu Ser Ser Pro Val Asn Val Ile Thr Gly Lys Val Glu
 275 280 285

Ser Ala Gly Asp Asn Phe Leu Ser Thr Leu Ser Arg Tyr Lys Thr Ser
 290 295 300

Gln Glu Ser Pro Ile
 305

<210> 3
 <211> 278
 <212> PRT
 <213> Photorhabdus

<400> 3

Met Glu Arg Glu Tyr Ser Glu Lys Gln Lys Asn Pro Ser Lys Leu Ser
 1 5 10 15

Arg Lys Thr Ala Ile Ser Glu Arg Ile Ala Ala Leu Glu Arg Ser Gly
 20 25 30

Leu Ser Asn Ser Asn Gln Pro Val Pro Gln Phe Ala Arg Pro Tyr Thr
35 40 45

Ser Asn Arg Pro Val Val Asn Ile Asn Pro Gly Arg Ser Ser Ile Ala
50 55 60

Val Ala Thr Ala Asn Ser Thr Ser Pro Val Asn Ile Pro Thr Pro Ala
65 70 75 80

Pro Ala Ser Pro Asp Lys Leu Leu Pro Ser Thr Ser Cys Asp Thr Thr
85 90 95

Ser Ser Ile Leu Ile Val Gly Lys Tyr Asn Leu Glu Leu Thr Ser Gln
100 105 110

Gly Lys Ile Val Val Phe Arg Gly Asp Asn Arg Thr Pro Glu Gln Ile
115 120 125

Val Ala Ala Gly Gly Phe Tyr Pro Trp Ser Lys Gln Asp Val Gly Lys
130 135 140

Ile Lys Lys Glu Leu Ile Asp Glu Phe Ile Glu Ile Gly Pro Ser Ala
145 150 155 160

His Met Met Gly His Val Arg Ser Pro Asn Lys Asn Tyr Val Ser Thr
165 170 175

Gly Met Asn Met Asp Ser Gly Gly Phe Gly Glu Gln Ser Asn Tyr Leu
180 185 190

Tyr Lys Met Glu Ile Pro Gly Leu Lys Pro Gln Asp Met Asn Glu Arg
195 200 205

Thr Leu Gly Glu Lys Ile Arg Gln Asp Lys Arg Gly Ile Asn Tyr Pro
210 215 220

His Phe Leu Met Ser His Leu Thr Leu Ala Glu Ser Glu Phe Val Ala
225 230 235 240

Met Ile Pro Ala Arg Ser Glu Glu Leu Thr Phe Ile Thr Pro Ile Pro
245 250 255

Leu Ser Tyr Ile Thr Ser Tyr Arg Lys Arg Gly Thr Asn Thr Trp Leu
260 265 270

Pro Met Pro Leu Lys Lys
275

<210> 4
<211> 1633
<212> PRT
<213> Photorhabdus

<400> 4

Met Ser Asn Tyr Glu Tyr Asp Ile Val Thr Gln His Asp Thr Tyr Gln
1 5 10 15

Ile Lys Asp Asn Glu Tyr Thr Val Val Asn Gly Lys Tyr Trp Gln Tyr
20 25 30

Glu Gln Glu Gly Asn Lys Asn Asn Asn Lys Val Ser Ile Ser Leu Met
35 40 45

Lys Glu Asn Gln Asn Asp Pro Val Trp Ile Thr Ser Asp Ile Lys Glu
50 55 60

Ile Ser Leu Tyr Ile Ile Glu Asn Leu Phe Ser Tyr His Lys Phe Ser
65 70 75 80

Ala Glu Leu Gln His Thr Leu Lys Asn Ala Val Lys Ala Val Phe Asn
85 90 95

Glu Tyr Ser Glu Ile Lys Tyr Ser Glu Leu Leu His Asn Ile Asn Asn
100 105 110

Ile Phe Asn Leu Phe Phe Ile Lys Ile Tyr Asn Thr Ser Asp Ile Asp

115

120

125

Thr Ala Ile Asn Ile Leu Thr Ala Lys Ile Glu Ile Tyr Asp Lys Leu
 130 135 140

Glu Lys Ile Asn Gln Asp Lys Thr Asp Ser Asn Asn Thr Asn Val Asp
 145 150 155 160

Ile Trp Glu Glu Leu Gly Ile Asn Ala Glu Glu Pro Leu Leu Lys Ile
 165 170 175

Tyr Arg Gln Ala Phe Ser Thr Gly Asp Ile Asp Asp Glu Val Tyr Ser
 180 185 190

Asp Ala Leu Leu Thr Phe Met Ser Asp Gly Asn Leu Glu Leu Gly Asp
 195 200 205

Lys Glu Lys Ser Asp Tyr Asn Gln Arg Ile Lys Asp Lys Thr Asp Leu
 210 215 220

Phe Glu Ser Tyr Lys Lys Gly Ile Glu Lys Val Ala Ser Leu Ile Thr
 225 230 235 240

Thr Asn Asn Ile Asn Pro Gly Ile Pro Ile Thr Tyr Pro Glu Thr Glu
 245 250 255

Lys Ser Ile Asn Ile Gly Asp Asp Leu Leu Leu Ala Gln Leu Ala Lys
 260 265 270

Glu Glu Ile Ala Leu Lys Lys Gln Asn Arg Thr Glu Tyr Ser Gln Gln
 275 280 285

Asp Ile Phe Glu Leu Gln Thr Leu Gln Ala Ala Lys Tyr His Leu Leu
 290 295 300

Ile Leu Ser Ser Leu Gly Ala Leu Leu Tyr Gln Ile Ala Pro Asn Val
 305 310 315 320

Glu Lys Met Thr Lys Gly His Gly Asp Tyr Arg Asp Ile Ile Phe Ser
325 330 335

Gln Glu Gln Ala Glu Ser Leu Phe Lys Lys His Asn Ile Gln Tyr Asp
340 345 350

Thr Asn His Val Leu Ser Gln Glu Ser Lys His Ile Glu Met Glu Gly
355 360 365

Cys Ile Ile Leu Thr Ala Ala Ile Ile Tyr Arg Met Arg Lys Glu Asn
370 375 380

Ala Thr Val Glu Gln Ala Leu Asn Tyr Ser Thr Leu Glu Thr Ile Lys
385 390 395 400

Leu Phe Glu Asn Asp Lys Lys Lys Leu Asn Pro Phe Asn Thr Asn Asn
405 410 415

Val Lys Pro Ala Gly Tyr Phe Ser Phe Ile Asp Phe Lys Lys Arg Asp
420 425 430

Lys Phe Asp Ser Gln Tyr Asn Phe Asn Glu Gln Phe Asn Val Tyr Lys
435 440 445

Asn Lys Tyr Ser His Tyr Glu Ser Ile Ser Phe Ser Lys Leu Ile Leu
450 455 460

Ser Ser Pro Ala Ala Gln Leu Thr Ala Glu Glu Ile Val Asn Pro Pro
465 470 475 480

Glu Glu Ala Phe Leu Tyr Ser Val Glu Gln Gly Met Gly Asn Val Ala
485 490 495

Met Ile Lys Met Tyr Gln Gly Asn Trp Leu Val Ile Ser Thr Ile Gln
500 505 510

Gly Gly Val Lys Ala Lys Lys Tyr Ser Arg Gln Gln Val Asp Ser Asn

515

520

525

Pro Thr Leu Arg Ala Met Ser Lys Pro Asn Ala Leu Phe Leu Ile Glu
 530 535 540

Arg Lys Met Glu Thr Gly Met Gly Ile Leu Met Pro Asn Met Met Val
 545 550 555 560

Asn Thr Gly Lys Arg Leu Phe Pro Thr Gly Tyr Glu Arg Ala Lys Thr
 565 570 575

Leu Ser Gly Phe Ala Glu Thr Ser Arg Tyr Lys Asn Ser Tyr Asn Ala
 580 585 590

Phe Trp Asn Asp Tyr Tyr Gly Ile Thr Ser Gly Met Asn Val Gly Ile
 595 600 605

Ser Phe Thr Gly Ser Pro Lys Phe Asn Phe Tyr Lys Glu Glu Asn Leu
 610 615 620

Leu Ser Val Thr Ala Thr Ile Ile Gln Gln Gly Leu Asn Asp Ile Ala
 625 630 635 640

Ile Lys Ser Lys Gln Ala Leu Asp Ile Thr Ser Gly Trp His Ile Ala
 645 650 655

Ala Thr Ile Leu Ile Pro Phe Tyr Asn Val Ile Tyr Lys Ser Thr Thr
 660 665 670

Asp Ser Glu Tyr Glu Leu Thr Gly Glu Asp Ile Gly Ser Ile Val Phe
 675 680 685

Asp Thr Ala Asn Val Leu Leu Val Val Ala Thr Leu Gly Met Ser Leu
 690 695 700

Thr Glu Ser Met Ala Ala Lys Val Thr Gln Thr Thr Leu Arg Leu Arg
 705 710 715 720

Gln Ala Gly Leu Thr Gly Arg Ala Leu Ile Thr Ala Val Val Arg Thr
725 730 735

Leu Pro Glu His Gly Ile Ile Thr Leu Arg Gln Ser Ser Gly Ile Ile
740 745 750

Leu Gly Gly Leu Ile Asp Leu Ile Glu Pro Leu Pro Ile Arg Ser Thr
755 760 765

Leu Thr Leu Thr Tyr Arg Gly Val Ile Asn Ala Val Gly Ala Met Arg
770 775 780

Asn Ser Ile Lys Leu Glu Lys Ser Phe Ala Asp Ile Phe Gly Lys Ser
785 790 795 800

Thr Arg Gly Leu Gly Lys Leu Lys Asn Glu Trp Lys Val Ser Asn Leu
805 810 815

Pro Leu Glu Glu Ile Val Pro His Ser Asn Gly Gly Glu Ile Tyr Lys
820 825 830

Gly Ile Tyr Ser Ile Arg Pro Thr Asn Pro Glu Thr Ala Val Lys Gln
835 840 845

Asn Phe Tyr Ile Lys Glu Ala Gly Ala Asn Tyr Gln Val Lys Trp Asp
850 855 860

Asp Ala Asn His Thr Trp Arg Val Val Asn Pro Thr Tyr Pro Glu Gln
865 870 875 880

Phe Ser Tyr Trp Pro Ala Val Lys Leu Asp Lys Asn Gly His Trp Val
885 890 895

Thr His Ala Asp Val Ser Asn Lys Phe Leu Ile Leu Glu Gln Ser Lys
900 905 910

Arg Ile Asp Gln Glu Leu Glu Ala Ala His Ser Asn Ile Asn Asn Asp

915

920

925

Asn Ile Leu Asp Ala Phe Ile His Ile Asn Thr Ala Phe Lys Asp Cys
 930 935 940

Glu Arg Tyr Asp Ile Asp Lys Leu Ser Asp Ile Thr Asp Thr Leu Thr
 945 950 955 960

His Phe Phe Glu Lys Ser Leu Lys Pro Gly Asp Lys Lys Ala Ile Phe
 965 970 975

Ser Thr Glu Ile Met Ser Ile Gln Gln Ala Trp Ile Arg Glu Val Ile
 980 985 990

Leu Pro Leu Gln Asn Asn Ser Ser Ile Ser Ile Glu Lys Ile Asn Ala
 995 1000 1005

Ile Lys Thr Glu Leu Pro Tyr Leu Leu Arg Lys Thr Phe Pro Ile
 1010 1015 1020

Glu Ser Gln Leu Pro Asn Gln Leu Val Ala Asn Lys Ile Ala Leu
 1025 1030 1035

Ala Ile Glu Glu Ile Pro Asn Thr Arg Ile Pro Lys Tyr Thr Ser
 1040 1045 1050

Gly Asn Ile Ser Lys Thr Val Gln Tyr Thr Ser Leu Leu Glu Asn
 1055 1060 1065

Asn His Val Asp Ile Pro Pro Val Gly Ile Thr Ile Thr Gly Asn
 1070 1075 1080

Asp Thr Phe Ile Asn Gln Val Thr Arg Val Leu Ser Glu Ile Asp
 1085 1090 1095

Glu Ile Pro Ser Gly Asn Ile Val Ile Gln Glu Leu Glu Lys Gln
 1100 1105 1110

Gly Leu Asn Ile Gln Pro Pro Thr Met Asn Asp Ile Val Arg Glu
1115 1120 1125

Lys Asn Gly Gln Phe Tyr Ala Asn Asn Ser Ala Gly Ser His Ile
1130 1135 1140

Ala Phe Asp Pro Glu Asn His Leu Ile Gly Thr Glu Glu Lys Leu
1145 1150 1155

Ile Asp Glu Pro Trp Arg Thr Arg Glu Pro Ala Ile Ala Leu Tyr
1160 1165 1170

His Glu Met Leu His Ile Tyr Tyr Asn Arg Tyr Pro Thr Trp Phe
1175 1180 1185

Thr Ser Ile Asp Asn Lys Val Ile Asp Gln Lys Val Ser Gly Gly
1190 1195 1200

Phe Ser Leu Leu Glu Glu Ser Arg Ile Val Gly Thr Lys Tyr Tyr
1205 1210 1215

Val Asn Asp Lys Asn Thr Leu Phe Asp Phe Asn Asp Ser Asp Tyr
1220 1225 1230

Leu Leu Glu Asn Asn Ser Ala Leu Leu Thr Glu Asn Arg Phe Arg
1235 1240 1245

Ala Glu Tyr Ala Ile Phe Lys Asn Lys Ser Glu Tyr Val Ile Arg
1250 1255 1260

Pro Tyr Ser Gly Lys Gly Asp Ser Gln Ile Pro Leu Thr Lys Thr
1265 1270 1275

Lys Ile Asn Ile Asn Glu Ser His Arg Asn Val Met Gly Val Gly
1280 1285 1290

Ser Gly Lys Pro Glu Lys Met Pro Asn Glu Ser Ala Thr Asp Tyr

1295

1300

1305

Arg Asn Arg Val Arg Glu Trp Arg Lys Ala Asn Lys Gln Pro Glu
 1310 1315 1320

Ala Asp Ile Gly Thr Gly Asp Met Arg Lys Thr Lys Ala Glu Ala
 1325 1330 1335

Arg Val Lys Leu Leu Lys Glu Asn Tyr Pro Gln Phe Glu Pro Gln
 1340 1345 1350

Lys Ile Glu Leu Gly Gly Ala Phe Gln Leu Trp Thr Val Pro Asn
 1355 1360 1365

Glu Pro Ala Asn Lys Leu Met Leu Ser Ser His Gly Tyr Phe Phe
 1370 1375 1380

Ser Asp Ser Ala Ala Thr Gln Val Pro Ala Gly Lys Thr Ile Gln
 1385 1390 1395

Phe Leu Gly Pro His Gly Lys Thr Leu Leu Glu Ala Pro Glu Asn
 1400 1405 1410

Pro Leu Tyr Ser Pro Phe Asp Val Thr Leu Gly Asn Ser Gly Phe
 1415 1420 1425

Thr Val Gln Pro Tyr Ala Thr Ile Glu Ser Gly Asn Lys Ala Gly
 1430 1435 1440

Leu Gly Ser Val Lys Ile Gly Asp Lys Thr Phe Thr Val Asn Asp
 1445 1450 1455

Ile Gln Asn Ile Ala Thr Asp Asp Val Glu Asn Tyr Leu Leu Ala
 1460 1465 1470

Thr Gly Val Glu Ala Asn Ala Ser Asn His Gly Lys Val Arg Asn
 1475 1480 1485

Tyr Gly Ile Lys Tyr Tyr Glu Lys Met Pro Asp Glu Glu Val Lys
1490 1495 1500

Ala Ala Ile Trp Lys Asn Arg Ala Asp Glu Thr Ser Thr His Lys
1505 1510 1515

Tyr Asp Ala Leu Leu Val Ser Pro Glu Ala Gly Asn Arg Lys Lys
1520 1525 1530

Leu Ser Asp Ile Phe Ala Leu Met Lys Thr Asp Glu Arg Met Ser
1535 1540 1545

Lys Tyr Asp Glu Ile Thr Phe Val Ala Cys Arg Glu Glu Leu Asn
1550 1555 1560

Arg Ile Asn Met Lys Ser Ile His Asp Thr Gly Leu Gly Gly Gly
1565 1570 1575

Tyr Glu Pro Lys Leu Glu Pro Thr Val Ile Leu Ser Arg Arg Arg
1580 1585 1590

Arg Glu Ala Thr Phe Thr Ala Asp Gly Ala Ile Ile Tyr Ser Ile
1595 1600 1605

Ile Ala Val Asn Leu His His Asn Phe Ile Thr Glu Glu Ile Val
1610 1615 1620

Gly Ile Ala Pro Phe Leu Phe Ile Asn Asn
1625 1630

<210> 5
<211> 324
<212> PRT
<213> Photorhabdus

<400> 5

Met Glu His Glu Tyr Asn Glu Lys Glu Lys Gln Arg Asn Ser Ala Ile
1 5 10 15

Lys Leu Asn Asp Ala Ile Arg Asn Asn Glu Glu Asn Met Asp Met Thr
20 25 30

Ser Pro Leu Glu Leu Asn Phe Gln Asn Thr Asn Arg Lys Ser Arg Gly
35 40 45

Leu Arg Glu Arg Phe Ser Ala Thr Leu Gln Arg Asn Leu Pro Gly His
50 55 60

Ser Met Leu Asp Arg Glu Leu Thr Thr Asp Gly Gln Lys Asn Gln Glu
65 70 75 80

Ser Arg Phe Ser Pro Gly Met Ile Met Asp Arg Leu Met His Phe Gly
85 90 95

Val Arg Thr Arg Leu Gly Lys Val Arg Asn Ser Ala Ser Lys Tyr Gly
100 105 110

Gly Gln Val Thr Phe Lys Phe Ala Gln Thr Lys Gly Thr Phe Leu Asp
115 120 125

Gln Ile Met Lys His Lys Asp Thr Ser Gly Gly Val Cys Glu Ser Ile
130 135 140

Ser Ala His Trp Ile Ser Ala His Ala Lys Gly Asp Ser Ile Phe Asn
145 150 155 160

Gln Leu Tyr Val Gly Gly Lys Lys Gly Lys Phe His Ile Asp Thr Leu
165 170 175

Phe Ser Ile Lys Gln Leu Gln Met Asp Gly Tyr Leu Asp Asp Glu Gln
180 185 190

Ser Thr Met Thr Glu Tyr Trp Leu Gly Thr Gln Gly Met Gln Pro Asn
195 200 205

Ile Gln Arg Asn Asp Asp Thr Asp Glu His Ser Ser Lys Val Val Gly
210 215 220

Glu Thr Gly Asn Arg Gly Thr Lys Asp Leu Leu His Ala Ile Leu Asp
225 230 235 240

Thr Gly Asp Lys Gly Ser Gly Tyr Lys Lys Ile Ser Phe Leu Gly Lys
245 250 255

Met Ala Gly His Thr Val Ala Ala Tyr Val Asp Asp Gln Lys Gly Val
260 265 270

Thr Phe Phe Asp Pro Asn Phe Gly Glu Phe Ser Phe Pro Asp Lys Thr
275 280 285

Ser Phe Ser His Trp Phe Thr Asp Asp Phe Trp Pro Lys Ser Trp Tyr
290 295 300

Ser Leu Glu Ile Gly Leu Gly Gln Glu Phe Glu Val Phe Asn Tyr Ala
305 310 315 320

Pro Glu Ala Pro

<210> 6
<211> 287
<212> PRT
<213> Photorhabdus

<400> 6

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Lys Pro
1 5 10 15

Leu Met Lys Ser Glu Ala Asn Asn Glu His Asp Ile Gln Asn Ser Ser
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Met Met Gly Asn Ser Ser Thr
35 40 45

Ser Leu Ser His Ile Gln Asp Tyr Ser Phe Trp Lys Glu Asn Ile Ser
50 55 60

Glu Tyr Tyr Lys Trp Met Val Val Val Lys Ala His Leu Lys Gln Leu
65 70 75 80

Asp Trp Thr Leu Lys Ser Met Asp Ser Pro Glu Ser Ala Gly Thr Asn
85 90 95

Ile Ala Lys Asn Thr Gly Thr Thr Ala Leu Gln Thr Leu Leu Asn Thr
100 105 110

Gly Gly Ser Ile Ala Gly Ala Ala Ile Gly Gly Ala Ile Gly Ser Ala
115 120 125

Ile Ala Pro Gly Val Gly Thr Ile Ala Gly Met Gly Ile Gly Ala Leu
130 135 140

Ala Gly Thr Gly Leu Asn Tyr Leu Asn Asp Thr Val Ile Glu Lys Leu
145 150 155 160

Asn Glu Lys Leu Glu Ile Ala Tyr Pro Tyr Pro Lys Thr Arg Asn Met
165 170 175

Ile Phe Asp Ile Asn Asn Tyr Asp Lys Asn Pro Ile Ile Lys Ala Ile
180 185 190

Lys Lys Lys Thr Asn Lys Asp Asn Leu Lys Val Thr Ala Gly Ser Ser
195 200 205

Leu Thr Ser Gln Leu Val Gly Lys Val Thr Ser Pro Ile Lys Phe Pro
210 215 220

Ala Tyr Lys Leu Ala Asp Leu Ala Ile Ala Leu Ala Gly Leu Ser Ser
225 230 235 240

Asp Lys Ala Arg His Ile Leu Asp Phe Thr Asp Ser Ile Arg Glu Val

245

250

255

Leu Asn Glu Ser His Ser Asp Ala Val Ala Phe Met Arg Lys Asn Tyr
 260 265 270

Gly Asp Asn Ala Met Gly Leu Ala Gly Leu Ser Ser Arg Ile Lys
 275 280 285

<210> 7

<211> 322

<212> PRT

<213> Photorhabdus

<400> 7

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys Arg Pro Ile
 1 5 10 15

Gln Leu Arg Asn Ser Ile Glu Gln His Glu Glu Glu Thr Ala Asn Asn
 20 25 30

Ser Leu Gly Leu Gly Leu Asp Leu Asn Gln Ala Thr Asn Pro Pro Lys
 35 40 45

Val Pro Lys Asp Asn Tyr Asn Glu Glu Asn Gly Asp Leu Phe Tyr Gly
 50 55 60

Leu Ala Asn Gln Arg Gly Arg Tyr Ile Lys Ser Val Asn Pro Asn Phe
 65 70 75 80

Asp Pro Asp Lys Ile Asn Ser Ser Pro Met Ile Ile Asp Val Tyr Asn
 85 90 95

Asn Asn Val Ser Asn Thr Ile Leu Asn Lys Tyr Pro Leu Asp Lys Leu
 100 105 110

Val Lys Leu Ser Gly Asn Pro Gln Lys Tyr Ala Asn Asn Ile Lys Val
 115 120 125

Glu Asn Ser Leu Gln Gln Asp Val Ala Ser Ser Lys Arg Gly Trp Tyr
130 135 140

Pro Leu Trp Asn Asp Tyr Phe Lys Thr Gly Asn Glu Asn Lys Lys Phe
145 150 155 160

Asn Ile Ala Asp Ile Tyr Lys Glu Thr Arg Asn Gln Tyr Gly Ser Asp
165 170 175

Tyr Tyr His Thr Trp His Thr Pro Thr Gly Ala Ala Pro Lys Leu Leu
180 185 190

Trp Lys Arg Gly Ser Lys Leu Gly Ile Glu Met Ala Ala Ser Asn Glu
195 200 205

Lys Thr Lys Ile His Phe Val Leu Asp Gly Leu Asn Ile Gln Glu Val
210 215 220

Val Asn Lys Gln Lys Gly Ser Thr Pro Leu Glu Gln Gly Arg Gly Glu
225 230 235 240

Ser Ile Thr Ala Ser Glu Leu Arg Tyr Ala Tyr Arg Asn Arg Glu Arg
245 250 255

Leu Ala Gly Lys Ile His Phe Tyr Glu Asn Asp Gln Glu Thr Val Ala
260 265 270

Pro Trp Glu Lys Ser Pro Glu Leu Trp Gln Asn Tyr Ile Pro Lys Asn
275 280 285

Lys Asn Gln Asn Glu Ser Ser Thr Pro Gln Arg Asn Asn Gly Thr Leu
290 295 300

Tyr Arg Leu Gly Gly Pro Phe Arg Lys Leu Arg Ala Ser Leu Arg Lys
305 310 315 320

Arg Ser

<210> 8
<211> 308
<212> PRT
<213> Photorhabdus

<400> 8

Met Met Glu His Glu Tyr Ser Lys Glu Glu Glu Lys Lys Arg Gln Gln
1 5 10 15

Ser Lys Pro Asn Asn Ala Thr His Asp Glu Ser Asn Leu Pro Leu Glu
20 25 30

Leu Glu Lys His Phe Asn Ala Arg Thr Pro Ala Thr Ala His Ser Lys
35 40 45

Trp Phe Thr Tyr Glu Asn Asp Thr Glu Val Glu Leu Thr Thr Glu Arg
50 55 60

Ile Lys Glu Ile Phe Ser Asn Lys Gln Pro Lys Ile Ile Ile Ala Gly
65 70 75 80

Asp Gly His Asn Lys Pro Pro Phe Gln Tyr Ala Lys Asn Ile Pro Asp
85 90 95

Val Asn Ser Ser Phe Asp Ala Gly Thr Leu Gln Leu Tyr Ile Glu Ala
100 105 110

Thr Asp Glu Gln Ile Asn Glu Asn Asn Pro Glu Tyr Ile Pro Lys Glu
115 120 125

Phe Met Ala Lys Pro Gly Leu Phe Thr Asn Lys Asn Arg Arg Ala Glu
130 135 140

Ile Val Gly Trp Glu Asp Ser Glu Leu Ser Asn Ala Met Lys Glu Met
145 150 155 160

Phe Glu Leu Ser Asp Lys Ser Thr Arg Glu Lys Leu Thr Pro Glu Glu

165

170

175

Thr Ser Ser Phe Tyr Lys Leu His Glu Thr Ala Ile Arg His Phe Phe
 180 185 190

Arg Pro Glu Phe Asn Gln Leu Arg Asp Glu Phe Phe Glu Ile Leu Ala
 195 200 205

Lys Ala Gly Ser Asn Arg Glu Leu Asp Lys Ile Ala Leu Glu Met Ile
 210 215 220

Gly Phe Thr Ser Gly Thr Trp Arg Asp Glu Tyr Ile Asn Pro Thr Leu
 225 230 235 240

Ala Glu Lys Ile Ala Lys His Ala Ala Glu Lys Glu Asn His Thr Phe
 245 250 255

Val Val Ser Ile Gly Asp Ala His Leu Ser Glu Asn Pro Met Gln Glu
 260 265 270

Tyr Leu Asn Lys Arg Arg Asn Gly Gly Glu Phe Lys His Gln Ile Ile
 275 280 285

Phe Thr Arg Asp Lys Arg Pro Ile Leu Pro Asp Asn Met Lys Thr Gly
 290 295 300

Asn Lys Asn Ser
 305

<210> 9
 <211> 298
 <212> PRT
 <213> Photorhabdus

<220>
 <221> misc_feature
 <222> (148)..(148)
 <223> Xaa can be any naturally occurring amino acid

<400> 9

Met Leu Lys Tyr Ala Asn Pro Gln Ala Val Pro Thr Gln Arg Thr Lys
1 5 10 15

Asn Thr Ala Lys Lys Pro Ser Ser Ser Ser Phe Asp Gly Gln Leu
20 25 30

Glu Leu Ser Asn Gly Glu Trp Ser Lys His Ser Glu Met Gly Leu Lys
35 40 45

Arg Gly Gly Leu Ile Asn Ser Ile Arg Arg Arg Ile Ala Arg Asn Gly
50 55 60

Asn Ile Gly Arg Phe Asn Glu Leu Ile Asp Ser Glu Ala Lys Lys Trp
65 70 75 80

Pro Ser Glu Pro Val Asp Lys Asn Ile His Met Ile Trp Ile Gly Thr
85 90 95

Arg Asn Ile Ser Glu Lys Asn Ile Lys Leu Ser Ile Asp Thr Ala Lys
100 105 110

Lys Asn Pro Asp Tyr Asn Thr Ser Ile Ile Tyr Asp Ser Gly Ile Ser
115 120 125

Gly His Glu Gly Ala Arg Asn Phe Met Leu Glu Lys Phe Glu Gly Ser
130 135 140

Asn Val Asn Xaa Ser Leu Ala Phe Pro Lys Gly Ile Gly Val Met Arg
145 150 155 160

Glu Tyr Ala Pro Glu Ala Gly Lys Ala Thr Ala Phe Pro Asn Thr Pro
165 170 175

Ile Ala Val Thr Lys Asn Asn Pro Ile Ile Asn Lys Thr Leu Asp Leu
180 185 190

Ala Val Gly Asn Tyr Gln Arg Gly Glu Lys Asn Val Leu Lys Leu Ala
195 200 205

Gly Pro Asp Val Phe Thr Gln Ala Leu Tyr Gln Glu Ile Pro Gly Leu
210 215 220

Asn Ser Lys Val Leu Asn Ala Gln Leu Asp Gln Phe Glu Leu Ala Lys
225 230 235 240

Arg Gln Ala Leu Gly Leu Pro Leu Glu Lys Pro Lys Ser Phe Ala Asp
245 250 255

Glu Lys Leu Thr Ser Val Glu Lys Glu Lys Ile Asn Arg Pro Tyr Gln
260 265 270

Ser Met Arg Gly Leu Ser Gly His Val Met Asn Gly Ala Asp His Ser
275 280 285

Trp Ala Val Asp Thr Glu Val Leu Gly His
290 295

<210> 10
<211> 299
<212> PRT
<213> Photorhabdus

<400> 10

Met Met Arg Glu Tyr Ser Asn Glu Asp Asp Cys Thr Lys Glu Lys Thr
1 5 10 15

Asn Leu Val Lys Ser Glu Asn Val Glu Ala Asp Asn Tyr Leu Glu Met
20 25 30

Glu His Leu Thr Tyr Leu Ala Lys Leu Ile Ser Met Thr Glu Arg Glu
35 40 45

Asn His His Leu Asn Ser Ile Lys Leu Ile Asp Asp Ile Ile Glu Leu
50 55 60

His Asn Asp Arg Lys Gly Asn Lys Leu Leu Trp Asn Asp Asn Trp Gln
65 70 75 80

Asp Lys Ile Ile Asp Arg Asp Leu Gln Ser Ile Phe Lys Lys Ile Asp
85 90 95

Glu Met Val Ser Glu Phe Gly Gly Leu Glu Ala Tyr Lys Asp Ile Val
100 105 110

Gly Glu Ser Pro Tyr Asp Pro Thr Glu Pro Val Cys Gly Tyr Ser Ala
115 120 125

Gln Asn Ile Phe Lys Leu Met Thr Glu Gly Glu Tyr Ala Val Asp Pro
130 135 140

Val Lys Met Ala Lys Thr Gly Lys Ile Asn Gly Asn Gln Phe Ala Glu
145 150 155 160

Lys Leu Glu His Leu Asn Ser Ser Asn Asn Tyr Val Ala Leu Ile Asn
165 170 175

Asp His Arg Leu Gly His Met Phe Leu Val Asp Ile Pro Ser Thr Asn
180 185 190

Arg Glu Arg Val Gly Tyr Ile Tyr Gln Ser Asp Leu Gly Asp Gly Ala
195 200 205

Leu Pro Ala Leu Lys Ile Ala Asp Trp Leu Lys Ser Arg Gly Lys Glu
210 215 220

Ser Ile Asn Val Asn Lys Leu Lys Lys Phe Leu Asn Asp Glu Phe Thr
225 230 235 240

Met Leu Pro Glu Asn Glu Gln Lys Gly Leu Ile Ala Glu Ile Phe Asp
245 250 255

Leu Asn Lys Asp Ile Asp Ser Val Lys Ser Gly Lys Ile Lys Lys Asp

260

265

270

Lys Ala Val Asp Ile Tyr Leu Arg Glu Tyr Asp Ile Asn Asp Phe Ile
 275 280 285

Ser Asn Val Glu Lys Leu Lys Thr Lys Leu Ala
 290 295

<210> 11

<211> 148

<212> PRT

<213> Photorhabdus

<400> 11

Met Ile Phe Lys Met Leu Asn Leu Ala Val Phe Tyr Leu Leu Gly Asn
 1 5 10 15

Ile Phe His Tyr Leu Ile Cys Gln Lys Phe Ile Cys Tyr Phe Cys Ser
 20 25 30

Val Leu Lys Ser Val Thr Met Phe Leu Thr Lys Val Ala Val Gln Ile
 35 40 45

Ala Leu Tyr Leu Asn Ile Leu Pro Thr Met Ala Gly Ile Ala Gly Leu
 50 55 60

His Ala Glu Val Gln Ala Leu Asn Asn Leu Phe Ile Ser Gly Asp Arg
 65 70 75 80

Gly Thr Glu Lys Arg Glu Asn Trp Lys Tyr Ile Arg Asn Met Leu Glu
 85 90 95

Ser Thr Ile Phe Thr Gln Arg Leu Thr Ala Gly Gln Ala Gly Lys Asp
 100 105 110

Phe Ala Ala Cys His Asn Cys Ser Gly Ile Leu Ser Ser Pro Val Asn
 115 120 125

Val Ile Thr Gly Lys Val Glu Ser Ala Gly Gly Asn Phe Phe Ile Asn
130 135 140

Ile Ile Ser Ile
145

<210> 12
<211> 170
<212> PRT
<213> Photorhabdus

<400> 12

Met Glu Arg Glu Tyr Ser Glu Lys Pro Lys Asn Leu Ser Gln Leu Ser
1 5 10 15

Arg Lys Thr Ala Ile Ser Glu Arg Arg Ala Met Phe Glu Arg Asn Ala
20 25 30

Ser Ser Asn Asn Glu Gln Pro Val Pro Gln Phe Ala Arg Ser Tyr Thr
35 40 45

Ser Asn Arg Ser Val Val Asn Ile Asn Pro Gly Arg Ser Ser Ile Ala
50 55 60

Val Val Thr Ala Asn Ser Thr Ser Pro Val Asn Ile Ser Thr Pro Ala
65 70 75 80

Ala Ala Ser Pro Asp Lys Leu Leu Pro Ser Thr Ser Cys Asp Thr Thr
85 90 95

Ser Ser Thr Leu Thr Val Gly Lys Tyr Lys Leu Glu Leu Thr Ser Gln
100 105 110

Gly Lys Val Val Val Phe Arg Gly Asp Asn Arg Thr Pro Glu Gln Ile
115 120 125

Val Ala Ala Gly Gly Phe Gly Glu Gln Ser Asn Tyr Leu Tyr Lys Met
130 135 140

Glu Ile Pro Gly Leu Lys Pro Gln Asp Met Asn Glu Arg Thr Leu Gly
145 150 155 160

Glu Lys Ile Arg Gln Asp Ser Arg Gly Asn
165 170

<210> 13
<211> 298
<212> PRT
<213> Photorhabdus

<400> 13

Met Lys Tyr Asp Pro Arg Leu Arg Thr Trp Val Glu Asp Asp Phe Asp
1 5 10 15

Tyr Glu Lys Asn Phe Lys Lys Gln Thr Asp Tyr Ile Asn Tyr Lys Asp
20 25 30

Leu Glu Lys Gln Leu Lys Glu Asn Val Asp Tyr Tyr Ala Leu Leu Asp
35 40 45

Glu Asn Glu Ala Ile Ile Phe Leu Lys Glu Leu Gly Cys Asp Ile Lys
50 55 60

Ser Phe Leu Asn Asp Thr Ala Phe Pro Val Thr Asp Val Leu Ser Asn
65 70 75 80

Phe Ala Gly Asn Ile Lys Asp Ala Leu Gly Val Phe Lys Val Ala Lys
85 90 95

Asn Phe Lys Pro Ile Asn Ile Gly Ile Phe Thr Tyr Ile Ile Asn Glu
100 105 110

Leu Lys Gly Lys Gly Ile Lys Ala Ile Glu Tyr Leu Gly Lys Asn Gly
115 120 125

Glu Arg Tyr Ile Lys Leu Thr Asp Arg Pro Gly Ile Arg Lys Tyr Leu
130 135 140

Asn Ala Thr Arg Tyr Leu Ile Asn Asn Lys Lys Ile Met Glu Val Gly
145 150 155 160

Ile Gly Ser Val Ala Met Glu Gly Ser Ile Val Lys Gly Ala Arg Phe
165 170 175

Gly Val Ile Tyr Ser Ala Ala Tyr Arg Ser Val Glu Leu Met Phe Lys
180 185 190

Ser Glu Tyr Asp Leu Thr Asn Phe Phe Val Asn Leu Ser Met Asp Met
195 200 205

Ala Lys Ile Ile Val Ala Thr Ile Ile Ala Lys Ser Thr Val Ala Ala
210 215 220

Ala Thr Ser Phe Val Val Thr Ala Ala Leu Ser Thr Thr Ala Ile Ala
225 230 235 240

Ile Gly Val Phe Ile Ile Gly Ala Leu Val Val Trp Gly Leu Met Trp
245 250 255

Leu Asp Asp Glu Phe Lys Ile Ser Glu Thr Ile Ile Arg Arg Leu Lys
260 265 270

Glu His Lys Val Lys Thr Pro Ile Ser Thr Tyr His Ser Asp Gln Ile
275 280 285

Phe Asn Ala Trp Gly Arg Tyr Tyr Arg Gly
290 295

<210> 14
<211> 328
<212> PRT
<213> Photorhabdus

<400> 14

Met Pro Asn Lys Lys His Ser Glu Asn Thr His Gln Gly Arg Lys Pro

1	5	10	15
Leu Ile Lys Ser Glu Ala Asn Asn Glu His Asp Ile Glu Asn Ser Ser	20	25	30
Leu Gly Ile Gly Leu Asp Leu Asn Ser Thr Ile Gly Asn Asn Ser Ala	35	40	45
Ser Leu Ser Gln Ile Gln Asp Tyr Ser Phe Trp Lys Glu Asn Ile Ser	50	55	60
Glu Tyr Tyr Lys Trp Met Val Val Val Lys Ala His Leu Lys Gln Leu	65	70	75
Asp Trp Thr Leu Lys Ser Met Asp Ser Ser Glu Ser Ala Gly Thr Asn	85	90	95
Ile Ala Lys Asn Ile Gly Thr Thr Ala Leu Gln Thr Leu Leu Asn Thr	100	105	110
Gly Gly Ser Ile Ala Gly Gly Ala Ile Gly Gly Ala Ile Gly Ser Ala	115	120	125
Ile Ala Pro Gly Val Gly Thr Ile Ala Gly Met Gly Ile Gly Ala Leu	130	135	140
Ala Gly Thr Gly Leu Asn Tyr Leu Asn Asp Thr Val Ile Glu Lys Leu	145	150	155
Asn Glu Lys Leu Glu Ile Ala Tyr Pro Tyr Pro Lys Thr Arg Asn Met	165	170	175
Ile Phe Asp Ile Asn Asn Tyr Asp Lys Asn Pro Ile Ile Lys Ala Ile	180	185	190
Lys Lys Lys Thr Asn Lys Asp Asn Leu Lys Val Thr Ala Gly Ser Ser	195	200	205

Leu Thr Ser Gln Leu Val Gly Lys Val Thr Ser Pro Ile Lys Phe Pro
210 215 220

Ala Tyr Lys Leu Ser Asp Leu Ala Ile Ser His Asn Arg Ala Leu Ala
225 230 235 240

Gly Leu Ser Ser Asp Lys Ala Arg His Ile Leu Asp Phe Thr Asp Ser
245 250 255

Ile Arg Glu Val Leu Asn Glu Ser His Ser Asp Ala Val Ala Phe Met
260 265 270

Arg Lys Asn Tyr Gly Asp Asn Ala Met Gly Leu Ser Gly Leu Ser Ser
275 280 285

Arg Ile Lys Gly Glu Lys Leu Thr Leu Ala Thr Leu Ala Arg Thr Arg
290 295 300

Asn Lys Ile Glu Asn Arg Ile Asn Ser Ile Asn Lys Gln Thr Leu Lys
305 310 315 320

Leu Ser Ser Lys Asn Ser Asn Glu
325

<210> 15
<211> 322
<212> PRT
<213> Photorhabdus

<400> 15

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys Arg Pro Ile
1 5 10 15

Gln Leu Arg Asn Ser Ile Glu Gln His Glu Glu Glu Thr Ala Asn Asn
20 25 30

Ser Leu Gly Leu Gly Leu Asp Leu Asn Gln Ala Thr Asn Pro Pro Lys
35 40 45

Val Pro Lys Asp Asn Tyr Asn Glu Glu Asn Gly Asp Leu Phe Tyr Gly
50 55 60

Leu Ala Thr Gln Arg Gly Arg Tyr Ile Lys Ser Val Asn Pro Asn Phe
65 70 75 80

Asp Pro Asp Lys Ile Asn Ser Ser Pro Met Ile Ile Asp Val Tyr Asn
85 90 95

Asn Asn Val Ser Asn Thr Ile Leu Asn Lys Tyr Pro Leu Asp Lys Leu
100 105 110

Val Lys Leu Ser Gly Asn Pro Gln Lys Tyr Ala Asn Asn Ile Lys Val
115 120 125

Glu Asn Asn Leu Gln Gln Asp Val Ala Ser Ser Lys Arg Gly Trp Tyr
130 135 140

Pro Leu Trp Asn Asp Tyr Phe Lys Ile Gly Asn Glu Asn Lys Lys Phe
145 150 155 160

Asn Ile Ala Asp Ile Tyr Lys Glu Thr Arg Asn Gln Tyr Gly Ser Asp
165 170 175

Tyr Tyr His Thr Trp His Thr Pro Thr Gly Ala Ala Pro Lys Leu Leu
180 185 190

Trp Lys Arg Gly Ser Lys Leu Gly Ile Glu Met Ala Ala Ser Asn Glu
195 200 205

Lys Thr Lys Ile His Phe Val Leu Asp Gly Leu Asn Ile Gln Glu Val
210 215 220

Val Asn Lys Gln Lys Gly Ser Thr Pro Leu Glu Gln Gly Arg Gly Glu
225 230 235 240

Ser Ile Thr Ala Ser Glu Leu Arg Tyr Ala Tyr Arg Asn Arg Glu Arg
245 250 255

Leu Ala Gly Lys Ile His Phe Tyr Glu Asn Asp Gln Glu Thr Val Ala
260 265 270

Pro Trp Glu Lys Ser Pro Glu Leu Trp Gln Asn Tyr Ile Pro Lys Asn
275 280 285

Lys Asn Gln Asn Glu Ser Ser Thr Pro Gln Arg Asn Asn Gly Ala Leu
290 295 300

Tyr Arg Leu Gly Gly Pro Phe Arg Lys Leu Arg Ala Ser Leu Arg Lys
305 310 315 320

Arg Ser

<210> 16
<211> 308
<212> PRT
<213> Photorhabdus

<400> 16

Met Met Glu His Glu Tyr Ser Lys Glu Glu Glu Lys Lys Arg Gln Gln
1 5 10 15

Ser Lys Pro Asn Asn Ala Thr His Asp Glu Ser Asn Leu Pro Leu Glu
20 25 30

Leu Glu Lys His Ser Asn Ala Arg Thr Ser Ala Thr Ala Tyr Ser Lys
35 40 45

Trp Phe Thr Tyr Glu Asn Asp Met Glu Val Glu Leu Thr Thr Glu Arg
50 55 60

Val Arg Glu Ile Phe Ser Asn Lys Gln Pro Lys Ile Ile Ile Ala Gly
65 70 75 80

Asp Gly His Asn Lys Pro Pro Phe Gln Tyr Thr Lys Asn Ile Pro Asp
85 90 95

Val Asn Ser Ser Phe Asp Ala Gly Thr Leu Gln Leu Tyr Ile Glu Ala
100 105 110

Thr Asp Glu Gln Ile Asn Glu Asn Asn Pro Glu Tyr Ile Pro Lys Glu
115 120 125

Phe Met Ala Lys Pro Gly Leu Phe Thr Asn Lys Asn Arg Arg Ala Glu
130 135 140

Ile Val Gly Trp Glu Asp Ser Glu Leu Ser Asn Ala Met Lys Glu Met
145 150 155 160

Phe Glu Leu Ser Asp Lys Ser Thr Arg Glu Lys Leu Thr Pro Glu Glu
165 170 175

Thr Ser Ser Phe Tyr Lys Leu His Glu Thr Ala Ile Arg His Phe Phe
180 185 190

Arg Pro Glu Phe Asn Gln Leu Arg Asp Glu Phe Phe Glu Ile Leu Ala
195 200 205

Lys Ala Gly Ser Asn Arg Glu Leu Asp Lys Ile Ala Leu Glu Met Ile
210 215 220

Gly Phe Thr Ser Gly Thr Trp Arg Asp Glu Tyr Ile Asn Pro Thr Leu
225 230 235 240

Ala Glu Lys Ile Ala Lys His Ala Ala Glu Lys Glu Asn His Thr Phe
245 250 255

Val Val Ser Ile Gly Asp Ala His Leu Ser Glu Asn Pro Met Gln Glu
260 265 270

Tyr Leu Asn Lys Arg Arg Asn Gly Gly Glu Phe Lys His Gln Ile Ile

275

280

285

Phe Thr Arg Asp Lys Arg Pro Ile Leu Pro Asp Asn Met Lys Thr Gly
 290 295 300

Lys Lys Asn Ser
 305

<210> 17
 <211> 1633
 <212> PRT
 <213> Photorhabdus

<400> 17

Met Ser Asn Tyr Glu Tyr Asp Ile Val Thr Gln His Asp Thr Tyr Gln
 1 5 10 15

Ile Lys Asp Asn Glu Tyr Thr Val Val Asn Gly Lys Tyr Trp Gln Tyr
 20 25 30

Glu Gln Glu Gly Asn Lys Asn Asn Asn Lys Ile Ser Ile Ser Leu Met
 35 40 45

Lys Asp Asn Gln Asn Asp Pro Val Trp Ile Thr Ser Asp Ile Lys Glu
 50 55 60

Ile Ser Leu Tyr Ile Ile Glu Asn Leu Phe Ser Tyr His Lys Phe Ser
 65 70 75 80

Ala Glu Leu Gln His Thr Leu Lys Asn Ala Val Lys Ala Val Phe Asn
 85 90 95

Glu Tyr Ser Glu Ile Lys Tyr Ser Glu Leu Leu His Asn Ile Asn Asn
 100 105 110

Ile Phe Asn Leu Phe Phe Ile Lys Thr Tyr Asn Thr Ser Asp Ile Asn
 115 120 125

Thr Ala Ile Asn Ile Leu Thr Ala Lys Ile Glu Ile Tyr Asp Lys Leu
130 135 140

Glu Lys Ile Asn Gln Asp Lys Thr Asp Leu Asn Asn Thr Lys Val Asp
145 150 155 160

Ile Trp Glu Glu Leu Gly Ile Asn Ala Glu Glu Pro Leu Leu Lys Ile
165 170 175

Tyr Arg Gln Ala Phe Ser Thr Gly Asp Ile Asp Asp Glu Val Tyr Ser
180 185 190

Asp Ala Leu Leu Thr Phe Met Ser Asp Gly Asn Leu Lys Leu Gly Asp
195 200 205

Lys Glu Lys Ser Asp Tyr Asn Gln Arg Ile Lys Asp Lys Thr Asp Leu
210 215 220

Phe Glu Ser Tyr Lys Lys Gly Ile Glu Lys Val Ala Ser Leu Ile Thr
225 230 235 240

Thr Asn Asn Ile Asn Pro Gly Ile Pro Ile Thr Tyr Pro Glu Thr Glu
245 250 255

Lys Ser Ile Asn Ile Gly Asp Asp Leu Leu Leu Ala Gln Leu Ala Lys
260 265 270

Glu Glu Ile Ala Leu Lys Lys Gln Asn Arg Thr Glu Tyr Ser Gln Gln
275 280 285

Asp Ile Phe Glu Leu Gln Thr Leu Gln Ala Ala Lys Tyr His Leu Leu
290 295 300

Ile Leu Ser Ser Leu Gly Ala Leu Leu Tyr Gln Ile Ala Pro Asn Val
305 310 315 320

Glu Lys Met Thr Lys Gly His Gly Asp Tyr Arg Asp Ile Ile Phe Ser
325 330 335

Gln Glu Gln Ala Glu Ser Leu Phe Lys Lys His Asn Ile Gln Tyr Asp
340 345 350

Thr Asn His Val Leu Ser Gln Glu Ser Lys His Ile Glu Met Glu Gly
355 360 365

Cys Ile Ile Leu Thr Ala Ala Ile Ile Tyr Arg Met Arg Lys Glu Asn
370 375 380

Ala Thr Val Glu Gln Ala Leu Asn Tyr Ser Thr Leu Glu Thr Ile Lys
385 390 395 400

Leu Phe Glu Asn Asp Lys Lys Lys Leu Asn Pro Phe Asn Thr Asn Asn
405 410 415

Val Lys Pro Ala Gly Tyr Phe Ser Phe Ile Asp Phe Lys Lys Arg Asp
420 425 430

Lys Phe Asp Ser Gln Tyr Asn Phe Asn Glu Gln Phe Asn Val Tyr Lys
435 440 445

Asn Lys Tyr Ser His Tyr Glu Ser Ile Ser Phe Ser Lys Leu Ile Leu
450 455 460

Ser Ser Pro Ala Ala Gln Leu Thr Ala Glu Glu Ile Val Asn Pro Pro
465 470 475 480

Glu Glu Thr Phe Leu Tyr Ser Val Glu Gln Gly Met Gly Asn Val Ala
485 490 495

Met Ile Lys Met Tyr Gln Gly Asn Trp Leu Val Val Ser Thr Ile Gln
500 505 510

Gly Gly Val Lys Ala Arg Lys Tyr Ser Gln Gln Gln Val Asp Ser Gln
515 520 525

Pro Thr Leu Arg Ala Met Ser Arg Pro Asn Ala Leu Phe Leu Ile Glu
530 535 540

Arg Lys Ile Met Ile Gly Ile Gly Ile Phe Met Glu Asn Gln Ile Val
545 550 555 560

Asn Thr Gly Lys Arg Leu Phe Pro Thr Gly Tyr Glu Arg Ala Lys Thr
565 570 575

Leu Ser Gly Phe Ala Glu Thr Ser Arg Tyr Lys Asn Ser Tyr Asn Ala
580 585 590

Phe Trp Asn Asp Tyr Tyr Gly Ile Thr Ser Gly Met Asn Val Gly Ile
595 600 605

Ser Phe Thr Gly Ser Pro Lys Phe Asn Phe Tyr Lys Glu Glu Asn Leu
610 615 620

Leu Ser Val Thr Ala Thr Ile Ile Gln Gln Gly Leu Asn Asp Ile Ala
625 630 635 640

Ile Lys Ser Lys Gln Ala Leu Asp Ile Thr Ser Gly Trp His Ile Ala
645 650 655

Ala Thr Ile Leu Ile Pro Phe Tyr Asn Val Ile Tyr Lys Ser Thr Thr
660 665 670

Asp Ser Glu Tyr Glu Leu Thr Gly Glu Asp Ile Gly Ser Ile Val Phe
675 680 685

Asp Thr Ala Asn Val Leu Leu Val Val Ala Thr Leu Gly Met Ser Leu
690 695 700

Thr Glu Ser Met Ala Ala Lys Val Thr Gln Thr Thr Leu Arg Leu Arg
705 710 715 720

Gln Ala Gly Leu Thr Gly Arg Ala Leu Ile Thr Ala Val Val Arg Thr
725 730 735

Leu Pro Glu His Gly Ile Ile Thr Leu Arg Gln Ser Ser Gly Ile Ile
740 745 750

Leu Gly Gly Leu Ile Asp Leu Ile Glu Pro Leu Pro Ile Arg Ser Thr
755 760 765

Leu Thr Leu Thr Tyr Arg Gly Val Ile Ser Ala Val Gly Ala Met Arg
770 775 780

Asn Ser Ile Lys Leu Glu Lys Ser Phe Ala Asp Ile Phe Gly Lys Ser
785 790 795 800

Thr Arg Gly Leu Gly Lys Leu Lys His Glu Trp Lys Val Ser Asn Leu
805 810 815

Pro Leu Glu Glu Ile Val Pro His Ser Asn Gly Gly Glu Ile Tyr Lys
820 825 830

Gly Ile Tyr Ser Ile Arg His Thr Asn Pro Glu Thr Ala Val Lys Gln
835 840 845

Asn Phe Tyr Ile Lys Glu Ala Gly Ala Asn Tyr Gln Val Lys Trp Asp
850 855 860

Asp Ala Asn His Thr Trp Arg Val Val Asn Pro Thr Tyr Pro Glu Gln
865 870 875 880

Phe Ser Tyr Trp Pro Ala Val Lys Leu Asp Lys Asn Gly His Trp Val
885 890 895

Thr His Ala Asp Ile Ser Asn Lys Phe Leu Ile Leu Glu Lys Ser Lys
900 905 910

Arg Ile Asp Gln Glu Leu Glu Ala Ala His Ser Asn Ile Asn Asn Asp
915 920 925

Asn Ile Leu Asp Ala Phe Ile His Ile Asn Thr Ala Phe Lys Asp Cys
930 935 940

Glu Arg Tyr Asp Ile Asp Lys Leu Ser Asp Ile Thr Asp Thr Leu Thr
945 950 955 960

His Phe Phe Glu Lys Ser Leu Lys Pro Gly Asp Lys Lys Ala Ile Phe
965 970 975

Ser Thr Glu Ile Met Ser Ile Gln Gln Ala Trp Ile Arg Glu Val Ile
980 985 990

Leu Pro Leu Gln Asn Asn Ser Ser Ile Ser Ile Glu Lys Ile Asn Ala
995 1000 1005

Ile Lys Thr Glu Leu Pro Tyr Leu Leu Arg Lys Thr Phe Pro Ile
1010 1015 1020

Glu Ser Gln Leu Pro Asn Gln Leu Val Ala Asn Lys Ile Ala Leu
1025 1030 1035

Ala Ile Glu Glu Ile Pro Asn Thr Arg Ile Pro Lys Tyr Thr Ser
1040 1045 1050

Gly Asn Ile Ser Lys Thr Val Gln Tyr Thr Ser Leu Leu Glu Asn
1055 1060 1065

Asn His Val Asp Ile Pro Pro Val Gly Ile Thr Ile Thr Gly Asn
1070 1075 1080

Asp Thr Phe Ile Asn Gln Val Thr Arg Val Leu Ser Glu Ile Asp
1085 1090 1095

Glu Ile Pro Ser Gly Asn Ile Val Ile Gln Glu Leu Glu Lys Gln
1100 1105 1110

Gly Leu Asn Ile Gln Pro Pro Thr Met Asn Asp Ile Val Arg Glu
1115 1120 1125

Lys Asn Gly Gln Phe Tyr Ala Asn Asn Ser Ala Gly Ser His Ile
1130 1135 1140

Ala Phe Asp Pro Glu Asn His Leu Ile Gly Thr Glu Glu Lys Leu
1145 1150 1155

Ile Asp Glu Pro Trp Arg Thr Arg Glu Pro Ala Ile Ala Leu Tyr
1160 1165 1170

His Glu Met Leu His Ile Tyr Tyr Asn Arg Tyr Pro Thr Trp Phe
1175 1180 1185

Thr Ser Ile Asp Asn Lys Val Ile Asp Gln Lys Val Ser Gly Gly
1190 1195 1200

Phe Ser Leu Leu Glu Glu Ser Arg Ile Val Gly Thr Lys Tyr Tyr
1205 1210 1215

Val Asn Asp Lys Asp Thr Leu Phe Asp Phe Asn Asp Ser Asp Tyr
1220 1225 1230

Leu Leu Glu Asn Asn Ser Ala Leu Leu Thr Glu Asn Arg Phe Arg
1235 1240 1245

Ala Glu Tyr Ala Ile Phe Lys Asn Lys Ser Glu Tyr Val Ile Arg
1250 1255 1260

Pro Tyr Ser Gly Lys Gly Asp Ser Gln Ile Pro Leu Thr Lys Thr
1265 1270 1275

Lys Ile Asn Ile Asn Glu Ser His Arg Asn Val Met Gly Val Gly
1280 1285 1290

Ser Gly Lys Pro Glu Lys Met Pro Asn Glu Ser Ala Thr Asp Tyr
1295 1300 1305

Arg Asn Arg Val Arg Glu Trp Arg Lys Ala Asn Lys Gln Pro Glu
1310 1315 1320

Ala Asp Ile Gly Thr Gly Asp Met Arg Lys Thr Lys Ala Glu Ala
1325 1330 1335

Arg Val Lys Leu Leu Lys Glu Asn Tyr Pro Gln Phe Glu Pro Gln
1340 1345 1350

Lys Ile Glu Leu Gly Gly Ala Phe Gln Leu Trp Thr Val Pro Asn
1355 1360 1365

Glu Pro Ala Asn Lys Leu Met Leu Ser Ser His Gly Tyr Phe Phe
1370 1375 1380

Ser Asp Ser Ala Ala Thr Gln Val Pro Ala Gly Lys Thr Ile Gln
1385 1390 1395

Phe Leu Gly Pro His Gly Lys Thr Leu Leu Glu Ala Pro Glu Asn
1400 1405 1410

Pro Leu Asn Ser Pro Phe Asp Val Thr Leu Gly Asn Ser Gly Phe
1415 1420 1425

Thr Val Gln Pro Tyr Ala Thr Ile Glu Ser Gly Asn Lys Ala Gly
1430 1435 1440

Leu Gly Ser Val Lys Ile Gly Asp Lys Thr Phe Thr Val Asn Asp
1445 1450 1455

Ile Gln Asn Ile Ala Thr Asp Asp Val Glu Asn Tyr Leu Leu Ala
1460 1465 1470

Thr Gly Val Glu Ala Asn Ala Ser Asn His Gly Lys Val Arg Asn
1475 1480 1485

Tyr Gly Ile Lys Tyr Tyr Glu Lys Met Pro Asp Glu Glu Val Lys
1490 1495 1500

Ala Ala Ile Trp Lys Asn Arg Ala Asp Glu Thr Ser Thr His Lys
1505 1510 1515

Tyr Asp Ala Leu Leu Val Ser Pro Glu Ala Gly Asn Arg Lys Lys
1520 1525 1530

Leu Ser Asp Ile Phe Ala Leu Met Lys Thr Asp Glu Arg Met Ser
1535 1540 1545

Lys Tyr Asp Glu Ile Thr Phe Val Ala Cys Arg Glu Glu Leu Asn
1550 1555 1560

Arg Ile Asn Met Lys Ser Ile His Asp Thr Gly Leu Gly Gly Gly
1565 1570 1575

Tyr Glu Pro Lys Leu Glu Pro Thr Val Ile Leu Ser Arg Arg Arg
1580 1585 1590

Arg Glu Ala Thr Phe Thr Ala Asp Gly Ala Ile Ile Tyr Ser Ile
1595 1600 1605

Ile Ala Val Asn Leu His His Asn Phe Ile Thr Glu Glu Ile Val
1610 1615 1620

Gly Ile Ala Pro Phe Leu Phe Ile Asp Asn
1625 1630

<210> 18

<400> 18
000

<210> 19
<211> 293
<212> PRT
<213> Photorhabdus

<400> 19

Met Phe Lys Tyr Asp Thr Ser Glu Lys Met Ala Lys Phe Gly Lys Gly
1 5 10 15

Lys Thr Ser Asp Gly Met Leu Leu Asp Thr Leu Tyr Leu Glu Ile Pro
20 25 30

Asp Glu Lys Ala Val Met Ser Ala Tyr Lys Ser Gln Ile Leu Asp Glu
35 40 45

Leu Arg Asn Phe Ser Glu Lys Thr His Ser Phe Phe Ser Gly Lys Lys
50 55 60

Pro Leu Tyr Ser Lys Lys Tyr Leu Ala Asn Leu Ala Ala His Ala Gly
65 70 75 80

Tyr Val His Val Thr Asp Tyr Asn Ser Ile Gly Asn Tyr Lys Asp Gly
85 90 95

Phe Val Asn Phe Lys Asp Asn Ser Arg Asn Leu Ala Glu Gly Lys Leu
100 105 110

Phe Pro Gly Ile Arg Leu Ile Lys Arg Pro Lys Leu Ser Ile Val Arg
115 120 125

Asp Lys Glu Thr Glu Arg Trp Lys Lys Gln Glu Ser Asp Glu Ala Asp
130 135 140

Ala Tyr Glu Ile Thr Asp Ile Glu Ser Phe Ile Ser Gly Val Arg Asp
145 150 155 160

Met Tyr Ser Arg Ala Asn Val Asp Leu His Pro Val Ile Glu Ser Leu
165 170 175

Ile Arg Asn His Ile Val Asn Asn Asp His Val Leu Pro Thr Met Ala
180 185 190

Gly Ile Ala Gly Leu His Ala Glu Val Gln Ala Leu Asn Asn Leu Leu
195 200 205

Ile Leu Ala Asp Gly Arg Ala Gly Lys Ile Val Gly Gly Arg Lys Ile
210 215 220

Glu Glu Tyr Met Gln Asp Met Leu Lys Ser Phe Ile Phe Thr Gln Arg
225 230 235 240

Leu Thr Thr Lys Gln Ala Gly Asn Asp Phe Ala Ala Cys His Asn Cys
245 250 255

Ser Gly Ile Leu Ser Val Pro Ala Asn Val Ile Thr Gly Lys Val Ala
260 265 270

Ser Ala Gly Ser Asn Phe Ser Leu Ile Leu Ser Arg Tyr Lys Asn Ser
275 280 285

Gln Glu Ser Pro Ile
290

<210> 20
<211> 340
<212> PRT
<213> Photorhabdus

<400> 20

Met Leu Lys His Ala Asn Pro Gln Thr Val Ser Thr Gln Arg Thr Lys
1 5 10 15

Ser Thr Ala Lys Lys Pro Ser Ser Ser Ser Phe Asp Arg Gln Phe
20 25 30

Glu Leu Ser Asn Ser Glu Asn Gln Pro Gly Glu Gly Asn Lys Asp Trp
35 40 45

Thr Ile Lys Gly Trp Arg Gln Arg Phe Ala Asp Arg Ser Leu Asn Lys
50 55 60

Gly His Ile Ser Pro Leu Met Asn Lys Gly Leu Leu Val Gly Ser Glu

65		70		75		80									
Glu	Ala	Leu	Ile	Asn	Val	Pro	Val	Val	Ala	His	Arg	Tyr	Asp	Ser	Ser
			85						90					95	
His	Gln	Leu	Thr	Asp	Ala	Gly	Pro	Leu	Lys	Ala	Asp	Ser	His	Ser	Asn
			100					105					110		
Asn	Leu	Asp	Pro	Phe	Tyr	Gly	Val	Val	Thr	Gly	Phe	Arg	Gly	Asp	Gln
		115					120					125			
Val	Thr	Ser	Ser	Glu	Ser	Gly	Ser	Gly	Ser	Ile	Gly	Gly	His	Trp	Gly
	130					135					140				
Lys	Asn	Thr	Leu	Asp	Ser	Asn	Ile	Thr	Gly	Ile	Asn	Val	Val	Asn	Gly
145					150					155					160
Ala	Ser	Gly	Thr	Val	Gly	Ile	Arg	Ile	Ala	Leu	Lys	Asp	Ile	Gln	His
				165					170					175	
Gly	Ala	Pro	Val	Ile	Val	Thr	Ser	Gly	Ala	Leu	Ser	Gly	Cys	Thr	Met
			180					185					190		
Val	Tyr	Ala	Val	Lys	Asn	Gly	Tyr	Phe	Phe	Ala	Tyr	His	Thr	Gly	Gln
		195					200					205			
Lys	Pro	Gly	Asp	Lys	Glu	Trp	Lys	Thr	Gly	Arg	Gln	Gly	Val	Val	Ala
	210					215					220				
Thr	Tyr	Arg	Ser	His	Gln	Ala	Leu	Ser	Pro	Asp	Ser	Glu	Pro	Met	Ala
225					230					235					240
Val	Gly	Glu	Gln	Asn	Asn	Asp	Leu	Val	Asn	Ile	Phe	Ala	Ser	Tyr	Asp
				245					250					255	
Gln	Gly	Ile	Ile	Thr	Tyr	Met	Gly	Lys	Pro	Gly	Val	Ile	Ile	Asp	Asn
			260					265					270		

Thr Ala Glu Asn Val Gly Val Phe Asn Tyr Asp Glu Val Lys Leu Glu
275 280 285

Lys Pro Asp Ile Arg Ala Gly Tyr Ser Tyr Ala Leu Leu Ala Lys Asp
290 295 300

Asp Lys Gly Lys Val Asn Val Lys Val Leu Ser Glu Asp Val Ile Val
305 310 315 320

Pro Leu Gly Asn Lys Gly Lys Thr Ile Lys Ala Ile Asn Ser Leu Lys
325 330 335

Lys Arg Leu Leu
340

<210> 21
<211> 336
<212> PRT
<213> Photorhabdus

<400> 21

Met Pro Arg Tyr Ala Asn Tyr Gln Ile Asn Pro Lys Gln Asn Thr Lys
1 5 10 15

Asn Ser His Gly Lys Ser Ser Ser Ser Asn Phe Ser Ser Gly Tyr Phe
20 25 30

Ser Ser Ser Asn Asn Ser Leu Asp Asp Ser Leu Ile Arg Gln Gln Val
35 40 45

Lys Arg Glu Phe Ile Trp Glu Gly His Met Lys Glu Ile Glu Glu Ala
50 55 60

Ser Arg Leu Gly Asn Phe Ala Val Ser Phe Arg Ala Ala Gly Gly Pro
65 70 75 80

Thr Leu Arg Ala Leu Gly Lys Gly Ala Ala Ala Lys Gly His Asp Ile
85 90 95

Leu Glu Lys Thr Ile Lys Pro Gly Ser Ile Asn Lys Ala Tyr Pro Lys
100 105 110

Asp Glu Ala Ser Asn Val Ile Lys Lys Val Gln Glu Ala Gly Ile Glu
115 120 125

Gly Tyr Val Gly His Trp Asp Lys Lys Thr Gly Arg Leu Leu Gly Ile
130 135 140

Tyr Met Ser Ser Gly His Gly Leu Ser Asp Glu Gln Val Asn Gly Lys
145 150 155 160

Ile Tyr Pro Ile Asp Leu Asn Asn Leu Glu Ala Ser Leu Ser Ala Leu
165 170 175

Lys Thr Lys Glu Asn Trp Ala Ala Leu Pro Phe Thr Gly Asp Tyr Asp
180 185 190

Met His Asp Met Ile Ser Phe Thr Gly Gln Pro His Ser Val Pro Ser
195 200 205

Asn Ser Ser Glu Glu Arg Lys Ile Ile Asp Arg Ile Asn Arg Leu Val
210 215 220

Ala Arg Ser Asp Pro Asn Arg Pro Phe Gly Asp Ile Glu His Asn Val
225 230 235 240

Ile Arg His Gly Ala Gln Val Ser Tyr Pro Ala Phe Ala Met Asp Lys
245 250 255

Glu Lys Glu Glu Ile Lys Lys His Gly Gly Ile Val Lys Ala Val Ala
260 265 270

Glu Pro Gly Glu Phe Pro Val Ala Ile Val Ser Lys Gly Lys Trp Thr
275 280 285

Ile Ala Asn Asn Ile Asp Glu Leu Asn Gln Phe Tyr Asn Ser Ile Gly
290 295 300

Ala Lys Met Lys Val Ser Trp Lys Pro Gly Ala Glu Asn Pro Gly Phe
305 310 315 320

Val Ser Asn Pro Gln Arg Pro Gly Met Ala Arg Phe Ser Arg Lys Arg
325 330 335

<210> 22
<211> 299
<212> PRT
<213> Photorhabdus

<400> 22

Met Met Arg Glu Tyr Ser Lys Glu Asp Asp Cys Val Lys Glu Lys Thr
1 5 10 15

Asn Leu Ala Glu Ser Glu Asn Val Glu Ala Asp Asn Tyr Leu Glu Met
20 25 30

Asp Cys Leu Asn Tyr Leu Ala Lys Leu Asn Gly Met Pro Glu Arg Lys
35 40 45

Asp His Ser Leu Asn Ser Thr Lys Leu Ile Asp Asp Ile Ile Lys Leu
50 55 60

His Asn Asp Arg Lys Gly Asn Lys Leu Leu Trp Asn Asp Asn Trp Gln
65 70 75 80

Asp Lys Ile Ile Asp Arg Asp Leu Glu Ser Ile Phe Lys Lys Ile Asp
85 90 95

Glu Met Val Ser Glu Phe Gly Gly Ile Glu Ile Tyr Lys Asp Ile Val
100 105 110

Gly Glu Asn Pro Tyr Asp Pro Thr Glu Pro Val Cys Gly Tyr Ser Ala
115 120 125

Gln Asn Ile Phe Lys Leu Met Thr Glu Gly Glu His Ala Val Asp Pro
130 135 140

Val Lys Met Ala Gln Thr Gly Lys Ile Asn Gly Asn Glu Phe Ala Glu
145 150 155 160

Lys Leu Glu Gln Leu Asn Ser Ser Asn Asn Tyr Val Ala Leu Ile Asn
165 170 175

Asp His Arg Leu Gly His Met Phe Leu Val Asp Ile Pro Ser Thr Asn
180 185 190

Arg Glu Lys Val Gly Tyr Ile Tyr Gln Ser Asp Leu Gly Asp Gly Ala
195 200 205

Leu Pro Ala Leu Lys Ile Ala Asp Trp Leu Lys Ser Arg Gly Lys Glu
210 215 220

Ser Ile Asn Val Asn Lys Leu Lys Lys Phe Leu Ser Asn Glu Phe Thr
225 230 235 240

Met Leu Ser Glu Ser Glu Gln Lys Glu Leu Ile Ala Glu Ile Phe Asp
245 250 255

Ile Asn Lys Asp Ile Ala Asn Val Lys Leu Gly Lys Ile Lys Lys Asp
260 265 270

Lys Ala Val Asp Val Tyr Leu Arg Glu Tyr Asp Leu Asn Asp Phe Ile
275 280 285

Ser Asn Ile Glu Lys Leu Lys Thr Lys Leu Val
290 295

<210> 23
<211> 327
<212> PRT
<213> Photorhabdus

<400> 23

Met Pro Ile Ile Gly His Lys Glu Asp Leu Ile Arg Thr Glu Arg Ser
1 5 10 15

Ser Val Asp Leu Thr Arg Ser Ser Asn Asn Arg Gln Thr Asp Asn Leu
20 25 30

Glu Leu Asn Ile Pro Gln His Lys Arg Asp Asn Lys Asp Ile Glu His
35 40 45

Ala Val Ile Tyr Gly Phe Ser Gln His Arg Gly Pro Glu Met Gln Lys
50 55 60

Ala Phe Ala Asp Asn Lys Asn Pro Val Thr Ile Asp Glu Tyr Asn Ala
65 70 75 80

Gly Leu Gly Ile Met Gly Glu Leu Ser Leu Ser Asp Tyr Phe Arg Ile
85 90 95

Ser Gln Asp Leu Lys Glu Asn Arg Leu Pro Glu Leu Asn Glu Lys Asn
100 105 110

Ile Gln Asn His Ser Leu Lys Tyr Phe Asp Ala Met Gly Val Asn Met
115 120 125

Lys Ser Ala Asp Pro Asn Val Lys Glu Glu Ala Lys Glu Gln Gln Arg
130 135 140

Ala Tyr Thr Arg Ser Trp Gly Phe Tyr Met Met Glu Asn Lys Glu Lys
145 150 155 160

Leu Asp Ile Gln Ser Lys Ile Asn Asn Leu Ile Pro Lys Lys Lys Ser
165 170 175

Phe Phe Ser Lys Ser Pro Gly Glu Asp Glu Tyr Lys Lys Leu Asp Glu
180 185 190

Phe Ile Leu Lys Asn Ser Asn Gly Ser Asn Leu Thr Ile Pro Lys Gln
195 200 205

Arg Lys Ile Leu Met Lys Phe Ala Ser Ala Lys Asn Ala Val Asp Val
210 215 220

Thr Lys Asn Leu Ser Gly Glu Glu Gln Thr Trp Leu Lys Asp Ile Ile
225 230 235 240

Ala Thr Ala Phe Phe Arg Gln Thr Ser Lys Leu Gly Met Ser Trp Phe
245 250 255

Ile Glu Gln Leu Ala Ser Pro Asp Phe Arg Phe Val Ile Val Gly Phe
260 265 270

Asn Gly Glu Glu Leu Thr Thr Asp Gln Ile Arg Ser Asn Lys Pro Trp
275 280 285

Lys His Gly Asn Arg Arg Lys Glu Gly Ala Ser Glu Tyr Ala Glu Pro
290 295 300

Ile Thr Phe Ser Glu Ile Arg His Ala His Arg Lys Gly Tyr Asp Ser
305 310 315 320

Lys Ile Asn Phe Ile Lys Lys
325

<210> 24
<211> 926
<212> PRT
<213> Photorhabdus

<400> 24

Met Ile Ser Thr Phe Asp Pro Ala Ile Cys Ala Gly Thr Pro Thr Val
1 5 10 15

Thr Val Leu Asp Asn Arg Asn Leu Thr Val Arg Glu Ile Val Phe His
20 25 30

Arg Ala Lys Ala Gly Gly Asp Thr Asp Thr Leu Ile Thr Arg His Gln
35 40 45

Tyr Asp Leu Arg Gly Asn Leu Thr Gln Ser Leu Asp Pro Arg Leu Tyr
50 55 60

Asp Leu Met Gln Lys Asp Asn Thr Val Gln Pro Asn Phe Tyr Trp Gln
65 70 75 80

His Asp Leu Leu Gly Arg Val Leu His Thr Val Ser Ile Asp Ala Gly
85 90 95

Gly Thr Val Thr Leu Ser Asp Ile Glu Asp Arg Pro Ala Leu Asn Val
100 105 110

Asn Ala Met Gly Val Val Lys Thr Trp Gln Tyr Glu Ala Asn Ser Leu
115 120 125

Pro Gly Arg Leu Leu Ser Val Ser Glu Gln Ser Ala Asn Glu Ala Val
130 135 140

Pro Arg Val Ile Glu His Phe Ile Trp Ala Gly Asn Ser Gln Ala Glu
145 150 155 160

Lys Asp Leu Asn Leu Ala Gly Gln Tyr Met Arg His Tyr Asp Thr Ala
165 170 175

Gly Leu Asp Gln Leu Asn Ser Leu Ser Leu Thr Gly Ala His Leu Ser
180 185 190

Gln Ser Leu Gln Leu Leu Lys Asp Asp Gln Met Pro Asp Trp Ala Gly
195 200 205

Asp Asn Glu Ser Val Trp Gln Asn Lys Leu Lys Asn Glu Val His Thr
210 215 220

Thr Gln Ser Thr Thr Asp Ala Thr Gly Ala Pro Leu Thr Gln Thr Asp

225		230		235		240									
Ala	Lys	Glu	Asn	Met	Gln	Arg	Leu	Ala	Tyr	Asn	Val	Thr	Gly	Gln	Leu
			245					250					255		
Lys	Ser	Ser	Trp	Leu	Thr	Leu	Asn	Gly	Gln	Leu	Glu	Gln	Ile	Ile	Val
			260					265					270		
Lys	Ser	Leu	Ala	Tyr	Ser	Glu	Ser	Gly	Gln	Lys	Ile	Arg	Glu	Glu	His
		275					280					285			
Gly	Asn	Gly	Val	Val	Thr	Lys	Tyr	Ser	Tyr	Glu	Pro	Asp	Thr	Gln	Arg
	290					295					300				
Leu	Ile	Asn	Ile	Thr	Thr	Gln	Arg	Ser	Lys	Gly	His	Val	Phe	Ser	Glu
305					310					315					320
Lys	Leu	Leu	Gln	Asp	Leu	Leu	Tyr	Glu	Tyr	Asp	Pro	Val	Gly	Asn	Ile
			325					330					335		
Val	Ser	Ile	Leu	Asn	Arg	Ala	Glu	Ala	Thr	His	Phe	Trp	Arg	Asn	Gln
			340					345					350		
Lys	Val	Ser	Pro	Arg	Asn	Thr	Tyr	Thr	Tyr	Asp	Ser	Leu	Tyr	Gln	Leu
		355					360					365			
Ile	Gln	Ser	Thr	Gly	Arg	Glu	Met	Ala	Asp	Ile	Gly	Gln	Gln	Asn	Asn
	370					375					380				
Lys	Met	Pro	Thr	Pro	Leu	Val	Pro	Leu	Ser	Ser	Asp	Asp	Lys	Val	Tyr
385					390					395					400
Thr	Thr	Tyr	Thr	Arg	Thr	Tyr	Ser	Tyr	Asp	Arg	Gly	Asn	Asn	Leu	Thr
				405					410					415	
Lys	Ile	Gln	His	Arg	Ala	Pro	Ala	Ser	His	Asn	Ile	Tyr	Thr	Thr	Glu
			420					425					430		

Ile Thr Val Ser Asn Arg Ser Asn Arg Ala Val Leu Ser His Asn Gly
435 440 445

Leu Thr Pro Arg Glu Val Asp Ala Gln Phe Asp Ala Ser Gly His Gln
450 455 460

Ile Ser Leu Pro Thr Gly Gln Asn Leu Ser Trp Asn Gln Arg Gly Glu
465 470 475 480

Leu Gln Gln Ala Thr Thr Ile Asn Arg Asp Asn Ser Ala Thr Asp Arg
485 490 495

Glu Trp Tyr Arg Tyr Asn Ala Gly Ser Ala Arg Ile Leu Lys Val Ser
500 505 510

Glu Gln Gln Thr Gly Asn Ser Thr Gln Gln Gln Gln Val Thr Tyr Leu
515 520 525

Pro Gly Leu Glu Leu Arg Thr Thr Lys Ser Gly Thr Asn Thr Thr Glu
530 535 540

Asp Leu Gln Val Ile Thr Met Val Glu Thr Glu Arg Thr Gln Val Arg
545 550 555 560

Ile Leu His Trp Ser Ala Gly Lys Pro Asn Asp Ile Ala Asn Asn Gln
565 570 575

Val Arg Tyr Ser Tyr Asp Asn Leu Ile Glu Ser Asn Val Met Glu Leu
580 585 590

Asp Thr Lys Gly Lys Ile Ile Ser Gln Glu Glu Tyr Tyr Pro Tyr Gly
595 600 605

Gly Thr Ala Ile Trp Thr Ala Arg Asn Gln Ile Glu Ala Ser Tyr Lys
610 615 620

Thr Val Arg Tyr Ser Gly Lys Glu Arg Asp Lys Thr Gly Leu Tyr Tyr

625		630		635		640									
Tyr	Arg	His	Arg	Tyr	Tyr	Gln	Pro	Trp	Leu	Gly	Arg	Trp	Leu	Ser	Ala
				645					650					655	
Asp	Pro	Ala	Gly	Thr	Val	Asp	Gly	Leu	Asn	Leu	Tyr	Arg	Met	Val	Lys
			660					665					670		
Asn	Asn	Pro	Ile	Arg	Tyr	Gln	Asp	Glu	Ser	Gly	Thr	Asn	Ala	Asn	Asp
		675					680					685			
Lys	Ala	Gln	Ala	Ile	Phe	Lys	Glu	Gly	Lys	Lys	Ile	Ala	Ile	Asn	Gln
	690					695					700				
Leu	Lys	Ile	Ala	Ser	Asn	Phe	Leu	Lys	Asp	Ser	Lys	Asn	Ser	Glu	Asn
705					710					715					720
Ala	Leu	Glu	Ile	Tyr	Arg	Ile	Phe	Phe	Gly	Gly	His	Gln	Asp	Ile	Glu
				725					730					735	
Gln	Leu	Pro	Gln	Trp	Lys	Lys	Arg	Ile	Asp	Ser	Val	Ile	Tyr	Gly	Leu
			740					745					750		
Asp	Lys	Leu	Lys	Thr	Thr	Lys	His	Val	His	Tyr	Gln	Gln	Asp	Lys	Ser
		755					760					765			
Gly	Ser	Ser	Ser	Thr	Val	Ala	Asp	Leu	Asn	Val	Asp	Glu	Tyr	Lys	Lys
	770					775					780				
Trp	Ser	Glu	Gly	Asn	Lys	Ser	Ile	Tyr	Val	Asn	Val	Tyr	Ala	Asp	Ala
785					790					795					800
Leu	Lys	Arg	Val	Tyr	Glu	Asp	Pro	Leu	Leu	Gly	Arg	Glu	His	Val	Ala
				805					810					815	
His	Ile	Ala	Ile	His	Glu	Leu	Ser	His	Gly	Val	Leu	Arg	Thr	Gln	Asp
		820						825					830		

His Lys Tyr Ile Gly Val Leu Ser Ser Pro Gly Ser His Asp Leu Thr
835 840 845

Asp Leu Leu Ser Ile Leu Met Pro Pro Ala Asn Glu Gln Asp Arg Thr
850 855 860

Glu Lys Gln Arg Arg Ala Thr Gly Ala Arg Lys Ala Leu Glu Asn Ala
865 870 875 880

Asp Ser Phe Thr Leu Ser Ala Arg Tyr Leu Tyr Tyr Thr Ala Gln Asp
885 890 895

Pro Asn Phe Leu Ser Ser Leu Arg Lys Ala His Arg Asp Phe Asn Asn
900 905 910

Lys Lys Thr Asp Arg Leu Ile Ile Arg Pro Pro Glu Arg Arg
915 920 925

<210> 25
<211> 324
<212> PRT
<213> Photorhabdus

<400> 25

Met Glu Arg Glu Tyr Asn Lys Lys Glu Lys Gln Lys Lys Ser Ala Ile
1 5 10 15

Lys Leu Asp Asp Ala Val Gly Asn Asn Glu Glu Asn Met Asp Met Thr
20 25 30

Ser Pro Leu Glu Leu Asn Ser Gln Tyr Thr Asn Arg Lys Arg Pro Gly
35 40 45

Leu Arg Glu Arg Phe Ser Ala Thr Leu Gln Arg Asn Leu Pro Gly His
50 55 60

Ser Met Leu Asp Arg Glu Leu Thr Thr Asp Gly Gln Lys Asn Gln Glu
65 70 75 80

Ser Arg Phe Ser Pro Gly Met Ile Met Asp Arg Ile Met His Leu Gly
85 90 95

Val Arg Thr Arg Leu Gly Lys Val Arg Asn Ser Ala Ser Lys Tyr Gly
100 105 110

Gly Gln Val Thr Phe Lys Phe Ala Gln Thr Lys Gly Thr Phe Leu Asp
115 120 125

Gln Ile Met Lys His Lys Asp Thr Ser Gly Gly Val Cys Glu Ser Ile
130 135 140

Ser Ala His Trp Ile Ser Ala His Ala Lys Gly Glu Ser Ile Phe Asp
145 150 155 160

Gln Leu Tyr Val Gly Gly Gln Lys Gly Lys Phe His Ile Asp Thr Leu
165 170 175

Phe Ser Ile Lys Gln Leu Gln Met Asp Gly Tyr Leu Asp Asp Glu Gln
180 185 190

Ser Thr Met Thr Glu Tyr Trp Leu Gly Thr Gln Gly Ile Gln Pro Asn
195 200 205

Arg Gln Lys Asn Asp Asn Met Asn Glu His Ser Ser Lys Ile Val Gly
210 215 220

Glu Thr Gly Thr Arg Gly Thr Lys Asp Leu Leu Arg Ala Ile Leu Asp
225 230 235 240

Thr Gly Asp Lys Gly Ser Gly Tyr Lys Lys Ile Ser Phe Leu Gly Lys
245 250 255

Met Ala Gly His Thr Val Ala Ala Tyr Val Asp Asp Gln Lys Gly Val
260 265 270

Thr Phe Phe Asp Pro Asn Phe Gly Glu Phe Asn Phe Pro Asp Lys Val
275 280 285

Ser Phe Ser His Trp Phe Thr Asp Asp Phe Trp Pro Lys Ser Trp Tyr
290 295 300

Ser Leu Glu Ile Gly Leu Gly Gln Glu Phe Glu Val Phe Asn Tyr Glu
305 310 315 320

Pro Lys Glu Pro

<210> 26
<211> 304
<212> PRT
<213> Photorhabdus

<400> 26

Met Val Tyr Glu Tyr Ala Lys Thr Asn Asp Arg Lys Arg Lys Leu Ser
1 5 10 15

Thr Gln Ser Asp Asn Tyr Glu Glu Lys Ser Phe Ser Pro Val Leu Asp
20 25 30

Leu Ser Arg Asn Asn Gln Asn Thr Pro Asn Met Glu Asp Glu Tyr Glu
35 40 45

Thr Pro Gln Asn Phe Ile Asn Arg Thr Gly Arg Glu Lys Leu Phe Arg
50 55 60

Ala Ile Arg Met Val Ala Ser Asn Lys Arg Asp Pro Ile Thr Lys Asp
65 70 75 80

Gln Val Ser Val Pro Pro Asp Gly Asn Leu Phe Thr Glu Leu Lys Asp
85 90 95

Lys His Leu Asp Arg Ala Ala Glu Tyr Lys Lys Leu Lys Thr Trp Pro
100 105 110

Thr His Ala Ser Ile Ile Ala Thr Ser Pro Ser Ala Asn Thr Pro Ile
115 120 125

Ala Gln His Val Ser Gly Asp Asp Ala Leu Ser Pro Tyr Ile Ser Thr
130 135 140

Gly Asp Lys Pro Gly Ala Val Gln Asn Thr Val Arg Asn Trp Asn Gly
145 150 155 160

Ile Gly Pro Ala Ser Glu Arg Arg Leu Arg Pro Glu Lys Thr Trp Ser
165 170 175

Pro Ile Ile Glu Ile Asp Val Asn Lys Leu Pro Asp Thr Thr Lys Ile
180 185 190

Phe Asp Leu Asn Lys Pro Asn Asn Thr Phe Phe Ser Thr Thr Asn Ser
195 200 205

Asp Ile Ala Gln Asn Ala Phe Ala Asp Lys Glu Val Leu Ile Ser Pro
210 215 220

Glu Ile Pro Gly Leu Ala Ile Thr Arg Val Ile Asn Asp Pro Glu Glu
225 230 235 240

Ile Lys Gln Ile Ala Asn Leu Asn Pro Ser Gln Ser Leu Ile Glu Lys
245 250 255

Lys Asn Thr Ile Pro Glu Glu Lys Ile Ile Phe Glu Glu Lys Lys Ser
260 265 270

Val Pro Ile His Asp Ser Asp Ala Asp Ile Pro Ser Ser Ser Phe Val
275 280 285

Phe Pro Lys Arg Lys Lys Pro Arg Asn Ile Arg Ser Arg Thr Asp Ser
290 295 300

<210> 27

<211> 542
<212> PRT
<213> Photorhabdus

<400> 27

Met Val Phe Glu His Asp Lys Thr Val Glu Arg Lys Arg Lys Pro Ser
1 5 10 15

Ile Gln Leu Gly Asn Asp Lys Glu Lys Ser Ser Glu Gln Ala Leu Glu
20 25 30

Leu Pro Gln Ser Lys Gln Asn Asn Pro Leu Leu His Asp Leu Ile Thr
35 40 45

Ser Asn Asn Leu Arg Lys Glu Ala Ala Val Phe Ala Lys Gln Ile Gly
50 55 60

Pro Ser Tyr Gln Gly Ile Leu Asp Gly Leu Glu His Leu His Asn Leu
65 70 75 80

Ser Gly Asn Glu Gln Leu Thr Ala Gly Phe Glu Leu His Arg Arg Ile
85 90 95

Thr Arg Tyr Leu Glu Glu His Pro Asp Ser Lys Arg Asn Ala Ala Leu
100 105 110

Arg Arg Thr Gln Thr Gln Leu Gly Asp Leu Met Phe Thr Gly Thr Leu
115 120 125

Gln Glu Val Arg His Pro Leu Leu Glu Met Ala Glu Thr Arg Pro Ala
130 135 140

Met Ala Ser Gln Ile Tyr Gln Ile Ala Arg Asp Glu Ala Lys Gly Asn
145 150 155 160

Thr Pro Gly Leu Thr Asp Leu Met Val Arg Trp Val Lys Glu Asp Pro
165 170 175

Tyr Leu Ala Ala Lys Ser Gly Tyr Gln Gly Lys Ile Pro Asn Asp Leu
180 185 190

Pro Phe Glu Pro Lys Phe His Val Glu Leu Gly Asp Gln Phe Gly Glu
195 200 205

Phe Lys Thr Trp Leu Asp Thr Ala Gln Asn Gln Gly Leu Leu Thr His
210 215 220

Thr Arg Leu Asp Glu Gln Asn Lys Gln Val His Leu Gly Tyr Ser Tyr
225 230 235 240

Asn Glu Leu Leu Asp Met Thr Gly Gly Val Glu Ser Val Lys Met Ala
245 250 255

Val Tyr Phe Leu Lys Glu Ala Ala Lys Gln Ala Glu Pro Gly Ser Ala
260 265 270

Lys Ser Gln Glu Ala Ile Leu Leu Asn Arg Phe Ala Asn Pro Ala Tyr
275 280 285

Leu Thr Gln Leu Glu Gln Gly Arg Leu Ala Gln Met Glu Ala Ile Tyr
290 295 300

His Ser Ser His Asn Thr Asp Val Ala Ala Trp Asp Gln Gln Phe Ser
305 310 315 320

Pro Asp Ala Leu Thr Gln Phe Asn His Gln Leu Asp Asn Ser Val Asp
325 330 335

Leu Asn Ser Gln Leu Ser Phe Leu Leu Lys Asp Arg Gln Gly Leu Leu
340 345 350

Ile Gly Glu Ser His Gly Ser Asp Leu Asn Gly Leu Arg Phe Val Glu
355 360 365

Glu Gln Met Asp Ala Leu Lys Ala His Gly Val Thr Val Ile Gly Leu
370 375 380

Glu His Leu Arg Ser Asp Leu Ala Gln Pro Leu Ile Asp Lys Phe Leu
385 390 395 400

Thr Ser Glu Asn Glu Pro Met Pro Ala Glu Leu Ala Ala Met Leu Lys
405 410 415

Thr Lys His Leu Ser Val Asn Leu Phe Glu Gln Ala Arg Ser Lys Gln
420 425 430

Met Lys Ile Ile Ala Leu Asp Asn Asn Ser Thr Thr Arg Pro Ala Glu
435 440 445

Gly Glu His Ser Leu Met Tyr Arg Ala Gly Ala Ala Asn Asn Val Ala
450 455 460

Val Glu Arg Leu Gln Gln Leu Pro Ala Glu Glu Lys Phe Val Ala Ile
465 470 475 480

Tyr Gly Asn Ala His Leu Gln Ser His Glu Gly Ile Asp His Phe Leu
485 490 495

Pro Gly Ile Thr His Arg Leu Gly Leu Pro Ala Leu Lys Val Asp Glu
500 505 510

Asn Asn Arg Phe Thr Ala Gln Ala Asp Asn Ile Asn Gln Arg Lys Cys
515 520 525

Tyr Asp Asp Val Val Glu Val Ser Arg Ile Gln Leu Thr Ser
530 535 540

<210> 28

<211> 2957

<212> PRT

<213> Photorhabdus

<400> 28

Met Lys Gly Ile Glu Gly Val Ile Met Leu Ser His Asp Ile Leu Pro

1	5	10	15
Glu Lys Leu Leu Val Ser Glu Lys Lys His Glu Asn Val Gly Ser Tyr	20	25	30
Phe Ser Asp Asp Ile Gly Glu Gln Ser Glu Gln Thr Glu Val Ser His	35	40	45
Phe Asn Leu Ser Leu Asp Asp Ala Phe Asp Ile Tyr Ala Asp Ile Ser	50	55	60
Ile Glu Asn Gln Gln Glu Leu Lys Asn Lys Asp Asn Asn Thr Asn Ile	65	70	75
Trp Ser Ser Leu Gly Arg Gly Asp Asp Asp His Asn Leu Lys Lys Ile	85	90	95
Ile Asn Asp Ala Phe Lys Glu Lys Leu Pro Gln Leu Met Glu Tyr Arg	100	105	110
Arg Lys Gly Tyr Asn Val Ile Gly Leu Asp Lys Glu Gly Ile Lys Lys	115	120	125
Leu Glu Gly Met Leu Lys Ala Val Pro Pro Glu Ile Gln Gln Pro Thr	130	135	140
Met Lys Asn Leu Tyr Ser Ala Ala Gln Glu Leu Leu Asn Thr Leu Lys	145	150	155
Gln His Pro Leu Leu Pro Glu Asn Gln Asp Met Ile Gln Gln Ser Asn	165	170	175
Leu Val Ile Arg Asn Leu Ser Asp Ala Leu Glu Ala Ile Asn Ala Val	180	185	190
Ser Lys Val Asn Gln Val Glu Trp Trp Glu Glu Val His Lys Thr Asn	195	200	205

Lys Ala Gln Ser Asp Arg Leu Ile Ala Ala Thr Leu Glu Glu Leu Phe
210 215 220

Phe Lys Val Lys Asp Lys Arg Leu Pro Gly Ser Asn Asp Asp Tyr Cys
225 230 235 240

Gln Gln Glu Arg Glu Glu Thr Glu Arg Lys Ile Lys Asp Leu Leu Leu
245 250 255

Tyr Asp Gly Tyr Gln Leu Thr Ala Glu His Phe Lys Phe Gly Arg Leu
260 265 270

Arg Lys Ser Leu Leu Ala Glu Ser Arg Val Thr Arg Leu Lys Leu Ala
275 280 285

Glu Tyr Leu Glu Lys Lys Ser Val Gly Ile Leu Thr Ala Ala Arg Asp
290 295 300

Ala Lys Met Tyr Ala Met Lys Ile Leu Leu Ala Gln Thr Arg Asn Asn
305 310 315 320

Gly Phe Asn Ala Lys Asp Leu Ile Asn Ala Gly Gln Val Asn Asp Arg
325 330 335

Leu Leu Ser Phe Gln Gln Tyr Ala Arg His Ile Arg Ala Val Asp Gly
340 345 350

Glu Ile Asp Gly Ile Ile Leu Ser Asn Pro Leu Val Val Ala Cys Ile
355 360 365

Lys Glu Thr Asn Asp Glu Pro Ala His Ile Lys Ile Ala Arg Ala Ile
370 375 380

Leu Pro Val Ser Glu Glu Leu Gly Thr Val Ser Lys Val Leu Arg Glu
385 390 395 400

Thr Lys Glu Lys Val Gln Pro Ser Lys Pro Lys Glu Glu Leu Asn His

405

410

415

Pro His Gln Asp Trp Trp Asn Arg Gly Asp Glu Leu Trp Lys Tyr Ile
420 425 430

Lys Lys Thr Ser Trp Asn Ile Lys Glu Thr Ser Val His Val Thr Gln
435 440 445

Met Val Gly Tyr Glu Ala Ser Lys Thr Ala Ser Arg Ala Lys His Lys
450 455 460

Leu Lys Glu Ser Ser Tyr Ser Glu Ser Ile Asn Gly Ala Val Lys Gly
465 470 475 480

Thr Ala Leu Leu Leu Leu Asp Glu Ile Gln Gln Ala Glu Asn Arg Ile
485 490 495

Arg Gln Ile Pro Gln Phe Ala Trp Asp Val Gln Glu Ala Val Glu Gln
500 505 510

His Ser Ser Val Ile Gln Arg Thr Ala Tyr Pro Asp Glu Leu Pro Glu
515 520 525

Leu Ser Glu Leu Leu Asn Glu Gln Leu Lys His Glu Glu Ala Arg Trp
530 535 540

Gln Ala Val Lys Lys Gln Ser Arg Asp Lys Leu Gln Glu Leu Ile Ala
545 550 555 560

Pro Ile Thr Arg Leu Ala Gln Glu Lys Trp Ala Gln Asp Leu Tyr Phe
565 570 575

Gln Leu Gly Glu Glu Leu Arg Lys Glu Arg Gln Asp Arg Trp Lys Asp
580 585 590

Ile Gln Gln Phe Asp Glu Ile Met Ala Glu Ala Val Gly Gln Phe Ala
595 600 605

Glu Met Ala Arg Glu Leu Asp Ser Glu Ala Val Arg Leu Ala Glu His
610 615 620

Gly His Ser Gly Gly Lys Glu Leu Gln Glu Lys Val Ala Lys Trp Leu
625 630 635 640

Arg Asp Leu Ser Lys Leu Lys Gly Lys Val Lys Ala Gly Val Ala Lys
645 650 655

Ile Thr Gly Thr Ser Leu Asp Asn Phe Ser Arg Ser Gly Met Leu Ala
660 665 670

Arg Gly Met Ser Glu Trp Ala Glu Asp Leu Lys Gln Ser Tyr Leu Gln
675 680 685

Glu Thr Leu Gln Glu Gly Ser Ala Val Ala Ala Glu Leu Phe Glu Arg
690 695 700

Thr Leu Met Glu Val Val Glu Glu Asn Arg Thr His Phe Ala Lys Glu
705 710 715 720

Ser Asp Pro Glu Ala Glu Arg Phe Leu Lys Arg Leu Ala Leu Ala Leu
725 730 735

Lys His Ala Ala Glu Asn Thr Thr Val Tyr Pro Pro Thr Pro Glu Glu
740 745 750

Ile Leu Ala Gly Ser Arg Ser Leu Pro Glu Asp Ile Arg His Trp Ala
755 760 765

Glu Lys Lys Val Val Ser Gly Ala Ile Ser Ala Ala Phe Arg Gly Gly
770 775 780

Phe Lys Leu Val Thr Gly Thr Phe Ser Leu Pro Val Arg Val Val Ile
785 790 795 800

Arg Gly Ala Lys Thr Gly Gly Thr Leu Tyr Arg Gly Val Arg Ala Ile

805

810

815

Asn Arg Ser Val Arg Leu Gly Gln Gly Pro Ala Thr Gln Val Lys Ser
 820 825 830

Lys Phe Ile Asn Gln Glu Leu Ser Lys Thr Ala Phe Arg Leu Thr Leu
 835 840 845

Ser Leu Ser Pro Leu Val Ala Trp Gly Met Ala Ala Ser Ile Thr Ala
 850 855 860

Gly Arg Leu Tyr Asn Glu Lys Asp Tyr Pro Glu Lys Ile Ile Lys Asn
 865 870 875 880

Ile Val Ile Asp Leu Pro Glu Glu Leu Leu Trp Ile Gly Gly Tyr Ala
 885 890 895

Gly Ile Asn Ala Ala Ile Arg Ala His Ala Glu Lys Ala Ile Gln Gln
 900 905 910

Ala Ile Gln His Ala Leu Asp Glu Gln Ala Asp Lys Leu Ala Leu Arg
 915 920 925

Ile Asn Lys Glu Ile Ala Gly Lys Ser Ala Asp Val Asn Val Glu Ile
 930 935 940

Ile Pro Gln Glu Thr Ser Val Ser Pro Ala Glu Thr Ala Gln Ser Thr
 945 950 955 960

Pro Glu Pro Leu Ser Asp Phe Ala Ser Thr Ser Gln Leu Thr Met Pro
 965 970 975

Glu Leu Ile Asp Ile Gln Asp Asn Asn Ser Ala Gln Gln Pro Lys Val
 980 985 990

Arg Arg Lys Arg Asp Val Ser Val Glu Ser Glu Ile Ser Ile Asp Asn
 995 1000 1005

Leu Asn Ile Ile Asn Ala Asn Thr Arg Glu Asp Lys Val Asn Ser
1010 1015 1020

Glu Ile Lys Ser Glu Leu Arg Ser Glu Leu Lys Arg Phe Glu Asn
1025 1030 1035

Ser Asp Ala Asn Ser Pro Met Ser Asp Val Glu Arg Ala Ile Phe
1040 1045 1050

Ile Asp Leu Phe Leu Tyr Lys Asn Lys Tyr Glu Val Ser Glu Ser
1055 1060 1065

Gln Gln Asp Tyr Lys Asn Thr Trp Leu Lys Phe Arg Arg Glu Leu
1070 1075 1080

Glu Ser Gln Glu Asn Lys Glu Ile Lys Glu Tyr Leu Arg Phe Arg
1085 1090 1095

Ser Ile Ile Glu Ala Tyr Glu Ile Tyr Asp Lys Lys Arg Leu Asp
1100 1105 1110

Asp Asp Thr Ile Pro Glu Ala Gly Thr Ile Ile Lys Glu Val Ile
1115 1120 1125

Asp Phe Phe Gln Lys Leu Lys Lys Glu Asn Pro Ile Thr Phe Met
1130 1135 1140

Lys Leu Ala Glu Ala Met Val Lys Phe Gln Tyr Tyr Tyr Glu Glu
1145 1150 1155

Glu Asp Glu Asn Glu Asp Arg Tyr Phe Lys Met Ala Glu Ile Tyr
1160 1165 1170

Tyr Phe Leu Asn Lys Thr Glu Asn Glu Lys Lys Ser Lys Thr Phe
1175 1180 1185

His Leu Asp Ile Ile Asp Lys Tyr Pro Asn Glu Asn Asn Arg Leu

1190

1195

1200

Leu Asp Glu Phe Phe Leu Asn Lys Asn Asn Asn Asn Pro Asp Leu
 1205 1210 1215

Asp Glu Ile Ile Tyr Lys Leu Gln Ser Met Gln Glu Lys Tyr Arg
 1220 1225 1230

Glu Ser Tyr Glu Met Leu Ser Lys Val Glu Asn Ile His Gln Val
 1235 1240 1245

Leu Ser Asp Asp Ser Lys Asn Glu Glu Asn Ile Phe Leu Asp Asn
 1250 1255 1260

Arg Ile Ile Ala Ala Gln Val Phe Asp Gly Ser Ile Asn Ile Ser
 1265 1270 1275

Leu Gln Asp Lys Lys Lys Trp Leu Asn Arg Tyr Asp Gln Ile Arg
 1280 1285 1290

Asn Glu Glu Gly Ser Asp Gly Trp Lys Leu Met His Ile Glu Ser
 1295 1300 1305

Ile Leu Ile Asn Leu Arg Arg Ile Asn Thr Ala Ile Asn Leu Thr
 1310 1315 1320

Ala Met Lys Ser Glu Ser Ala Leu Leu Leu Ile Asp Lys Leu Leu
 1325 1330 1335

Asn Phe Gln Lys Lys Ala Arg Glu Asn Ile Leu His Ile Ser Glu
 1340 1345 1350

Thr Pro His Glu Asp Phe Thr Ser Tyr Ser Gln Phe Lys Thr Arg
 1355 1360 1365

Lys Glu Leu Gly Asn Asp Asp Ser Lys Tyr Tyr Ala Gln Phe Asp
 1370 1375 1380

Asn Tyr Lys Asp Asn His Asp Ala Glu Lys Glu Ala Lys Glu Ile
1385 1390 1395

Leu Ser Gln Val Val Ala Arg Ala Ser Leu Ser Phe Ser Glu Leu
1400 1405 1410

Phe Asp Lys Val Glu Ser Ile Lys Leu Phe Ser Phe Val Tyr Lys
1415 1420 1425

Asn Arg Asp Gly Gly Ala Pro Leu Ala Ala Pro Gly Arg Thr Val
1430 1435 1440

Val Ile Lys Phe Pro Gly Lys Asp Thr Gly Gly Leu Val Ile Ser
1445 1450 1455

Asn Leu Phe Leu Arg Asn His Val Lys Arg Ile Ser Thr Lys Glu
1460 1465 1470

Met Glu Asp Leu Lys Pro Leu Thr Glu Gly Met Tyr Thr Arg Ala
1475 1480 1485

Thr Gln His Arg Ser Leu Gly Ser Tyr Tyr His Ile Gly Ser Gln
1490 1495 1500

Ser Glu His Thr Asn Ala Leu Glu Ile Leu Ser Gly Met Asn Lys
1505 1510 1515

Glu Glu Leu Lys Thr His Leu Lys Lys Gln Gly Ile Trp Phe Gly
1520 1525 1530

Glu Pro Ala Leu Phe Ser Asn Glu Tyr Pro Lys Gln Glu Asn Thr
1535 1540 1545

Gly His Leu Glu Asn Thr Thr Leu Lys Asn Ala Ile Ile Gly Val
1550 1555 1560

Ser Thr Ile Gln Asn Asn Ala Ala Ala Asn Tyr Leu Arg Ser Thr

1565

1570

1575

Met Tyr Glu Ser Thr Gly Trp Glu Lys Leu Gly Asp Arg Phe Ile
1580 1585 1590

Pro Phe Tyr Glu Ile Gly Arg Arg Lys His Tyr Asp Arg Glu Tyr
1595 1600 1605

Glu Ile Asn Ser Glu Gln Leu Thr Leu Asp Ile Ile Thr Ser Ile
1610 1615 1620

Ala Ile Ala Tyr Pro Ala Ala Arg Gly Ile Val Ala Thr Ile Arg
1625 1630 1635

Ser Ser Ala Ile Pro Ser Ile Leu Lys Ser Gly Leu Arg Gly Ser
1640 1645 1650

Ala Leu Phe Lys Ser Leu Ser Leu Glu Leu Gly Lys Met Gly Phe
1655 1660 1665

Asn Ala Ser Lys Val Phe Gly Gly Ala Val Tyr Glu Leu Ile Glu
1670 1675 1680

Pro Tyr Pro Ile Asn Ser His Leu Asn Arg His Asn Val Phe Asn
1685 1690 1695

Lys Val Lys Asp Thr Ala Trp Glu Phe His Thr Asp Val Gly Leu
1700 1705 1710

Lys Gly Gly Gly Leu Lys Asp Phe Ile Asp Arg Phe Thr Lys Glu
1715 1720 1725

Pro Lys Glu Ile Thr Ile Ser Gly Tyr Lys Phe Lys Arg Ile Lys
1730 1735 1740

Tyr Asn Gln Glu Asn Phe Asp Thr Met Gln Arg Met Ala Leu Asp
1745 1750 1755

Tyr Ala Tyr Asn Pro Asp Ser Lys Gly Lys Ile Ala Gln Ala Gln
1760 1765 1770

Gln Ala Tyr Lys Thr Gly Lys Glu Asp Tyr Asn Ala Pro Gln Tyr
1775 1780 1785

Asp Asn Phe Asn Gly Leu Ser Leu Asp Lys Lys Ile Glu Arg Tyr
1790 1795 1800

Ile Ser Pro Asp Thr Asp Ala Thr Thr Lys Gly Val Leu Ala Gly
1805 1810 1815

Lys Met Asn Glu Ser Ile Lys Asp Ile Asn Ala Phe Gln Thr Ala
1820 1825 1830

Lys Asp Ala Gln Ser Trp Lys Lys Ser Ala Asn Lys Ala Asn Lys
1835 1840 1845

Val Val Leu Thr Pro Gln Asn Leu Tyr Leu Lys Gly Lys Pro Ser
1850 1855 1860

Glu Cys Leu Pro Glu Ser Val Leu Met Gly Trp Ala Leu Gln Ser
1865 1870 1875

Ser Gln Asp Ala Lys Leu Ser Lys Met Leu Met Gly Ile Tyr Ser
1880 1885 1890

Ser Asn Asp Ile Thr Ser Asn Pro Leu Tyr Lys Ser Leu Lys Glu
1895 1900 1905

Leu His Ala Asn Gly Asn Ala Ser Lys Phe Asn Ala Ser Ala Thr
1910 1915 1920

Ser Ile Ser Asn Ile Asn Val Ser Asn Leu Ala Thr Ser Glu Thr
1925 1930 1935

Lys Leu Phe Pro Thr Glu Ile Ser Ser Val Arg Val Asp Ala Pro

1940

1945

1950

Lys His Thr Met Leu Ile Ser Lys Ile Lys Asn Arg Glu Asn Lys
 1955 1960 1965

Ile Lys Tyr Val Phe Tyr Asp Pro Asn Tyr Gly Met Ala Tyr Phe
 1970 1975 1980

Asp Lys His Ser Asp Met Ala Ala Phe Phe Gln Lys Lys Met Gln
 1985 1990 1995

Gln Tyr Asp Phe Pro Asp Asp Ser Val Ser Phe His Pro Leu Asp
 2000 2005 2010

Tyr Ser Asn Val Ser Asp Ile Lys Ile Ser Gly Arg Asn Leu Asn
 2015 2020 2025

Glu Ile Ile Asp Gly Glu Ile Pro Leu Leu Tyr Lys Gln Glu Gly
 2030 2035 2040

Val Gln Leu Glu Gly Ile Thr Pro Arg Asp Gly Ile Tyr Arg Val
 2045 2050 2055

Pro Pro Lys Asn Thr Leu Gly Val Gln Glu Thr Lys His Tyr Ile
 2060 2065 2070

Ile Val Asn Asn Asp Ile Tyr Gln Val Glu Trp Asp Gln Thr Asn
 2075 2080 2085

Asn Thr Trp Arg Val Phe Asp Pro Ser Asn Thr Asn Arg Ser Arg
 2090 2095 2100

Pro Thr Val Pro Val Lys Gln Asp Thr Asn Gly Glu Trp Phe Lys
 2105 2110 2115

His Ser Glu Thr Gly Leu Lys Gly Gly Gly Pro Ile Asp Asp Ile
 2120 2125 2130

Arg Lys Tyr Ile Ala Arg Lys Ser Ala Ile Lys Ile Phe Asn Gln
2135 2140 2145

Ser Ile Asn Tyr Ser Ala Thr Lys Trp Pro Pro Glu Pro Ile Asp
2150 2155 2160

Lys Asn Ile His Met Ile Trp Ile Gly Thr Lys Asn Ile Ser Glu
2165 2170 2175

Lys Asn Ile Lys Leu Ser Ile Asp Thr Ala Lys Lys Asn Pro Asp
2180 2185 2190

Tyr Asn Thr Ser Ile Ile Tyr Asp Ser Gly Ile Ser Gly His Glu
2195 2200 2205

Gly Ala Lys Lys Phe Met Leu Glu Lys Phe Gln Asp Ser Asn Val
2210 2215 2220

Asn Ile Ile Asp Phe Arg Lys Lys Ser Tyr Phe Ser Gln Leu Lys
2225 2230 2235

Gln Glu Pro Ser Phe Ala Tyr Tyr Glu Gln Val Ile Ala Glu Asn
2240 2245 2250

Lys Tyr Ala Gln Ala Ser Asp Ile Leu Arg Leu Leu Val Leu Lys
2255 2260 2265

Tyr Glu Gly Gly Ile Tyr Lys Asp Ile Asp Asp Ile Gln Val Lys
2270 2275 2280

Gly Phe Gly Ser Leu Thr Phe Pro Lys Gly Ile Gly Val Met Arg
2285 2290 2295

Glu Tyr Ala Pro Glu Ala Gly Lys Ala Thr Ala Phe Pro Asn Thr
2300 2305 2310

Pro Ile Ala Val Thr Lys Asn Asn Pro Ile Ile Asn Lys Thr Leu

2315

2320

2325

Asp Leu Ala Val Ser Asn Tyr Gln Arg Gly Glu Lys Asn Val Leu
 2330 2335 2340

Lys Leu Ala Gly Pro Asp Val Phe Thr Gln Ala Leu Tyr Gln Glu
 2345 2350 2355

Ile Pro Gly Leu Asp Ser Lys Val Leu Asn Ala Gln Leu Tyr Gln
 2360 2365 2370

Leu Glu Leu Ala Lys Arg Gln Ala Leu Gly Val Pro Leu Glu Lys
 2375 2380 2385

Pro Lys Asn Phe Ala Asp Glu Gln Leu Thr Ser Ala Glu Lys Glu
 2390 2395 2400

Lys Ile Asn Arg Pro Tyr Gln Ser Ile Arg Gly Leu Ser Gly Tyr
 2405 2410 2415

Val Glu Asn Gly Ala Asp His Ser Trp Ala Val Asp Thr Asn Ile
 2420 2425 2430

Pro Ser Thr Ser Thr Gln Thr Ser Thr Ile Val Thr Pro Leu Ala
 2435 2440 2445

Pro Lys Thr Glu Met Leu Pro Pro Val Pro Ser Ser Ser Thr Lys
 2450 2455 2460

Ser Ser Thr Ser Ala Pro Val Leu Gln Glu Lys Ile Ser Tyr Asn
 2465 2470 2475

Leu Ala Thr Asp Ile Asp Ala Thr Asp Tyr Leu Asn Gln Leu Lys
 2480 2485 2490

Gln Lys Thr Asn Ile Asn Asn Lys Ile Ser Ser Pro Ala Gly Gln
 2495 2500 2505

Cys Glu Ser Leu Met Lys Pro Val Ser Asp Phe Met Arg Glu Asn
2510 2515 2520

Gly Phe Thr Asp Ile Arg Tyr Arg Gly Met Phe Ile Trp Asn Asn
2525 2530 2535

Ala Thr Glu Gln Ile Pro Met Asn His Phe Val Val Val Gly Lys
2540 2545 2550

Lys Val Gly Lys Asp Tyr Val Phe Asp Val Ser Ala His Gln Phe
2555 2560 2565

Glu Asn Lys Gly Met Pro Asp Leu Asn Gly Pro Leu Ile Leu Ala
2570 2575 2580

Ala Glu Asp Trp Ala Lys Lys Tyr Arg Gly Ala Thr Thr Arg Lys
2585 2590 2595

Leu Ile Tyr Tyr Ser Asp Phe Lys Asn Ala Ser Thr Ala Thr Asn
2600 2605 2610

Thr Tyr Asn Ala Leu Pro Arg Glu Leu Val Leu Glu Ser Met Glu
2615 2620 2625

Gly Lys Thr Phe Ile Thr Ser Pro Asn Trp Tyr Gln Thr Phe Lys
2630 2635 2640

Arg Thr His Asn Ile His Pro Glu Val Thr Val Ser Asp Pro Ala
2645 2650 2655

Thr Phe Ser Leu Asn Tyr Ser Val Asn Pro Thr Ala Glu Asn Leu
2660 2665 2670

Ser Pro Pro Pro Pro Pro Pro Ile Pro Ser His Gly Gln Val Pro
2675 2680 2685

Lys Thr Val Thr Pro Pro Pro Pro Pro Met Arg Ser Pro Leu Ser

2690

2695

2700

Leu Ser Gln Pro Leu Glu Arg Leu Pro Ala Asn Lys Thr Lys Pro
 2705 2710 2715

Ile Gly Phe Asn Pro Gly Glu Asn Lys Ala Ser Phe Ser Lys Leu
 2720 2725 2730

Glu Glu Ala Gly Lys His Tyr Tyr Lys Asp Asp Lys Ser Arg Gln
 2735 2740 2745

Ala Ala Pro Val Asn Thr Met Ser Asp Phe Asp Asn Arg Tyr Leu
 2750 2755 2760

Ser His Thr Thr Glu Ala Pro Ala Pro Ser Asn Val Ala His Leu
 2765 2770 2775

Ala Pro Gly Asn Ile Tyr Asn Thr Lys Val Thr Ala Lys Gly Ala
 2780 2785 2790

Glu Lys Pro Ala Tyr Asp Ile Tyr Ile Ser Lys Asp Gly Glu Ser
 2795 2800 2805

Leu Ile Thr Ser Ser Ser Tyr Lys Val Asp Asp Ile Thr Thr Asp
 2810 2815 2820

Ser Lys Phe Gly Lys Pro Leu Pro Tyr Ser Glu Ile Met Phe Asn
 2825 2830 2835

Ser Leu Lys Lys Ser Gly Val Asp Pro Lys Asn Leu Lys Arg Ser
 2840 2845 2850

Val Gln Ala Ser Ile Glu Asn Lys Val Thr Gln Asp Val Ile Ser
 2855 2860 2865

Ala Ile Gly Thr Arg Ile Gln Arg Gly Gln Val Ile Arg Val Ser
 2870 2875 2880

Pro Thr Glu Asn Pro Asp Ala Phe Tyr Thr Leu Leu Gly Thr Asp
2885 2890 2895

Asn Cys Lys Ala Thr Leu His Met Leu Asn Gln His Ala Glu Glu
2900 2905 2910

Phe Gly His Lys Val Val Thr Ser Ile Glu Phe Lys Gly Thr Gly
2915 2920 2925

Tyr Leu Val Met Asn Ile Gly Thr Ser Thr Gln Thr Ser Thr Ile
2930 2935 2940

Val Thr Pro Pro Pro Met Pro Gly Thr Ser Gln Leu Val Gln
2945 2950 2955

<210> 29
<211> 327
<212> PRT
<213> Photorhabdus

<400> 29

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Lys Pro
1 5 10 15

Leu Ile Lys Ser Glu Ala Asn Asn Glu His Ala Ile Asp Asn Ser Pro
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Ile Leu Gly Asn Asn Ser Ala
35 40 45

Ser Leu Ser Gln Ile His Asp Tyr Ser Phe Trp Lys Glu Asn Ile Ser
50 55 60

Glu Tyr Tyr Lys Trp Met Val Val Val Lys Ala His Leu Lys Gln Leu
65 70 75 80

Asp Trp Thr Leu Lys Ser Met Asp Ser Pro Glu Ser Ala Gly Ala Asn
85 90 95

Ile Ala Lys Asn Ile Gly Thr Thr Thr Leu Gln Thr Leu Leu Asn Thr
100 105 110

Gly Gly Ser Ile Ala Gly Gly Ala Ile Gly Gly Ala Ile Gly Ser Ala
115 120 125

Ile Ala Pro Gly Val Gly Thr Ile Ala Gly Met Gly Ile Gly Ala Leu
130 135 140

Ala Gly Thr Gly Leu Asn Tyr Leu Asn Asp Thr Ala Ile Glu Lys Leu
145 150 155 160

Asn Glu Lys Leu Glu Ile Ala Tyr Pro Tyr Pro Lys Thr Arg Asn Met
165 170 175

Ile Phe Asp Ile Asn Asn Tyr Asp Lys Asn Pro Leu Ile Lys Ala Ile
180 185 190

Lys Lys Lys Thr Lys Lys Asp Asn Leu Lys Val Met Ala Gly Ser Ser
195 200 205

Leu Thr Ser Gln Leu Leu Gly Arg Ile Thr Pro Ile Lys Ile Pro Ala
210 215 220

Tyr Lys Leu Ala Asp Leu Ala Val Ser His His Arg Ala Leu Ala Gly
225 230 235 240

Leu Ser Ser Asp Lys Ala Arg His Ile Leu Asp Phe Thr Asn Ser Ile
245 250 255

Arg Glu Val Leu Asn Glu Ser His Ser Asp Ala Val Ala Phe Met Arg
260 265 270

Lys Asn Tyr Gly Asp Asn Ala Met Gly Leu Ser Gly Leu Ser Ser Lys
275 280 285

Ile Lys Gly Asp Lys Leu Thr Leu Asp Thr Leu Ala Arg Thr Arg Asn
290 295 300

Lys Ile Glu Asn Arg Ile Asn Ser Ile Asn Lys Gln Thr Leu Lys Leu
305 310 315 320

Ser Ser Lys Asn Ser Asn Glu
325

<210> 30
<211> 322
<212> PRT
<213> Photorhabdus

<400> 30

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys His Pro Ile
1 5 10 15

Gln Leu Arg Asp Ala Ile Glu Gln His Ala Glu Glu Thr Ala Asn Asn
20 25 30

Ser Leu Gly Leu Gly Leu Asp Leu His Gln Ala Ile Asn Thr Pro Lys
35 40 45

Val Pro Lys Asp Asn Tyr Asn Glu Glu Asn Gly Asp Leu Phe Tyr Gly
50 55 60

Leu Ala Ala Gln Arg Gly Arg Tyr Ile Lys Ser Val Asn Pro Asn Phe
65 70 75 80

Asp Pro Asp Lys Thr Asn Ser Ser Pro Met Val Ile Asp Val Tyr Asn
85 90 95

Asn His Val Ser Asn Thr Ile Leu Asn Lys Tyr Pro Leu Asp Lys Leu
100 105 110

Gly Lys Leu Tyr Gly Asn Pro Gln Lys Tyr Ala Lys Asp Ile Lys Val
115 120 125

Thr Asn Ser Leu Gln Gln Asp Val Ala Ala Ser Lys Arg Gly Trp Tyr
130 135 140

Pro Leu Trp Asn Asp Tyr Phe Lys Ala Gly Asn Glu Asn Lys Lys Phe
145 150 155 160

Asn Ile Ala Asp Ile Tyr Lys Glu Thr Arg Asn Gln Tyr Gly Ser Asp
165 170 175

Tyr Tyr His Thr Trp His Glu Pro Thr Gly Ala Ala Pro Lys Leu Leu
180 185 190

Trp Lys Arg Gly Ser Lys Leu Gly Ile Ala Met Ala Ala Ser Asn Glu
195 200 205

Lys Thr Lys Ile His Phe Val Leu Asp Gly Leu Asn Ile Gln Glu Val
210 215 220

Val Asn Lys Gln Lys Gly Ser Thr Pro Leu Glu Gln Gly Arg Gly Glu
225 230 235 240

Ser Ile Thr Ala Ser Glu Leu Arg Tyr Ala Tyr Arg Asn Arg Glu Arg
245 250 255

Leu Ala Gly Lys Ile His Phe Tyr Glu Asn Asp Gln Glu Thr Ile Ala
260 265 270

Pro Trp Glu Lys Ser Pro Glu Leu Trp Gln Asn Tyr Ile Pro Lys Asn
275 280 285

Lys Ser Gln Asn Glu Ser Ser Thr Pro Gln Arg Asn Asn Gly Ala Leu
290 295 300

Tyr Arg Leu Gly Gly Pro Phe Arg Lys Leu Arg Ala Ser Leu Arg Lys
305 310 315 320

Arg Ser

<210> 31
<211> 297
<212> PRT
<213> Photorhabdus

<400> 31

Met Val His Glu Tyr Ser Ile Asn Asp Arg Gln Lys Arg His Ser Phe
1 5 10 15

Ser Ser Ala Asn Pro Ile Asp Pro Glu Val Thr Asn Arg Glu Asn Ser
20 25 30

Arg His Arg Phe Pro Lys Asp Asn Tyr Asn Lys Gly His Gly Asp Leu
35 40 45

Phe Tyr Gly Leu Ala Pro Glu Arg Gly Lys Tyr Ile Lys Glu Ala Asn
50 55 60

Pro Lys Phe Asp Pro Asn Asn Pro Glu Asn Ala Ala Met Ile Ile Asp
65 70 75 80

Val Tyr Asn Asp Glu Ile Ser Arg Val Ile Leu Asn Asn Asn Ala Asn
85 90 95

Lys Ile Ser Thr Asn Arg Leu Leu Asn Phe Ile Tyr Asn Phe Arg Lys
100 105 110

Asn Arg Leu Glu Asn Leu Met Lys Asn Pro Glu Lys Tyr Ala Lys Asp
115 120 125

Ile Lys Val Lys Asp Asn Leu Arg Glu Asn Ile Ser Pro Lys Lys Ile
130 135 140

Glu Lys Tyr Pro Leu Trp Asn Asp Tyr Phe Glu Ala Gly Ile Arg Asn
145 150 155 160

Lys Lys Phe Asn Ile Ala Glu Ile Phe Lys Glu Thr Ala Ser Gln Tyr
165 170 175

Asn Ser Asp Tyr Tyr His Ala Trp His Ile Gly Gly Asn Ser Ala Pro
180 185 190

Arg Leu Leu Trp Lys Arg Gly Ser Lys Leu Gly Ile Glu Ile Ala Ala
195 200 205

Ser Asn Gln Arg Thr Lys Ile His Phe Ile Leu Asp Gly Leu Lys Ile
210 215 220

Glu Asp Val Val Asn Lys Thr Lys Gly Pro Ala Pro Leu Lys Ala Gly
225 230 235 240

Pro Gly Glu Ser Ile Thr Ala Ser Glu Leu Arg Tyr Ala Tyr Arg Asn
245 250 255

Arg Ala Arg Leu Ala Gly Arg Ile His Phe Tyr Glu Asn Gly Lys Glu
260 265 270

Thr Ile Ala Pro Trp Asp Lys Asp Pro Glu Leu Trp Gln Lys Tyr Thr
275 280 285

Pro Lys Asn Arg Ser Gly Met Glu Leu
290 295

<210> 32
<211> 340
<212> PRT
<213> Photorhabdus

<400> 32

Met Leu Lys Tyr Ala Asn Pro Gln Thr Val Ala Thr Gln Arg Thr Lys
1 5 10 15

Asn Thr Ala Lys Lys Pro Pro Ser Ser Thr Ser Phe Asp Gly His Leu
20 25 30

Glu Leu Ser Asn Gly Glu Asn Gln Pro Tyr Glu Gly His Lys Ile Arg
35 40 45

Lys Ile Lys Gly Leu Arg Gln His Leu Ala Asp Arg Ser Leu Asn Lys
50 55 60

Gly His Ile Ser Pro Leu Met Asn Lys Gly Leu Leu Val Gly Ser Lys
65 70 75 80

Asp Val Ser Ile Asp Ile Pro Val Ile Ala His Arg Tyr Asp Ser Ser
85 90 95

His Gln Leu Thr Asp Ala Glu Pro Leu Lys Ala Asp Ser His Ser Asn
100 105 110

His Leu Asp Pro Phe Tyr Gly Val Ile Ala Gly Phe Arg Gly Asp Gln
115 120 125

Val Thr Ser Ser Glu Ser Gly Ser Gly Ser Ile Gly Val His Trp Gly
130 135 140

Lys Asn Thr Leu Asp Ser Asn Ile Met Gly Val Asn Val Val Asn Gly
145 150 155 160

Ala Ser Gly Thr Val Gly Ile Arg Ile Ala Leu Lys Asp Ile Gln His
165 170 175

Gly Ser Pro Val Ile Val Thr Ser Gly Ala Leu Ser Gly Cys Thr Met
180 185 190

Val Tyr Ser Val Lys Asn Gly Tyr Phe Phe Ala Tyr His Thr Gly Gln
195 200 205

Lys Pro Gly Asn Asn Glu Trp Lys Thr Gly Arg Gln Gly Val Val Ala
210 215 220

Thr Tyr Leu Ser His Gln Ala Leu Ser Pro Asp Ser Glu Pro Met Thr

Lys Arg Glu Phe Ile Trp Glu Gly His Met Lys Glu Ile Glu Glu Ala
50 55 60

Ser Arg Leu Gly Asn Phe Ala Val Ser Phe Arg Ala Ala Gly Gly Pro
65 70 75 80

Thr Leu Arg Ala Leu Gly Lys Gly Ala Ala Lys Gly His Asp Ile
85 90 95

Leu Glu Lys Thr Ile Lys Pro Gly Ser Ile Asn Lys Ala Tyr Pro Lys
100 105 110

Asp Glu Ala Ser Asp Val Ile Lys Lys Val Gln Glu Ala Gly Ile Glu
115 120 125

Gly Tyr Val Gly His Trp Asp Lys Lys Thr Gly Arg Leu Leu Gly Ile
130 135 140

Tyr Met Ser Ser Gly His Gly Leu Ser Asp Glu Gln Val Asn Gly Lys
145 150 155 160

Ile Tyr Pro Ile Asp Leu Asn Asn Leu Glu Ala Ser Leu Ser Ala Leu
165 170 175

Lys Ala Lys Glu Asn Trp Ala Ala Leu Pro Phe Thr Gly Asp Tyr Asp
180 185 190

Met His Asp Met Ile Ser Phe Thr Gly Gln Pro His Ser Val Pro Ser
195 200 205

Asn Ser Ser Glu Glu Arg Lys Ile Ile Asp Arg Ile Asn Arg Leu Val
210 215 220

Ala Arg Ser Asp Ser Asn Arg Pro Phe Gly Asp Ile Glu His Asn Val
225 230 235 240

Ile Arg His Gly Ala Gln Val Ser Tyr Pro Ala Phe Ala Met Asp Lys
245 250 255

Glu Lys Glu Glu Ile Lys Lys His Gly Gly Ile Val Lys Ala Val Ala
260 265 270

Glu Pro Gly Glu Phe Pro Val Ala Ile Val Ser Lys Gly Lys Trp Thr
275 280 285

Ile Ala Asn Asn Ile Asp Glu Leu Asn Gln Phe Tyr Asn Ser Ile Gly
290 295 300

Ala Lys Met Lys Val Ser Trp Lys Pro Gly Ala Glu Asn Pro Gly Phe
305 310 315 320

Val Ser Asn Pro Gln Arg Pro Gly Met Ala Arg Phe Ser Arg Lys Arg
325 330 335

<210> 34
<211> 328
<212> PRT
<213> Photorhabdus

<400> 34

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Asn Pro
1 5 10 15

Leu Met Lys Ser Gly Ala Asn Asn Glu His Asp Leu Gln Asp Ser Pro
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Met Leu Val Asn Ser Ser Thr
35 40 45

Ser Leu Ser Gln Ile Gln Asp Tyr Ser Phe Trp Lys Glu Asn Ile Ser
50 55 60

Glu Tyr Tyr Lys Trp Met Val Val Val Glu Ser His Leu Lys Gln Leu
65 70 75 80

Asp Trp Thr Leu Lys Ser Met Asp Ser Pro Glu Ser Ala Gly Thr Asn

85

90

95

Val Ala Lys Asn Met Gly Val Thr Ala Leu Gln Ser Leu Leu Asn Thr
 100 105 110

Gly Ser Ser Ile Ala Gly Gly Ala Ile Gly Gly Ala Ile Gly Ser Ala
 115 120 125

Ile Ala Pro Gly Val Gly Thr Ile Ala Gly Ala Gly Ile Gly Ala Leu
 130 135 140

Ala Gly Thr Gly Leu Asn Tyr Leu Asn Asp Thr Ala Met Ser Lys Leu
 145 150 155 160

Ser Lys Lys Leu Glu Ile Ala His Pro Tyr Pro Lys Thr Arg Asn Met
 165 170 175

Ile Leu Asp Ile Asn Asn Tyr Asp Lys Asn Pro Ile Ile Lys Ala Ile
 180 185 190

Lys Lys Asn Val Asn Lys Asp Asn Leu Lys Val Thr Ala Gly Ser Ser
 195 200 205

Leu Thr Ser Lys Leu Val Gly Thr Val Thr Ser Pro Ile Lys Phe Pro
 210 215 220

Ala Tyr Lys Phe Ala Glu Leu Ala Val Ser His His Arg Ala Leu Glu
 225 230 235 240

Gly Leu Ser Asp Asp Lys Ala Arg His Ile Leu Asp Phe Thr Asn Ser
 245 250 255

Ile Arg Glu Val Leu Lys Glu Ser His Ser Asp Ala Val Ala Phe Met
 260 265 270

Arg Lys Asn Tyr Gly Asp Asn Ala Met Gly Leu Ser Gly Phe Ser Ser
 275 280 285

Lys Ile Lys Arg Glu Lys Leu Thr Leu Asn Thr Leu Ala Lys Thr Lys
290 295 300

Asn Glu Ile Glu Asn Arg Ile Asn Ser Ile Asn Lys Gln Thr Leu Lys
305 310 315 320

Val Ser Ser Arg Ser Arg Asn Glu
325

<210> 35

<211> 324

<212> PRT

<213> Photorhabdus

<400> 35

Met Leu Ser Thr Glu Lys His Asn Lys Asp Thr Lys His Pro Arg Asn
1 5 10 15

Arg Glu Lys Lys Phe Ser Ile Gln Pro Glu Asn Ser Thr Gln Asp Asp
20 25 30

Glu Asp Ile Lys Asn Asn Ser Leu Gly Val Gly Leu Asp Leu Asp Gln
35 40 45

Met Ile Arg Asn Thr Ser Ser Thr Leu Thr Asn Ala Pro Gln Lys Pro
50 55 60

Glu Asp Gly Tyr Tyr Tyr His Ile Ser Arg Gly Asn Asn Leu Gln Ser
65 70 75 80

Phe Leu Gln Asn Gly Phe Lys Pro Gln Gly Ser Pro Gly Pro Thr Leu
85 90 95

Ser Glu Glu Asp Phe Ser Arg Arg Lys Ile Gly Ile Ile Lys Leu Ile
100 105 110

Tyr Ser Ile Ile Ala Thr Thr Ile Asn Lys Asn Arg Lys Ala Lys Lys
115 120 125

Ile Ser Lys Asp Asn Phe Leu Met Pro Gln Glu Phe Trp His Glu Phe
130 135 140

Lys Asn Phe Tyr Gln Asn Ile Pro Thr Gln Thr Asn Ile Asp Asp Gln
145 150 155 160

Leu Leu Lys Lys Ser Ile Thr Glu Ser Ile Asp Lys Leu Asp Gln Asn
165 170 175

Lys Phe Met Glu Lys His Ser Asp Arg Lys Gln Thr Ile Ile Asn Asn
180 185 190

Glu Arg Glu Ala Ile Leu Gln Gln Asp Glu Arg Ile Asn Glu Ile Ile
195 200 205

Ser Ser Arg Ala Lys Met Ile Gln Gln Arg Glu Ala Glu Asn Thr Glu
210 215 220

Gly Tyr Ile Tyr Leu Ala Pro His Lys Asn Thr Leu Leu Glu Tyr Met
225 230 235 240

Lys His Leu Gln Glu Glu Lys Asn Leu Phe Leu Ile Leu Ala Val Lys
245 250 255

Glu Asp Ile Phe Thr Glu Lys Gly Leu Glu Gln Asp Pro Gln Glu Pro
260 265 270

His Gly Ala Val Arg Tyr Lys Gly Ala Leu Ser Thr Glu Glu Leu Asn
275 280 285

Phe Val Asn Gln Glu Gly Gln Ile Cys Ala Ile Pro Ala Ser Ile Gly
290 295 300

Glu Met Asp Tyr Gly Asp Phe Ile Leu Asn Gln Gln Gln Val Ile Asp
305 310 315 320

Phe Cys Lys Lys

<210> 36

<211> 336

<212> PRT

<213> Photorhabdus

<400> 36

Met	Pro	Ile	Asn	Asp	Leu	Lys	Lys	Lys	Phe	Glu	Ile	Ser	Pro	Gln	Ala
1				5					10					15	

Ala	Gln	Ala	Ile	Gly	Ala	Pro	Ala	Arg	Ser	Asn	Ser	Ser	Lys	Gln	Ala
			20					25					30		

Glu	His	Gln	Thr	Glu	His	Leu	Glu	Leu	Asp	Thr	Ser	Lys	Asn	Arg	Arg
		35					40					45			

Asp	Arg	Lys	Asp	Leu	Asn	Ala	Gln	Ala	Thr	Pro	Asn	Gln	Gln	His	Thr
	50					55					60				

Lys	Lys	Leu	Glu	Thr	Glu	Val	Asn	Asn	Gly	Gly	Asn	Lys	Ser	Lys	Ala
65					70					75					80

Gln	Ala	His	Thr	Pro	Asp	Leu	Val	Met	Lys	Lys	Glu	Ser	Ser	Val	Thr
				85					90					95	

Pro	Asn	Thr	Arg	Lys	Ser	Pro	Asn	Glu	Lys	Ile	Lys	Ala	Glu	Asp	Ile
			100					105					110		

Phe	His	Arg	Tyr	Lys	Asp	Arg	Phe	Ser	Pro	Ser	Asp	Arg	Glu	Leu	Pro
		115					120					125			

Phe	Glu	Ile	Met	Asn	Glu	Ile	Thr	Asn	Asn	Gly	Ile	Ala	Phe	Ser	Ser
	130					135					140				

Glu	Lys	Ala	Pro	Glu	Ser	His	Leu	Asp	Lys	Val	Lys	Asp	Lys	Lys	Phe
145					150					155					160

Thr Leu Arg His Tyr Thr Ser Gly Asn Gly Gln Glu Lys Pro Thr Phe
165 170 175

Asn Glu Ile Gly Ser Asn Phe Asn Leu Val Asn Glu Gly Ile Lys Thr
180 185 190

Leu Lys Arg Thr Gln Gly Ser Asn Thr Asn Glu Asp Asp Trp Asn Arg
195 200 205

Leu Gly Asn Thr Ala Phe Thr Phe Phe Leu Leu Ala Ile Asp Gly Glu
210 215 220

Val Ser Asp Arg Lys Phe Leu Ser Asn Thr Thr His Phe Ala Glu Ile
225 230 235 240

Asp Ile Glu Asn Pro Ala Glu Leu Lys Glu Leu Gly Leu Asp Glu Thr
245 250 255

Glu Phe Phe Ala Ser Pro Asp Leu Leu His Glu Lys Asn Leu Ser Gln
260 265 270

Ala Pro Ala Val Lys Gly Lys Leu Ser Asp Leu Lys Ser Leu Leu Leu
275 280 285

Lys Gln Ser Gly Ile Lys Pro Val Gln Leu Gln Ser Leu Gly Ala Lys
290 295 300

Gly Ile Leu Glu Arg Ile Asp Ser Lys Phe Asn Gly Ser Leu Glu Ile
305 310 315 320

Lys Ile Pro Gly Asn Val Lys Val Lys Glu Trp Lys Lys Val Glu Lys
325 330 335

<210> 37
<211> 315
<212> PRT
<213> Photorhabdus

<400> 37

Met Pro Asn Ser Lys Tyr Ser Glu Lys Val Asn His Ser Ala Asn Gly
1 5 10 15

Ala Glu Lys Cys Ser Ile His Ser Asn Gln Tyr Asn Ile Asn Asn Cys
20 25 30

Thr Leu Gly Leu Gly Leu Asp Leu Asn Lys Lys Leu Arg Thr Gly Asn
35 40 45

Glu Arg Asn Ile Glu Gly Ala Gln Pro Phe Ile Pro Phe Pro Ser Lys
50 55 60

Gln Lys Gln Tyr Ser Thr Ser Pro Ile Ala Met Ala Asp Ile Leu Asn
65 70 75 80

Glu Ser Ala Leu Thr Ser Gln Pro Ile Ile Thr Asp Leu Ile Asn Pro
85 90 95

Gln Lys Ile Lys Met Ser Asp Gly Val Lys Asn Ile Leu Asn Asn Lys
100 105 110

Glu Gly Gly Gly Asp Leu Val Phe Lys Ala Leu Gln Ile Lys Pro Ser
115 120 125

Asp Glu Thr Leu Pro Phe Asn Ala Leu Lys Ile Val Asp Thr Tyr Gln
130 135 140

Glu Glu Met Pro Asn Lys Asp Met Ser Ile Ser Ala Tyr Trp Ala Pro
145 150 155 160

Gln Gly Gly Tyr Val Asp Ile Pro Ala Gln Pro Asp Ile Ser Arg His
165 170 175

Pro Gln Tyr Val Phe Thr Pro Asn Phe Ser Gly Cys Ser Phe Val Val
180 185 190

Asp Lys Met Asn Glu Asp Thr Leu Arg Val Arg His Val Gln Gly Gly
195 200 205

Gln Glu Asp Val Glu Tyr Asn Asn Gln Asn Ile Asp His Gly Met Gly
210 215 220

Met Ile Thr Ala Met Glu Phe Arg Asp Tyr Gly Tyr His Glu Ala Asp
225 230 235 240

Asp Lys Val Ile Glu Asn Thr Tyr Gly Phe Ala Phe Leu Lys Phe Asn
245 250 255

Gln Glu Lys Lys Gln Trp Gln Leu His Tyr Gln Lys Ile Ala Ala Ala
260 265 270

Pro Asn Ile Ile Asn Ile Lys Thr Lys Ser Ser Trp Leu Pro Phe Ser
275 280 285

Lys Pro Ser Ile Glu Ala Asp Thr Phe Thr Phe Lys Asn Met Lys Val
290 295 300

Pro Gly Tyr Ser Arg Lys Asn Ile Asn Asn Asn
305 310 315

<210> 38
<211> 309
<212> PRT
<213> Photorhabdus

<400> 38

Met Pro Lys Leu Thr Glu Leu Leu Ser Arg Phe Glu Asn Pro Ile Gln
1 5 10 15

Asn Gln Pro Asn His Ile Ser Lys Lys Asn Pro Ile Ser Asn Ser Lys
20 25 30

Val Leu Asn Asn Ser Glu Glu Lys Thr Ala Pro Leu Glu Leu Lys His
35 40 45

Asp Asp Ser Lys Ile Lys Ser Gln Val Ser Ile Pro Asn Leu Val Lys
50 55 60

Lys Asn Glu Lys Pro Ala Ala Ser Asn Thr Pro Asn Asn Ser His Glu
65 70 75 80

Lys Val Lys Ala Glu Asp Ile Phe Asn Arg Phe Lys Ser Lys Phe Asp
85 90 95

Pro Tyr Asp Arg Glu Leu Pro Phe Asp Ile Met Asn Lys Ile Thr Asn
100 105 110

Asn Glu Ile Lys Phe Ser Ser Glu Lys Ser Lys Asp Asp Tyr Leu Ala
115 120 125

Lys Val Lys Asp Lys Lys Phe Thr Leu Arg His Tyr Thr Ala Gly Thr
130 135 140

Gly Gln Glu Lys Pro Thr Phe Asp Glu Ile Ser Ser Asn Phe Asn Leu
145 150 155 160

Val Asn Lys Gly Ile Lys Thr Leu Asn Arg Thr Gln Gly Ser Asn Thr
165 170 175

Asn Glu Asp Asp Trp Asn Arg Leu Gly Asn Thr Ala Phe Thr Phe Tyr
180 185 190

Leu Leu Ala Ile Asp Gly Glu Val Ser Asn Arg Lys Phe Leu Ser Asn
195 200 205

Thr Thr His Phe Ala Glu Ile Asn Ile Glu Asp Ser Glu Glu Leu Lys
210 215 220

Glu Leu Gly Leu Asp Gln Ala Glu Phe Phe Ala Ser Pro Asp Leu Leu
225 230 235 240

His Glu Lys Asn Leu Ser Gln Ala Pro Ala Val Lys Gly Lys Leu Ser

245

250

255

Asp Leu Lys Ser Leu Leu Leu Lys Arg Ser Gly Ile Ser Ser Val Gln
 260 265 270

Leu Gly Arg Leu Asp Ala Lys Ala Ile Leu Lys Ser Ile Asp Asn Glu
 275 280 285

Phe Gly Asn Ser Leu Glu Ile Lys Ile Pro Gly Asn Val Lys Val Asn
 290 295 300

Lys Trp Asn Lys Ile
 305

<210> 39
 <211> 340
 <212> PRT
 <213> Photorhabdus

<400> 39

Met Pro Arg Tyr Ser Asn Ser Gln Arg Thr Pro Thr Gln Ser Thr Lys
 1 5 10 15

Asn Thr Arg Arg Thr Ser Pro Ser Ser Asn Ser Ser Thr Glu His Leu
 20 25 30

Ser Leu Ser Asn Ala Pro Thr Asn Asp Ser Ser Val Arg Gln Glu Val
 35 40 45

Lys Glu Lys Phe Ile Trp Glu Gly His Trp Glu Gly His Met Glu Ala
 50 55 60

Ile Glu Lys Ala Ser Ile Leu Gly Asn Phe Ala Val Ser Phe Arg Ala
 65 70 75 80

Ala Gly Lys Pro Thr Leu Glu Ala Leu Gly Lys Gly Ala Ala Ala Lys
 85 90 95

Gly His Asp Ile Leu Glu Lys Thr Ile Lys Pro Gly Ser Ile Glu Lys
100 105 110

Ala Tyr Pro Glu Asn Glu Ala Ser Asp Val Ile Lys Lys Val Arg Glu
115 120 125

Ala Gly Ile Glu Gly Tyr Val Gly His Trp Asn Lys Glu Thr Gly Arg
130 135 140

Leu Glu Gly Ile Tyr Met Ser Ser Gly His Gly Leu Pro Asn Gly Gln
145 150 155 160

Val Asn Gly Lys Ile Tyr Pro Ile Asp Leu Asn Asn Leu Glu Ala Ser
165 170 175

Leu Ala Pro Leu Lys Glu Lys Lys Asn Trp Ala Ala Leu Pro Phe Thr
180 185 190

Gly Asp Tyr Asp Met His Asp Met Ile Ser Phe Thr Thr Gln Pro His
195 200 205

Ser Val Pro Ser Asn Ser Ser Glu Glu Lys Lys Ile Ile Asp Arg Ile
210 215 220

Asn Glu Tyr Ile Ala Lys Ser Asp Ser Asn Arg Pro Phe Glu Asp Ile
225 230 235 240

Glu His Asn Val Ile Arg His Gly Pro Gln Val Ser Tyr Pro Ala Phe
245 250 255

Ala Met Asp Lys Glu Lys Lys Glu Ile Lys Glu Arg Gly Gly Ile Val
260 265 270

Lys Ala Val Ala Glu Pro Gly Glu Phe Pro Val Ala Ile Val Ser Lys
275 280 285

Gly Lys Trp Thr Ile Ala Asn Asn Ile Asn Glu Leu Glu Gln Phe Tyr
290 295 300

Asn Ser Ile Gly Ala Lys Met Lys Ala Ser Trp Lys Pro Gly Ala Gly
305 310 315 320

Asn Pro Gly Phe Val Ser Asn Pro Gln Lys Pro Gly Met Ala Arg Phe
325 330 335

Ser Arg Lys Lys
340

<210> 40
<211> 280
<212> PRT
<213> Photorhabdus

<400> 40

Met Phe Ser Thr Tyr Ser Ser Lys Asn Asp Asn Gln Thr Ile Asn Lys
1 5 10 15

Ile Asn Thr Glu Glu Lys His Glu Asn Thr Glu Thr Asp Asn His Leu
20 25 30

Glu Ile Asn Leu Glu His Thr Gly Lys Ser Lys Pro Asp Ile Glu Pro
35 40 45

Lys Asp Val Thr Thr Gly Thr Ile Asn Ala Gly Thr Leu Leu Tyr Lys
50 55 60

Thr Thr Ala Ile Pro Glu Phe Leu Asp Asn Ala Lys Ser Leu Gly Leu
65 70 75 80

Ala Glu Tyr Glu Lys Arg His Lys Asp Ile Gln Asp Tyr Leu Asn Leu
85 90 95

Gly Lys Ala Glu Asp Ala Glu Lys Leu Lys Asn Lys Ser Gln Trp Ala
100 105 110

Gly Gln Tyr Phe Ala Leu Glu Lys Ser Tyr Asp Glu Tyr Ala Asn Glu

115

120

125

Ala Pro Asp Ser Tyr Asn Asn Leu Leu Lys Asn Ala Gly Lys Asp Leu
 130 135 140

Leu Glu Asn Thr Glu Glu Val Lys Val Phe Leu Tyr Thr Phe Lys Val
 145 150 155 160

Thr Lys Asp Ile Lys Val Leu Lys Pro His Asn Asn Ser Asn Ser Tyr
 165 170 175

Tyr Val Gly Asp Thr Glu Gly Trp Glu Lys Ala Lys Glu Ile Met Asn
 180 185 190

Asp Val Gln Ser Gln Ser Glu Lys Asn Asp Asn Pro Phe Pro Glu Leu
 195 200 205

Lys Asn Leu Glu Asp Lys Asn Phe Leu Leu Glu Glu Leu Gly Glu Lys
 210 215 220

Gly Tyr Ala Trp Met Gly Pro Leu His Ala Lys Glu Gly Ala Glu Lys
 225 230 235 240

Gly Thr Glu Phe Ser Tyr Glu Leu Ala Ile Ser Pro Asn Leu Leu Arg
 245 250 255

Gln His Leu Thr Leu Glu Ser Glu Glu Leu Leu Gly Thr Tyr Lys Asn
 260 265 270

Arg Tyr Gly Tyr Trp Asp Lys Lys
 275 280

<210> 41

<211> 138

<212> PRT

<213> Photorhabdus

<400> 41

Met Lys Lys Thr Asp Glu Lys Tyr Gly Gln Tyr Glu Tyr Lys Asp Glu
1 5 10 15

Asp Ile Thr Ser Tyr Pro Ile Ala Trp Thr Asn Pro Asp Asn Gly Lys
20 25 30

Ile Tyr Ile Gly Ile Asn Ser Pro Glu Tyr Ser His Leu Asn Asn Lys
35 40 45

Gly Glu Ser Glu Leu Asn Leu Ala Lys Ile Ile Ser Thr Ile Ile His
50 55 60

Glu Ser Leu His Ala Ser Ser His Gln His Lys Gly Leu Gln Ser Gln
65 70 75 80

Thr Asp Thr Gly Ala Asp Asn Leu Asn Tyr Asp Glu Tyr Val Thr Asp
85 90 95

Tyr Phe Ala Arg Glu Val Tyr Lys Gln Ile Leu Pro Asp Lys Asp Tyr
100 105 110

Val Ala Asn Cys Phe Thr Lys Gly Leu Gly Gly Glu Asn Lys Ile Trp
115 120 125

Gly Gly Asn Ile Val Glu Phe Met Ile Gln
130 135

<210> 42

<211> 539

<212> PRT

<213> Photorhabdus

<400> 42

Met Val Tyr Glu Tyr Asp Lys Thr Ile Glu Arg Arg Arg Asn Pro Ser
1 5 10 15

Ile Gln Leu Asn Asn Asn Glu Lys Ser Ser Glu Gln Ala Leu Glu Leu
20 25 30

Ser Gln Asn Asn Pro Leu Leu His Asp Leu Ile Thr Ser Asn Asn Leu
35 40 45

Arg Lys Glu Ala Ala Val Phe Ala Lys Arg Ile Gly Pro Ser Tyr Gln
50 55 60

Glu Ile Leu Asp Glu Leu Glu His Leu His His Leu Ser Gly Asn Glu
65 70 75 80

Gln Leu Ala Ala Gly Phe Glu Leu His Arg Arg Ile Thr His Tyr Leu
85 90 95

Glu Glu His Pro Asp Ser Lys Arg Asn Thr Ala Leu Arg Arg Thr Gln
100 105 110

Thr Gln Phe Gly Asp Leu Met Phe Thr Gly Thr Leu Gln Lys Ile Arg
115 120 125

His Ser Leu Leu Glu Met Ala Glu Thr Arg Pro Glu Met Ala Ser His
130 135 140

Ile Tyr Gln Ile Ala Arg Glu Glu Val Lys Gly Asn Thr Pro Gly Leu
145 150 155 160

Thr Asp Leu Met Val Arg Trp Val Lys Glu Asp Pro Tyr Leu Ala Ala
165 170 175

Lys Thr Gly Tyr Gln Gly Lys Ile Pro Asn Asp Leu Pro Phe Glu Pro
180 185 190

Lys Phe His Val Glu Leu Gly Ala Gln Phe Asp Asp Phe Lys Lys Trp
195 200 205

Leu Asp Thr Ala Gln Ser Lys Glu Leu Leu Thr His Thr Arg Leu Asp
210 215 220

Glu Gln Asn Lys Gln Val His Leu Gly Tyr Ser Tyr Asn Glu Leu Leu

225		230		235		240
Asp Met Thr Gly Val Glu Ser Val Gln Met Ala Val Tyr Phe Leu Lys						
	245			250		255
Glu Ala Ala Lys Gln Ala Glu Pro Gly Ser Thr Lys Ser Gln Glu Asp						
	260			265		270
Ile Leu Leu His Arg Phe Ala Asn Pro Thr Tyr Leu Ala Gln Leu Glu						
	275			280		285
His Ser Arg Leu Ala Gln Ile Glu Ala Ile Tyr His Ser Ser His Asp						
	290			295		300
Thr Asp Val Thr Ala Trp Asp Gln Gln Phe Ala Ser Asp Ala Leu Thr						
305		310		315		320
Gln Phe Asn His Gln Leu Asn Asn Thr Val Asp Leu Asn Ser Gln Leu						
	325			330		335
Ser Leu Leu Leu Lys Asp Arg Gln Gly Leu Leu Ile Gly Glu Ser His						
	340			345		350
Gly Ser Asp Leu Asn Gly Leu Arg Phe Val Glu Glu Gln Met Glu Val						
	355			360		365
Leu Lys Ala His Gly Val Thr Val Ile Gly Leu Glu His Leu Arg Ser						
	370			375		380
Asp Leu Ala Gln Pro Leu Ile Asp Lys Phe Leu Ala Ser Gly Asn Glu						
385		390		395		400
Pro Met Pro Ala Glu Leu Ala Ala Leu Leu Lys Thr Lys His Leu Ser						
	405			410		415
Ala Asn Leu Phe Glu Gln Ala Arg Ser Lys Gln Met Lys Ile Ile Ala						
	420			425		430

Leu Asp Asn Asn Ser Thr Thr Arg Pro Thr Val Glu Gly Thr Gln His
435 440 445

Gly Leu Met Tyr Arg Ala Gly Ala Ala Asn Asn Val Ala Val Glu Arg
450 455 460

Leu Arg Gln Leu Pro Ala Gly Glu Lys Phe Val Ala Ile Tyr Gly Asn
465 470 475 480

Ala His Leu Gln Ser His Glu Gly Ile Asp His Phe Leu Pro Gly Ile
485 490 495

Thr His Arg Leu Gly Leu Pro Ala Leu Lys Val Asp Glu Asn Asn Arg
500 505 510

Phe Thr Ala Gln Val Asp Asn Ile Asn Gln Arg Lys Arg Tyr Asp Asp
515 520 525

Val Val Glu Leu Pro Arg Ile Gln Leu Thr Ser
530 535

<210> 43
<211> 323
<212> PRT
<213> Photorhabdus

<400> 43

Met Glu His Glu Tyr Ser Glu Lys Glu Lys Pro Gln Lys Cys Pro Ile
1 5 10 15

Gln Leu Arg Asp Ser Ile Glu His Asp Lys Glu Asp Ile Asn Thr Thr
20 25 30

Thr Pro Leu Glu Leu Asn Ser Gln Tyr Thr Asn Arg Lys Arg Ala Gly
35 40 45

Leu Arg Glu Arg Phe Ser Thr Thr Leu Gln Arg Asn Leu Pro Gly His
50 55 60

Ser Met Leu Asp Arg Glu Leu Thr Thr Asp Gly Met Lys Asn Gln Glu
65 70 75 80

Ser Arg Phe Ser Pro Ala Met Ile Met Asp Arg Met Met His Phe Gly
85 90 95

Val Arg Thr Arg Leu Gly Lys Val Arg Asn Ser Ala Ser Lys His Gly
100 105 110

Gly Gln Val Thr Phe Lys Phe Ala Gln Thr Lys Gly Thr Phe Leu Asp
115 120 125

Gln Ile Met Lys His Lys Asp Thr Ser Gly Gly Val Cys Glu Ser Ile
130 135 140

Ser Ala His Trp Ile Ser Ala His Ala Lys Gly Glu Ser Ile Phe Asp
145 150 155 160

Gln Leu Tyr Val Gly Gly Gln Lys Gly Lys Phe His Ile Asp Ser Leu
165 170 175

Val Ser Ile Lys Gln Leu Gln Met Asp Ser Tyr Leu Asp Asp Glu Gln
180 185 190

Ser Thr Met Thr Glu Tyr Trp Leu Gly Thr Gln Gly Ile Gln Pro Ile
195 200 205

Met Gln Lys Asn Asp Val Asp Glu His Ser Ser Lys Val Val Gly Gln
210 215 220

Thr Gly Asn Lys Gly Thr Thr Asp Leu Leu Arg Ala Ile Leu Asp Thr
225 230 235 240

Gly Asp Lys Gly Ser Gly Tyr Lys Lys Ile Ser Phe Leu Gly Lys Met
245 250 255

Ala Gly His Thr Val Ala Ala Tyr Val Asp Asp Gln Lys Gly Val Ile
260 265 270

Phe Phe Asp Pro Asn Phe Gly Glu Phe Ser Phe Pro Ser Ile Thr Ser
275 280 285

Phe Ser Arg Trp Phe Thr Asp Asp Phe Trp Pro Lys Ser Trp Tyr Asn
290 295 300

Leu Glu Ile Gly Leu Gly Gln Gln Phe Glu Val Phe Asn Tyr Glu Leu
305 310 315 320

Lys Lys Ser

<210> 44
<211> 381
<212> PRT
<213> Photorhabdus

<400> 44

Met Tyr Asp Ser Lys Lys Lys Asn Ser Glu Pro Thr Thr Lys Lys Lys
1 5 10 15

Phe Glu Arg Ser Asn Tyr Ser Gln Trp Asp Asp Ser Ile Asn His Tyr
20 25 30

Glu Asp Met Asn Arg Ala Arg Ile Lys Asn Arg Asn Asp Ile Leu Thr
35 40 45

Thr Val Asp Tyr Phe Gly Glu Lys Lys Lys Thr Met His Thr Phe Glu
50 55 60

Tyr Gln Ser Asp Ile Lys His Asp Thr Asn Phe Asn Asn Lys Asn Lys
65 70 75 80

Ser Leu Phe Glu Ser Phe Ala Ala Ser Phe Val Leu Gln Asn Pro Ser
85 90 95

Phe Phe Ser Gly Val Ile Asp Lys Leu Ser Lys Lys Leu Phe Asn Ile
100 105 110

Ile Ser Lys Ile Asp Glu Arg Asn Asn Phe Gln Lys Lys Leu Tyr Asp
115 120 125

Phe Ile Glu Lys Asp Thr Ser Pro Glu Gly Gln Phe Gly Arg Phe Thr
130 135 140

Leu Gly Lys Asn Glu Ile Leu Asn Val Leu Gln Val Lys Ser Asp Thr
145 150 155 160

Pro Gln Leu Phe Val Lys Lys Met Leu Leu Ile Lys Ser Leu Gly Ala
165 170 175

Phe Ile Ile Asp Phe Ser Ser Lys Asp Ile Gly Asn Tyr Asp Phe Ile
180 185 190

Phe Asp Gly Lys Gly Arg Glu Val Asn Asp Ile Ile Glu Lys Asn Arg
195 200 205

Pro Thr Asn Leu Phe Lys Val Arg Gly Arg Thr Asn Ile Lys Ser Ser
210 215 220

Gln His Arg Ser Asp Ile Gly Ile Leu Asp Thr Pro Thr Phe Asp Ser
225 230 235 240

Leu Thr Glu Glu Gln Lys Ser Phe Leu Thr Ile Pro Glu Leu Thr Lys
245 250 255

Arg Arg Pro Leu Phe Arg Thr Phe Thr His Glu Leu Asp Ala Glu Asp
260 265 270

Lys Arg Val Val Glu Ser Val Phe Val Asn Arg Thr Phe Asp Cys Asp
275 280 285

Ser Pro Leu Ile Gly Ser Val Ser Gly Ser Thr Ser Cys Val Leu Val

290

295

300

Ala Ala Asp Ile Leu Phe Pro Asp Met Thr Met Val Glu Arg Lys Lys
 305 310 315 320

Leu Ala Ile Ala Thr Phe Ala Phe Leu Val Gly Gly Gly Tyr His Ser
 325 330 335

Ala Thr Glu Val Phe Asp Val Ala Tyr Pro Gly Leu Asp Leu Asn Lys
 340 345 350

Glu Ile Glu Glu Leu Ile Glu Asn Asn Pro Ile Gln Glu Asn Ala Gly
 355 360 365

Val Ala Thr Leu Arg Gln Leu Ile Gly Asn Ser Gly Phe
 370 375 380

<210> 45
 <211> 308
 <212> PRT
 <213> Photorhabdus

<400> 45

Met Pro Ile Ser Asn Leu Ala Lys Glu Ser Glu Val Arg Ala Val Lys
 1 5 10 15

Asp Ile Pro Cys Lys Asn Ile Glu Thr Asp Asn His Leu Glu Ile Gly
 20 25 30

Leu Ser Ser Gly Leu Ser Arg Ser Lys Asp Thr Ser Lys Phe Lys Lys
 35 40 45

Asn Ser Ile Asn Thr Ile Lys Leu Ile Asp Asp Ile Ile Ala Leu His
 50 55 60

Asn Asp Pro Lys Gly Asn Lys Leu Leu Trp Asn Asp Asn Trp Gln Asp
 65 70 75 80

Lys Ile Ile Asn Arg Asp Leu Ala Asn Ile Phe Glu Lys Ile Asp Glu
85 90 95

Ser Val Ser Glu Leu Gly Gly Leu Glu Met Tyr Gln Glu Met Val Gly
100 105 110

Val Asn Pro Tyr Asp Pro Thr Glu Pro Val Cys Gly Leu Ser Ala Gln
115 120 125

Asn Ile Phe Lys Leu Met Thr Glu Gly Glu His Ala Val Asp Pro Val
130 135 140

Glu Met Ala Gln Thr Gly Lys Ile Asp Gly Asn Glu Phe Ala Glu Ser
145 150 155 160

Val Asp Gln Leu Ser Ser Ala Lys Asn Tyr Val Ala Leu Val Asn Asp
165 170 175

Arg Arg Leu Gly His Met Phe Leu Ile Asp Ile Pro Ser Asn Asp Gln
180 185 190

Glu Thr Val Gly Tyr Ile Tyr Gln Ser Asp Leu Gly Gln Gly Ala Leu
195 200 205

Pro Pro Leu Lys Ile Ala Asp Trp Leu Asn Ser Arg Gly Lys Asp Ala
210 215 220

Val Ser Leu Asn Lys Leu Lys Lys Leu Leu Ser Arg Glu Phe Asn Leu
225 230 235 240

Leu Ser Asp Asp Glu Lys Arg Ala Leu Ile Ser Glu Thr Leu Asp Ile
245 250 255

His Lys Asp Val Ser Asn Val Glu Leu Asp Arg Ile Lys Arg Asp Arg
260 265 270

Gly Val Asp Ile Tyr Leu Thr Glu Tyr Asp Val Asn Asn Phe Tyr Glu
275 280 285

Asn Ile Glu Thr Leu Lys Ser Lys Leu Ser Asn Tyr Asp Lys Lys Leu
290 295 300

Ser Lys Pro Lys
305

<210> 46
<211> 295
<212> PRT
<213> Photorhabdus

<400> 46

Met Leu Ala Asn Val Leu Pro Asn Leu Ala Ser Phe Leu Lys Tyr Glu
1 5 10 15

Lys Glu Thr Pro Leu Phe Phe Ile Glu Asp Gly Phe Asn Phe Gln Asn
20 25 30

Leu Asn Pro Gly Arg Val Pro Leu Ile Lys Thr Pro Glu Gln Arg Lys
35 40 45

Ala Gly Asp Thr Gln Ser Pro Ala Phe Leu Cys Ser Gly Val Ile Leu
50 55 60

Arg Gly Thr Ile His Ser Asn Asp Tyr Lys Phe Trp Gln Pro Ser Pro
65 70 75 80

Ser Ser Ile Lys Ser Gly Gly Val Ser Phe Ser Tyr Leu Arg Lys Asp
85 90 95

Ala Lys Phe Lys Arg Leu Ala Tyr Gly Tyr Lys Asn Gly Phe Ile Ile
100 105 110

Phe Pro Glu His Ile Ala Pro Glu Asp Arg Val Asp Phe Ser Val Leu
115 120 125

Cys Ala Phe Pro Ile Asp Gly Tyr Thr Asn Glu Arg Ala Asn Gln Gly

130

135

140

Cys Gly Glu Asn Ile Thr Lys Ala Lys Asp Lys Gly Lys Ser Cys Gln
 145 150 155 160

Glu Gln Asn Val Thr Asn Ser Asp Asp Trp Ile Lys Asn Tyr Arg Lys
 165 170 175

Val Asn Ser Gln Asp Phe Phe Gln Cys Gly Phe Asn Val Thr Lys Asp
 180 185 190

Val Asn Asn Pro Ala Ile Ala Phe Tyr Gln Met Leu Glu Ser Ile Lys
 195 200 205

Lys Leu Pro Arg Thr Pro Asn Thr Pro Pro Lys Gln Asn Glu Ile Arg
 210 215 220

Ile Ser Thr Trp Glu Glu Ser Asp Pro Asn Lys Leu Pro Ile Glu Ala
 225 230 235 240

Leu Phe Tyr Ser Glu Asn Ser Gly Leu Ala Asp Ala Gln Lys Asp Gln
 245 250 255

Arg Asp Tyr Lys Asn Ala Thr Gly Lys Phe Leu Pro Ile Val Lys Met
 260 265 270

Leu Leu Pro Arg Thr Leu Asn Glu Asp Ala Leu Phe Lys Phe Asn Ile
 275 280 285

Lys Asp Gln Val Ile Asn Pro
 290 295

<210> 47

<211> 50

<212> PRT

<213> Photorhabdus

<400> 47

Met Met Arg Glu Tyr Ser Asn Glu Asp Asp Phe Ile Lys Glu Lys Thr
1 5 10 15

Asn Leu Val Lys Ser Glu Asn Val Glu Ala Asp Asn Tyr Leu Glu Thr
20 25 30

Glu Tyr Leu Thr Tyr Leu Ala Lys Leu Ile Gly Met Thr Glu Arg Glu
35 40 45

Asn His
50

<210> 48
<211> 50
<212> PRT
<213> Photorhabdus

<400> 48

Met Phe Gln Asn Arg Ile Arg Asn Glu Lys Thr Thr Gln Ser Gly Lys
1 5 10 15

Gly Lys Thr Leu Asp Arg Met Thr Asp Ser Leu Tyr Leu Glu Ile Pro
20 25 30

Asn Val Glu Ala Val Thr Leu Ala Tyr Gln Lys Leu Thr Ser Lys Tyr
35 40 45

Arg Lys
50

<210> 49
<211> 50
<212> PRT
<213> Photorhabdus

<400> 49

Met Glu Arg Glu Tyr Ser Glu Lys Gln Lys Asn Pro Ser Lys Leu Ser
1 5 10 15

Arg Lys Thr Ala Ile Ser Glu Arg Ile Ala Ala Leu Glu Arg Ser Gly
20 25 30

Leu Ser Asn Ser Asn Gln Pro Val Pro Gln Phe Ala Arg Pro Tyr Thr
35 40 45

Ser Asn
50

<210> 50
<211> 50
<212> PRT
<213> Photorhabdus

<400> 50

Met Ser Asn Tyr Glu Tyr Asp Ile Val Thr Gln His Asp Thr Tyr Gln
1 5 10 15

Ile Lys Asp Asn Glu Tyr Thr Val Val Asn Gly Lys Tyr Trp Gln Tyr
20 25 30

Glu Gln Glu Gly Asn Lys Asn Asn Asn Lys Val Ser Ile Ser Leu Met
35 40 45

Lys Glu
50

<210> 51
<211> 50
<212> PRT
<213> Photorhabdus

<400> 51

Met Glu His Glu Tyr Asn Glu Lys Glu Lys Gln Arg Asn Ser Ala Ile
1 5 10 15

Lys Leu Asn Asp Ala Ile Arg Asn Asn Glu Glu Asn Met Asp Met Thr
20 25 30

Ser Pro Leu Glu Leu Asn Phe Gln Asn Thr Asn Arg Lys Ser Arg Gly
35 40 45

Leu Arg
50

<210> 52
<211> 50
<212> PRT
<213> Photorhabdus

<400> 52

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Lys Pro
1 5 10 15

Leu Met Lys Ser Glu Ala Asn Asn Glu His Asp Ile Gln Asn Ser Ser
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Met Met Gly Asn Ser Ser Thr
35 40 45

Ser Leu
50

<210> 53
<211> 50
<212> PRT
<213> Photorhabdus

<400> 53

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys Arg Pro Ile
1 5 10 15

Gln Leu Arg Asn Ser Ile Glu Gln His Glu Glu Glu Thr Ala Asn Asn
20 25 30

Ser Leu Gly Leu Gly Leu Asp Leu Asn Gln Ala Thr Asn Pro Pro Lys
35 40 45

Val Pro
50

<210> 54
<211> 50
<212> PRT
<213> Photorhabdus

<400> 54

Met Met Glu His Glu Tyr Ser Lys Glu Glu Glu Lys Lys Arg Gln Gln
1 5 10 15

Ser Lys Pro Asn Asn Ala Thr His Asp Glu Ser Asn Leu Pro Leu Glu
20 25 30

Leu Glu Lys His Phe Asn Ala Arg Thr Pro Ala Thr Ala His Ser Lys
35 40 45

Trp Phe
50

<210> 55
<211> 50
<212> PRT
<213> Photorhabdus

<400> 55

Met Leu Lys Tyr Ala Asn Pro Gln Ala Val Pro Thr Gln Arg Thr Lys
1 5 10 15

Asn Thr Ala Lys Lys Pro Ser Ser Ser Ser Ser Phe Asp Gly Gln Leu
20 25 30

Glu Leu Ser Asn Gly Glu Trp Ser Lys His Ser Glu Met Gly Leu Lys
35 40 45

Arg Gly
50

<210> 56
<211> 50
<212> PRT
<213> Photorhabdus

<400> 56

Met Met Arg Glu Tyr Ser Asn Glu Asp Asp Cys Thr Lys Glu Lys Thr
1 5 10 15

Asn Leu Val Lys Ser Glu Asn Val Glu Ala Asp Asn Tyr Leu Glu Met
20 25 30

Glu His Leu Thr Tyr Leu Ala Lys Leu Ile Ser Met Thr Glu Arg Glu
35 40 45

Asn His
50

<210> 57
<211> 50
<212> PRT
<213> Photorhabdus

<400> 57

Met Ile Phe Lys Met Leu Asn Leu Ala Val Phe Tyr Leu Leu Gly Asn
1 5 10 15

Ile Phe His Tyr Leu Ile Cys Gln Lys Phe Ile Cys Tyr Phe Cys Ser
20 25 30

Val Leu Lys Ser Val Thr Met Phe Leu Thr Lys Val Ala Val Gln Ile
35 40 45

Ala Leu
50

<210> 58
<211> 50
<212> PRT
<213> Photorhabdus

<400> 58

Met Glu Arg Glu Tyr Ser Glu Lys Pro Lys Asn Leu Ser Gln Leu Ser
1 5 10 15

Arg Lys Thr Ala Ile Ser Glu Arg Arg Ala Met Phe Glu Arg Asn Ala
20 25 30

Ser Ser Asn Asn Glu Gln Pro Val Pro Gln Phe Ala Arg Ser Tyr Thr
35 40 45

Ser Asn
50

<210> 59

<211> 50

<212> PRT

<213> Photorhabdus

<400> 59

Met Lys Tyr Asp Pro Arg Leu Arg Thr Trp Val Glu Asp Asp Phe Asp
1 5 10 15

Tyr Glu Lys Asn Phe Lys Lys Gln Thr Asp Tyr Ile Asn Tyr Lys Asp
20 25 30

Leu Glu Lys Gln Leu Lys Glu Asn Val Asp Tyr Tyr Ala Leu Leu Asp
35 40 45

Glu Asn
50

<210> 60

<211> 50

<212> PRT

<213> Photorhabdus

<400> 60

Met Pro Asn Lys Lys His Ser Glu Asn Thr His Gln Gly Arg Lys Pro

1	5	10	15
Leu Ile Lys Ser Glu Ala Asn Asn Glu His Asp Ile Glu Asn Ser Ser	20	25	30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Thr Ile Gly Asn Asn Ser Ala	35	40	45
---	----	----	----

Ser Leu
50

<210> 61
 <211> 50
 <212> PRT
 <213> Photorhabdus

<400> 61

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys Arg Pro Ile	1	5	10	15
---	---	---	----	----

Gln Leu Arg Asn Ser Ile Glu Gln His Glu Glu Glu Thr Ala Asn Asn	20	25	30
---	----	----	----

Ser Leu Gly Leu Gly Leu Asp Leu Asn Gln Ala Thr Asn Pro Pro Lys	35	40	45
---	----	----	----

Val Pro
50

<210> 62
 <211> 50
 <212> PRT
 <213> Photorhabdus

<400> 62

Met Met Glu His Glu Tyr Ser Lys Glu Glu Glu Lys Lys Arg Gln Gln	1	5	10	15
---	---	---	----	----

Ser Lys Pro Asn Asn Ala Thr His Asp Glu Ser Asn Leu Pro Leu Glu

20

25

30

Leu Glu Lys His Ser Asn Ala Arg Thr Ser Ala Thr Ala Tyr Ser Lys
 35 40 45

Trp Phe
 50

<210> 63
 <211> 50
 <212> PRT
 <213> Photorhabdus

<400> 63

Met Ser Asn Tyr Glu Tyr Asp Ile Val Thr Gln His Asp Thr Tyr Gln
 1 5 10 15

Ile Lys Asp Asn Glu Tyr Thr Val Val Asn Gly Lys Tyr Trp Gln Tyr
 20 25 30

Glu Gln Glu Gly Asn Lys Asn Asn Asn Lys Ile Ser Ile Ser Leu Met
 35 40 45

Lys Asp
 50

<210> 64
 <211> 50
 <212> PRT
 <213> Photorhabdus

<400> 64

Met Glu His Glu Tyr Asn Glu Lys Glu Lys Gln Arg Asn Ser Ala Ile
 1 5 10 15

Lys Leu Asn Asp Ala Ile Arg Asn Asn Glu Glu Asn Met Asp Met Thr
 20 25 30

Ser Pro Leu Glu Leu Asn Ser Gln Asn Thr Asn Arg Lys Ser Arg Gly

35

40

45

Leu Arg
50

<210> 65

<211> 50

<212> PRT

<213> Photorhabdus

<400> 65

Met Phe Lys Tyr Asp Thr Ser Glu Lys Met Ala Lys Phe Gly Lys Gly
1 5 10 15

Lys Thr Ser Asp Gly Met Leu Leu Asp Thr Leu Tyr Leu Glu Ile Pro
20 25 30

Asp Glu Lys Ala Val Met Ser Ala Tyr Lys Ser Gln Ile Leu Asp Glu
35 40 45

Leu Arg
50

<210> 66

<211> 50

<212> PRT

<213> Photorhabdus

<400> 66

Met Leu Lys His Ala Asn Pro Gln Thr Val Ser Thr Gln Arg Thr Lys
1 5 10 15

Ser Thr Ala Lys Lys Pro Ser Ser Ser Ser Phe Asp Arg Gln Phe
20 25 30

Glu Leu Ser Asn Ser Glu Asn Gln Pro Gly Glu Gly Asn Lys Asp Trp
35 40 45

Thr Ile

50

<210> 67
<211> 50
<212> PRT
<213> Photorhabdus

<400> 67

Met Pro Arg Tyr Ala Asn Tyr Gln Ile Asn Pro Lys Gln Asn Thr Lys
1 5 10 15

Asn Ser His Gly Lys Ser Ser Ser Ser Asn Phe Ser Ser Gly Tyr Phe
20 25 30

Ser Ser Ser Asn Asn Ser Leu Asp Asp Ser Leu Ile Arg Gln Gln Val
35 40 45

Lys Arg
50

<210> 68
<211> 50
<212> PRT
<213> Photorhabdus

<400> 68

Met Arg Glu Tyr Ser Lys Glu Asp Asp Cys Val Lys Glu Lys Thr Asn
1 5 10 15

Leu Ala Glu Ser Glu Asn Val Glu Ala Asp Asn Tyr Leu Glu Met Asp
20 25 30

Cys Leu Asn Tyr Leu Ala Lys Leu Asn Gly Met Pro Glu Arg Lys Asp
35 40 45

His Ser
50

<210> 69

<211> 50
<212> PRT
<213> Photorhabdus

<400> 69

Met Pro Ile Ile Gly His Lys Glu Asp Leu Ile Arg Thr Glu Arg Ser
1 5 10 15

Ser Val Asp Leu Thr Arg Ser Ser Asn Asn Arg Gln Thr Asp Asn Leu
20 25 30

Glu Leu Asn Ile Pro Gln His Lys Arg Asp Asn Lys Asp Ile Glu His
35 40 45

Ala Val
50

<210> 70
<211> 50
<212> PRT
<213> Photorhabdus

<400> 70

Met Ile Ser Thr Phe Asp Pro Ala Ile Cys Ala Gly Thr Pro Thr Val
1 5 10 15

Thr Val Leu Asp Asn Arg Asn Leu Thr Val Arg Glu Ile Val Phe His
20 25 30

Arg Ala Lys Ala Gly Gly Asp Thr Asp Thr Leu Ile Thr Arg His Gln
35 40 45

Tyr Asp
50

<210> 71
<211> 50
<212> PRT
<213> Photorhabdus

<400> 71

Met Glu Arg Glu Tyr Asn Lys Lys Glu Lys Gln Lys Lys Ser Ala Ile
1 5 10 15

Lys Leu Asp Asp Ala Val Gly Asn Asn Glu Glu Asn Met Asp Met Thr
20 25 30

Ser Pro Leu Glu Leu Asn Ser Gln Tyr Thr Asn Arg Lys Arg Pro Gly
35 40 45

Leu Arg
50

<210> 72

<211> 50

<212> PRT

<213> Photorhabdus

<400> 72

Met Val Tyr Glu Tyr Ala Lys Thr Asn Asp Arg Lys Arg Lys Leu Ser
1 5 10 15

Thr Gln Ser Asp Asn Tyr Glu Glu Lys Ser Phe Ser Pro Val Leu Asp
20 25 30

Leu Ser Arg Asn Asn Gln Asn Thr Pro Asn Met Glu Asp Glu Tyr Glu
35 40 45

Thr Pro
50

<210> 73

<211> 50

<212> PRT

<213> Photorhabdus

<400> 73

Met Val Phe Glu His Asp Lys Thr Val Glu Arg Lys Arg Lys Pro Ser
1 5 10 15

Ile Gln Leu Gly Asn Asp Lys Glu Lys Ser Ser Glu Gln Ala Leu Glu
20 25 30

Leu Pro Gln Ser Lys Gln Asn Asn Pro Leu Leu His Asp Leu Ile Thr
35 40 45

Ser Asn
50

<210> 74
<211> 50
<212> PRT
<213> Photorhabdus

<400> 74

Met Lys Gly Ile Glu Gly Val Ile Met Leu Ser His Asp Ile Leu Pro
1 5 10 15

Glu Lys Leu Leu Val Ser Glu Lys Lys His Glu Asn Val Gly Ser Tyr
20 25 30

Phe Ser Asp Asp Ile Gly Glu Gln Ser Glu Gln Thr Glu Val Ser His
35 40 45

Phe Asn
50

<210> 75
<211> 50
<212> PRT
<213> Photorhabdus

<400> 75

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Lys Pro
1 5 10 15

Leu Ile Lys Ser Glu Ala Asn Asn Glu His Ala Ile Asp Asn Ser Pro
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Ile Leu Gly Asn Asn Ser Ala
35 40 45

Ser Leu
50

<210> 76
<211> 50
<212> PRT
<213> Photorhabdus

<400> 76

Met Glu Arg Glu Tyr Ser Glu Lys Glu Lys His Lys Lys His Pro Ile
1 5 10 15

Gln Leu Arg Asp Ala Ile Glu Gln His Ala Glu Glu Thr Ala Asn Asn
20 25 30

Ser Leu Gly Leu Gly Leu Asp Leu His Gln Ala Ile Asn Thr Pro Lys
35 40 45

Val Pro
50

<210> 77
<211> 50
<212> PRT
<213> Photorhabdus

<400> 77

Met Val His Glu Tyr Ser Ile Asn Asp Arg Gln Lys Arg His Ser Phe
1 5 10 15

Ser Ser Ala Asn Pro Ile Asp Pro Glu Val Thr Asn Arg Glu Asn Ser
20 25 30

Arg His Arg Phe Pro Lys Asp Asn Tyr Asn Lys Gly His Gly Asp Leu
35 40 45

Phe Tyr
50

<210> 78
<211> 50
<212> PRT
<213> Photorhabdus

<400> 78

Met Leu Lys Tyr Ala Asn Pro Gln Thr Val Ala Thr Gln Arg Thr Lys
1 5 10 15

Asn Thr Ala Lys Lys Pro Pro Ser Ser Thr Ser Phe Asp Gly His Leu
20 25 30

Glu Leu Ser Asn Gly Glu Asn Gln Pro Tyr Glu Gly His Lys Ile Arg
35 40 45

Lys Ile
50

<210> 79
<211> 50
<212> PRT
<213> Photorhabdus

<400> 79

Met Pro Arg Tyr Ala Asn Tyr Gln Ile Asn Pro Lys Gln Asn Ile Lys
1 5 10 15

Asn Ser His Gly Lys Ser Ser Ser Ser Asp Phe Ser Ser Gly Tyr Leu
20 25 30

Ser Phe Ser Asn Asn Ser Leu Asp Asp Pro Phe Ile Arg Gln Gln Val
35 40 45

Lys Arg
50

<210> 80
<211> 50
<212> PRT
<213> Photorhabdus

<400> 80

Met Pro Asn Lys Lys Tyr Ser Glu Asn Thr His Gln Gly Lys Asn Pro
1 5 10 15

Leu Met Lys Ser Gly Ala Asn Asn Glu His Asp Leu Gln Asp Ser Pro
20 25 30

Leu Gly Ile Gly Leu Asp Leu Asn Ser Met Leu Val Asn Ser Ser Thr
35 40 45

Ser Leu
50

<210> 81
<211> 50
<212> PRT
<213> Photorhabdus

<400> 81

Met Leu Ser Thr Glu Lys His Asn Lys Asp Thr Lys His Pro Arg Asn
1 5 10 15

Arg Glu Lys Lys Phe Ser Ile Gln Pro Glu Asn Ser Thr Gln Asp Asp
20 25 30

Glu Asp Ile Lys Asn Asn Ser Leu Gly Val Gly Leu Asp Leu Asp Gln
35 40 45

Met Ile
50

<210> 82
<211> 50

<212> PRT
<213> Photorhabdus

<400> 82

Met Pro Ile Asn Asp Leu Lys Lys Lys Phe Glu Ile Ser Pro Gln Ala
1 5 10 15

Ala Gln Ala Ile Gly Ala Pro Ala Arg Ser Asn Ser Ser Lys Gln Ala
20 25 30

Glu His Gln Thr Glu His Leu Glu Leu Asp Thr Ser Lys Asn Arg Arg
35 40 45

Asp Arg
50

<210> 83
<211> 50
<212> PRT
<213> Photorhabdus

<400> 83

Met Pro Asn Ser Lys Tyr Ser Glu Lys Val Asn His Ser Ala Asn Gly
1 5 10 15

Ala Glu Lys Cys Ser Ile His Ser Asn Gln Tyr Asn Ile Asn Asn Cys
20 25 30

Thr Leu Gly Leu Gly Leu Asp Leu Asn Lys Lys Leu Arg Thr Gly Asn
35 40 45

Glu Arg
50

<210> 84
<211> 50
<212> PRT
<213> Photorhabdus

<400> 84

Met Pro Lys Leu Thr Glu Leu Leu Ser Arg Phe Glu Asn Pro Ile Gln
1 5 10 15

Asn Gln Pro Asn His Ile Ser Lys Lys Asn Pro Ile Ser Asn Ser Lys
20 25 30

Val Leu Asn Asn Ser Glu Glu Lys Thr Ala Pro Leu Glu Leu Lys His
35 40 45

Asp Asp
50

<210> 85
<211> 50
<212> PRT
<213> Photorhabdus

<400> 85

Met Pro Arg Tyr Ser Asn Ser Gln Arg Thr Pro Thr Gln Ser Thr Lys
1 5 10 15

Asn Thr Arg Arg Thr Ser Pro Ser Ser Asn Ser Ser Thr Glu His Leu
20 25 30

Ser Leu Ser Asn Ala Pro Thr Asn Asp Ser Ser Val Arg Gln Glu Val
35 40 45

Lys Glu
50

<210> 86
<211> 50
<212> PRT
<213> Photorhabdus

<400> 86

Met Phe Ser Thr Tyr Ser Ser Lys Asn Asp Asn Gln Thr Ile Asn Lys
1 5 10 15

Ile Asn Thr Glu Glu Lys His Glu Asn Thr Glu Thr Asp Asn His Leu
20 25 30

Glu Ile Asn Leu Glu His Thr Gly Lys Ser Lys Pro Asp Ile Glu Pro
35 40 45

Lys Asp
50

<210> 87
<211> 50
<212> PRT
<213> Photorhabdus

<400> 87

Met Lys Lys Thr Asp Glu Lys Tyr Gly Gln Tyr Glu Tyr Lys Asp Glu
1 5 10 15

Asp Ile Thr Ser Tyr Pro Ile Ala Trp Thr Asn Pro Asp Asn Gly Lys
20 25 30

Ile Tyr Ile Gly Ile Asn Ser Pro Glu Tyr Ser His Leu Asn Asn Lys
35 40 45

Gly Glu
50

<210> 88
<211> 50
<212> PRT
<213> Photorhabdus

<400> 88

Met Val Tyr Glu Tyr Asp Lys Thr Ile Glu Arg Arg Arg Asn Pro Ser
1 5 10 15

Ile Gln Leu Asn Asn Asn Glu Lys Ser Ser Glu Gln Ala Leu Glu Leu
20 25 30

Ser Gln Asn Asn Pro Leu Leu His Asp Leu Ile Thr Ser Asn Asn Leu
35 40 45

Arg Lys
50

<210> 89
<211> 50
<212> PRT
<213> Photorhabdus

<400> 89

Met Glu His Glu Tyr Ser Glu Lys Glu Lys Pro Gln Lys Cys Pro Ile
1 5 10 15

Gln Leu Arg Asp Ser Ile Glu His Asp Lys Glu Asp Ile Asn Thr Thr
20 25 30

Thr Pro Leu Glu Leu Asn Ser Gln Tyr Thr Asn Arg Lys Arg Ala Gly
35 40 45

Leu Arg
50

<210> 90
<211> 50
<212> PRT
<213> Photorhabdus

<400> 90

Met Tyr Asp Ser Lys Lys Lys Asn Ser Glu Pro Thr Thr Lys Lys Lys
1 5 10 15

Phe Glu Arg Ser Asn Tyr Ser Gln Trp Asp Asp Ser Ile Asn His Tyr
20 25 30

Glu Asp Met Asn Arg Ala Arg Ile Lys Asn Arg Asn Asp Ile Leu Thr
35 40 45

Thr Val
50

<210> 91
<211> 50
<212> PRT
<213> Photorhabdus

<400> 91

Met Pro Ile Ser Asn Leu Ala Lys Glu Ser Glu Val Arg Ala Val Lys
1 5 10 15

Asp Ile Pro Cys Lys Asn Ile Glu Thr Asp Asn His Leu Glu Ile Gly
20 25 30

Leu Ser Ser Gly Leu Ser Arg Ser Lys Asp Thr Ser Lys Phe Lys Lys
35 40 45

Asn Ser
50

<210> 92
<211> 50
<212> PRT
<213> Photorhabdus

<400> 92

Met Leu Ala Asn Val Leu Pro Asn Leu Ala Ser Phe Leu Lys Tyr Glu
1 5 10 15

Lys Glu Thr Pro Leu Phe Phe Ile Glu Asp Gly Phe Asn Phe Gln Asn
20 25 30

Leu Asn Pro Gly Arg Val Pro Leu Ile Lys Thr Pro Glu Gln Arg Lys
35 40 45

Ala Gly
50

<210> 93
<211> 19592
<212> DNA
<213> Photorhabdus

<400> 93
atgtctacaa gtacatctca aattgcggtt gaatataccta ttcctgtcta tcgctttatt 60
gtttctgtcg gagatgagaa aattccattt aatagtgttt caggattaga tattagttat 120
gacaccattg aataccgaga tgggtgttgg aattggttca aaatgccggg tcagagtcag 180
agcactaata tcaccttgcg taaaggcggt ttcccgggga aaacagaact gtttgattgg 240
attaactcta ttcagcttaa tcaggtagag aaaaaggata ttaccatcag ttttaactaat 300
gatgcaggta ccgaattatt aatgacctgg aatgtttcta atgcttttcc cacttcattg 360
acttcacctt catttgatgc caccagtaat gatattgcag tacaggaaat tacgctgatg 420
gcagatcggg tgattatgca ggctgtttga agcattgata tttaatcatc tcatataagg 480
gaacttttat gacaaccgtt accagttatc ctggcgttta tattgaagaa ttaaatagcc 540
tggccttgct agtttcaaat agcgccacag cggttcctgt ttttgctgtg gacgaacaaa 600
accaatatat tagtgaagat aatgcaatcc gtattaattc gtggatggat tatcttaatc 660
tgattggcaa ttttaataat gaagacaaat tagatgtttc tgtgcgtgct tattttgcca 720
atggagggtg atattgttat ctctgcaaaa caacgagttt agaaaaaatt attccaacct 780
tggatgatgt aaccttattg gttgctgcgg gcgaagatat taaaacgaca gtagatgttt 840
tatgtcagcc aggaaaaggg ttattcgcag tctttgatgg ccctgaaaca gagttgacta 900
tcaacggtgc ggaagaggca aaacaagcct ataccgccac accattcgct gcggtttatt 960
atccttggtt gaaagcggat tgggctaaca tagatattcc acccagtgca gtgatggcgg 1020
gagtttatgc atcgggtggat ttatcccgtg gtgtatggaa agcgcctgcc aatgttgctg 1080
tgaaaggggg cctggaacct aaatttttag tcacggatga attgcagggt gaatataaca 1140
ctggccgcgc tatcaatatg attcgttaatt tcagtaacac aggtactacg gtttgggggtg 1200
caagaacctt ggaagataaa gacaattggc gttatgttcc agtgcgacgc ttgtttaatt 1260
ctgtggagcg ggatatcaag cgtgccatga gctttgctat gttcagacct aataatcagc 1320

ctacttggga gcggttacgg gcggcgatta gcaactacct ttatagcctg tggcaacagg	1380
ggggattagc tggcagcaaa gaagaagacg cttattttgt gcaaattggt aaaggtataa	1440
cgatgacaca ggagcagatt gatgcagggc aaatgattgt taaagtcggt ttggctgctg	1500
tacggcctgc ggaatttatc attctccagt ttacgcaaga tgtagaacag cgттаатсат	1560
atgattatga ggagttatca tgtctgctat tctgaaagcg cctggcgttt atattgaaga	1620
agacgcttcc ctagcgttgt ctgtcagtaa cagcgcgact gccgtgcctg tttttatcgg	1680
aaaatttact ccgacagtgg ttgattcaat ccaagtctgt acccgatatca gcaactggct	1740
tgaattcact tcctcttttt ccctagctcc aacagttgag attgttgtcc aatctaacac	1800
tgaatctgaa tctgaatctg aaacttacca ctatattgag acaatcaatt tatctccagc	1860
tgtggaagca ttgcgactct attttcaaaa tggcggagga gcttgctata tctaccatt	1920
aaatgatgct gaagatgaat tggttctggc ggccatacca gaagtcattg aacagaaagg	1980
tgatattact ctgttggttt gcccggaaact cgatctggat tacaaaacta agatctatgg	2040
cgcagtgagc tctactgttg atgataacaa agtgggctat ttcctgattg cggatagcaa	2100
tgatggagaa tctgtgtcag gagtatggaa tagtgctaag gccgccgcct attatcccca	2160
gttggaact aacctaanaa tttccacgtt gcctggggat aaggacattc gtatcagcgg	2220
ttatcaggat gatgatgaaa cacataaacc gaaaaacttg gatgagctca ggacaatcaa	2280
cgaggcggtg gcacaggata ttgatgcaag attgctcgag gagaaacaac gtgctgtcat	2340
cattccgcca agtgctgcca ttgcgggcat ttattgcaa acggataatc gtcgcggtgt	2400
ttggaaagcg ccagccaacg ttgcgctcac agggatcggg agtttgcttg ataaggtaga	2460
cgatgaacgg caggagaga tgaatgacaa gggaatcaat gtcatccgtt catttaccga	2520
ccgtgggttt atggctctgg gagcccgtac ttgtgtggac gctgccaaca tcagctggcg	2580
ttatattcct gttcgtcgcc tgttcaattc cgttgaacga gatatccgcc aggcgctgcg	2640
cgctgtgttg tttgaaacta atagtcagcc tacctgggta cgtgctaagg ctgccgttga	2700
tcaatatctt tataaccctt ggacagaaaaa tgcatgatg ggtgctcgcc cggaagaagc	2760
ttattttgtg caaattggtc aggatatac catgtccgag gctgatatta aacagggtaa	2820

gatgatcatg actgttgggtt tggcagcagt gcggccagct gagttcatca ttctgcaatt	2880
tacgcaggat gttgttcagt aatctccatg actaaacgcc aggcactgta ttgacagtgc	2940
ctactctaac catcttggag gaggtgatga tgatggagag actccaaccg ggtgtgactt	3000
taacagaaaag tataatcacg atgggtcagc aagagatacc cagtgtgtg ccggtgttta	3060
ttggttacac cgttcgttat ccggaacaat cggaagcatc agtccgtatc gacagtttgg	3120
ccgagtatac cagcctgttt ggtgacgacc atgtgatgat gtttgctgtc aggcactatt	3180
ttgataatgg cgggcaacag gcatttgttt taccctgaa ggacaatatg ccatcagtgg	3240
agatgaccac agctgaagcg gaaaatctga tagccgcatt gcgctctgct acggttagcg	3300
aagccattgg tgggcatagt cagattacac tgattttgggt accggatatg gctcggctta	3360
atgacagtga tattgatgac tcctcaacc aggtaagcct gtggtcccaa ggctgggagg	3420
cgctgctgca attgagtcag gttaggccca acctcttgt gctgttagat gcgccggata	3480
atgttgaaca ggcgcagaag tgtatgacaa cgctatcgtc agattatcgt caatgggggg	3540
cagcatattg gcctcgtctg gaaactacct atcagaaaaga aatatctggc aaggacaatg	3600
aatctcaggg aattttccag gggactgttc tgtcaccac agccgcggtc gcagcggtaa	3660
ttcaacgcac ggataacgac gcgggtgttt ggaaagcacc ggccaatatt gccttatccc	3720
aggttattcg acctgttaaa tcttatcttc aggggaagtgt actgtttaac agcagcggca	3780
cttcgctcaa tgtgatccgc agtttcccag gtaagggcat acgggtatgg ggatgccgca	3840
ctctggaaaa cacggataat acgcagtggc gctatctgca aacacgtcgg ctggtttcct	3900
atgtaacagc gcatttgacc caattggctc gcatgtatgt ctttgagcca aataatgaac	3960
ttacctggat gaagttaaaa ggacaaagtt acaactgggt acggcaatta tggttgcagg	4020
gtggcttgta tggttcacag gaggatgagg catttaacat tctgttaggc gtaaacgaga	4080
cgatgactga ggatgatgtt cgtgcaggaa aaatgatcat gaaagttgag ttggctgtgt	4140
tgtttcctgc cgaatttatt gagatcagtt tgggtgtttaa taccxaaaca gaggcgctgt	4200
cttaagaagg aaaaagtacg atgaacgatt attacacacc cgtgggtatcc catcgtttta	4260
tggcgagttt tatttttaac cgcattcccg atccgctgga tattcgtttt cagcgtatct	4320

ctggccttag tcgggaacta caggtgactc agtacagtga gggaggagaa aatgcccgt	4380
ataactatatt agctgagaaa atccaacacg gtacgttgac tttggaacgg ggcgtgatga	4440
cagtctcgcc attgacctgg atgtttgatc gggatttgag tggtgaaaaa atcgcttatg	4500
ccgatgtggt ggtgatgcta ctgaatgaaa attcactgcc attgtccagt tggacgttga	4560
gcaatgcgct gccggtacgc tggcaaacca gcgactttga cgctaacagc aatgccatat	4620
tggatgaatac ctttgaattg cgttaccagg atatgcgctg gcttggagtc aaaatatgac	4680
agtagaaatc agagagttac ttatccaggc aaaggtagtg ccatcaacac gaccgactga	4740
atcagaacgg caaaaccatt ctttgataca ggaaagtctg gatgaggcga cttgggtgga	4800
aacgataaaa cgcgaagtgt tggccgcatt acgcgatgag gaagggtggc gtccatgagt	4860
ctgattgaac gtggttttagc taagctgaca attaatgctt ataaggatag ggaagggaag	4920
atacgggcag gaacgttgca ggccatgtat aaccctgact ccttgcaact ggattaccaa	4980
acggattatc agcaatccca agcgattaat agcgaaaagc aaagtagcat ttatgtacag	5040
gccaagcccg cagggttatc acttgaatta atttttgatg ccacgatgcc gggtaacaaa	5100
acccccattg aagagcagct catgcagctc aagcaactgt gcagtgtgga tgcaaccagt	5160
aacgagacgc gattcctgca agttaaatgg ggcaaaatgc gttgggaaag tcggggttac	5220
tttgctggca gggccaagag tttgtctgtg aattacactt tgtttgatcg tgatgcgact	5280
cccttgaggg tacgggtaat attggcatta gtggctgatg aaagtctggt gttgcaggag	5340
actgaacaaa atctgcaatc tccggcaaaa atcgcatcac gcatacagga tggggtatct	5400
ctggctctga tggcagccag tacggcatca acattgtcag gcggtgtgga ttatctgacg	5460
ctggcctggc aaaacggtct ggataatctc aatgggttcg ttccgggtga aatattgcag	5520
gccaccaggg gagacgaatc atgagccacc aactgaaaat tattgcagat ggtaaggcac	5580
tgtcactttt ggccgcggta gatgtggaca cctgttatcg ggttaacagt ataccttctg	5640
cgacattgaa actgagcgta ccggataggc cactctcttc tttcagtcag acggatgttc	5700
agacagaact ggcccactgt caggtaggga aaaccctgcg tctggaattg attgatggta	5760
gcaaaaaatg ggtgctgttt aatggtctta ttaccgtaa ggctctgaga attaagaata	5820

agcaattatt gctcactctg gttgtcaagc atcggttgca actgatgggtg gatacccagc	5880
attcacagct gtttaaagac aaaagcgaaa aagcgatctt aagcacgcta ttgaatcaga	5940
ccggaatcaa tgctcgcttc ggaaagatag cggcgttaga tcaaaagcat gaacagatgg	6000
tgcaatttcg ttgttcagac tggcattttc tgttgtgccg actgtcggca accggtgcat	6060
ggttgttacc tgccatagaa gacgttcagt ttgttcaacc tgatgctctg aaatcaaact	6120
cagcctatac cttgaagagc aggggggatg agaacaaaga catcgttgtc aaggatgctt	6180
actggcagtt tgacaatcaa atcaaccccg ctttgctgga agtcagtggc tgggatatca	6240
gtaagcagca ggtacaatca ggcggtcgct acggaaaaat cgcgttgggt aaggcggcac	6300
tctctcctga tggattggca tcccttaata aaacgggttg ggacatttgt tatagcagtc	6360
cgtaacaac ccaggaaagc ggttatctgg cacagggatt attgcttaac cagcgcattt	6420
ctggggtgac aggagaattt ttgctcaaag gagatgggcg ttaccagttg ggagacaaca	6480
ttcagctgac tggatttgggt tcacagttag atggtacggc aagcattact gaggttcgcc	6540
accgtcttaa tcggcgaatt gattgggaaa ccacggtgag cattggttta caacatgaat	6600
atttgccgat attacctgat gctcccgaac tacatattgc gacagtagcg aaatatcagc	6660
aggacagtgc ggtgttaaac cgtatcccca ttattctgcc ggtactgaat cgtcccaatg	6720
aatttttttg ggccagattg gggaaacctt atgctagcca tgaaagcgggt ttctgttttt	6780
accagagcc aggtgacgaa gttattattg gtttttttga aaatgatccg cgttatccag	6840
ttatttttagg tgctatgcat aatccgaaaa ataaggcccc ttttgaacca acccaagata	6900
atagggaaaa agtattgatc gttaaaaaag gtgaagcgca acaacaatta gtcattgatg	6960
gcaaagagaa aatgatccga attaatgcgg gtgaaaatca aataatgctt cagcaagata	7020
aagacatttc tctgtcaacg aaaaaagaat taacactgaa agcgcagaca atgaatgcc	7080
cgatggataa atcattggca atgtccggga aaaacagtgt tgaaatcaaa ggcgcaaaaa	7140
ttaatcttac ccaatgaaag gtgacgatga atggaaaatc aaatactgac acaactctat	7200
ggtcgtgggt gggcttttcc tccggtcttt tcccttgaaa agggggtaga gatggctgaa	7260
ggggcggaag atgtgagaca aagtttgcag attctgttta gtactgagcc gggggaacgt	7320

cttatgcgtg aaaattatgg ctgcggatta aatgatttta tgtttgaaaa tatccgcaat	7380
gaacttattg ctgaaattga atcccatatc catgacaacg tattacgata tgaaccccg	7440
gctgatatga ctgatattca ggttcgtcaa tcccctggca tggggaatac tttgcaagt	7500
caggatcatgt atcgcctgag agggagtgat atcaatcaac aaatccaggg agtacttgca	7560
ctgagtgaag gccgggtgac ggaggtagta tgagtgaagc gattgtggtg gatggtgacg	7620
tgttacagtt tgatcccaac tttggcaatc ggcaggtgac ggttcccagc ccaggaaaaa	7680
ttagcggcac aggacatgcg caggtaagtg gaaaaaaagt gtgtattctg ggggatgaga	7740
aacaggtcag ggtttctgca acctatatta caacaacaca tactacgccg ggaacaggaa	7800
ccattactat cagtgcctctg gatgctggcc agcaggccct tcagtgtacc agtggggcgg	7860
ctttaattat caaggggcag caatttacgg cgatgtttac gcctgaattg ccagccatga	7920
ataatacagt gactccgcca caaccggatg ttacgacacc ttcatcagga aaaggacgtt	7980
ttatcactca acaaaattht gctaccgtaa attagagtat tgactgaatt aaatagaatt	8040
aacgaaggtg taaataatta tttatttgct gacgaatcgc tgtgacaaat aaacacaggt	8100
gatgttatgg aattaaatga gttaactaac aaattgtcaa atttggtgcc aatgaccgat	8160
tttaaattag ataatcgagc cagtttgcaa ttgcttaaat atattgaagc gtatacgaag	8220
ataataccct ttaattctgg cgataaatat tggaatgact ttttctttat gtcaggaaat	8280
acgccagaga aacttgcaaa attatatcag aaagaaatag aaccaatgg ggagttatta	8340
cctcagcagg cttttttgtt ggcggttttg cgtttattgg aaacaccaat atccttatta	8400
aatgtattac ctgctgctca tcgtgagctc tattatcggg agcttttagg cttgtcttcc	8460
catgcggcac agcctgatca ggttgcttta tctatggaac tgaattcgac agtgatggaa	8520
cagctgctcc ctgaaggaac cctgtttgag gctggtcagg atgaacaagg caatgcattg	8580
caatatgccc tggatgccag tttgctggct aatcgtggat atatcagtga cttgcgctgg	8640
ttacggaatg acggggaaaa gcaatgggtt acttctgctc catgggattt acaggcacag	8700
gtgtcactgc cgtctgatgg gatacgatta tttggtaaga caaatagtga tcagcaggta	8760
tttgggtggg tgttgataac gtcactactt ctggcgatgg aagcggggat aaggaagatc	8820

attgttactt ttgagcagga gatgaacacc caagaactgg tggcacaggt cagcagtgga	8880
aatcaatggc taacattgac gtctgaggta aataagaaag aggtcacact gacactgtca	8940
gacaaagaac cggcaatcag tgcgccagag gatctggata atctcttttt cacgcaaccg	9000
gtactcaggc tacagggaaa ggatagtcag gactgccgg aggtgacggg tatcagcggt	9060
tcggaaaagg atgatactaa ggatacctct tttgagatgt atcacttaac accatttgggt	9120
tatagcagt atatatagacc attggaggaa aatccagcgt tatatttagg ctttactgat	9180
gtaaagccag ggcaaacact ggcgctgtat tggaaattaa aatccccgca gcaaccaacc	9240
gtttcctgggt attacctgga tcaacataat caatgggctg aattggattc atgggtcagt	9300
gatggaaccc agaattctgta tcaggatgggt acttggcacg ttgagttgcc tgtggatgca	9360
tccaatcagg cagagcagat gccagttgga cgctattgggt tgcgggcagt ggtggaggta	9420
cccgctcatg agggggcggt ggggaaggct ccttggctat atggtctaata ctataacgcc	9480
atgacggcaa ccttgggttaa tgtagatagc atcagtgaca gccatttctt aacccttttg	9540
cctgccagca gcatacagcg gcccgttgaa cccatcattg tgttggcatc ggtcaaccag	9600
ccttgggcat catgggggtg acgtatacct gaatcctaca gtgccttttt tgaacggata	9660
gctcaaaacc tgtctcatcg aaaccgggtcc ttaacctggg gaaatatggt gacattactc	9720
aaagagcggt atgtcagcat ctttgatgtt aagtatccag gtaatgatga actcaccaga	9780
gtgccagcat tggagcagca gcaactaaca gtgattccag caaacggta caacgatagc	9840
gatgattctc tgcgtccggt actgaatcct gctcgtctgc aagagatggc tgattggttg	9900
cagcagaaaag actctccctg ggcctctatt gaggtcagga atccagaata cttggatgtg	9960
aaaatccatt acgaggtgat ttttaaacct gatgtgaacg aagatttttg ctatcgccag	10020
ctacagcagc aactgtgtga ggtgtatatg ccttggagca tagatgagca gcggcccgtt	10080
gtattgaata acagcattaa ttatttccag ttgttagcca ctattcaaca gcaaccgctg	10140
gttgagcgag tcactcgtct gacactacat cgggctgatt cttctgatga gagtgatggt	10200
acagcatctg tggaagccaa agataatgaa gtgcttattt tagtctggga agaggacgat	10260
aatctgcaat accgaggaaa tgactatgag taatcaggat gcactgtttc atagcggttaa	10320

agacgatatt cactttgata ccttgctgga acaagctcat caggtgattg aaaaacaggc	10380
tgaaaaactg tggagtgata cggcagagca tgatccgggt atcacatttt tgcagggaat	10440
cagttacgggt gtgtcagatt tggcttacg acatacatta cccctgaaag atttactgac	10500
tccggcgccg gatgagcagc agcaagaggg aatttttcct gccgaatttg gccgcataa	10560
tacactgact tgtgggcccgg tgacagcggg tgattatcgc aaggcattgt tagatctaca	10620
cagcagcgac agcctggatg gtactcagca ggatgagggg gattttctgt tccggagtgt	10680
gcaactgggtg cgtgaaccgg aaaaacagcg ttatacctat tggtatgatg caaccaagag	10740
ggaatatagc tttgtcaaca gtgaaggggc taaagagttt accttgccggg ggaattactg	10800
gttgatatctg gaaccaaccc gttggactca gggtaatatt gccgctgcta ccagacaact	10860
gacagaattt ttgactaaaa atcgcaatat tggatgaatct gtcagcaaca ttatctggct	10920
acaaccggtt gatctgccac tgttgctgga tgttgaactg gatgatgatg taggtgcaca	10980
ggatgtcccc ggtatTTTTTg cggcgggtgta tagcaccgca gagcagtatc tgatgcctgg	11040
agcacagcgt taccgtacgg aagtactgca aaatgctggg atgagcaatg atcaaacttt	11100
cgaagggtcca ttattggaac atggctggat accagagctg ccggcagccc gtgattatac	11160
tcaaaggctc actctcaatc ttagccggtt ggtaaatagt ctgcttgaga ttgagggcat	11220
taaacatgtg aatcgtcttc gtctggatga tagcttcgat aaaactgcta ttgaaccctg	11280
taagggggat acctggtcgt ggtcgaatca agagggtat tatccacgtc tttggggaga	11340
agaccactt aaccaattgg cgcaacaaaa tggcccgctt agggatgatg ccaaaggagg	11400
gattagcgtc agtgtgagta aagagcaaat ccaggccagt ttaccagtc aatcactgat	11460
tcaaaatgag ccggtaatat tggcttacgg ccagcaccgt gacgttggca gctattatcc	11520
cgtcagtgat actttgccgc cttgctatgg actacaacat tctttgtctg aaagtgaaca	11580
cttattgcca cttcatcaat ttatgttgcc atttgaacaa ttattggcct gtggttgtca	11640
acagatagcc atgctccgc ggttactggc ttttcagcgc gaaggttatg aggtttgggg	11700
tgatcagtgg ccctttaagt caggctcagt gaatgatgac gcccatcaag attatgcccc	11760
tgcattaaag gatttgtag gacagattgc gctggatagt gatcatgaat tggatattat	11820

taattacttg ctgggttact ttggcacaca gcgggcaccg cgtaccttta cgacacaact	11880
cgatgatttt cgtgcggtcc aacagggtta tctggcccag caaccgacat tgacttacca	11940
ccgctccaat attcgtatcg atcaggtatc gtcgctacaa aaacgtattg ctgctcgcat	12000
ggggctgggc ggtgagttgt ttaaacctca accggatctg agccaactgc ctttttattt	12060
gattgaacat cgagcgttgc tgccagtcaa acccaatagt cagtttgata aggaacagaa	12120
accagcctcg gtgacagagg agggggggcag ccaaacaggt caacattatg tggtcattga	12180
acagaagggc attgatggca agctgacaca ggggcaagt atcaatttaa ttctgtatga	12240
aggagagcag ggagaaaccc aatttacgat acgcggtcag atggtattca aaaccgaggg	12300
ggataagttt tggttggatg tgaataatag tgcgcaactg gaatataatc tggcgcgggt	12360
aatgacagca gccaaaggcga gtaaactctt ttggcaaac agcccgggtat ggatggagga	12420
tatgggctat cgtctggcct atgctagtga ccaatcctca ttgcctgtga atcaacggcg	12480
cttgacccgc acagtgcaaa ctccattccc gccgatggtt gttgtaggta gcgaaatcac	12540
cctgttaaag caggtgggga tagtcaattt aaaaaagcg gagtcagaaa aactttatgc	12600
aaaagttgtt agctttgatc gcattgaagg gaccttgatt attgagcgtt tgggtaattc	12660
cactctggct tttcctacct cggaagaggc gtggcgggtat agttggtatt tttcggggga	12720
gaaatatgaa aggactgacc gcttttcatt tgtgattagc gtagtagtga acagtgactt	12780
aattaaattg cccggtgttg atccctataa attggaagaa tgggtgaaag aaacgattct	12840
taccgaattt ccagctcata tttctatgat tatccattgg atggatcggg aagccttttt	12900
aaatttcgcc aatacctatc agcgttggca aaataatggt acgccactgg gggatgcggc	12960
ttattccatt ctagaaagtt tgacacttgg taaattgcc a tctgccttaa aaggtgttgg	13020
cacaatgcgt attgccacat ctagtcaaag agaagaagt gtgggtagta atggtgatca	13080
atggaataca gatggaataa cccagaatga attattctat gttcctaaag agagctagga	13140
aaaataaata tctgccacta atgatgttga attaaatatg ttttctggag ttaatcatga	13200
acgaaactcg ttataatgca actgtacaag aacaacaaac attatctaatt ccaaaagctg	13260
ttggacctga catcgataaa ttaaaggata aatttaaaga gggcagtatt cccctgcaaa	13320

ccgatttcaa tgagttaatt gatattgccg atattggacg taaagcctgt ggtcaagcgc	13380
cacaacaaaa tggcccagga gaaggattga aattggctga tgacggtacg cttaatTTaa	13440
aaataggcac tttttccaat aaagactttt ctccattaat attaaaagat gatgttttat	13500
ctgtagatct tggtagtggt ctgactaatg aaaccaatgg aatctgtgtc ggtcagggcg	13560
atggtattac agttaacact agcaatgtag ctgtaaaaca aggtaacgga attagcgTTa	13620
ctagtagtgg tggTgttgcc gttaaagtta gtgctaataa gggacttagc gttgatagta	13680
gtggTgttgC agttaaagtt aatactgata agggaattag cgTtgatggT aatggTgttg	13740
cagttaaagt taatactagt aaaggaatta gcgttgataa tacaggtgtt gcagttatag	13800
ctaAtgctag taagggaatt agcgttgatg gtagtggtgt tgcagttata gctaatacta	13860
gtaaaggaat tagcgttgat gtagtggtg ttgcagttat agctaatact agtaaaggaa	13920
ttagcgttga taatacaggt gttgcagTTa tagctaAtgc tagtaaggga attagcgttg	13980
atggtagtgg tgttgCagtt atagctaata ctagtaaagg aattagcgtt gatggtagtg	14040
gtgttgCagt tatagctaAt actagtaaag gaattagcgt tgatagtagt ggtgttgCag	14100
ttaaagttaa agctaAtggc ggaattaaag tagatgctaa tggTgttgca attgatccta	14160
ataatgtact cccaaggga gtgattgtaa tgttctctgg cagtactgca ccaactggtt	14220
gggcgttatg tgatggcaat aatggTacac caaatttaAt cgatcgattt attttaggtg	14280
ggaaaggGac tgatattaat ggagtgagta ctaatacagc ttcaggtact aaaaatagta	14340
agttattcga tttcagttct gatgaagcta cattaactat tgatggtaaa aactgggga	14400
gagcattatc gttacagcaa atacctaAtc atgcacactt tagtggaata attatggata	14460
cagagaaaagt taattattat ggaagtaaaa aaatcacaac aaatgtgtgg ggtgtaacaa	14520
caggagataa tacttcagta cgatatattt ataagtcAtc aggtgtactt gactctaaca	14580
ataatgtctc caacagtacc ttaggcggaa acagtctgca gacgcacgat catgatatta	14640
agataacggg cacaggaaaa cattctcaca aaaacaaagt aacagtcctt tattatattc	14700
tggctttcat cataaagctt taatatatat gaaaaattga aaatataaat tatccattaa	14760
taataaagag gatattagca tgacttcgga gccaaatctg ttaaaccgga ttacaattac	14820

tattgaagct aataatcaac aagtagctag aaaagtattg catggctcct tgcttaatca	14880
agctaataata aataaattat ttaattcata ctttaatgaa tatgaaatta ataggggtgt	14940
ttatttagaa acattaatcc tgaatcttgg tacgataaat ttccatgatt ttaattcatt	15000
gtttcctact ctctataaag ctgcattgaa taaagaattc agtcaatatc agataaacia	15060
ccatagggaa gaaatgctat ttaatgagac aatatcaaat caagctactg ataagtctta	15120
catatttggc gataacaaat taattgatgc agagaatttc attcactttt tatatcaaaa	15180
gcattccaca ttaaatctag tagaagcaat gggaaataat ggtattgaaa aattaacaaa	15240
tcagttaaca caaatagaaa ataaatttgc gttattattg gcaaaaagtt gtttgtctga	15300
ggaaggctta aaacgactct tggctatcaa acaaccgat ttattaatcg ctatcaatcg	15360
cagattatct gaaagaataa atagaccaca atatcaggag aagcttgttt cctgcggaca	15420
actgatattt agtgctctgg gatataatac acagtacaat atacaggaaa ttcctaaacc	15480
ggatgaaaaa gttattgcac gcataacaac tgaacttaat aataatggtt tgcttaatac	15540
aatacctatt attacactat ttcgtcagag tgggattaac gattcatcac taaatgattg	15600
gctaaagaaa atctggcagg tgagatcaat ttcacagtta tgcagaaagt atctttctgc	15660
taaggaatac caatatctgt cagaacattt tgtttcaaag agcgtcgata aaaatagata	15720
tgatgaagag cccgtaaatc agagcatatt atcaaggttg aataataatt ccattaaaga	15780
aggaaataat cacagtcaac tctgtactct cagtagacta tattctgaac ccgttgattt	15840
acctgaacia accattctac gtcaggtag taatacagta gatcagagca tattatcaag	15900
gttgaataat gcctccatta aagaaggaaa taaccaaagt caacttcgca ctctcagtag	15960
actatattct gagcccgttg cattacctga acaaaccatt ccacgtcagg ttagtaatac	16020
aggatatatta attctatggc caatgctacc tacactattt aaccagcttg gtctacttga	16080
gaaaaagaaa tttatccatc gtcaggcca gtttaatgcc gttgattttc ttgattacct	16140
gatttgggga accgaagatg tgaaagtgga acgaaagggt ttgaataatg ttctatgtgg	16200
gttaatggct gatgaaatta ctgaaccaat gcctattgaa ccagaaaaac aatggataat	16260
aattcaatgg ctggacgcta ttatctcca actttctggc tggaaaaagt taagtcgtaa	16320

tgacgtccgt caattatttc tacaacgacc aggagaatta ctgatcaatg aacaggaaat	16380
taaaatcaca atacagcaac aaccatttga tgctctgtta actgattggc cgtggccaat	16440
gaatatggct tgtttttagct gggtgagtca accattaacc attacgtggt tataaccatt	16500
gaccacaatg acttagtctg agtaaaaaat atgaatatat cgcctgtttt ttatgattca	16560
ttgaatcagg ataacgaccg tgatctatcg tttttattta gcgaactgga acgaatagat	16620
ctcgctcttc aacaccattt ttattgtgta gaaagtcagc gaagtgagct cctggatgag	16680
tttctgctca ctgaggcgga agtggtgacc aggctggata agccacttgg taaacctcat	16740
tggataaatg atgattatct ggcgatatcg caaaagggca atgtaagcct aatggcagcg	16800
tccagattaa tggatctgat cgaacgcttt gaactgactg attttgagcg cgatgtttta	16860
ctattaggct tattgcccc ttttgatagc cgctattatc gactgttttc gctgattcaa	16920
gggggacaac agggtcgatt accttctttt gcgctggcat tggaactgtt ttgccactcg	16980
gcgctggaga aacaggtaca gcaagcgagt tttctgcacc gggcaccttt gatgggttgc	17040
cagctattat ccatcgatac tagtcaaaaa acgctggcct ggctccagac tccctttatt	17100
actgacagcg gggtatatca ctttttactg gggcatcact acattatgcc ggcttttagaa	17160
catttgctg agtgggttaac accgacaggg attggctgtt atcctgaagg attaaaacaa	17220
gtactgggta acgtattgtt atctgacaac gataatatta gaccgattgt cttattacgg	17280
ggaatggccg gcagtgccag agcttatacc attactaata tgatggcttc agaagggaag	17340
caaacactgc tggtagatat atccaaactt gctgatagcg atgaaaaaaaa cattattctt	17400
cagataaagc atattttgcg ggaaaccgc atgcatggag catgtttatt attacggaat	17460
ttttgcttgt tagtggaaca gaataaacia ctattggact ccctgtcaga gttattgaat	17520
caacctgaat taagaattgt ttgcctgatt gagccttatt cccatttggg atggctgaaa	17580
aagataccgg tattactgat tgagatgcca cttttaacgc ctgcggaaaa agccagattg	17640
ttaattgcca gcttaccgga taattgttcc gaggatattg atacgataac ttttaagccag	17700
cgttacactt ttaaccaga aaccctgcca ttgattttgc aagaggcca gctttatcaa	17760
cagcagcgag atccgctgga tatcttgag caatgcgata tacgccaggc attaaatttg	17820

cgtgctcaac	aaaatttcgg	tcaattggca	cagcggatta	ttcctaagcg	ctcattaaag	17880
gatttattgg	tatccgatga	gattgctcag	cagttacggg	aaatactcat	agcaattaag	17940
tatcgggaac	aggttctggc	gggagggttt	aaagataaaa	ttgcctatgg	cactggtatc	18000
agcgccctgt	tttatggtga	ttcaggcact	ggaaaaacca	tggcagcaga	agtgattgct	18060
gaccacattg	gcgttgactt	aataaaagtg	gatttatcta	cagtagtgaa	taaatacatc	18120
ggtgaaacag	aaaaaaactt	atcccgtatt	ttcgatttgg	cggaacagga	tgcaggggta	18180
ttattctttg	atgaagctga	cgcaactgtt	ggtaaacgca	gtgaaactaa	agattcccag	18240
gacagacatg	ccaatattga	agtttcttac	ttattacagc	gcctggagaa	ttacccgggt	18300
ctgggtcattt	tatccaccaa	taatcgtggg	catttagaca	gtgcttttaa	tcgtcgtttt	18360
actttcatta	cccgttttac	ttacccggat	gaaaaaatcc	gtaaaaaat	gtggcaggaa	18420
atttggccta	gaaatataaa	aatatcggaa	gatatcgatt	ttaacgaatt	agctcaacga	18480
acaagcgtga	ctggcgcgaa	tatccgcaat	attgctttat	tgtcttcatt	ctttgcttca	18540
gagcagggga	atgatgaagt	cagtaatgaa	aatattgaaa	ttgcattgaa	gcgtgaatta	18600
gctaaagtcg	gacgattaac	attttaaaag	ttatcacaat	gaaagtattg	aaatattaaa	18660
taaatttatt	acaaaaaagt	tatcacgata	taatttaaga	gaggtttttt	atgttaaaca	18720
cgcaaaactat	tattgatgtc	aataaggcaa	tggatgccat	gctgcgcgca	tatctgaatc	18780
aagatattgc	cattcgtttt	gatctacctg	aattggatac	tatgcaatct	gatgcgatgg	18840
taagtatctt	tctttatgac	attcatgaag	atttacagct	tcgctcggca	gaatcaagag	18900
ggtttgatgt	ttatgccggg	aggttattgc	ctggttgggt	aaatattaaa	tgtaactatc	18960
tgattaccta	ttgggaagct	tctaagccag	cgactgatgc	cagcagtcg	gatagccaac	19020
ctgataacca	ggcaatacaa	gtgatgtcac	aagtattaaa	tgcccttgatt	aataatcgtc	19080
aattggcagg	tattcctggg	gcttatactc	aggttgtacc	gcctaaagag	agtttaaata	19140
gcctggggaa	tttctggcaa	tactgggta	atcgcccacg	gctttctctc	aattattcag	19200
tgacagtacc	tgtagccta	aacgatggtc	aggatagcgc	gactccgggt	accgcggttt	19260
cttctacagt	ggaacaaacg	gcatcgctca	gtcaagaagt	ggttagtcat	gctttacgcg	19320

aattactcat tacggaatta ggaggaggag aggataaccg gttggtactg agtaaagttg	19380
aattatccgc agtgaaagag acgatgactc aagacagtcc ggctcagatg attatatattgt	19440
tgtctgtttc aggcatcata cgacaggaat atttgaagga aattgataat atctttgatc	19500
gttgggtaaa taatgctgaa gttattacca ctattgatga ttgtgggatt agaattgaaa	19560
gtataacgaa agataatctt gtaggaatth aa	19592

<210> 94
 <211> 18490
 <212> DNA
 <213> Photorhabdus

<400> 94	
atggccacaa ccacagttga ctatccaata ccggcttatc gatttggtgt ctccgttggt	60
gatgaacaaa tcccttttaa cagcgtttcg gggctggata ttacttatga tgtcatcgag	120
tataaagatg gcaccggtaa ttattataaa atgccgggtc aacgtcagtt aatcaatatt	180
acactgcgta aaggggtatt ccctggcgac actaaacttt ttgattggct taattccatt	240
cagcttaatc aggttgagaa aaaagatgtt tcaattagct tgaccaacga agttggaact	300
gaaattttta tgacctggag cgtagccaat gcattcccaa cctcattaac atctccttct	360
tttgatgcca ccagcaatga tatcgctgtt caagaaataa aactgactgc cgatcgagtc	420
actattcagg cagcttaaag catcacgatg attgatatat cagacgggac aaaatgatcc	480
tcaaaatttg gcacaacggc taccctgcca actaaattta ccctcttaca gttcacgcaa	540
aatatcgcac aatacaattg gaggcaatat gccacaaca acttatcccg gcgtttatat	600
tgaagaagac gcctcactgt cactttccgt tcgctcaagt gcaacggcgg tgcccgtttt	660
taccgttgaa gatgacagtc aacttcatac tcctaccaga gtgaatagtt ggttagaata	720
tctgacaaaa aaagcagata aaaaattcaa ttctaccgac aaacttgata tcgcattgcg	780
cgcttattht attaacggcg gcggatatgg ttatctcgtc aaagcgggtg aattaacaaa	840
tcaaaattcca aaacttaacg atgtcacatt actggtcgcg gctggagaaa atatcaaaga	900
tgctgtgagt acactttgtc aaccgggcaa aggcttatth gccattctgg atggcccaac	960

cgaagagtta aagtctgatg gcaaattccag agatccgtat gatcaaagcc cttttgccgc	1020
cgtttattac ccctggctag ttgctgattg ggcagacaat attccgcaa gcgcggccat	1080
tgccggtatc tattgttcag ttgaccgtac ccgcggtgtc tggaaagccc cagcaaattgt	1140
catattacaa ggcggggtga aaccgaagtt taaagtcacc gatgacttac aaggtattta	1200
caacaccggt aaagccatca atatgatccg tgaatttccg aataccggtg tcaccatctg	1260
gggcgccccgc aacttaagg acgaagataa ctggcgttac atcccagttc gccgcctgtt	1320
taacagtgca gagcgagaca ttaaaaatgc catgagtttc gcggtctttg aacctaacag	1380
ccaaccacc tggaaagctg tacaccgagc tattgataat tatctctatg ccctttggca	1440
acaaggaggg ctagcaggaa acaaagctga acaagcttac tttgtgcaaa ttggtaaagg	1500
gataaccatg accgatgatg atatcaagca agggaaaatg attgttaaag tgggtatggc	1560
cgcagtgcgc ccggctgaat ttatcatcct tcaattttca caaaatgtag cacagtaacc	1620
gtactgaggc gcggtttaac accgcgtcca ttcagtctat tgaatggagg agacaataat	1680
gataacggag ataaaacagc cgggcgtcac catcacggaa aattcgatat ccccgaaatc	1740
agataatgaa tttatcggcg tccccgtttt tattggccat accgaaaaaa attcaagcca	1800
taaaacggct gttaaactaa atagcctgat ggactttacc caagctttcg gtgcatcagg	1860
attaacctat tattcagtac gccacttttt tgaaaatggg ggacagcaag cttatatctt	1920
gtcactgggg attaatcaac agctaaaaga ttttcaatca ttgattaccg ccctgcaatg	1980
gaactgggta aaacaagcca ttgccgcaga aaacgaaatc acattgattg ttgtgcctga	2040
tattaccctg tttaatgatc tcagcgtca aaaaagcctt tggctacaac tctggcaatc	2100
aatacttgaa ctgtgtaaaa gtcggcgtgg catcatggga ttactggacg cgcctgatga	2160
tccaacatta gcaactgagt gtttaaaaca attctcttcc actgatcgcc aatggggcgc	2220
cgtatactgg ccaaggctaa aaagtaccta ccaagaaaac ggtacatata ttgtactttc	2280
acctactgct gcggtcgccg ccgttatgca acgcaatgac agtcagaaaag gcatatggac	2340
tgctcccgcc aatgtggctt tagccaacgt catcgggtccg gtacgttctt acattgaagc	2400
tggaaccttg ctgaatcaag aaggcacttc gttgaatctg gtgcgtagct tccccggcaa	2460

aggcattaata atctggggct gccgcactct ggataacata cctcattctc cctggcggtta	2520
tatccaaatt cgccgtttgg tttcctatat cgaagctcat ataaccaac ttggccgcgc	2580
ctttgtcttt gaaccaaca acgcatcac ctggatgaaa tttaaaggctc agggccacaa	2640
ctggctacgt caattatggc taaaagggtg attacggggc actcaggaag atcaagcatt	2700
tgagggtgta ctgggtgta atgaatccat gaggtaaagc gatattcttg ccggaaaaat	2760
gatcatgaaa atcagggtgg cgctgttaat tccggcagaa ttatttgagc tgagtctgac	2820
gtttgatatc cgtaacaata ccgtacctag ctaattctaa caggggaaaa acatgtacaa	2880
cttatacacc ccgtcagtat ctcaccgttt tatcgccagt tttctgttta acaacattcc	2940
cagcccactt gatatcgctt ttccagcgtat atctggcctg agccgagaac tgcaaaccac	3000
ccaacatagc caagggtggag aaaacgccag aaacgtctgg ttatccgaga agatccaaca	3060
tggcagcctg gtgctggagc gcggtgttat gaccatcact cccctcacct tggtttttga	3120
tcgctgctg cgcggtgaaa aagccgtgta tgccgatgtt gtcattcatgc tactgaatga	3180
aaatgcgtta cccgtggcga gctggacagt cagtaacgcg ctaccggttc gttggtccac	3240
cagcgacttt gatgctaata gcaacaccgt actggtgagt tctctggaat tacgttatca	3300
ggatatgcgc tggttaggag taaaagcatg acggtagaaa ttaaagaact gattattcag	3360
gctaaagtca ccgattctac gaggatcaa ctgcgcccaa gaacattagc ccaagaaaag	3420
ctggataacg cccgtttgat tgacatagtg aaacgggaag tgtagaggc attacgtgaa	3480
ggaggccatc atgagtttaa ttgaacgtgg tttatccaga ctcaccctaa ccgcttttaa	3540
agaccgagaa ggtaaagttt ccgtgggtcg cttacaagcc atgtataacc ccgatacgat	3600
ccagcttgac taccaaacc gctaccaaca ggatgaaagt gttaatcgtg ccagccaaag	3660
cagccgttat gtattatccc aaccgcccgg attatcctta gttctgctgt ttgatgcctc	3720
gatgcccgat aataacatgc cgatagaaac ccagcttgcg accctgaaat ccctgtgtgc	3780
gattgatgcc agcaccaaag taccctactt cttaaaaatc aaatggggca aaatgcgctg	3840
ggaaaacaaa ggttatttcg cctgccgagc cagtagcctg gccgtcaact ataccctgtt	3900
tgaccgggat gccacacat tgcgggccag cgccactcta tctctggtag cggacgaaag	3960

ctttattatt caagctaccg aacggcagtt aaaatcacccg ccggccactg cggtttagcgt	4020
aactgatatg ctctccctgc ctttgattgc tttagatgct ggagcgtctc tggctggtgg	4080
cattgattat ctctcgtgg cctggcaaaa cggctctggat aatcttgatg actttacccc	4140
cggacaaaca ctgcaagcgc ggggggatgc atgaagatac ccatgataac cctcaaaata	4200
ggtggcaaaa cgctcaatca attgactgtc atcagtctga caataaacca tcaaatcaat	4260
ggcattccct cgaccaacat caccttgggg atcgctggcg atgcgagcca tattttcgac	4320
accaaagccc aagctgaact ggcaagttgt cgccccaata atgaactcac cctacagatc	4380
caaaaaaccg tgggtgtttaa agggagcatc gtctgacaag cacttgaact gaaaggtcaa	4440
gacagcatca ttaccctgac agcaaacat ccactacaaa agttaactca tagcctccat	4500
tcacaattat tcagtcaaca gagtgatgaa gcgattatca ggaaattatt caatcaggcg	4560
ggtatccaaa caacgataaa gcaggctcct caacttaaaa ccgttcatga acaaatggtg	4620
caatttcgtt gcaatgactg ggcattccta aaaagccgat tgattgccac taatacctgg	4680
ctgttgcccc gcaatgaatc gggtactttg ataacaccta aggccctgaa tcaatcgaca	4740
gtgcatactc ttcacgaca ggccagtgct gaagatatg tgttatttgc agcggatctc	4800
caatggaata accaatatag ccctaaaacg gtgagtgtac gtgcctggga tattgctcaa	4860
caaaagcttt ccccagcaat taatacccaa aacagtcagc ttggcagtca taaattggcc	4920
gtggacagta tcgccgcact ggctgataaa gagtggcaat gggcttacag ctatccatta	4980
gataatgaac aagccaaaca cttgctcaa ggcattatga ataacctgcg aagccataat	5040
atatctggca gttttgaaat cgaaggtaat caccgttatc aaccggggga tgtcttggcg	5100
ttaaatggtt ttggtcaggg gatggacggg caagggatta tcaccggagt cagtcagata	5160
attaatcagc ggcaaggctg gcacacccta ttaaccttag gcatgttacc cgatgtagaa	5220
ccgccggtgc ctgagtgaa agagttgcat atcggtatcg tggaaaaata ccagcaagac	5280
cgccaatcac taagccgtat ccagtcaga ataccgcat taaacttgac caaaggtgtc	5340
ctttttgccc ggctaggtaa accttatgcc agtcatgaaa gcggattttg cttttatccc	5400
gaaccgggag atgaagtgat tatcggattc tttgaatgtg atcctcgttt tccagtgata	5460

ttaggttcca tgcataatcc gaaaaataaa ccaccgttag aaccagtgga aaaaaatccg	5520
gtgaaaactt tagttatcaa gcaaggggat aaacaacaag cattaatatt cgataataaa	5580
gaaaacacgg tggcacttaa tagcggcgaa aataaagtct ctctgcaaca ggataaaaac	5640
attacgtca attcaactaa aaatctcatc actcaggccc aagaaattaa tatacaagcg	5700
gaaaaatctc tgtcagccac aggaaaatct ggcgtcgata ttaaggcgcg gaaaattaac	5760
ttaacccagt aatgaggtat tgaaatgaca agccaaatat tagccaatat ttacggttgc	5820
ggctggaaat ttccgccaca gttttctatt gaaactggcg tagaaatggc cgaaggtgcc	5880
gaaaacgttc gccaaagtat gaaaatcctt tttttaactg aaccgggtga acgaattatg	5940
cgtgaagatt atggttgtgg tctgaatgat tacatgtttg aaaatatcag tgatgaatta	6000
ttatcggaga ttcaaaccg cattgaagaa cgagtattgc gctatgaacc ccgtgctgaa	6060
atcacagata tccaagtaac tcagaaaaca gactcaccga atactttaca tattcaagtg	6120
acctatgccc tgagaggcag ccaaatcagt caacagcttg aaggggttct tgagatcaac	6180
gaaggtcagg caaaggtgag tctatgagca aacaactcat tattgatggc gacagcctgc	6240
tattcgagcc attattcggc aaccggcagg tcactatfff gatgccagcg accatcagag	6300
gcagcggaca cgcgcaaadc caaggcagaa agatagcgat tgtcggcgat gaaaaaaagg	6360
tacaacttca agcgcaatac attaccccaa gccacccggt acctggcata ggcacagtta	6420
ccattgctca attagatacc agccagcaag tcaacttttg ccacagccct gccacagtga	6480
tagttgtcgg gcagcaattt accgctcgat ttaccccatc acagccggca attaatccgt	6540
caaccgggcc agatgtcaca acaccagta tgggcaaagg ccgttttatt gccagtcaac	6600
atactatcaa cgccggataa ataactctgc aaaatcatta ttcaataacg ttcctattct	6660
gcaatagcta tcagcaatat attcaaataa caggtggtat aatatgggac tcaccgaatt	6720
aaaaaataaa ctctctgcta tcgtactcga tacggatttt aaacttgatg aaagaagtac	6780
actggatatt ttaaactggc tacaagaata tgctaaaaaa atccctttca atcaagagaa	6840
aaaacagttc tgggtagatt tctattttat tcaggaaaat agtcctgaga aattagccga	6900
tctttaccaa aacgttaata aaacgaatgg ccatttaccg gcccatcaag cttttgtttt	6960

agccttttta aaacttttag aaaccaccaa agtattattht aatactttttc cggcacgaca	7020
tcgtgatctt tattaccggg aattattagg tctaaaaccc agaaatgccc aagcagatag	7080
tgttgcttta ggcattacct taaatacaga taacacagaa catcttattc ctaaaggaac	7140
cttgttcgat gccgggcagg acagggccgg aaatccgcta caatacgcat caaatgcaga	7200
tttactggcg aatcaaggaa aattgagcga tctgcgttgg tgtcgaagag ataatgatag	7260
ctggcaatct gcaatactac tgaaccactc agataatatt gaattacctg aaaacagtat	7320
tcgacttttt agtccaacgc cggatgatat tcccgtttta tccggttatt tgataacttc	7380
gtctttattht gctatgccaa cgggggaacg cagtattaca ttgacttttag cagataattg	7440
gcatggatgat attaaacaca tcaccgctaa aatcagttcg ggagatcact ggcttttact	7500
atcagtaaaa aaagaacaag acaatagtat tcactatctt aaactttatt tatcaaccaa	7560
tgatgacccc atcgggtcctc ctgatgcttt ggataatata gcgtttgatg taccggtatt	7620
aaagctgggc actgttcagg gacctatact acccaagatt acgggtattg aaattagcat	7680
taacggcaac agtaatgtac attattcctc tgataacggg attgaaaaaa tagatgcagc	7740
tagttttccc tttggacaat caccgtcacc aggttccggg tttaatctga ttgcccctga	7800
atggatggg acagaaagcg ccaaaattac tcttactcct caatggactg gattacccaa	7860
agagggggtt aaagagtggg atcaaggata tagttctacc cccgaaaata atgcatttaa	7920
agtacaggct tatttaatca cacctcaaaa gagagaaaaa tttaatgaag ctcatgcatt	7980
atttaatgaa agtaaagaca agaaaccaca aggaaaaagc ctaactttta ctttacctgc	8040
aatggattat tcctttgcaa acagcccatc atctaataac tggcccgcat caatacgcat	8100
agaactaacc gaacaggatt ttatgcatgc ccaatattgg caaaatccta cgggtaaaaa	8160
acagcccctat acccccaaaa tgaacacatt acaaattcag ttcagtgcc aagttaaacc	8220
cgaacaattht tccgtttatt ctctcacgcc ttttggttgg ggaaaaacag gagaaaatag	8280
aacatcatta acccatgata cattctattht aggttttacc gatgtattac caggacaaac	8340
tttatccctg tactggcagt tagaaggat taataagctc cctttatcct ggtcttatct	8400
gaatcaagaa aatacttga gtccatttga taatcaggtg catgaccaa cccacaacct	8460

atttgatcga ggaatctggc gtacctcatt gccacatgat gcttcaaacc aagcctctca	8520
aatgccaaaa ggacaatatt ggggtgaaggc acacatttta caaacgaatc aagcaaccct	8580
gactgatctg tattgggtatc gaaaagataa tgatgtctgg aaatccgcaa cacctcttag	8640
cctttcaaat aacatgaaat taccgcgaaa cggtattcag attttttagcc caacatctca	8700
tgatgttcca gttcgatacg gctacctaat tacttcatct ttatttctcat tcctcaagaa	8760
aggacgcaat atcacattaa ttttagcagg agatagctgg gagggtaatc ctgaaaacat	8820
caccgctaaa atcagttcag gaaatcactg gttaacacta tccgtcgaat atctgagtaa	8880
tactaatagt ctttaagttgc aattatcaga taataataat gatcccatca gccccctaa	8940
tgctctggat aatatgacgt ttgacacgcc attgttaaaa ctagaagcca ctcaggattt	9000
cactttgccc tggatttata aggtatgcgt taatagcaac aatatactct ctacctctga	9060
cagctcagat gcagcgatta ctcgtttccc ctttggccaa tcaccatcgt tgggttccag	9120
cttttagtccg aaaatcgttt tcccggaatg gtttgaatct gaatacgcac cagacaccac	9180
gatcacgatt acccctcaat gggttaacct gccacagaa aacttttcat cgtggtatga	9240
cggatatatt aataaacctg ccgataatag cgtattttaa atagagggtt atttacttac	9300
tcattatcag ggaaaaatca aactcacaga agctgagaca ggaagcgaaa cccaagcatt	9360
attcaatgga aacaatgcac cacaaggaaa aagcctgact ttcactttac ctaataggta	9420
taacttctat ccgcgcaacc atcagtcaat gaagatagaa ataaaactcg ttaaacaaga	9480
ctttatgcac actcaacata agagcaatcc cacaggcaaa aaaccaccct ataccccgca	9540
aatcagtgcc ttacaggtgg aattcaatgc tacagctttc catcgaaaat tctccgttta	9600
tcctctcacg ctttttggct ggggcaaaac aggagaaaat agcacaccat taattcatga	9660
tacattttat ttaggcttga ccgatatatc accagagcaa actttttctc tgtattggca	9720
gctaaagggc cttaaagagc tacctttgtc ttggttttat ctaagtgaag aaaatagctg	9780
gaaatcatta aatagatcaa cttaacaaca aaccacaaac ctgtttgaat cagcagaaca	9840
aagtatccta ttaccacggg atgcttcaaa ccaagcctct caaatgccat taggacggta	9900
ttggctgaaa gcacagatag aacaggagaa aaaacagata aagatagcgc ttcctgatta	9960

ttatccaaga atcagggggc tgttgataa cgctaccatc gccactttaa tcaacgctga	10020
agctgttgag caatctcacc ttatcaacgg attggctgct aacaacatta aacaaccggt	10080
taactcatcc gttgcatca acgaagtat tcaaccctgg acatcctgga acggctgccc	10140
aaaagaaacc gagtcagcat tcctggcacg agttcctgcc cggctctctc atcgtaacg	10200
agtgctaagc tggggtaaca ttgccacttt attaaaagag aatttttagta gcttattcga	10260
tgtcaaatac ctttctgtca gtgaattaac caaaattcca gcgccagaaa agcgacaatt	10320
aaccatcatc cccgacaacc gctataaaga taatgatgat tcactacgcc cagtattgaa	10380
ccaagccaga ctgaccgaga tggtcgaatg gttagatcga ttaagtagcc cttggacaac	10440
tattgaaatt aaaaatccca catatgttaa cgttctgac cactatgaac tgatatttac	10500
ctcggatgtt aaccccgatt atggcctcca tcagctacaa caagaactca gtcgaaaata	10560
tatgccgtgg ggagaaaatg cagctattgg cgtaacaccc ggtaatcgta ttgactactt	10620
ccagttatta gcctcaattc aacaatcacc gctggttgaa cgggtcacca acttaacgtt	10680
aaaaaaaggc agccagccta ccgtaagtga aagtatagaa gccgccgatg atgaagtact	10740
gatttttagtc tggtcataaa aacttcccca acctaaggaa ttaacaaatg aataatcgag	10800
atatgctatt tcctatcatt aaagacgata ttacctttga ttctttattc gcccaggcaa	10860
aagccgttat tgaacaacaa tcgggggcagc tctggaataa tacaggtgaa aatgatcccg	10920
gcattacttt attagaagcc tgttggttatg gcgcatccga tctggcctat cgccacacat	10980
tgccactgcg agatttgctt actcctcaag aaaatgaacg aatagatgat ggcatttttc	11040
ccaaagaatt tgggtccacaa caaatactga cctgcggccc aattaccgcg gaagattacc	11100
gtcgagcttt gttagatttg cgtagtgata acaccgttga aggttatttt ttctttaatg	11160
atgcacagct cattcgtgaa ccggaaaatc aacgctattc atattggtat aacaaagaaa	11220
aacgcgaata cagttttact caagaccaat acagcgaaca attacagtta aactgagag	11280
gaaactattg gctctattta cttcccagtc ggaaaaccca gctcgataac accctggctg	11340
aagaaagact caacattttt ctgaaagata accgaaactt aggagaatcg gtcagtaaaa	11400
ttatttggct agaaccatt aaactgtcat tgaaaattga tattcagctt gatgatgacg	11460

ccaaagatat	tgctgatata	tttgctaaag	tttatatgat	tgcagaacaa	atggtgcttg	11520
aaaaaccatt	acgttatacc	actcaagcga	tgaaagaact	gggttacagt	caggaacaaa	11580
tatttgaagg	cccttattta	caccacgggt	ggataccgaa	attacctcaa	accaaagatt	11640
atactcacc	taccgtatta	aatctcagtc	ctttaattaa	tcagttactg	gctatcaaag	11700
gggtgaaaca	tattacccaa	tttacattgg	ataagcctga	taaaaaaatt	tctaagttac	11760
caaatgataa	ttggtccttg	gaaatcgctc	cgggatatta	cccaaaaacta	tggggagata	11820
ctccattaga	attaattacc	tcaccaacaa	gccactcac	catcacggca	aaagggggaa	11880
ttaaaattgc	tattactaaa	caacagatag	aaaaaaacat	aatgacagaa	ccactaatta	11940
atacacagcc	agaattattg	aactggggta	aacatcgcaa	agtcctggat	tactatccga	12000
taagcaataa	attacccgct	tgctatggat	tacaaactaa	taccaacaa	cagctacagt	12060
tgcatcaatt	tatgctgcct	tttgaacaaa	tgctagcgaa	taactgcgct	gaacttgctt	12120
tattgccaag	actattagct	tttaaacaac	gaggaaatac	ggtacatggc	attcaatggc	12180
cttttaaaga	aaatacgggt	ggtcaacatg	ttcataagga	catagtatct	aatttaaaca	12240
ataatgctac	gaaaatcgat	aataatgccg	atgactacga	caaggaactc	gttattctag	12300
attatttgtt	aagatatttt	ggggctcaat	gtgcaatccc	acgactatca	ccagaccac	12360
cacaatcatc	attaacagaa	cctcagacta	aaaaagattt	tctatctact	cagcgcgaat	12420
atctgggtca	acagccaaaa	ctgacttatc	agcgtaacaa	tattcggatt	gataaagtat	12480
cagcactgca	aaaacgtatc	gctgcccgat	taggtctggg	aggagaatgt	ttcaaagcag	12540
agcctgactt	agctcacctt	cctttctacc	tcattgaaca	tcgtaggctc	ttaccagtaa	12600
aacctgatat	aaaattctat	attgagcaac	aacctaattc	tctggaaatt	gaaaatgata	12660
aattaaaaat	cacacagaaa	gattcagcgg	gtcggttact	gcaaggtcaa	gttattaacc	12720
tggaatttcg	tgagggtctat	gatgaattta	cattgctaaa	cttaatgata	actgaagtga	12780
caagagatac	attcaccatt	agcattaata	atagccgtga	tctcagagac	aatctggaca	12840
aagtgcaaca	cgcgtttgaa	caaacgaata	atctgagctg	gcacaatagc	ttaatatgga	12900
tggaagatat	ggattatcaa	ttggtttatg	ccaatggaga	acaactggaa	aaagcggaaa	12960

atgaacgatg gattaccatt aacaatcaaa gtgctttccc tgctatgatc ggagagaatg	13020
atgaaatcac actaaaaatt caatccgatt atgaacttaa aaccaaagtc gtgcggcttg	13080
attataacaa caaaaaaatt ctgattataa aagatgcgac atcaataaat aattttccgc	13140
caaaaagaga agcatcatat tattcttgct cttctctaaa agacaatggg tacggatatt	13200
cggatgaata taaatatgaa cttacttata ttgatacaga ttctacaaaa gaaaatgagt	13260
gctggattac tatcagcgat ccaaataatt tgttttctcc tgatatcatc gcagagaatg	13320
acgaaattat attgaaagct aaccctaatt atgagtttaa aacgcacgta gtaaaatttg	13380
atcgtattaa tagacaaata ttacttagga aaaatacaga cctggaaaat aattttccat	13440
cagaaaacaa cacatcgcac tatcgctggc atttctctgg tgaaaaatat gcccaaactg	13500
accatttttc atttgttgtc agtgcagtac tgaatcgaga attaattgag aggggcacag	13560
tcgatctcta taaattagag tcttgggtaa aaactgagat tttatctgaa ttacccgcgc	13620
atatctcact cgttattcat tggctatcat cggaagaatt cgaaaaattt gccagtactt	13680
ataaagtttg gcaaaataat ggcgctcctt taggtgatca cgcatataaa attctagaaa	13740
cattaacact tgggaaaaaa ctttctactt cagcaagaag gtccagcagc tatatagaag	13800
cacagtaata attcttacag aacattaacc catattttatc ttataatatc aaacatcata	13860
aaaacaatct tcagctcatt ataatgacat atttcatact caggtttctt catatctgtt	13920
aattacaaag agaattattaa tatgatctca gcaccaaadc tgttaaadcg gattatcatt	13980
actattgaag cgaataacgc acaggcagct aaaaaagtat tgcatggctc cctgcttaat	14040
caatccagta taaacaaact ctttgattca tactttaacc aatatgttgt taatcagact	14100
atctacctga agacactcac cctgaatctt ggcgaaatac gattaaatag ttttaattca	14160
cagtttggtt ttcggcttaa tactattctg agtcaagcat tgagccaata tcaggtaaatt	14220
aatcaaactg atattgagaa atttatttat tacttatatc gaaaagattc tatattaaac	14280
ccaatagagg aaatcaataa tcgtgaaatt actgacatca atattaagca attaatattc	14340
caattacccc agatacaaaa caattggaca ctattattgg caaaaagctg tttatccaca	14400
catagcctga aaaaactcct ggctatcaaa aaaacagctt tattaaccgc cattaatcgt	14460

aaattatctg aaaagatcaa tatatcacc	tatcagcagg aatcggtttc cacctggcaa	14520
ttgatactga atgcgctgaa atatatacag	cgacataata cacaggaaat acctgaaccc	14580
gatgcgaaaag tcatatcact cattacaacg	gaactcaatg acaatgccat taatacagca	14640
ccaattattg cattattttcg ccaagttata	accaaccatt cccactgaa taagtggctg	14700
gaacaactgt ggcaaacaaa gcgaatttca	cagttatgta aaaaacagct gtcaattgaa	14760
gaataccaac atctatcgga gcgctttatt	gccaaacacg ggaataaaaa taaatctgat	14820
aaaaaatcat ccatgacttc cgaaccgctg	ttattacctg aacaccctcc accacgtcag	14880
gtcaataatg ctggaatatt agttctgtgg	ccgatgttac ctactctatt taaccaattc	14940
ggcctgtttg aaaaacaaaa atttattcat	cgtcaagctc aatttagggc tgттаатcta	15000
cttgattatc tcat ttgggg aaacgaagaa	acacagacag aacgaaaaat attgaattgc	15060
gttctgtgtg ggттаатtgс cgatgaggac	acggaatcaa tccctattga gccagaaaaa	15120
caacaggtaa tagaacaatg gttagatgca	gttatcagtc aacttcctgc ctggaaaaaa	15180
ttaagccgca atgatagccg ccaattgttt	ttacaacgcc cgggggaatt gctgacaaat	15240
gagcaggaaa tcaaaattac ggtacaacct	caaccattcg atgcactgtt aaataactgg	15300
ccctggccgt taaatatcgc caaacttccc	tggtctggatc gccctttatt aatcaactgg	15360
taaaacattg acaaggttta tatgaaagaa	catcaatata gaatagtcga tctacgtctg	15420
atttattccc atttggagcg catcgatctg	ctgttacaac gtcactatta ccaaaagaga	15480
gacaaatacg attcattgcc agaaagtttt	ttgcttgaag aagatgaatt agaacaacgt	15540
ctagcaaaac cgttgggtat tcctcattgg	ctaacagcaa ataccggcgc tggtgataca	15600
gaaacagaaa atcattctgc ttccggcaca	ttatcactgc tagtcacgcg ttttaaactc	15660
actgaatttg aacgtgatgt gttattgcta	ggttttattac cgcattttga caaccgctat	15720
catgcgttat ttgctactct gcacggtaac	agtaaaaaac agtggcccag ttttgattta	15780
gcgattgaat tatttagcca acatcaaagt	aactggcaat tattttcaaca ccacttttta	15840
ccgcaagctc cattaatcaa tcaccattta	ttacgactca ataaccaaga ggaaccatt	15900
tggtacaaa ctcaattttt aactcacaat	gcagtctggt cttttttatc cggtcagcgc	15960

gtcattttac ctcccttaat atcctgcgct tactggcata ttccaacctc acagacttgg	16020
tatccaccaa tccttgggtca tgcatttgaa aaaatattgc tgaatgaaac ggacgaaata	16080
cgcccgctgg tggttcttaa aggaaaacag gacagcgcca gagaactggc agtcagtaat	16140
attatgggaa ttcacggcat taacacttta acgttcgatt tatttcacct gccagatgaa	16200
gagtgcacca cctcaatact caatctgcta atagatgcaa tacgagaaac ccggctacat	16260
aatgcctgtt tattaatccg taacttttct ttgctggcag aggaaaagag aatatcgcat	16320
agagaattat cagctctact gaatcaaccc aaattacgtg tggtttgtct ggcagagtca	16380
gaagaatcat tagcatgggt taaacacctg ccgatagtgc aaattaatat gccaccggcg	16440
acgctggcag ataaaaaac gatgctggaa gccagtttgc cagataatgt cactaaagga	16500
attaatataa ctcaattatg tcaacgtttt tcatttacag cagaaacatt accgttaatt	16560
atcaaggaag ctcatcaata ccaaatcctc cgacaaccgg aagatcaatt gaaagaatct	16620
gatctacgta aggcatataa ttgccgcgcc caacaaaatt tcggtaaatt agcccagcgt	16680
atgacaccaa aacgaagttt taatgatttg gttatttccg ctgacttaac tcaacagttg	16740
aaagaaatca tcgcagcaat taattaccgt gaccaaattc tgggcgcagg ttttcgggaa	16800
aaaatcagct atggtactgg tattagcgcc ctatttttacg gtgaatccgg gacggggaaa	16860
accatggccg cagaagtgat tgccagctat cttggtgttg atctgattaa ggtagatctt	16920
tctaccgtgg tgaataaata catcggtgaa accgaaaaaa atatctcccg tatttttcgat	16980
ctggccgaag cggattccgg ggtgctgttt ttcgatgaag ccgatgcctt attcggtaaa	17040
cgcagtgaaa ccaaagatgc ccaagataga catgccaata ttgaagtttc ttatttatta	17100
cagcgactag aaaattatcc gggattagtg attttagcga ctaacaatcg caaccatttg	17160
gatagtgcgt ttaatcgccg ctttaccttt attaccgct ttacttatcc cgatgaagca	17220
ttacgcaaag caatgtggca ggcaatttgg cctgaacaac ttaagttatc agatcaactt	17280
gattttgagc atttggctaa acaggcaa atctgaccggtg ctaatatcag aaatattgcc	17340
ttattatcat caatattagc tacagataat aatagtgatc aaattgaaaa taaacatata	17400
gcgcgagcat tgatacttga attaaataaa acgggccgat tgatttttta atcatttata	17460

cccaataaat ttcgagttgc agcgcggcgg caagtgaacg aatccccagg agcatagata	17520
actatgtgac tgggggtgagt gaaagcagcc aacaaagcag caacttgaag gatgaagggt	17580
atatagaatt ggagtgaata tgacaaatat aattaaccct aataatgcga ttcttgaagt	17640
taataacgca ttaaatgata ttttatctca gtatttaact aatattgata tccgctttga	17700
tctaccagaa ataaattcaa tcccatcaac ccctacagtg agtatatttc tttatgatat	17760
acatgaagac ctacaattac gttctgctga accaagaagt tatcatccta ccaccagctc	17820
attattgccg ggatgggtaa atattaatta taactattta attacttact ggcattcaag	17880
taatccatca agcgacagtt ctaccctga tagtcaaccc aataatcaag cggcacaagt	17940
catgactgct attttaaag cattgggttaa caaccgacaa ttacctaataa ttcctggcgc	18000
atataccaga gtcattccac ctcaagaaaa tctaaatagc ttaggtaact tttggcaagc	18060
gcttggcaat cgccctcgc tttctttatt atattcaatt accgcaccgg taaaactgca	18120
aaatattaaa gatgtcataa agcccattag ccaaatttcc acttctgttg atcaaaaatc	18180
aaatctggat aattcgcaaa tcaaccaagc cttatttagc aaattgggtg ccgatttagg	18240
tggcacacaa gatgttcgtc ttgctcttgc gaaagtgaat ctgacaacca aacctgctaa	18300
agaaaaataat gaaaatcaaa ataataaaaa tgtaattatt gaagtttctg gcattacca	18360
tttggattat ttaccagaa taaaaggat tctttcaaca tgggtaaata gtcatagtgc	18420
tgttgttagg ataaatgata ttggtattat tgtttcagaa tataaatatg ataaattaac	18480
aggcgtttaa	18490

<210> 95
 <211> 22492
 <212> DNA
 <213> Photorhabdus

<400> 95	
atgaatacag ctcaagaaat tattaaccgt ttatcgggga gagccgttac gcttggttgg	60
gatgttggtta ttgcttatga ccgaaaaaaaa attaacactc tgtttagagca acaatatggt	120
gaaaaggtaa aaaacgggga gaacttcccg cttatcaact gggagaacca gagaaaaaca	180
cttcaattta aagatcttca attaggtgtt ccacttattt cttttgagaa ttcaaacactg	240

gaaaattcaa gggcgcttgc cacgatagaa tttatttcag gagctattat tgaatttagt	300
gactccgggc aaataatcaa ctataagaag attgaaccta gtcattggtta tggcatggtg	360
ctgactatcg atctcatggc tggtagaggt tcagtagaag aacaaggctg ggtgataata	420
aatcttaacg aaggcgccat actcgatttg catgttatcc aacaaccgcc agcagaagtg	480
gtagaatttt tccgcacttg gttgatggct aataaaatga cttatgaatt aggtaagctg	540
gatctgagta gtcaagctgg tctagtcct cgttcttttc gtattcgtac tcagcgggcg	600
cctgaaaaaa ttcgtaaagc gacgagcgat gaaggaaatg gcgctgtttt gttgtttgtt	660
gccactaact ataaccctac aagtggaact ttacctgcca aggattatcc gtggctaatac	720
cctgaggaat attcaggcgc attgcttatac ggtaataaat gcttatttaa agacattctg	780
aaaccgaatc tggatcagtt gtttgataaa ggggaatgga cattaaaagt tcagcaaacg	840
gattctgatac aactgctgca ttatctggag gcaaactctg catatataac agataagcct	900
tatatggcag actttgaagg aactcaggat ggagtctgga caggacgtta taaatttgag	960
actggccggg gacattatgg ggtgtatgaa aatgtacgct ttcctatcaa tggaatgttg	1020
atgaaaccgg ctaaaactgg attacagtta tcaatagatt caccacaaag ccatcaattt	1080
aatgttgatt tcggaatgaa gtggttccat tgtgctaata taatgtgtgg ttattcctgg	1140
tttaacgaga cttaccatt ttatcttgat ggaaaatcat tttatcaagt tcatattgac	1200
cctgataaag aggtgattta ttttactggg ccagatgaag atattaatat tgtaggaaat	1260
tacagccgc ctgcgtgggtg gcaatctaaa tggcaaaaac atatcagtga tgattttacg	1320
gatatttcct cggaaaaatt taagcgactc agtcaaataa aattgccaga aatatgcatg	1380
tttgccgtga accatttatt atttcctggc cataataactt tgctgttgaa agacgtttat	1440
ttaccgggtg atatggtgat tttcgggtgat attaaccat cacttaccgc ttttcgggtt	1500
acgccattaa aagcaacagt ggtggcaaag ggaacccaac aatttaaagc catagaaact	1560
aattgatgat tatacccttc atccttcaag ttgctgcttt gttggctacg ttcactcacc	1620
ccagtcacat agttagctat gctccggggg attcgctccc tggccgtcgc gatgcatctt	1680
gaaatccata gggtatatat ttaattgat aagtcttttt tattttaaca ttataacctg	1740

attctttttg gataaaatta aaggattatt aacatgtcta ttacacaaga acaaatcgct	1800
gctgaatatc ctattcctag ttaccgtttt atggtttcta taggagatgt gcaagtcctt	1860
tttaatagtg tttcgggatt agataggaaa tatgaggtta ttgaatataa agatggcatt	1920
ggtaattatt ataaaaatgcc aggacaaata cagagggttg atattacact tcggaaaggc	1980
atattctctg ggaaaaatga tttatttaat tggattaatt ccattgaact caatcgggta	2040
gaaaaaaagg atattacaat tagtttaact aatgatactg gcagtaaagt cttaatgagt	2100
tgggttgttt cgaacgcctt tccgagctca ctgacggccc cttcatttga tgcttcaagt	2160
aatgaaattg cagtacaaga aatttcatta gttgctgacg gggtacaat tcaggttccc	2220
tgataactaa aaactttaag gaaaaataat gtctgtacaa acaacttatc ccggaattta	2280
tattgaagaa gatgcatcat tgtctctatc tatcaataat agtccaacag caatccctgt	2340
ttttatcggg aaattttaca acttggatgg ttccttacct aaagtgggaa catgttctag	2400
aattaccagt tggtttagatt tcactaaaaa attttcggta gctcctcctc aaaccatttc	2460
attgatcgcg tcgccaatg ctgacacaca agaaagtgtg cccaaagcag ttcaatatac	2520
ttataaggcc gagtttgaaa cctcagaaaa tctggcaaat ggtgcctatg cggtacaaca	2580
ttatttccag aatggcggtg gtatttgcta tatcatacct ttagttagcg tgaaaaaaga	2640
ggatgctgcg attgagttaa caaaattacc tgaattaatt gaaagacaac aagagattac	2700
gttaatcgtc tgcccggagg acgataagac gctcactgtt gatagcagta aaaaatcgga	2760
tgtttataac agcatcaata cattattgag taataaggta ggttattttc tcattgcaga	2820
ttcagatgat ggcaaagcag ttcctgatac gttgccggaa aaaactgcgg tctattatcc	2880
tggtttacta acttctttta cacaacgcta tgcccgcctt gccgattctg ctatcaaagt	2940
gaccggtatt acaaatatat caactctggc tgatattcac accaacttgg ccgatgacta	3000
ctcaacagca agtcaggtta ttaatgatgt tttggaaaaa aataataagc tcgcatcgtc	3060
tcccattatt ttacctcca gcgccgctgt tgctgggtgt tatgccgctg ttgatgtgag	3120
tcgtgggtgt tggaagcac ctgcgaatgt gatgttaagt aatgccacgc caatcattag	3180
tatttccgat gcggaacaag gtgtgatgaa cccattaggt attaatgcta ttcgtagttt	3240

tactggtaga ggtactttga tttgggggagc tcgtactctg gataaaacgg ataactggcg	3300
ctatgttcct gtacgtcgtt tattcaatag cgcagagcga gatattaagt tagcaatgcg	3360
ttttgcagtt tttgagccta actcccaacc aatttgggaa aaggtcaagg ctgctatcaa	3420
tagctatttg cagtcacttt ggagcaagg tgcactgcaa ggcaataaac ccgatgaagc	3480
ctggtttgta caaattggta aaggcgtgac catgacagat gatgatatta agaatgggag	3540
aatgattatc aaaatcggca tggcggcagt acgtccggca gaattcatta ttttacagtt	3600
tacgcagaat atcgcccagt aacttaggtc tataccctat agatttcaag atgcatcgcg	3660
gcggcaaggg agcgaatccc cgggagcata tacccaatag atttcaagtt gcagtgcggc	3720
ggcaagtga cgcaccccca ggagcataga taactatgtg actggggtaa gtgaacgcag	3780
ccaacaaagc agcagcttga aagatgaagg gtatagataa cgatgtgacc ggggtgagtg	3840
agtgcagcca acaaagaggc aacttgaaag ataacgggta tatttaatat gggcgattta	3900
ttgcccattt ttgtgaaagg aaatgagtta tgtcgccaac gctaccggt gtaacgatga	3960
ctcaggcgca gataacagcg ttcgggtgtca gtacattaaa tatgcccgtt ttcatagggt	4020
attgtacgag attgcctgcc ttttcagcgc ctgtaaaagt aaacagttta gctgaaacag	4080
aacaaataat agggaaagaa gggcgtttgt atgctctatt gcgccacttt ttcgataacg	4140
atgggataca agcttttatt ctgtcgttag gcgcacctgc tggggaaaat gctaatagtt	4200
ggcttgaggc attacaacag cccgatttgt atgcggctgt tgcagcagag ccgctaatta	4260
cacttttagc cgtcgttag gcaagtgaac tgaacaaaa agaaggtaat gaggctgtgg	4320
aagcttggcg acagtactgg aaagcagtat tagcgttatg tcaggcacgc agtgacttgt	4380
ttgcatatt ggaggcacca gatgataccg cattaatcaa gcgtagtttg caggattttc	4440
atcataaggc acgtcagttt ggcgctctct actggccaag gctagaaaca tcttatcaat	4500
cctctcagtt aaaaattttg tctcctattg gtgcagtagc agcggttatt caaagtaatg	4560
atgtccggcg aggggtagga catgcacctg ccaatatagc gttaaaacag acgattcgcc	4620
cgataaagtc ccgcctggaa ttagaagagt tgtatgaaga atcggatggt tcaactgaatc	4680
tgattttag ttttccagct cgtggtactc gtatttgggg atgtcgtacg ttggcgggta	4740

ttgattcacc ttggcgttat attcaaacc gattattgac ttcacacgtg gaaaggcaac	4800
tcagccagtt aggggtgcatg ttgatgtttg aacctaataa cgcagtcact tggatgaagt	4860
ttaaaggcca tgctgggaat ctattaaggc agctttgggtt acaaggggtg ctgtatgggc	4920
agcgtgaaga tgaagccttt tccgttgaaa tagatgaaaa cgaaacgatg actcgccagg	4980
atattgatga aggcagaatg attgctcgta ttcatttggc attgttagca ccggcagagt	5040
ttatcgctgt gactttgaat tttgatactc gctcaggcat tgcgacgagt acataataaa	5100
tcggaatatc tccatgacac taccagcaga gctttatacc ccagcggttt cacatcgttt	5160
tattgttaat tttcttttta aaggtttact tccttctccc gtagatattc gatttcaacg	5220
tgtttctggt ttagggcggtg agttacaggt tgaacagcgc catcaggggg gagaaaacgc	5280
acggaatcat tggttggctg aacgtataca gcataatagc ttgatattag aaagaggggt	5340
tatggtcgtt acccctttaa cactgatgtt tgatcaggtg atgcgggggg aaactctcaa	5400
ttgggcagat gtggttaatta ttcttctcga tcaggctcaa cgtccgataa caagttggac	5460
cttgagtcat gcgctaccgg ttcgctggca aacaggagat ttagatgcca acagtaacca	5520
agtgtgatt aacaccttag agctgcgtta tgaagatatg cgcattatag gggtaaaatt	5580
atgactatcg aaatccgtga actcattgtt caagcccgtg ttgtcgggac tgataccaaa	5640
acaacacgaa ccgttccttt atctattgtg caaatggaaa cacttataga acaacgtctg	5700
gttgaaaaag tgaagcgga gatattagac gtactccggg aagaacaagg tggtaggtta	5760
tgagcttgct tgaacgaggt ctggctaaac tcacgattac gggttggaag gagcgtgagc	5820
gtaaacaatca gattggtaaa ctagaagcaa tgtataacc ggaaacactt caactggatt	5880
atcaaactga ttatctccct gatgttagca ataacaggt aacagtgagt aaccgctacg	5940
ttttgtcaaa gcccgagggt ttaacactat cttgttatt tgatgccaat atggctggtc	6000
ttacgacaac cgtcgagtcc caaatcacta ccctcaaadc gctttgttta gttaatgcaa	6060
gtactgatga acccaatttt ttggaaatta attggggggc aatgcgttgg gaaaataaaa	6120
attattttgt tggtcgggct agtggattgt ctctgactta tttgcgcttt gatcgtaacg	6180
caacaccatt gcgtgtgagt gcgcagctca cattagtcgc agatgaaagc tttgtgctcc	6240

aggataacca agccaagtta gatgcgccgc cggtatcagt agttaatgtc ccggatctga	6300
cttcattacc tgcactggcg aatatcgcta gcgtaaccac tatgttggga gtggattatt	6360
taatgttagc ccgcaccaat gatatggata atttggatga tatgcagcca ggtcagacat	6420
tgccaacacc ggaggcatca tgagtttttt agataacagt aacttcaagc catcagatat	6480
caaaactgttc gttaacattc agggagtggga gaaggaactc aacgaactga tagtaagcga	6540
attgaaaatc tcccgacgta tcaatgccat tccgcaggca gttgtaaagc taagagcgaa	6600
agagagtga agtggtgtat atcagtctga tgtacagcgg atgttgaaga gttgccgtcc	6660
gggagtaaag gcagagcttc gtattttgaa taccggcta ttcagtggcg atattgtgca	6720
gcaaaaaaca gagttagtgt atgcgaaaac acacactatc aaattggtgc tacgcatga	6780
cttacagcgc atcaccggta attttcgtac cagagtgttt gcgaataccc gtgacgtaa	6840
agtgatagcc gatctattga ataccgcaac attaaagccg gcattttcgg ggacatcaca	6900
ttgggatata gatcatgagc aactggttca gtatcgttgc agtgattggc aatttttgtt	6960
gcaacggctc tatgctacga atagctggtt gttagctgaa gaagataaag ataacactca	7020
ggggaaagt accattattg ctccaaattc tttgccctg aatgagcgtt ggacactgca	7080
acatcaggct gatcatcagg ctatccggct ttacagcacg gagctgatgc tggataaccg	7140
gtttgataca gcggaggctg ttgttagtgc ttgggatatt gatgatcagg cattactcgt	7200
ggcgtggaaa gaaaccctta gtcaagttgg gaaagatgcg ttagcgtcag ataattttag	7260
ccagacaaat aaagattcga gtgaactgtt attaagttgt ccgctctcta caaaagaagt	7320
tcaattttta acgcgtagcc aattagtcac gcggcgcttg acggccgttc gtggttcact	7380
gaaggttgaa ggcagtacta agtaccgttt agggcatgaa ctgatgttgt caggttttgg	7440
tgaaaatatg gatggctcac aaatactgac gggagtggat catcgaataa cggcagaaga	7500
aagttgaaa acaaccttac atgtgggatt agaactgccg tttaaaggcag agtatgtcac	7560
tcaggttaac ggtgttcata tcggcaaggt tgctgattat caatcagata gcaaaaaatg	7620
ggatcgtatt cctgttttga tccctgcatt tggaacgaat attcccttgt ttgcccgtt	7680
gggaaaacc tacgccagcc accaaagtgg attttgtttc tatcctgaaa cgggtgatga	7740

agtcattctc agttttttgg aaggggaccc tcgttatcct gtcattattg attccctgca	7800
taatcctaaa caacagactc cattgcaa atcagcaaagag aataatctca aaatgttgat	7860
gattaagcag agcgataaag atgagcaaca attgttattt gatagccagc aacaaacagt	7920
cgcgttaatc ggtaagaaaa atatcgaggt taaaggtgag tatatcaacc tgactaaatc	7980
aaaggggact cgataatggc aaatacgctt attggccagg tatatgggtca aggatgggct	8040
tttcccatta aattttattcc tgataataaaa gaaaccgcag atcaaacagc cggtattgtt	8100
atggctcaag ggattgaaga tgtcagtcaa tcgctggaaa tattatttct taccgagcct	8160
ggcgaacgaa ttatgcgtga agattttgggt tgtgggtttac aagattttgt ttttgaaaat	8220
attagtata cgctaatttc tgccatcaaa aatcgtattc agcaagcaat attacgttat	8280
gaacctcgcg catatttatt gaacgttgat attcaaacca aagaaaacca acctggacat	8340
ctgctcattc agattaattg gaaattacgt ggtagtgata tatctcagcg tttagacgga	8400
gtgcttagac tccattcagg tcaagcattg gaactgttat gaccaattat attattatcg	8460
acggggatct cattcaaata aatcccaa attgagggtga tcgaactctt acgattaatg	8520
gtattcctaa aataagcggg aatggagatg cgcaaattga aggaaaaaat atttgtgtgt	8580
caggtagatca cttactgtc tcaattccag ccatttatat aacctccaga catcctgttg	8640
caggtagtgg aaaagtga aaatacaatt tatctgacga ccaactagca gaattttgtg	8700
ttagtgggga tgttgtgatt attgaaggca gtcagtttga agctcagttt acaccggata	8760
agccggccac taatccaagt aaccaagatg cagataatcc tgcgccttcg aatgggagtg	8820
ggagatttat acactcacag aacttcgtta aggcagaaaa ataaaaaatt ttgccgaagc	8880
ggtaataaag tatgaataag cggggcggat aaaaacatgg atcttgctga attaaataat	8940
acgttgatga atgacttacc aacgaccaat tttagtttag aaacaaagga cccattaacg	9000
caattaaagt gggtacaacg ttatacagaa aatattcgtt tttatgcgaa tgatgattat	9060
ttctggcatc aattctgggt cttaaaaaat cacacaccag aagcgctctt tgctcgtttg	9120
caaggtgaaa cgttgggtga tggagaattg cctcctcatc aagcgctatt gctggccttt	9180
ttacaacagc ttaagacgcc aggaatcatg cttgatactt tttcagcccgc tcatcggtca	9240

ttgtactatc aggaattgct agggataacg cagaaagatg cacaacctga tcatgtggcg	9300
cttggcgtgg tattaagtac tggatttgca gaatatttat taccgacagg cacattagtg	9360
gatggtggac aagacagcag cggaaattca ctgcaatatg cgttggatac cgattttattg	9420
gttaatccag ggcaattaac agatgttcgc tacagctatt tggatcataa gacctataaa	9480
atcttcatct tgcaagatga taaagcgaat atcagttggc cctcttcagg cgctcgttta	9540
ttttagtcac ctgagggcaa cggacaggaa aaggcacctg aaaaaagtt ggcactttac	9600
ctgggatttg atgatataca gccagggcaa actctttctt tattttggca attcattgca	9660
tcaactcccc tgacattaaa atggttttat ctgaacgaga taaataactg ggtgaagcta	9720
gatatgtca gagataacac ggatggcttt tttatcagtg gattatggca agcgatatta	9780
cctgatgatg cggtgaaaat gtattttcca gagacaactt ctgtaaaacg ctactggatt	9840
aaagctgagg tggaatcgct tactgaatct ggcgatttgt ggcaaccgct attagaaggc	9900
atcttgtata acgctcaaac agcaacgctg gttgatgcag acaacacaga tgaaaagcac	9960
tttcatgatg ggctgatgcc ttttagcgtg cagcatttgg tcaacaccgt ttcagaggta	10020
aaaaaaattg agcagccctg gtcttcttgg gggggaacgc cacaggaaga cactactgat	10080
ttcttccatc gagcggcaac acgtcttcag catcgccagc gtgcgttaac ttgggataac	10140
caaattgcca tgttgaaggc tgaatttccg cggatttatg atgtcatctc accaaatatc	10200
acgtggatga accaacttca gacatcaaat acgcaaacgc tgatcgttat tcctgatgtg	10260
aactacagcg acaacaagga tcgcttacgg ccacaattca gccctgccag cttgcgacaa	10320
atgagtgact ggttacagat tcacactagc gcatgggcga atccacaagt ggaaaatcca	10380
atttatattg atgtctctgt gacctatgag gtgcaattta gtgcgggtgt gaatcctgat	10440
tatgccctcc ggcaattaca acaatggttg agttcaattt atatgccatg gtatcacgca	10500
gataaaaaag gtgttgccgc tggcgatcaa atcgattttt accaactggt tgcagatatt	10560
cagcgagtac cttacgtgga gcatgtcaaa acattgacat tgaccacaaa agacacctca	10620
ttaaccaatg gcgggggttat taaggcacag caaaatgaag tgctggtgtt ggtatggcaa	10680
caaggagaac aaattaggca gggagaatcg aaatgaggca gcataatgag ttatttcctg	10740

tagtaaaaga cgcgataagc tttgaaaacc tgcaagctca gggtgagaag gttattagtg	10800
atcagtccgg taacatatgg agcgataaag ataaacatga tcctggtata acattactag	10860
actctttaag ttacgggtgtt tcggatttag cgtatcggca ctcattacct ttaaccgatt	10920
tattaaccat tgctggaaaa gatacgcttt ttccagccga attcgggcca cagcagacgc	10980
taacttgtgg ccctataaca ctggatgatt accggcggtgc gttacttgat ttacatggta	11040
atgatgcatt taaaatatca gctagtgacc ccagagactt tttgtttcag gatatacagt	11100
taatttgtga gccaaaaagt aagcggtata aatactatct caatcccgaa acgcttgaat	11160
atacattcac gccaccttca ggggataaat ttaaaacttt aacactacga gggaattatt	11220
ggctttattg gataccaacc cggtgggcag gtaaatacgc taatttgccg ttagttaagc	11280
gggtgatgga agattttctc cgtgaaaatc gaaatttggg ggaaaatgtt gttcaagtga	11340
cacgggtgat atcaacgcct atttatcctg agctgggtcat tgagctggcg gatgatatta	11400
cagatgcggc atcagtatta gcatcaatct atatgctatt agaacagtgg gcgatgccga	11460
tgcttgctcg ctttactacc gaagcattac aggccaaggg attaacaaac gaagagatct	11520
ttgatgggcc gtggttgctg catggttgga tacctcagtt accgacctct caaaactacc	11580
atacaggcat ggttctgaag atgaatcatc tgattaacca attgctggcg gttgaaggta	11640
taaagcgcgt agttagcctg acgttgccag aaacagaata tttgcatcag ataaaagatg	11700
ataattggtc ctggcaatta gatgttggtt attatccatt attatgggga gctaattcac	11760
tagaggtaat tacagagaaa aataacaatt atgtcaaatt gttcgcaaaa ggtgggggtac	11820
gattacaacc tgatcagaaa agtgttgagc ggttattatc acaggaatca ctcattaata	11880
atgctgcatc cacgttaccg gctggtaagg tgcgtgatct caaagcctat acacctataa	11940
gccgcagggt gcctgcctgt tatggtttgc agaatacttt gcaaaaagtt aaacctgaac	12000
aacgacactt atatcagttc ctattaccat tggagcaaat gcttgctgat ggatgtgcgc	12060
ggcttgcat tttgccacat ttgtagcat ttagggaccg aagcggaat atcagtgata	12120
cactctggcc tttcaagaat acagaggaca caattgccca acaggttcat caggaatatg	12180
ccggtacatt aaaagccttt caacagcagg aaattagcct gtttgatgat aaaaatagac	12240

cgcatcatgg caatatcaat cggaattag atattcttga ttatctgcta gggatatttg	12300
gtacacaacg tgcaaagcgt ccattaacgc aggatattca tgattttctg caaaccagc	12360
gaggttattt ggcacagcag ccggagttgg gttatcagcg tgataatatc cgtattgac	12420
gagtttcagc tttaaaaaa cgtatagcag cccgaattgg gctagatggt actattttca	12480
aagaatcggg tgatttaagt aagttacctt tttatttgat tgaacatcgt cagcttttac	12540
caaatttacc ccatcttgac tttcaacatg atcaaactcc ccaatctttt gtgatttccg	12600
acaacattgt taaagtgaag caagcgggaa tagcagataa aatcgttcgt ggacagctta	12660
ttgattttat agatattgaa agcaaattta ccgttcgtgc ccaaattgatt gtcgctgtag	12720
agggaaatga attttctctg gataaaaaa atagtattca acttgaaaag aatctgcagt	12780
tattacaatc agcgtctgag aaaaacaatt tacgatggag aaatagcacg gcgtgggttag	12840
aggatatgac gtatcgtatc aattatactg acgatcaggt tatagacgat aaaacaaaac	12900
aatgtcgttt acaaagtaat actaaatcgc cttttccagc ctttaattgca caaaaaata	12960
agattacgat tattaagcaa tcttctccac tctccagtat tgctgaattt actgatgaac	13020
cagaattcaa attagttgca acggtgacag agattgatcg gattgaaggg atattgacta	13080
tcgaacggga tgacaaccaa ctccctttcc cgactaaaga agagagtaat caatatatat	13140
ggtacatatc tgatgaaaac tatatttcaa gtgatcgttt ctcttttgtg gtgagcgtcg	13200
tgctgaatcg cggtttggtt gaaagggaag atattgatca atataagcta gaggaatgga	13260
tagagcgtga aacacttgca gagtttcctg cacatatttc gtttaattact cattggctgg	13320
catctgaaaa tttcgatgat ttgcaaga catatcaacg ttggcaaac aatggggcgc	13380
agttagggga tgaatcctac accatttttg aaaaactgac attagggcat ttaccaacag	13440
gacttactgg cattagtaat atgtttattg ctacagaagc tcagcgtcta gaagttgttg	13500
gcgagagtgg taatgagtgg aatacccagg caattattaa caacgaacta ttctatgttc	13560
cctcacagaa tagttaatac cgagtgttgt gatcaacttt tattataagc cggaggataa	13620
atggacaaca aaaataacaa acctactgat caagagattc taaaaacatc acgggctgtc	13680
ggagaaattc cttcagcgga taatttaaaa aatcgtttta aagctcgttc gattccatta	13740

gagacggatt ttactaatct cattgacctt gctgaagttg gacgattggc tatcggccag	13800
tcaccatcgc agcaaagtaa aacgcctggc accggaatgg aattaacttc ggatggtaaa	13860
ttacaagtca aggctggggc aggtgttgat atcgataata ataatcgtat tactattaag	13920
tctggtcatg gaattaaggt tgatggaaac ggcatttccg ttaaaccagg ttcgggtatt	13980
aaggttgata gtaatggtgt aaatgtcaat attgatgatt tttgggagga aatacgaat	14040
aaaattatgc ctaaaggaac catgctgcct atttatggca cacctaacc cttcgcgctg	14100
ccaacaggat gggaatggtg tgatggtaaa gatggcagac ctaatttaaa aaaaggga	14160
tataacttac tatcaggcca gtcttcaggc actgatactt tttgggcaga taataagaat	14220
ggagatacag agatcaacgt gttatttgtt tactatatga ttaaggttgt gtaatatctt	14280
aagtaatatg cattactcta aaatgaatga tttatattta agtaacataa taattaagtt	14340
gtgtttagg gctgttttta tgagaaatat aaaaacggag gtaataattg gcttcaaat	14400
atcagtgatg aaatagagtt atttcgcttt ataaaaattt tgttttattt cttttaataa	14460
ttatttatag aaggtaatga tatgtgcaca caaaaaaacg tgttagatag actgaaagat	14520
agaaatatta cattgggttg ggatgttggt gttgcatata accaagaaag tgtaataag	14580
ttattgaagc aacaatatgt tgaaaaagtt tactcaaagc aacattttgt ttttaagat	14640
tggcatgatg ataataaaac gaaatttatt gagggattaa cagtaggcgc tccactagtt	14700
tcatttgagg aggcgtcttt atccgatgct aatgtaaaag tgacacttaa ctttctttct	14760
ggtagatgga gagttataca agcaaatacc ggcacaccaa ttgaatggaa agaaattggt	14820
cctggcagtg gctataaagc agaattagtt gttccgctta aatcaataac tggtagtgta	14880
agtaaaaaag atatcatatt aaaattcaaa gatgctgtcg taaaaaaat aaatttattt	14940
gacaatcaag agcctgattt tattaattat ttcaagcaat cgatcagtga gggaaattat	15000
actttagggc aactggtgac agacagcaca ccgggattaa ttcctgctga atttcatatt	15060
cgactcaac cccatccaaa aacacgtgag cgtggttctc aatatgtagg aaatggtgag	15120
gtactgttgt ttattaaaaa gcaatatggc ggaagtggaa cattgcctgt aaatgatttt	15180
gattggttaa ttcctgatga tcatactagc gcattagtca tttcgagtaa gaccatgatg	15240

gggcaaatat tgccaaaaca atacaaagat aaattgcctg gtgatacctca gtttagccca	15300
ccaaaaagag tcaatgataa acaagactct gcttattata ttacgattac cgatgggtgga	15360
tttgatggta atagccctat agagaagtca tggttacgtt ctgattatag caatgggatt	15420
tggactgggtg aacgtggtaa tgctattatt ggtgaaaaag gaaagcggat accaccacgt	15480
tttccatacc aaaattttgt tattaaacct catgggtgaat cgttatttca aggatgggag	15540
aataagataa attacactca aaagtgtgca agatatttcc gacatcatag taatagtata	15600
actttcgaag atactgcatt aatggatctc agtattgggtg gacaaggtag tatcaattgc	15660
cagattgatg gtgaacattt ctatttaaaa tcagatgatt tttcccccac tgtcagctat	15720
gaaccaactt cattctggga taaatttatc ggtgggggtgg atgcaaagt gaaagatgaa	15780
ttcagagatg aattagcaca acaggcagaa gcaaagttaa aacaggtatt taatattgaa	15840
ttgcctgaaa tcagtctgtt ttctattaaa catctgctct ttcctggcat ggatgttatg	15900
caacttaaac agggttattt cccaggagat ttgattatct ttggggatat ttcacctaaa	15960
ttgaccacaa ttcagggtggc tcctttggaa gccatgggtg cccttaaaga aaatcaaaaa	16020
ttcactgtcg tacctgaaaa taaaaatgtt agttggaagt tggatcataa tagtgaggct	16080
atcaatgatc cgggaaatat tgatgataaa ggtatttata cggcaccggg cagaatcaga	16140
tctggttctg aagtcattaa agtcactgca actgacggcg atggaaatca ggcacggcg	16200
gcgctgacgt tggttccttc ttctgttgca ttaacacctt cttttgcttt tatctctgaa	16260
gcagataaga aacctatatt attattggcg aatgtcctag acggaaaagc agtaacatgg	16320
aatgtggaaa gctgtacagg cagccaatgt ggttctgttg atcagaatgg gctttatact	16380
ccaccagcag ggcgttttaa cgatggattt acttttgcac ccatcaccgc aactgcaaaa	16440
gatggtagtc aagcacgaac cattatttgt ctaatggcat caatgccagg acatggtttt	16500
tacaagggtg aacctaatat acgtttgaat gtgaaagtag gggaagaaat tatctttaaa	16560
gcgcaggcag atagctataa tggatgacct gatacttggg aaattttccc tcctcgcgga	16620
aaattaagtg aacctgagtt tgaaccaat aatgatcctg aaactaatga tacaattttt	16680
ggtcattata aggtgaccta taccgcgccg actaatgtta cctcacctga attgcttggt	16740

gtccatgtat gggagaaaaa taggcataat gagaaaaaca aaggtaaggc aggatatgca	16800
cttattgaaa ttatcccaga tgataaatag aaaatttatt taaataaaaa tcacagcggg	16860
tttatctcgc tgtgattaa gtcacttttt tttatagatt gtttatctct aataataatt	16920
ttattttata atataaagga aattaaaatg aataatgaat ataaaaataa caccgtgaat	16980
tggcgtatth cacctgatac ggtaggaagt attgataata acggtttata tacagcacct	17040
aatcgggtaa agaatatcga atttgtccaa gtaatggcaa gcgatgctaa taataatcaa	17100
tcttctgcga ttattactgt tattccctct tctgttgctg taacgccatc gtttactttt	17160
atctctgagg caaaaaaac atcagtcact tttaaagcga cagaacttga agggaaaaaa	17220
gtgacatgga gtataaataa ttataaccagt aatcagtatg gttccatcga tcaaatgggt	17280
atctacacac caccggaaag tcgttttaac gatggatata cttttgtatc tattacagca	17340
aaagcggaaa atggcgctga agcgcaagcg cttatttgct tgatggccaa aattccaggg	17400
catgcctttt tcgatgttca gcctaataa tgtttaagtg tgaagcctgg agaagaaatc	17460
attttttagag ctaacgcaga tcgttataat ggtgatcctg attcctggga aattttcccg	17520
tctcttggtg aattgggtga gcctgagtat ataaaaata acgatccaga aattcctatt	17580
tatggatatt atcaagtga atatatgtcg ccaaccaata taaattcttc ccaaatactc	17640
gttgtgcgta cttgggaata tgacaaacat gatgagcata atcaaggtaa agcaggatat	17700
gcattcattg aaattgtgcc agaaaatgag ctttaataa tataaccaat agatttcgag	17760
ccgcagcgcg gcggcaagtg aatgaatccc caggagcata gataacgatg tgactgggggt	17820
gagtgaacgc agccaacaaa gaggtactt gaaagataat gagtataaat gacttttagta	17880
agagaaatta tggcttcatt cagaactatt tattagagta attaaactta taaagacatt	17940
taatggaaaa tataatagaa aaatttaata ttaatatga agtctcatct gaaattattg	18000
gagagagttt attaaactcc cttttattga tgagtagaga aatcagcaat caattatctg	18060
aaatattatt agattataaa gaataataa ttgcattgga taagttagtg ttaaataatag	18120
gagaaatacc ctatgaaata tttgaacaac aattctatgg tcgtttggga aaattattaa	18180
atgaaaagtt aacaataata ataaatgata aattattgggt aaaaaacata tcaacctcgt	18240

tatttcctga atgttttagt gaaaaaagaa acccattatt aaatagagtc ataaaaaatt	18300
taccttctaa tttgggtttt gaagttcatt caatggtaaa aatagaatca gtaaataaca	18360
aaaaacaagc taatatattg acatcttatc tggcttattc tttttttaat aaaagcaaat	18420
tacaacaaca tttattttcc actagtaata ataaattaat tgagagctta tacgcacttt	18480
ttctaacgga tcagaatcga atacctactg ctcataaaat aggaaaaggt gcacttatac	18540
tatctgccct tatttggctt tatttctaatt ccaatgatta tctgccc aaa ccagaaagca	18600
ctctgttgtt acaaatagaa caggatataa aacaaggata tttgccttta acgttggtta	18660
tcactttctt ccagaacaga aatggcgggc gtgttttttg cgattggcag tatgcgttat	18720
ggcaaatacga tatcatcaaa aatcacttag gcattaaaat aacatcgaaa gaacccatt	18780
tacgggagaa aataatgtta caaccagtta atgcttctga tcgatcctct gtgctgatat	18840
cagacgaaaa attgacaata ccgttaacaa ttacaggtgc gggattagtg cttctctggc	18900
cactattaac tccactatth tcgtcttttg atttgttaga taagaaaagt ttttcagaca	18960
atgttgacaca ggaaatagca ttttaatttat tggaatgggt agtctgggga gatgagatgc	19020
tggtacatca ggaatcatca ttatctttat tactctgcgg aatagatcac caaacaatac	19080
tggagcgcca ggttcttatt cctgagcaca aggaaaaatt aaataactgg ttgcaaggta	19140
tttgtactca acttttctct tggaaaaagc tagggatcga tgatatgcgc caactttttt	19200
tgcagcgtca ggctgcactt tattatgaag atgatggccg ttggttatta acggtgcagc	19260
gtgaagctta tgatgtatta ctgactcaaa tgccttggcc gtggccattg aatattgtga	19320
cattaccttg gctagctgag ccgattagta tcacttggga aggtatctct gaaccaacgg	19380
atgtgtcatt ttggtaatcc aatatctcat taggaactct atgcatgtac gatttatctg	19440
atgatcttgc cagacagaat atttcaccgg aatatgaatt gacggttttg ctgtctcaga	19500
ctgctatatt ggataaacga attcgtttac gaattcagga attaatgcaa cagcaaacac	19560
tattgggaga aagtggacag acgtcttttg atgatatttc attttcattc gtttcgagt	19620
aacaacaaaa atcatcttat ttggtgtcac cgcatacaaa ttggacgaaa gaggattttc	19680
ctcctgagcc gatcccatct cgtagccgtc taggacaatt agttgaacgg tttgacttaa	19740

ctcaatttga aattgatttg attttattgt gcctgttgcc tcattcttgac agacgttatc	19800
taacgttatt ttctcttggt ccggtaagtg gaggtaataa cagcaaaaag cagatgttaa	19860
cgttgggatt ggctttggag ttgctttgtc cgagtgtagt agagcgcaat gcgcaacgtg	19920
ccagtttatt accacaggca ccgctttggg attatcgttt atttcagttg cgcggtgata	19980
tgtctgtttc ctacgatgaa ataccgttag caatcgataa ttctcttatg cattggttat	20040
tggggcatga tgctctcccg atttctcttc tctcccgggc tcattggctt cctgttcctg	20100
aagtgcctga tattttgcct gatttcacca accaattgat agaactctgc caaatggaac	20160
aagaggggat gctgacaata atcgccggcg gagccggaag tggcagcaaa acaagtgttg	20220
cacgcgcagc atcacaagta gggcgctctg tattgttggt atcgttagca tcagtgcac	20280
tgagtgaaca tgaaactatt aactgataa cactggcatt acgtgaagca caactaagaa	20340
atgcctgtct tatgtttgaa gctttggatg agttttgtga agcacgccc gctttgcagc	20400
tctggctagg aaatcgactg gctcgttggt cgattccgct gttttgtcaa ttacctaagc	20460
aagcatcatt attgccattg gatgcaattt cacaagttgt attgtctatg ccaatgcctt	20520
ctttaatggg gaaggctgca gcattagctt caatgatgac gaattatatt ccagacaatt	20580
cattggatgt tgaaagttaa gtgacatgtt tccatccttc tccattgata ttgaaaaagg	20640
cccttagtga agcagaaatt tatcgccgac tacgggggga aacggctagt ttgagattag	20700
atgatgtgca aatgtccctg cgttttcggg tacagcagaa ttttggacgt ttagcacaga	20760
gaattacacc acaacgaacc tttgatgatt tgatcatcag tgaatctcaa cagcaacaat	20820
tacaagaaat cctggcggct attcggcaac gagataggat gctagagcaa ggatttgctc	20880
gtaaagtgag ctatgggacg ggtatcagca cgctatTTTT tggtgaatct ggcacaggaa	20940
aaacgatggg agcagaagtg ttagctgggt ttttaggtgt ggatttgatc aaggtagatt	21000
tgtccactgt ggtaacaaa tatattgggt aaactgaaaa aaatctggct cgtgtttttg	21060
attatgccc aagaagacgc ggggtattgt tctttgatga ggcagatgca ttgtttggca	21120
aacgaagtga aactaaagat gcaaaagatc gtcatgctaa tattgaagtt tcctacctat	21180
tgcaacgcct tgaaagttaa ccagggtgg tgatattagc caccaattac cgtaatcatt	21240

tagactcagc atttagtcgt cgcctgactt tttcgggtacg attctctttt ccagatgttt	21300
ccttacggga acggatgtgg cggattatct ggccatcggg aattcaatta gccgacgaca	21360
tcagtttttc agcgttggca aaacgggctg aattaacggg ggcgaaatc cgtaatattg	21420
cgctactcgc tagttggctg gcagtagatg aaggaaatga aaaaattact atggctcata	21480
ttgaatgcgc attacgacgt gaactgagta aagttgggcg cattgattta ccttaatttt	21540
tctttgtaat cgggagacaa ctatggttaa aaatatcaaa tcagatgaaa ctttactgat	21600
attaaatagt aaaatagaag atgcattaaa agcgtattta ccgggcgaag atgtcgttat	21660
tcggttcgat atgtttggta aaaatgaaaa tccagattct cctaccgtgt gcgtttttct	21720
ttatgatatt caggaagatc tgcaattacg cgtgggagaa gggcggcaat acctgcctgc	21780
gacaggaaat tttgtcccgg gatgtgtcaa tgttcgttgt aattatctta tttcctactg	21840
ggagccggaa cagagcggag ggcagggatc gccaacata cgttctaata gtcaatcaat	21900
gaagataatg aactgtgtat tgaatgcatt aattaatcat cgttcatttc ctggtttacc	21960
cagaacttat acgagagttc ttcctcctaa tgaacaatta aatagcttag gaaacttttg	22020
gcaatcatta gataataagc ctcgactatg ttttaagttat atggtgacta ttcctattca	22080
acttaccctg ccgacagaga aggtatctcc tgtcattacc tcaaaaactg atattactcg	22140
aaaaccatcg cttaactttt atcttgaggc agatgaaatt atccgtcagg cattagttga	22200
tgccttaata tctcaaaca cagaatctat ggatacgata actagctggc tggcaaaagt	22260
tgttattatt tgtcgaccac cagaaataat gaataaaca atgattgaac aaactgtgaa	22320
attaattatt gctggaatta cagaagaggg attagctgga aatataaaga caatcactca	22380
aaagtgggtg gaagagaaga cgattattgg tgaaatcgac gatgtttctc tagttatttc	22440
ccaagttgac acgacagcgt tgtctgctgt aacaataccg acatctgttt aa	22492

<210> 96
 <211> 14
 <212> PRT
 <213> Photorhabdus

<400> 96

Thr Gly Gln Lys Pro Gly Asn Asn Glu Trp Lys Thr Gly Arg
1 5 10

<210> 97
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 97
tatcatatgt ctacaactcc agaacaaatt gctg 34

<210> 98
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Artificial

<400> 98
atctctagaa cagatattcc agccagc 27

<210> 99
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 99
ggcgtcacac tttgctatg 19

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 100

tcggtggcag taaattgtcc 20

<210> 101
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 101
atgtctacaa gtacatctca aattgcg 27

<210> 102
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 102
gactcccttg agggtagcg 19

<210> 103
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 103
ttctgatgag agtgatggta c 21

<210> 104
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 104
tgaataaaga attcagtcaa tatc 24

<210> 105
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 105
tagtggctga tgaaagtctg 20

<210> 106
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 106
ggaagccaaa gataatgaag tg 22

<210> 107
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 107
catttcttcc ctatggttg 19

<210> 108
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 108
ttaaattcct acaagattat cttt 24

<210> 109

<211> 133
<212> PRT
<213> Homo sapiens

<400> 109

Arg Ser Ser His Ser Arg Leu Gly Arg Ile Glu Ala Asp Ser Glu Ser
1 5 10 15

Gln Glu Asp Ile Ile Arg Asn Ile Ala Arg His Leu Ala Gln Val Gly
20 25 30

Asp Ser Met Asp Arg Ser Ile Pro Pro Gly Leu Val Asn Gly Leu Ala
35 40 45

Leu Gln Leu Arg Asn Thr Ser Arg Ser Glu Glu Asp Arg Asn Arg Asp
50 55 60

Leu Ala Thr Ala Leu Glu Gln Leu Leu Gln Ala Tyr Pro Arg Asp Met
65 70 75 80

Glu Lys Glu Lys Thr Met Leu Val Leu Ala Leu Leu Leu Ala Lys Lys
85 90 95

Val Ala Ser His Thr Pro Ser Leu Leu Arg Asp Val Phe His Thr Thr
100 105 110

Val Asn Phe Ile Asn Gln Asn Leu Arg Thr Tyr Val Arg Ser Leu Ala
115 120 125

Arg Asn Gly Met Asp
130

<210> 110
<211> 399
<212> DNA
<213> Artificial Sequence

<220>
<223> Artificial

<400> 110
 cgggtcaagtc actcgcgtct ggggagaatc gaggctgata gtgagagcca agaggatatc 60
 ataagaaaca tagcacgcca tttggcacag gtaggcgatt ctatggatcg ctccatcccg 120
 cctggacttg tcaatgggtct tgcgcttcaa cttcgtaaca cttcccggtc cgaggaagac 180
 agaaatcggg accttgcgac tgctctggaa caactgcttc aagcatatcc tcgtgacatg 240
 gagaaagaaa agactatggt agtattagct cttcttttag ctaaaaaggt agcttcgcac 300
 actccaagtt tattgcggga cgtttttcac accactgtta atttcatcaa tcagaacctg 360
 cgtacttatg tgagatcttt ggcgagaaat ggtatggat 399

<210> 111
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 111
 Leu Ser Glu Ser Leu Lys Arg Ile Gly Asp Glu Leu Asp Ser Asn
 1 5 10 15

<210> 112
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Artificial

<400> 112
 ctgtcggaga gtttgaagcg tataggtgac gagctggaca gcaat 45